

# Velindre University NHS Trust

## Annual Report

### 2021-22



GIG  
CYMRU  
NHS  
WALES

Ymddiriedolaeth GIG  
Prifysgol Felindre  
Velindre University  
NHS Trust



Canolfan Ganser Felindre  
Velindre Cancer Centre



Gwasanaeth Gwaed Cymru  
Welsh Blood Service

## A MESSAGE FROM THE CHAIR AND CHIEF EXECUTIVE



Professor Donna Mead  
OBE, CStJ. Chair



Mr. Steve Ham  
Chief Executive

### ***Welcome to Velindre University NHS Trust Annual Report for 2021-2022 – a story of recovery, review and resetting.***

Delivering excellent services in the face of continued phases of COVID remained our collective priority during the past twelve months, but that is not all that we have achieved at Velindre University Trust. With the persistent dedication, ambition and support of our staff, we have taken the opportunity to recover, review and reset our strategy for the next ten years.

Throughout, the interests of our patients and donors continue to be at the heart of everything we do.

#### ***Review***

Learning from our experiences is core to how our Trust operates. Listening to the experiences of our staff and understanding what is important to our patients and donors is key to a new culture of engagement we want to embed within our structures and processes. Over the past 12 months a new online system has been implemented to support the systemic capture of patient feedback and we have developed a new patient engagement strategy to support Velindre cancer services to ensure that patient voices are threaded through our cancer services from the outset, that we partner with our patients to improve what we do today and plan what we need for the future.

The Welsh Government's approval of the outline business case for the new Velindre Cancer Centre for south east Wales resulted in the commencement of the competitive dialogue to secure a design for the new centre and a programme of engagement with our key stakeholders including the local community. Plans to increase opportunities for our partners and neighbours to influence the design and the shape of community work in support of the development are well underway and will be implemented as we plan to commence the enabling works in summer 2022.

The pandemic and its aftermath has strengthened our resolve to deliver a world-class facility that delivers unrivalled care for cancer patients across south east Wales, is an inspiring workplace for our dedicated staff to thrive, provides a focal point for international research and is a place that benefits the local community.

The challenges presented to the Welsh Blood Service during the initial phases of the pandemic saw the service not only maintain a healthy blood supply but also embrace new ways of working. Reviewing the efficacy of these changes has been fundamental to the development of a new strategy for the Blood Service that embraces a new blood collection model developed in response to COVID, continues to develop strong local partnerships, as recognised by the Football Association Wales for its work for the Blood Sweat and Cheers Community Partnership and has innovation at its heart. A fine example of this is the launch of the service's new Component Development Research Laboratory to help realise our ambition of being a centre of excellence in blood component advancement.

The pandemic also deepened the good working relationship between our divisions. A new flagship collection centre site opened at the Velindre Cancer Service for the Welsh Bone Marrow Donor Registry and the pinnacle of our success was winning a Scaling up Innovation and Transformation Award at the Advancing Healthcare Awards, highlighting our success in identifying new ways of working and promoting innovation.

### ***Recovery***

Our staff are the foundation of our Trust's success which is one of the reasons their continued wellbeing is so important. Plans to develop the Bobath Centre into a new wellbeing centre for Velindre Cancer Service took shape for opening in May 2022. The newly refurbished space will offer staff an opportunity to step away from the hospital environment to relax & re-charge. This development complements our commitment to increasing opportunities for staff to access psychological support as they undertake their work. In addition, we are reimagining the purpose and outputs of our staff networks with the goal of improving and increasing opportunities for staff to connect outside their immediate daily routine.

We also recognise the importance of learning from lessons and stories from elsewhere, from colleagues in the health sector and outside, as we all recover from the pandemic. One such example of successful collaboration was a new partnership forged between the Trust, Health Boards, and the Universities of South Wales and Trinity St David in securing funding for a Digital Transformation Intensive Learning Academy. We are committed to supporting such ventures in the future for the benefit of our staff, patients, donors and our organisation.

## **Reset**

Our review and recovery from COVID has resulted in ways of working we had either already begun to explore or improvements that have been accelerated in response. They provide firm foundations for our Trust as we embark on the next chapter in our development.

This new direction was subject to consultation with our staff, patients, donors and wider public in 2021. The Trust's new 10 year Strategy '**Destination 2032**' sets out our ambition and road map for a dynamic, innovative future in ever evolving landscape.

It captures the ambition and priorities our staff and public and sets out a mission to improve lives and a vision to deliver excellent care, inspirational learning and healthier people. By 2032, we will be recognised as:

- Outstanding for quality, safety and experience
- An internationally renowned provider of exceptional clinical services that always meet, and routinely exceed, expectations
- A beacon for research, development and innovation in our stated areas of priority
- An established 'University' Trust which provides highly valued knowledge and learning for all
- A sustainable organisation that plays its part in creating a better future for people across the globe

We face our future with a strengthened leadership team. This year, we welcomed Professor Andrew Westwell and Vicky Morris as Independent Members to the Trust Board who bring a wealth of experience and expertise to our deliberations. They were appointed following the departure of Professor Donald Fraser and Jan Pickles to whom we are incredibly grateful for their wisdom and support in their time with the Trust. The appointment of a new Executive Director of Finance, the permanent addition of the Chief Operating Officer to the team and the appointment of a new Director to the Welsh Blood Service were also key milestones for us this year.

Our story is evolving and so will our organisation's design. We are already making significant inroads as we travel to our final destination all of which depends on continued good partnerships with our staff, patients, donors, and NHS' colleagues across Wales and our numerous stakeholders.

Celebrating our success is important as we continue our organisational transformation. Reminding ourselves of what our capabilities and commitment can achieve should be

celebrated and we are glad that these suite of annual report documents showcase how our staff continue to rise to the challenges they face. Innovation, improvement, accountability and engagement will continue to be core themes along our journey but for now, it is as important to reflect on where we are today, and how far we have come.

We continue to be immensely proud of the work and people of Velindre University NHS Trust and to be members of this outstanding team.




**Professor Donna Mead, OBE, CStJ**

A handwritten signature in black ink, appearing to read 'Donna Mead', with a horizontal line underneath.



**Mr. Steve Ham**

A handwritten signature in black ink, appearing to read 'Steve Ham', with a horizontal line underneath.



Velindre University NHS Trust Annual Report is part of a suite of documents about our organisation. It tells the story of the services and care we provide. What we do to plan, deliver and improve healthcare for you, and how we are setting out to meet changing demands and future challenges.

It provides information about how we have performed during 2021-22, what we have achieved and our aims for improving further next year. It explains how we are working with our patients and donors in developing our services for the future, and how we recognise the value of listening to you and your needs in planning our services going forward.

Efforts to achieve the Trust's vision and strategic objectives is driven by our Integrated Medium Term Plan (IMTP). However, this year, in line with the revised NHS Wales Annual Planning Framework, our plans were driven through the production of an Annual Plan for 2021/2022 rather than the normal three year Integrated Medium Term Plan, due to the continued impact of the COVID-19 pandemic.

Our Annual Report for 2021-2022 includes:

- Our **Performance Report**, detailing how we have performed against our plans and how we will seek to maintain or improve our performance further.
- Our **Accountability Report**, providing information about how we manage and control our resources and risks, and comply with our own Governance arrangements.
- Our **Financial Statements**, detailing how we have spent the Trust's funding allocation in meeting our obligations.

If you would like copies of any of these publications in print form and/ or alternative formats or languages, please contact us using the details below:

Velindre University NHS Trust Headquarters  
2 Charnwood Court  
Heol Billingsley  
Parc Nantgarw  
Cardiff  
CF15 7QZ  
☎ 02920 196161

✉ [corporate.services2@wales.nhs.uk](mailto:corporate.services2@wales.nhs.uk)

<http://www.velindre-tr.wales.nhs.uk/home>

---

## ABOUT VELINDRE UNIVERSITY NHS TRUST THE SERVICES WE PROVIDE

---



Velindre University NHS Trust provides specialist services to the people of Wales. The operational delivery of services is managed through Velindre Cancer Service and the Welsh Blood Service.

Velindre University NHS Trust delivers specialist cancer services for South East Wales using a hub and spoke model. The hub of our specialist cancer services is Velindre Cancer Service. This is a specialist treatment, teaching, research and development service for non-surgical oncology. We treat patients with chemotherapy, Systemic Anti-Cancer Treatments (SACTs), radiotherapy and related treatments, together with caring for patients with specialist palliative care needs.

The Welsh Blood Service plays a fundamental role in the delivery of healthcare in Wales. It works to ensure that the donor's gift of blood is transformed into safe and effective blood components, which allow NHS Wales to improve quality of life and save the lives of many thousands of people in Wales every year. The Welsh Blood Service, also houses the Welsh Bone Marrow Donor Registry which supports the local and international transplant programmes through the Welsh Transplantation and Immunogenetics Laboratory.

The Trust Board is accountable for Governance, Risk Management and Internal Control for those services directly managed and those managed via hosting arrangements. As Accountable Officer, the Chief Executive has responsibility for maintaining appropriate governance structures and procedures as well as a sound system of internal control that supports the achievement of the organisation's policies, aims and objectives, whilst safeguarding the public funds and this organisation's assets for which the Chief Executive is personally responsible. These are carried out in accordance with the responsibilities assigned by the Accounting Officer of NHS Wales.

During the reporting period, 2021-2022, the Trust also hosted two organisations (which are explained in more detail below). Hosting status is defined by the fact that the organisations have their own “Board” where the more detailed discussions, review and approval of strategy and performance takes place. By having such arrangements they are outside of the usual management arrangements, for example ‘managed’ Divisions whose Directors are directly accountable for strategy and operational management to the Chief Executive and are represented on the Trust Board and members of the Executive Board. Directors of the Hosted Organisations are bound by an Annual Governance Compliance Statement (or their own Annual Governance Statement in the case of NHS Wales Shared Services Partnership) with the Velindre University NHS Trust Chief Executive and in accordance with the individual hosting agreements with Velindre University NHS Trust.

---

## THE SERVICES WE HOST

---



GIG  
CYMRU  
NHS  
WALES

Partneriaeth  
Cydwasaethau  
Shared Services  
Partnership

The National Health Service Trust Wales Shared Services Partnership (NWSSP) is a dedicated organisation that supports the statutory bodies of NHS Wales through the

provision of a comprehensive range of high quality, customer focused support functions and services.

---

## HEALTH TECHNOLOGY WALES (HTW)

---



Technoleg Iechyd Cymru  
Health Technology Wales

HTW is funded by Welsh Government under the Efficiency through Technology Programme. HTW was established to facilitate the timely adoption of clinically and cost effective health technologies in Wales, working with, but independently of, NHS Wales. Its remit covers all health technologies that

are not medicines. This could be medical devices, surgical procedures, tele-monitoring, psychological therapies, rehabilitation or any health intervention that is not a medicine. HTW independently critically assesses the best available international evidence about the clinical and cost effectiveness of a health technology. This evidence is reviewed by experts and the HTW Appraisal Panel to put the evidence into the Welsh context. HTW also coordinates a Front Door process to support health technology developers to navigate NHS Wales. As well as its Front Door and appraisal functions, HTW also has roles in horizon scanning, evaluating uptake and disinvestment of technologies and



providing advice to health technology developers. It does this in partnership with other organisations in NHS Wales to ensure there is no duplication of work and sharing of limited skilled assessment resources. The Director signs an Annual Governance Compliance Statement to support the Trust Chief Executive in signing the Velindre University NHS Trust Annual Governance Statement.

---

## **THE PARTNERS WE WORK WITH**

---

The Trust works with a wide range of partners in a range of capacities including health, local authorities, and the voluntary/charity sector.

## Suite of Documents

As indicated on page 6, Velindre University NHS Trust Annual Report is made up of a suite of documents that describe our work between April 2021 and March 2022.

- 1 Performance Report
- 2 Accountability Report
- 3 Financial Report

We invite you now to read the further sections of the Velindre University NHS Trust Annual Report

# Velindre University NHS Trust

# Performance Report

# 2021-2022



GIG  
CYMRU  
NHS  
WALES

Ymddiriedolaeth GIG  
Prifysgol Felindre  
Velindre University  
NHS Trust



Canolfan Ganser Felindre  
Velindre Cancer Centre



Gwasanaeth Gwaed Cymru  
Welsh Blood Service

---

## INTRODUCTION AND CEO STATEMENT

---

This Annual Performance Report, describes how we delivered services from 1<sup>st</sup> April 2021 to 31<sup>st</sup> March 2022 in the context of the ongoing COVID-19 pandemic. It also outlines how we ensured patient, donor and staff safety and demonstrates our total commitment to Quality, Care and Excellence.

During 2021 - 2022 I am proud that our patients, donors and families have continued to benefit from the highest standards of care, innovation and professionalism across the range of services we deliver. We successfully maintained the supplies of blood and blood products to the whole of NHS Wales, transplant services both solid organ and stem cells, and delivered essential tertiary cancer services to South East Wales. We believe the strong foundations and clinical operating models that we have established will stand us in good stead, as we enter 2022/2023.

The NHS Wales Annual Planning Framework Guidance required the production of a three year Integrated Medium Term Plan (IMTP), covering the period 2022 - 2025. In line with this guidance we submitted our plan to the Welsh Government on 31<sup>st</sup> March 2022. Our plan builds upon the excellent work undertaken by teams from across the Trust, working with our many partners, to develop a set of ambitious priorities, which build on our strengths and which will result in people who use our services receiving excellent care, service and support. Our plans are outlined in three distinct areas.

Firstly, the plan sets out our commitment to delivering high quality, safe services which provide an excellent experience and outlines how we deliver this in context of the living with COVID-19. It describes what services we will provide, where they will be provided from and how we will meet the expected increase in demand for services over the coming years. The foundation of our services will be work we are progressing on our clinical and scientific plans and value-based healthcare.

Secondly, the plan identifies our priorities related to the implementation of enhanced models of care and services for blood and cancer services. This will see donors and patients being able to access services as close to home as possible, receive a wider range of information services digitally, and have access to a trials and other services provided by our partners which may add value for them. We will also seek to significantly develop our buildings and upgrade our equipment by 2025 and this, together with our clinical and sustainability plans, will provide us with the opportunity to deliver a carbon Net Zero organisation and a range of wider benefits to support the development of thriving and resilient communities across Wales.

The third area, and related priorities, signal the continued strategic development of the Trust and its transformation into new and potentially exciting areas of work in accordance with the challenge laid down by 'A Healthier Wales'. This will see us explore opportunities across the health and social care system to identify areas where we can further support our partners in achieving outcomes and benefits for the populations we serve.

The plan we have set out demonstrates the exciting times ahead of Velindre University NHS Trust. We look forward to working with our staff, patients, donors and partners to deliver the changes set out within the plan and continue our transformation into the future.

---

## **IMTP PROCESS ANNUAL PLANNING FRAMEWORK 2021-2022 AND DELIVERY FRAMEWORK 2021-2022**

---

The Welsh Government NHS Wales Planning Framework for 2022 - 2025 confirmed the re-instatement of three year Integrated Medium Term Plans (IMTP) for the current planning round.

The submission of our IMTP 2022- 2025 was approved by the Trust Board, on 31<sup>st</sup> March 2022, as part of the Trusts' statutory duty under the Finance (Wales) Act 2014.

The development of the IMTP has been challenging this year, given the level of uncertainty in the operating environment resulting from the ongoing impact of Covid-19 together with the range of challenges faced by the healthcare system and wider public services in Wales.

The IMTP 2022-2025 is framed within the Trusts' ambition for the future, following the Boards' approval of the Trust strategy '*Destination 2032*' and brings together the immediate, medium and long-term ambitions of the organization.

Notwithstanding this, and in accordance with the Welsh Government guidance, the IMTP is particularly focused on 2022 – 2023, to ensure that there are robust plans in place to deliver the required levels of service which achieve the appropriate levels of quality, safety and experience in a Covid-19 operating environment.

The core principle in developing the IMTP has been our commitment to quality and safety. Our IMTP will ensure that we put our patients and donors at the centre of everything we do; working towards optimum quality, safety and experience; and continual learning and improving. This is the '*golden thread*' throughout our organization.

Our strategic goals will be achieved by ensuring that all of our services are developed and delivered in collaboration with the patients and donors who use them, continually reviewing outcomes and experience and using these to learn and improve.

These priorities set out within our IMTP have been discussed and agreed with our commissioners and reflects their service needs.

The Trust's IMTP for 2022 - 2025 will be subject to internal performance management arrangements and reporting to various stakeholders, including the Welsh Government Integrated Quality Planning Delivery (IQPD) progress review meetings and audit/regulatory bodies throughout the year.

---

## **THE FIVE HARMS OF COVID-19**

---

In March 2020, Covid 19 arrived in the United Kingdom and fundamentally changed the lives of our population during the pandemic.

Harm related to COVID-19 can be broadly grouped into 5 key areas; 4 harms have been identified previously, but a fifth cross-cutting harm has been added, explicitly recognising the important impact of inequality on the harm experienced by people.

<b>1. Harm directly arising from SARS-CoV2 infections (COVID-19)</b>
<b>2. Indirect COVID-19 harms due to surge pressures on the health and social care system, such as cancellation or postponement of urgent and non-urgent treatments and delayed management of long-term conditions.</b>
<b>3. Harms arising from population based health protection measures such as, educational, psychological, isolation from shielding and other measures</b>
<b>4. Economic harms such as unemployment and reduced business income arising both from COVID-19 directly and population control measures e.g. lockdowns, social distancing and masks wearing</b>
<b>5. Harms arising from the way COVID-19 has exacerbated existing, or introduced new, inequalities in our society</b>

The impact on people's health and well-being in Wales has, and will continue to be profound in range of ways:

- People who did/were not able to access services with health concerns and subsequently receive a diagnosis later than would have occurred pre-COVID.
- Patients who were waiting for treatment, which was delayed and affected the outcome.

Looking ahead, NHS Wales is working with a wide range of partners to move to a position where Covid-19 can be managed as an endemic factor i.e. 'living with COVID' This means that the level of disease is more predictable and therefore planning can be undertaken with greater levels of certainty and confidence.

---

## IMPACT OF COVID ON DELIVERY OF SERVICES

---

The pandemic continues to affect our service planning and delivery for both our cancer and blood and transplant services. COVID related absences, capacity reductions due to enhanced Infection Prevention Control (IPC) measures and increasing patient numbers are all having an impact on our service provision and waiting times.

The pressure on our services continues to be intense, as we seek to deal with the complex needs of people using them, ongoing staff illness and a backlog of people's treatments that have been delayed as a result of the measures put in place to manage the health, safety and well-being of society during the pandemic.

However, it is important to note that despite all the challenges we continue to respond in providing excellent care for our cancer patients, by relocating staff from other areas, maximising the use of hypofractionation, reviewing the utilization of our Linac fleet and drawing upon private sector capacity in the short term.

Our blood and transplant services also continue to operate under COVID restrictions which impact upon blood collection and manufacturing capacity. However, work is in hand with the Infection Prevention and Control team to assess removal of triage and reducing social distancing within collections which should help improve this position as Wales begins to lift COVID restrictions.

The total Trust Covid funding requirement for 2022-23 as presented in the tables below is £12,310k. The Trust has received confirmation that the £710k National response programme costs relating to both Mass Vaccination (£375k), PPE (£335k) and Covid IPC (£1394k) will be funded directly by Welsh Government, whilst our Commissioners have included £6,056k within their financial plans for Covid Recovery capacity costs.

<b>Covid Funding Requirement 2022-23</b>	<b>Total £000</b>
Mass Vaccination	375
PPE	335
<b>Subtotal Covid Programme Funding</b>	<b>710</b>
Covid Recovery & Response Funding	
- Welsh Government (IPC)	1394
- Local Health Boards (capacity)	6056
Covid Additional Outsourcing for SACT & Radiotherapy	4,150
<b>Subtotal Covid Recovery and Response Funding</b>	<b>11,600</b>
<b>Total Covid Funding Requirement 2022-23</b>	<b>12,310</b>

---

## **PLANNING AND DELIVERY OF SAFE, EFFECTIVE AND QUALITY SERVICES FOR COVID CARE**

---

### **Clinical safety for our Patients and Donors:**

Velindre University NHS Trust is committed to ensuring the delivery of safe, high quality and effective care to our patients and donors. It is also committed to continuous quality improvement in order to achieve this.

During 2021 – 2022, the Trust was focused on maintaining the safe delivery of its core priority services during the various waves of the COVID pandemic. In the main, Velindre Cancer Centre and the Welsh Blood Service were both able to continue to provide their core clinical services. This required a tremendous effort from all staff who continue to go over and above for the benefit of our patients and donors.

Throughout the COVID pandemic, all relevant national IPC & COVID guidelines and policies were adhered to, and stringent infection prevention and control measures were maintained. This necessitated a reduction in the in-patient bed base at VCC, however, this was mitigated by extending ambulatory care pathways / infrastructure.

As well as responding to the challenge of maintaining service delivery in the pandemic, we have also played a key role in supporting the National Vaccination Programme by not only delivering vaccinations to our own staff and vulnerable patients but by also delivering vaccinations to the wider health and social care staff and some cancer patients.



---

## PLANNING AND DELIVERY OF SAFE, EFFECTIVE AND QUALITY SERVICES FOR NON-COVID CARE

---

### Welsh Blood Service:

The Welsh Blood Service has continued to adapt its blood collection and processing service model and its transplant support services in response to changing public health and IPC guidance. This was vital in ensuring continuity of service during the pandemic and the ongoing need for infection prevention adaptations will create a need for further evolution during 2022/23.

The pattern of change in demand for our services is clearly aligned to that of Local Health Board services and we have continued to work closely with NHS colleagues through the National Oversight Group for Blood Health and blood bank managers to respond as required.

In addition, as we move through into 2022/2023, we will be continuing to work through several other major initiatives such as our Blood Supply Chain and Digital programmes as well as commencing work to scope the further collection of Plasma for the benefit of patients in Wales.

### Our Priorities Delivered in 2021/22:

**Provide an efficient and effective collection Service, facilitating the best experience for the donor, and ensuring blood products and stem cells are safe, high quality and modern** – Our donor engagement strategy has been revised and relaunched for both whole blood and stem cell donors. The newly-established Component Development Research laboratory has worked with the Transfusion laboratories team to review and implement changes to our strategy platelet, plasma and cryoprecipitate strategy. Significant progress has been made on the plans for occult Hepatitis B screening which will be introduced in 2022.

**Meet the patient demand for blood and blood products through facilitating the most appropriate use across Health organisations** - WBS has sustained supply of blood and blood products for Wales in extremely difficult circumstances and whilst it has had to rely on support from other UK blood services on occasion, WBS has also found itself supporting those services at other times during the year. The Blood Health team continue to work with hospitals across Wales, providing training and support to ensure that blood products are used appropriately.

**Provide safe, high quality and the most advanced manufacturing, distribution and testing laboratory services** – In the last year, Welsh Blood has procured new Blood Group Analysers for whole blood, and a new Bacteriological monitoring and alerting system for platelets. New processes have been developed to support the screening of donors for occult Hepatitis B infections. Screening of platelet donors for HNA antigens has been introduced.

**Provide safe, high quality and the most advanced diagnostic, transplant and transfusion services** – Welsh Blood has implemented state of the art Next Generation Sequencing in the Histo-compatibility and Immuno-genetics laboratories and has implemented changes to cross-matching tests used to assess compatibility in solid organ transplantation. During 2022/2023 WBS will introduce a Consultant Clinical Scientist on-call service to support organ transplantation.

**Provide, services that are environmentally sustainable and benefit our local communities and Wales** – The programme of work is underway to develop and implement an energy efficient, sustainable, SMART estate at Talbot Green site that will facilitate a future service delivery model. Other projects are working to reduce the use of non-recyclable materials such as water bottles and disposable cups in donation clinics, and to reduce the use of printed documents across the service.

**Be a great organisation with great people dedicated to improving outcomes for patients and donors** – Welsh Blood continues to offer a variety of career development pathways for its people. We have maintained support for higher education and vocational training for scientists and health professionals. This includes the national Higher Specialist Scientific Training programme for consultant clinical scientists as well as management and leadership development. Trade union engagement continues to be positive with close collaboration as we seek to align terms and conditions across our collection teams. Work is ongoing to design an agile model of working where lessons from the pandemic can be applied to allow our people flexibility in where they work.

### **Challenges faced during 2021/22:**

Whilst we always will plan to collect enough blood to meet the forecast issuing needs of hospitals across NHS Wales, 2021/22 has continued to present unique challenges as a result of the pandemic, as outlined below:

#### **Collection of Blood and blood products, processing and distribution:**

- Fewer fixed donation sites, incorporating social distancing and infection prevention control measures.
- Competition for donation sites from vaccination clinics.
- The need to increase stocks of Fresh Frozen Plasma to support stock replacement as part of the occult Hepatitis B screening programme.
- Access to timely, up to date demand information to support forward planning.

#### **Wholesale Distribution of Commercial Blood Products:**

- Ongoing monitoring of availability of stock and contingency planning.
- Pressure to increase and maintain critical stocks in response to forecast global shortages of donated plasma from which these products are made.

**Blood and stem cell donor selection regulations:**

- Continuing to meet stringent and changing donor selection guidelines and regulations for blood and stem cells including the forthcoming introduction of screening for occult Hepatitis B Infections and the potential need to review historical donations from donors who test positive.
- Continuing to meet COVID-19 requirements for facilitation of export and import of stem cell products such as transport from restricted countries and COVID-19 testing of couriers.

**Maintaining an engaged healthy donor panel:**

- Focus on 'targeting' to meet specific and fluctuating requirements for specific groups.
- Strategy for bone marrow donor recruitment, where age group differs to whole blood donors.

**A healthy and sustainable workforce:**

- Specialist staff shortages.
- Recruitment and retention.

Work is ongoing through the Blood Health Team and Collections Team to align the collection profile with demand for specific blood groups, but this remains difficult to determine. We are also challenged by lack of certainty from Health Boards regarding activity levels. Furthermore, there is a requirement to ensure the supply of blood by blood group meets the demand, which adds to the risk of supply and issuing alignment being achieved.

We continue to plan to use our donor recruitment plans to flex to meet demand and our donors are responsive. However, in the event of shortage, we will draw on our mutual aid agreement with the UK Blood Services or in extreme circumstances initiate the National Blood Shortage Plan to actively manage stocks with hospitals.

**Velindre Cancer Service:**

The sustained delivery of our services, with sufficient capacity in the context of COVID-19, was our primary focus during 2021/22. Our overarching aim has been to safely maintain the delivery of non-surgical cancer services for the population of South East Wales, while ensuring that staff and patients are safe when attending our treatment locations and to minimise the risk of COVID-19 transmission.

The Transforming Cancer Services programme will continue to be a core area of work for us and the recommendations of the Nuffield Review, finalised in March 2021, where we continue to work in partnership with South-East Wales Local Health Boards and the Collaborative Cancer Leadership Group (CCLG). Existing regional projects such as the Acute Oncology Service Project also continue to be key strategic priorities for us and our LHB partners.

In taking account of the above determining factors, the Velindre Cancer Service pursued the following priorities during 2021/22.

### **Our Priorities in 2021/22:**

**Priority 1: Ensuring that Staff and Patients are Safe at our Treatment Locations** – we minimised the Risk of COVID-19 transmission through enhanced infection control measures, revised patient and care delivery pathways and the implementation of robust and comprehensive vaccination and testing strategies during 2021/22.

**Priority 2: Delivery of appropriate capacity to meet patient demand** – despite the pressures caused by the pandemic we continued to deliver all of our services by adapting our clinical model to ensure that we responded to the service pressures brought by the pandemic.

**Priority 3: Delivery of business critical initiatives** – we continued to deliver a number of business critical and strategic initiatives. These included:

- Outline Business Case approval for a new Velindre Cancer Centre.
- Outline Business Case approval for the construction of a Radiotherapy Satellite Centre in partnership with Aneurin Bevan University Health Board
- Programme Business Case approval for the redevelopment of the Welsh Blood Service facility at Talbot Green.

**Priority 4: Engagement with Health Boards and Regional Service Planning** – we have continued to lead and support regional service developments, including:

- The development of a South-east Wales Acute Oncology Service.
- The development of a research and development facility in partnership with Cardiff and Vale University Health Board and Cardiff University.

**Priority 5: Patient Experience and Engagement (recognising and responding to the impact of COVID-19)** - our patient engagement strategy has been developed in collaboration with our staff, our patients and donors and with other key stakeholders. It outlines how we will engage with our patients, donors and their families and carers in the future to ensure that their voices are at the heart of how we plan and deliver our services.

### **Performance Analysis:**

We have developed a wide range of measures which are routinely used to monitor the quality and performance of our core services (Note: excludes hosted organisations). The performance summaries are explored further with supporting narrative in the Trusts performance reports received by the Trust Board. These papers are available on the Trusts internet site via the following link ([insert link](#)).

## **Challenges faced during 2021/22:**

The year 2021/22 provided significant challenges for VCC in responding to the COVID-19 pandemic and a number these will remain as we move into 2022/23 and as we move out of the pandemic and move into business as usual.

We are preparing to *'flex'* to the changing scenarios that the next phases of the pandemic will bring as we manage the predicted 'surge' of patient activity following the pandemic. Ensuring effective and safe utilisation of the site to accommodate services remains a challenge; particularly in respect of delivery of SACT services as we work with health boards on repatriation of pre pandemic SACT outreach facilities.

The wellbeing of our staff has been a key priority during 2021/22, and the professional and personal impact of the pandemic and the way in which we work will continue to be a key area of focus, particularly as we plan for increases in capacity to meet suppressed demand as referrals increase through the year. The recruitment of additional staff with specialist skills that we require and the most effective use of our staff skill sets and skill mix will be critical. This will require very different ways of working and delivering our services.

In addition, we will continue to operate against the background of the challenges for tertiary cancer services in addition to those that resulted from the pandemic. These include increasing cancer rates and health inequalities, a growing gap in the forecast demand between supply and demand, increasingly complicated and personalised treatments and supporting people to live with and beyond cancer.

## **Velindre Futures:**

The Velindre Futures programme was established in 2020, and is the vehicle through which we are delivering the transformation needed to meet the aspirations of the South East Wales Transforming Cancer Services programme, the further regional opportunities which we have identified and the existing ambitious plans for service modernisation.

Over the past year, a number of the transformation programmes have made good progress despite the impact of the COVID pandemic – these have included progress on the Unscheduled and Acute Oncology pathways with our local Health Board partners, the development of a Research and Development Hub at the University of Wales Hospital, the Radiotherapy service change programme and the development of a formal engagement strategy for the Trust.

The outpatient transformation programme (linked with Values Based Health Care), and the replacement of the CANISC system through the delivery of the Digital Health and Care Record system are continuing.

As we move on from the recent wave of the COVID pandemic, we will further drive the transformation agenda at the Cancer Centre via the Velindre Futures Board. Core to these ongoing service changes is ensuring that the voice of the patient, their carers, families and the public are involved in shaping what we do.

## **New Velindre Cancer Centre:**

Since Welsh Government's approval in March 2021 for the outline business case for the new Velindre Cancer Centre the Trust has successfully continued to take forward the plans to the next stage. The Trust has been working with two consortia as part of the competitive dialogue process to design, build and operate the new VCC. This work includes working with our patients and staff to develop a hospital design that will deliver our ambition of a world-class facility that will deliver unrivalled care for cancer patients across South-East Wales, be an inspiring workplace for our dedicated staff to thrive and be a focal point for international research. In addition, the Trust and consortia have been actively seeking to ensure the new hospital is a place that benefits the local community.

The Trust has successfully started the enabling works on the new site, which is a key dependency for the opening of the new centre, which is programmed to open in 2025.

We are all continuing to work to develop the new Velindre Cancer Centre to be one we can all be proud of for generations to come.

## **Digital Innovation:**

The Trust continues to progress its digital agenda, to improve the delivery of patient / donor care and to improve quality and safety. A new Digital Strategy is being developed, due to be published in May 2022, which will set out the future vision for the delivery of digital services across the Trust over the next 5 – 10 years. Its focus is on using digital services to support key Trust ambitions, such as the delivery of cancer treatment closer to home, automating currently manual, largely paper-based processes to improve efficiency and release capacity for staff to focus on operational and clinical duties, and to deploy new operational and clinical IT systems to further improve the quality of care being delivered to patients and donors.

Over the past 12 months, the primary focus of activity within the Velindre Cancer Centre has remained the Digital Health & Care Record – a programme to replace the existing 'CANISC' IT system with the national Welsh Patient Administration System (WPAS) and an enhanced version of the Welsh Clinical Portal (WCP) – both national (NHS Wales) systems managed and developed by Digital Health & Care Wales (DHCW). In aligning the IT systems used within VCC to the national IT portfolio, this will build on the gains made in recent years and support the further sharing of clinical information, across organisational boundaries in support of the delivery of effective cancer treatment for the patients of southeast Wales.

Activity within the Welsh Blood Service has largely been focussed on the delivery of a number of upgrades to its Blood Establishment Computer System (BECS) and Welsh Transplantation & Immunogenetics Laboratory (WTAIL) IT systems.

Whilst the DHCR programme and the broader challenges associated with the COVID-19 pandemic have been the focus of much of the digital agenda over the last 12 months, progress has been made in a number of areas, where new digital services have been enabled or upgraded in support of the quality, safety and performance agenda, such as:

- The enablement of the 'GovRoam' service, enabling clinicians to connect seamlessly to the local VCC IT services when working remotely at other NHS Wales hospitals across southeast Wales.
- Deployed the Welsh Nursing Care Record (WNCR) service in the Velindre Cancer Centre, to being the transition from the recording of nursing documentation on paper to a fully digitized solution, thus allowing for important nursing notes and information to be routinely shared with other organisations via the Welsh Clinical Portal (WCP).
- Deployed the Welsh Clinical Portal (WCP) within the Welsh Blood Service, to enabling clinical staff to access the medical / clinical history of donors when providing supplementary advice and clinical follow-up to Welsh blood donors. This helps ensure the advice being given takes a donor's full medical history into account, improving both the safety and quality of the clinical / medical advice they are able to offer.
- Continued to enhance the Blood Establishment Computer System (BECS), to ensure the Welsh Blood Service complied with changing regulatory requirements and deliver improvements to service delivery for Welsh donors.
- Deployed the new IT system into the Velindre Cancer Centre pharmacy, moving the VCC off its previous 'end of life' system onto the all-Wales platform, which is used by all other Health Boards in Wales.
- Continued use of the 'Attend Anywhere' virtual consultation service, to allow outpatient consultations to take place without the need for patients to attend on-site – a key aid in supporting the wider Trust response to the COVID-19 pandemic.
- Enhanced the IT systems used by the Welsh Transplantation & Immunogenetics Laboratory (WTAIL), based in the WBS, to enable more effective delivery of the services provided by the Welsh Bone Marrow Donor Registry (WBMDR) and the work undertaken by the laboratory team who provide support for renal transplantation in Wales.
- Further enhanced our local cyber security systems and procedures, to help secure patient and donor data and protect critical Trust IT services.

Aligned to the aforementioned digital strategy, looking forward to 2022/23 the Trust is developing a digital transformation programme, to develop and deploy new digital capabilities that will enable transformative ways of delivering cancer and blood and transplant services to all stakeholders.

In support of our digital aspirations, we are working with the Centre for Digital Public Services (CDPS) and Digital Communities Wales (DCW), to develop our approach to improve patients', donors' and staff digital accessibility and acceptability and work towards addressing wider digital exclusion.

Lastly, the Digital Services team continue to play a key role in the new Velindre Cancer Centre (nVCC) programme, to ensure digital and 'SMART' capability is built into the design of the new hospital from the outset.

---

## **PUTTING THINGS RIGHT**

---

We are committed to managing, and learning from, concerns in accordance with The National Health Service (Concerns, Complaints and Redress Arrangements) (Wales) Regulations 2011.

During 2021/2022, we received a total of 191 concerns. This was comparable with the volume of concerns raised during 2020 – 2021. 44% of the concerns were raised to the Trust via email, 41% received verbally by telephone, 7% via letter, 6% verbally in person and 1% via social media.

The Trust has continued to achieve above 75% compliance of providing a response to the complainant within 30 days of receipt of their concern. The compliance breakdown per quarter is listed below and demonstrates a continuous compliance improvement over the year:

Q1 – 83% Q2 – 67%, Q3 – 75%, Q4 – 100%

Over 96% of the concerns raised were graded 1 and 2, and 59% were successfully resolved via the 'early resolution' process. The Trust has continued to have a low number of re-opened complaints of less than 2% for the year.

8 complaints have been referred to the Ombudsman during the year. 5 Ombudsman cases remain open and the current decision status for each case referred to the Ombudsman during 2021-22 are below:



- 2 cases were upheld
- 1 case was partially upheld
- 3 cases were not upheld/rejected

The Trust awaits an Ombudsman decision for 2 cases. Following an evident increase in the number of Covid related concerns reported at Quarter 1 (3 concerns) through to Quarter 3 (5 concerns), there has since been a reduction in the number of concerns raised relating to the impact of Covid resulting in no Covid related concerns raised during the last quarter of 2021-22.

The main theme of the concerns raised throughout the year related to communication, attitude and behaviour. Communication regarding appointments, communication regarding treatment decisions, communication regarding the manner on which patients / donors had felt they had been spoken to / treated.

For the Cancer Centre, the main focus of the communication issues related to concerns around the lack of seamless / 'joined up' care between Health Boards. For the Welsh Blood Service, the communication concerns centred on the booking of appointments and regarding changes in clinic venues.

We remain committed to encouraging patient / carer feedback so that we can learn from this to improve our services. We are continuing to refine our complaints management processes so that we can resolve concerns fully and ensure that any actions required are taken promptly and that learning from complaints is fully embedded. Our concerns policy was approved at the March 2022, Executive Management Board and Quality, Safety and Performance Committee.

## **Redress**

During the reporting period, the Trust has investigated 5 Redress cases to determine if harm has resulted from breaches of duty in care, which would amount to a qualifying liability.

Two cases involved the instruction of a joint independent medical expert to seek an opinion on whether harm occurred following the breaches of duty identified. In both cases the independent expert did not identify harm, which would amount to a qualifying liability under the Putting Things Right Regulations, and these two cases were closed during the reporting period.

Two further cases identified harm following further investigation, for which offers of financial compensation up to £15,000 have been agreed by the Putting Things Right

Panel. During the reporting period, one offer of £8,500 has been put forward to settle the case.

One case remains under investigation, with a potential liability of £25,000. However, early indications, following independent expert medical review, suggest that there is no Qualifying Liability.

The themes have mainly consisted of communication, mis-diagnosis, delay in treatment/referrals and wrong mode of treatment.

Where learning has been identified from these cases, these have been reported to the Welsh Risk Pool in accordance with the governance arrangements in place and learning has been implemented to prevent future occurrence.

We remain committed to encouraging patient / carer feedback so that we can learn from this to improve our services. We are continuing to refine our complaints management processes so that we can resolve concerns fully and ensure that any actions required are taken promptly and that learning from complaints is fully embedded. Our concerns policy was approved at the March 2022, Executive Management Board and Quality, Safety and Performance Committee.

## **Claims**

Throughout the reporting period, the Trust's role is to handle claims to achieve a fair resolution for all parties. Where claims are valid, the Trust looks to settle these or defend where there is sufficient merit to do so.

Of the 18 claims managed by the Trust during the reporting period;

- 4 new claims were received, comprising of three personal injury claims and one clinical negligence claim.
- 5 claims were withdrawn following denials of liability made by the Trust.
- 5 claims were settled, due to the risk of increased litigation costs and proceeding to trial. These were closed during the reporting period.
- The caseload of claims as at the end of the reporting period is 8. These comprise of 5 clinical negligence cases and 3 personal injury cases against VCC. The themes relate mainly to defective equipment, slip trip and falls, misdiagnosis, misreporting and treatment complications.

The number of new claims against the Trust continues to remain low, however, the clinical negligence claims that are brought against the Trust are often complex and can take a number of years to resolve. Clinicians and staff continue to provide support and witness commentary when required. This includes attending meetings with solicitors and medical experts. Reports on clinical negligence cases are shared with

the appropriate Trust Committees and with other key Divisional Groups to highlight learning and improve services to prevent a recurrence.

Decisions taken to settle claims against the Trust are often made as a consequence of lack of evidence. The ability to defend claims relies heavily on the quality of the Trust's documentation, its records and the decisions taken, or not taken, at the time. Where learning is identified from these claims, the Trust continues to play its part in reducing the cost of claims through the actions it takes to improve the standard of care.

As part of learning assurance, the Trust is required to submit a Learning from Events Report (LfER) to the Welsh Risk Pool that demonstrates what lessons are learnt. When a breach of duty has been identified, the Quality and Safety team will work with directorates and services to identify the learning and actions that are required to satisfy the Welsh Risk Pool criteria and the way in which learning can be implemented to reduce the risk of reoccurrence and future impact. These actions drive down cost in litigation and continues to promote and encourage a culture of learning that benefits both patient, service user and staff. The Trust is required to pay the first £25,000 of any claim with the Welsh Risk Pool (WRP) indemnifying the balance of any individual claim.

During the reporting period, 6 learning from Events Reports (1 relates to Redress) were submitted to the Welsh Risk Pool for approval. 4 received approvals during the reporting period. Two are awaiting outcomes from the Learning Advisory Panel.

Recent developments in technology has provided opportunities to adopt an enhanced analytical data that is a feature of the new RL Once for Wales Datix Claims Module. All claims have now been transferred across to the new RL Once for Wales Datix Claims Module from the previous Datix V14 claims model.

The Trust's estimated liability as at the end of the reporting period has seen a considerable reduction from the previously reported period, the figures of which are outlined below:-

- Estimated Claims Value: £957,966.97 (previously £9,519,299.87).
- Anticipated Trust Liability: £125,000.00 (5 potential claims and 1 redress).

---

## DELIVERING IN PARTNERSHIP

---

The Trust works with a wide range of partners including health, local authorities, emergency services and the voluntary/charity sector. Our primary health partners are set out below:

Organisation	Relationship
Aneurin Bevan University Health Board	Commissioner
Betsi Cadwaladr University Health Board	Commissioner
Cardiff and Vale University Health Board	Commissioner
Cwm Taf Morgannwg University Health Board	Commissioner
Hywel Dda University Health Board	Commissioner
Powys University Health Board	Commissioner
Swansea Bay University Health Board	Commissioner
Welsh Ambulance Service NHS Trust	Provider
Public Health Wales NHS Trust	Provider
Health Education and Improvement Wales	Provider
NHS Wales Shared Services Partnership	Provider of services
Digital Healthcare Wales (DHCW)	Provider of services
Welsh Health Specialist Services Committee	Specialist Commissioner

Effective planning and commissioning of services is fundamental to achieving the best outcomes for the people we serve across Wales and the cultural shift required to reduce health inequalities, improve population health and well-being and achieving excellence across Wales.

The Trust has worked in close partnership with our Local Health Board partners to ensure that our key strategies are aligned, that there are a clear set of shared priorities and to ensure that we can provide sufficient capacity and capability to deliver commissioned services of the highest quality.

## Engagement with people who use our services to design them in partnership



Effective and ongoing engagement is vital in the development of our services and we strive to make it as easy as possible for patients and donors to share feedback following their care.



There are a number of ways used to listen, discuss and learn about our services.

### **Cancer Services - Non-surgical Tertiary Oncology**

Our service plans respond to feedback from patients and donors, their families and carers, Velindre staff, Health Boards, third sector and other partners. A range of engagement events and workshops have been undertaken with key stakeholders over the last 12 months.

Social Media continues to offer a productive two-way conversation tool with our online cancer community. This helps us to listen and respond to compliments, queries and concerns. Our Patient Advice and Liaison Service is able to respond in a timely and efficient manner, capturing mini-stories and signposting to wider online surveys.

### **Blood and Transplant Services**

The Blood Service also has daily interactions with members of its community of donors. We are committed to listening to our donors and we do this by circulating a comprehensive survey to every donor that enters a donation session each month.

The service operates a dedicated donor contact centre which exists to inform, educate and assist donors in contributing to the health of the nation by donating their blood, platelets or bone marrow. The service also engages existing and prospective donors through its donor engagement team. This team uses social media, the press, the website and face-to-face interactions to promote blood, platelet and bone marrow donations in Wales.

The engagement department is present in the communities of Wales, building close links and partnerships with community groups, sports teams, businesses, education providers and other socially engaged groups that have an influence in their localities. The engagement team is also committed to having a presence at the high profile national events that occur each year across Wales, such as the National Eisteddfod.

---

## WORKFORCE AND WELLBEING

---

**Our overall workforce aims for our people, articulated in our People Strategy, are:**

- To develop a Skilled and Developed Workforce, given clear career pathways, provide them with leadership, skills and knowledge they need to deliver the care our patients and donors need now and in the future.
- To support a Healthy and Engaged Workforce where wellbeing is key, recognizing and valuing their diversity in a bi-lingual culture.
- To have a Planned and Sustained Workforce having the right people with the right values, behaviors, knowledge, skills and confidence to deliver evidence based care and support patient and donor wellbeing.

2021/22 has been a challenging year and one where we have had to deal with ongoing restrictions and challenges caused by the pandemic. Throughout the year the focus has been on supporting the health and wellbeing of our staff who have worked hard to continually provide excellence in the care for our patients and donors.

From the beginning of the pandemic the Trust established a COVID Workforce Operating Framework to manage workforce issues. This framework has been adapted throughout the pandemic to ensure a flexible and agile approach to meet the service need ensuring safe staffing levels.

### **Supporting Staff Wellbeing**

2021 has seen the establishment of the Trust's Health and Wellbeing Steering Group and Agile Working Group. The main aim of these groups are to ensure effective provision of the right health and wellbeing interventions across the Trust to deliver timely and effective support to staff whether they are working on Trust sites or working from home. These groups work together in partnership with our Trade Union colleagues and Clinical Advisory groups including a multi-disciplinary membership of Nursing, Allied Health Care professionals and Medical colleagues.

### **Wellbeing Developments:**

- From the start of the pandemic, the Trust developed a daily communications newsletter to all staff from the Executive Management Board, containing latest guidance, key information and wellbeing updates and links.
- The Trust has utilised a universal text messaging service to ensure staff who are unable to access emails on a regular basis, receive important COVID updates and links to wellbeing information.
- The Executive Management Team have established online Q&A sessions to address concerns of staff.
- Staff networks continue, providing a safe space for staff from minority groups to discuss the impact of the pandemic, raise concerns and provide feedback. Networks include LGBT+ Network, BAME Network, Disability Network,

Menopause Café, and a Shielding Network to support staff who are, or have been, shielding.

- Ongoing engagement sessions have taken place with staff to gain feedback on wellbeing provision ensuring a 'you said, we did' approach.
- The Trust's Health and Wellbeing Resources internet area is available for all staff that can be accessed remotely, enabling wider access to self-help resources and toolkits, and additional support.
- The trust has created a physical wellbeing facility, covering the Bobath Centre, to provide a wellbeing area for staff to access wellbeing support.
- Drop in sessions for managers to support and advice effective wellbeing management.
- Thank you card for staff including links to wellbeing services.
- Letter to staff including wellbeing leaflet and signposting information.
- Ongoing provision of an Employee Assistance Programme (EAP) – 24/7 support for staff and their families.
- Manager Assist – advice for managers available 24/7 via the EAP.
- Neyber Financial Wellbeing programme supporting staff with financial hardship.
- On-line Aware Mindfulness Stress Reduction Course - via EAP
- Mediation provision via our EAP.
- VCC Mindfulness App has been developed and is available to all staff.
- Complementary Therapy provision accessible for all staff.

---

## **WELLBEING OF FUTURE GENERATIONS ACT / CREATING A SUSTAINABLE ORGANISATION**

---

### **Our Approach to the Well-Being of Future Generations Act:**

We have a commitment to transform the Trust and to create a sustainable organisation. We will commence the acceleration of our journey of transformation with the publication of the Trust Strategy together with those for specialist Cancer and Blood and Transplantation Services for 2022 - 2032. These will set out what good look like in five years' time and the actions we will take over the coming years to achieve the excellence we are committed to.

These strategies have been developed within the context of the Well-Being of Future Generations Act (*the Act*) and we will seek to implement the principles of the Act within the Trust to ensure that they become the central organising principle of each and every action that our staff take on a daily basis. This will take time but we are committed to ensuring we translate the intentions and spirit of the Act into tangible and sustainable benefits for the people of our region.

The Act requires public-sector organisations in Wales to focus on delivering long-term well-being goals in a sustainable manner. Whilst we have made progress in embedding the *Act* across the organisation we know that we have much more to do.





## Our Well-Being Objectives:

The Trust, recognised under the Act as a national body, was required to develop and publish a set of its own well-being objectives.



**Trust Well-being Objectives**

**GIG** | Ymddiriedolaeth GIG  
**NHS** | Prifysgol Felindre  
**WALLES** | Velindre University  
NHS Trust

-  **Reduce health inequalities, make it easier to access the best possible healthcare when it is needed and help prevent ill health by collaborating with the people of Wales in novel ways**
-  **Improve the health and well-being of families across Wales by striving to care for the needs of the whole person**
-  **Create new, highly skilled jobs and attract investment by increasing our focus on research, innovation and new models of delivery**
-  **Deliver bold solutions to the environmental challenges posed by our activities**
-  **Demonstrate respect for the diverse cultural heritage of modern Wales**
-  **Bring communities and generations together through involvement in the planning and delivery of our services**
-  **Strengthen the international reputation of the Trust as a centre of excellence for teaching, research and technical innovation whilst also making a lasting contribution to global well-being**



These objectives were developed following extensive engagement and were designed to focus the Trust's contribution to the realisation of the national well-being goals.

### **Delivery Arrangements:**

Our approach is built upon the personal support and leadership from the Chair and our Board. At Executive level, the Director of Transformation, Strategy and Digital holds the responsibility for sustainability within their portfolio and discharges this through a range of Offices which are co-ordinated and led by the Director of Commercial and Strategic Partnerships. The Trust has established a Sustainability Community Group to facilitate and support work across the Trust and the Sustainability Manager plays a key role in this process.

However, it is important to emphasise that our approach is to expect all of our workforce, suppliers and service providers to contribute to the well-being goals and to embody the five ways of working in their day-to-day actions and behaviours. The Act is viewed as adopting a '*way of being*' rather than simply demonstrating compliance to standards. In this regard, at its heart, it is viewed as whole system organisational development and emphasis is being placed on induction, education and training, relationship management, communication and workforce health and well-being.

The workforce, and the processes they utilise to function, will be supported and enhanced respectively so that they: clearly reflect what 'long-term' means, identify the root causes of problems through system wide perspectives, support work across organisational boundaries to maximise value, establish shared processes and ways of working. Importantly, our actions will be framed and facilitated by our strategic approach.

### **Progress against Delivery:**

There are a number of actions that we are progressing:

#### **Doing things differently to deliver change:**

- The Trust is considering the Sustainability Development (SD) principle when developing its main strategic programmes, in new Velindre Cancer Centre and the Talbot Green Infrastructure Upgrade Project
- The Trust is considering how it can evolve existing partnerships to a greater extent, and develop new relationships within the health sector and beyond, to maximise its contribution to A Healthier Wales and to support others in doing the same.

#### **Developing core arrangements and processes:**

- The Trust has developed an ambitious Sustainability Strategy and plans to use it to embed the Sustainable Development principle and utilises the Well-being Goals at its core.
- Responsibility for delivering the Act and embedding the Sustainable Development principle sits within the Strategic Transformation, Planning and Digital Division. The Trust is developing current capacity within the team to deliver the requirements of the Act.

- The Trust is considering the merging or better alignment of its well-being objectives and strategic goals, ensuring we meaningfully contribute to our set objectives.
- The Trust will be developing a strategic planning framework, with the aim of ensuring that the Act genuinely underpins all service development work and the Trust's Integrated Medium Term Plan. All planning activity throughout the Trust will utilise this framework in order to ensure that the Sustainable Development Principle is fully embedded across the organisation. The Trust intends for all investment proposals to demonstrate how they align to the Act.
- The Trust is currently undertaking work to create a more systematic approach to tracking and monitoring progress.

**Involving citizens and stakeholders:**

- The Trust is actively identifying ways to improve how it engages with citizens, stakeholders, patients and donors when developing its services.
- The Trust is exploring possibilities for collaborating with other health bodies to develop a wider regional '*whole system*' Cancer Community and a public health promotion agenda.

Whilst recognising we have much more to do, it is important to acknowledge the achievements of the organisation to date and the strengths it can draw on as we grow together as a sustainable community.

The Welsh Blood Service is currently developing ambitious Business Case to reduce the carbon footprint of the Talbot Green site. A key and ambitious objective of this Programme is to transition to a carbon neutral footprint for the building. This will be achieved through an increased focus on the use of renewable technologies, solar photovoltaic arrays, ground source and air source heat pumps and bio- mass boilers.

We have also focused considerable efforts on ensuring that the TCS Programme has embedded the requirements of the Act. The new Velindre Cancer Centre project is championing sustainable developments, such as integrating sustainable transport into the design of the new VCC, and encouraging the use of sustainable travel. We have identified several proposals for community benefits in the design of the new VCC. In this regard, a number of fundamental deliverables can be evidenced. The project aims to the

We have applied, and continue to apply, the Sustainable Development Principle when designing and developing the TCS Programme clinical service model and supporting infrastructure. The new TCS Programme clinical service model has a clear preventative focus and there are opportunities to educate patients and the wider community on healthier lifestyles to help prevent cancer. The TCS Programme clinical service model and supporting infrastructure also has a strong long-term focus based on a sophisticated understanding of current and future needs.

We have worked in an integrated way to design and develop the TCS Programme and supporting infrastructure and have considered how it can deliver wider benefits as the programme progresses to ensure it has a positive impact on social, economic, environmental and cultural well-being. We are also collaborating with partner organisations across South East Wales to develop and improve cancer services.

In addition, we have a range of strategic and operational examples of good practice in implementing the Act. A number of these are shared below.

---

## TRUST STRATEGY DEVELOPMENT

---



The Director of Transformation, Planning and Digital is leading on the development of the Trust Strategy. A comprehensive engagement plan has been created which includes presenting to Patient Liaison Group to ensure members of the community are involved in the strategy development.

---

## SUSTAINABLE TRAVEL PLAN


---

The Trust Staff Travel Plan for the 2022-2027 period was launched. The aim of the plan is to inform, and enact change in the everyday lives of staff, in and outside of the workplace, causing a shared behavioural change. The plan was written in response to the Staff Travel Survey, incorporating staff feedback into initiatives to encourage the use of sustainable travel methods, including cycling, walking, using public transport and car-sharing.

---

## BIODIVERSITY ENHANCEMENTS

---



As part of our obligations to enhance biodiversity under Section 6 of the Environment Wales Act, the Trust has created an action plan to increase local flora and fauna. This has included 'No Mow May' and 'Let it Bloom June'. To promote the enhancements, a competition with a local schools was undertaken to design 'Nature Notices' which display facts of the benefits of enhancing biodiversity. The CEO & Chair & IM Sustainability Champion picked the final design.

---

## ISO14001:2015 - REACCREDITATION

---

Welsh Government sets a requirement for all NHS bodies to be credited by the ISO14001:2015 standard, an environmental management system. We have successfully obtained the ISO 14001:2015 standard for the last five years for all sites. Following the assessment in November 2021, the Trust successfully obtained recertification, with no non-conformities raised.

---

## GREEN SOCIAL PRESCRIBING

---

The Trust has collaborated with the charity Ray of Light, to deliver a safe and non-judgemental support group for patients, carers and families affected by a cancer diagnosis, based at Velindre Cancer Centre. Ray of Light centre their sessions on the well-being benefits of nature, with many activities to choose from, including painting, whittling, forest bathing and many more.

---

## NEXT BIKE

---

To encourage active travel, a Next Bike station was reinstalled in the Cancer Centre. Integrating the station into everyday service will contribute to the Travel Plan; encourage active travel, which aligns with the Welsh Government targets of active travel. The Trust aims to join the Healthy Travel Charter, having the bike sharing scheme will contribute to achieving one of the fourteen actions.



---

## DECARBONISATION GRANTS

---

The Trust was successful in obtaining bids in Welsh Governments Decarbonisation Grant funds. The Trust has successfully obtained funding for the following Velindre Cancer Centre Building Management System Upgrade and Trust Headquarters LED (light emitting diode) Lighting Upgrade. Alongside the LED lighting upgrade, motion sensors have been installed to reduce consumption and it does not rely on staff remembering to turn off the light. At VCC, the specification for the Building Management System optimisation has been installed to provide increased management of our consumption.

---

## LITTER PICKS

---

Within the fortnight celebration by Keep Wales Tidy 'Spring Clean Cymru' [28th May – 15th June] litter picks were held across the Trust with positive engagement with staff with volunteers for the litter pick. Since the success of the campaign, litter picks are held across the Trust.

---

## CANTEEN

---

To prevent the production of unnecessary waste, single use plastic cups have been removed from the Parkside dining room at VCC. Beverages are now served in ceramic mugs and staff are encouraged to use re-useable Eco to Go cups made from natural materials and supplied in collaboration with Keep Wales Tidy. The launch in VCC was so successful it has been rolled out to all divisions and hosted organisations. Furthermore, the canteen has introduced Vegeware for all takeaway containers to reduce single use plastic.



---

## WELSH LANGUAGE REGULATIONS AND COMPLIANCE

---

### **Introduction:**

This report will focus on the value the Trust gives to enhancing bilingual provision. It will demonstrate a commitment to the Welsh language standards but also highlight the work we are currently doing on our Welsh language Cultural plan, which is our platform for celebrating and recognising the cultural importance of Wales.

We continue to provide support for the needs of our bilingual patients and donors. We are keen to ensure the services we provide are even more visible than previously especially at a time where the pandemic has made it difficult to communicate face to face.

We continue to strengthen the Governance around this area and recognise the importance of the Welsh language Standards but are also eager to do more than is required of us. We have begun a Trust wide conversation this year on the meaning of Culture and have recognised that our values need to emulate what it means for our staff to provide a bilingual service under continued pressures that the pandemic has brought to us.

We value the work of our staff and at a time of continued change we seek to support them with all that they need to belong to an organisation with true values of Welsh language and Culture. The ethos of our new Cultural plan was accepted by the Executive Board and moving forward we will embrace its aims and objectives and seek to further integrate our support for staff, patients and donors who need or chose to use the Welsh language.

### **Celebrating Welsh Culture:**

The Trust continues to actively seek ways in which to engage its staff in the culture of Wales as well as its languages. We recognise the need to comply with its legal obligations but we aim to do more than is needed as this celebrates the diversity of our staff and services.

This reporting year we have drafted a Cultural Plan that aims to strengthen our engagement with staff around the language and Culture of Wales and promote a value of inclusion that encompasses all that we believe. The Executive management board have taken on roles of responsibility for certain aspects of the Equality and Diversity agenda and this includes an Ambassador role responsible for the Welsh language.

The Trusts draft Cultural plan aims to be as inclusive as possible and the Welsh language Ambassador will drive the ethos of this plan throughout the work of the Executive Board.

### **Welsh language Standards Compliance:**

As of November 2021 our Trust compliance of the Welsh language Standards stands at over 50%. This evidence is collected through our internal divisional working groups and reported to our Trust wide Welsh language development group. It is our way of ensuring we can build on the regulated compliance year on year and put projects in place to ensure we focus our provision productively.

### **Patient and donor correspondence:**

We previously reported on a systematic approach to ensuring our patient correspondence was bilingual. Since last year this has been put on hold in a number of areas as the old system generating the letters has been put on hold. All development initiatives were ceased due to the pandemic and the roll out of the new patient system has also been slower than anticipated.

As a Trust we are determined to ensure our bilingual correspondence is accessible and although at the Welsh Blood Service this is a process historically followed we have some way to go to ensure Velindre Cancer Centre are in line with our ambitions.

One of our departments are leading the way in this. Radiotherapy have translated and are using bilingual letters as standard and they have also ensured that reception is supported by Welsh speaking triage staff as the number of Welsh speaking reception staff continues to be low. This is a positive way to ensure a department is supported when needed by other members of staff which is the ethos that underpins the 'more than just words' framework.

Monitoring telephone calls to and from the Trust is extremely challenging. At the Welsh Blood Service this is more achievable. In this reporting year, calls to the Donor Collection team was 1004. This is 2% of the overall calls into the donor contact centre.

Our Welsh language Working group at Velindre Cancer Centre will take the monitoring of this on board as a matter of urgency this reporting year.

## Meetings:

In light of the continued change to working arrangements under the pandemic it has been necessary to think of ways in which we can internally support bilingual staff at meetings if they wish to use the Welsh language.

For external meetings we continue to be mindful of the ongoing work underway by Welsh Government with Microsoft and look forward to hearing how this progresses over the coming months. Internally we are piloting a method of language identification within Teams (at the Welsh Blood Service) and will monitor the take up of this. The process will then be disseminated Trust wide as an option for language identification at internal meetings.

## Recruiting Welsh Speakers:

As we stated in last's years report our aim in this reporting year was to finalise our recruitment and language assessment process. We have completed this and are now ensuring that ALL posts going out for recruitment complete a language assessment table that is discussed with the Welsh language manager should questions arise. It has taken some time to integrate this process but we are confident that this will change the way in which we assess the need for language skills, not only as part of the individual post but for the wider teams across the Trust.

The process is in its infancy but will over time give us the data we need to evaluate its success.

As you will see from the figures below the pandemic has placed clinical priorities over language needs and we will be monitoring the increase in the number of 'essential' roles once the recruitment process has embedded.

Moving forward we will also be looking at the translation of our adverts and supporting materials. This will begin in 2022.

### Velindre University NHS Trust 2021-2022

Total number of vacancies advertised as:	
Welsh language skills are essential	1
Welsh language skills are desirable	98
Welsh language skills need to be learnt when appointed to the post	0
Welsh language skills are not necessary	6

Total Number of vacancies advertised 01/04/2021 to 31/03/2022	105
---------------------------------------------------------------	-----

### Welsh Blood Service 2021-2022



Total number of vacancies advertised as:	
Welsh language skills are essential	0
Welsh language skills are desirable	97
Welsh language skills need to be learnt when appointed to the post	0
Welsh language skills are not necessary	1

Total Number of vacancies advertised 01/04/2021 to 31/03/2022	98
---------------------------------------------------------------	----

### Velindre Cancer Centre 2021-2022

Total number of vacancies advertised as:	
Welsh language skills are essential	0
Welsh language skills are desirable	269
Welsh language skills need to be learnt when appointed to the post	0
Welsh language skills are not necessary	23

Total Number of vacancies advertised 01/04/2021 to 31/03/2022	292
---------------------------------------------------------------	-----

## Communication

### Translation:

The Trust has committed additional financial support to translation and we now have two dedicated translators to support our work. We also have a translation agreement with one of our hosted organisations for additional support when needed.

This has meant that we can focus our translation priorities more and has enabled us to begin to translate important documentation such as Job descriptions and build a bank of dedicated bilingual descriptions for future use.

Translation figures continue to demonstrate the commitment given by the Trust to provide bilingual internal and external information and services. This reporting year we have progressed with the purchase of a memory software and are in the process of using this to ensure consistency with translation and as a time saving of resource. Liaising with our translation colleagues across the NHS we can move this forward again this year and share a productive resource with other translation teams.

### Websites:

Work continues on the Trust Website and the Welsh Blood Service have updated their site in line with priorities and bilingual requirements. This year they have also developed a dedicated Welsh language page mirroring that of the Trust's but specific to local requirements. The Promotion of this was extremely successful on St David's day as was the celebration of its dedicated Welsh language working group.

1.12% (3,390) of the Welsh Blood Service website booking portal users (April 2021 to March 2022) have their browsers set in Welsh.

Overall, the Trust main website has received 3,200 Welsh language hits in the reporting year.

### **Welsh language Education:**

This year we have been actively promoting providing Welsh language training in the workplace. In addition to regularly advertising the opportunities provided by 'Iaith Gwaith' we have been supported by Cardiff University to run two courses for our staff.

Providing in house training is not as simple as ensuring financial support it is crucial that staff are able to attend classes and are supported to do so. Unfortunately within a clinical setting this is not as successful as we would like, however, we are proud to announce that eight of our staff have successfully completed their first year and will be further supported by us to proceed to the next level of training.

Providing continued training and support to a small number of staff is more productive for the them and the needs of the services we provide. Our focus in the coming year is to further promote e-learning opportunities and a stronger in house support for those who wish to practice and become more confident in the work place.

We are pleased to note that the new Welsh language awareness package supported by the Welsh Government is now completed. The Trust has been eager to receive this and will now be integrating this as part of its regular training Trust wide initiatives.

### **Welsh language Skills:**

We have increased our data entry compliance this year and are now showing an 84.5% compliance within ESR.

Collecting the language data is extremely important, however we are aware that even though our recruitment processes use this information to ensure future recruitment needs, we now need to use this data to enable us to strengthen our services further.

Workforce planning and our People Strategy are central to this, being drafted with


*'A Healthy and Engaged workforce, within a culture of true inclusivity, fairness and equality across the workforce. A workforce that is reflective of the Welsh population's diversity, Welsh language and Cultural identity'*

The Trust is demonstrating its commitment to ensuring the bilingual needs of its staff and services are central to planning at all levels and will continue this year to integrate these aims across the Trust.

	Assignment Count	Required	Achieved	Compliance %
	1587	4761	4027	84.58%
Org L4	Assignment Count	Required	Achieved	Compliance %
120 Corporate Division	172	516	442	85.66%
120 Research, Development and Innovation Division	51	153	137	89.54%
120 Transforming Cancer Services Division	25	75	54	72.00%
120 Velindre Cancer Centre	860	2580	2193	85.00%
120 Welsh Blood Service	479	1437	1201	83.58%

**Promotion:**

Our Trust wide promotion continues with celebrations such as ‘Diwrnod Shwmae / Sumae’ and St David’s day. This year we had an excellent colourfull day at the Cancer Centre with a themed menu at the restaurant and a drop in opportunity for staff.



At the Welsh Blood service the launch of a dedicated Intranet page to assist staff was the main theme and an opportunity once again for staff to hear about the work of the Welsh language working group. It was also a great opportunity to congratulate the Welsh language learners who



have completed the first year of their courses.

They will progress this coming year to a second level giving them opportunity to further develop their Welsh language skills.

## **Concerns and Complaints**

### **The Welsh Blood Service:**

Three donor complaints were received by the Welsh Blood Service this reporting year.

The first two were relating to text messaging errors and the standard of Welsh sent and the other relating to a website error. Unfortunately an old message had been used and not a professionally translated message but this was rectified. All three complaints were investigated thoroughly and as a consequence changes have been made to the service and checking processes.


None of the complaints resulted in a formal investigation being undertaken by the Welsh language Commissioner.

### **Velindre Cancer Centre: Patient Experience:**

During this reporting period, we have introduced a new digital feedback system at Velindre Cancer Centre. CIVICA Experience is a cloud-based insights platform which supports multi-channel survey data collection, real-time reporting, smart text analytics, workflow tools, event-driven alerts and push reporting. It was procured in 2021 as part of a Once for Wales exercise to support improvement across NHS Wales.

Capturing feedback from patients and their families in line with the National Framework for Assuring Service User Experience can now be conducted digitally and in real-time, enabling us to capture more data in a timely and responsive system. The CIVICA Experience implementation has seen an increase in survey responses and in particular Question 3 which references the Welsh language.

A total of 592 people answered the question “*Were you able to speak Welsh to staff if you needed to?*” with 5% of respondents saying “Never”. This equates to 30 patients who feel they were never able to use Welsh in Velindre. This powerful data is now informing our local improvement plans and will be used to continually monitor the impact and progress of service developments.



## Hosted Organisations:

The Trust continues to host Health Technology Wales (HTW) and the Shared Services Partnership (NWSSP). Both organisations are committed to ensuring the Welsh language standards are a high priority.

HTW have been actively translating Job descriptions in line with the requirements of the Welsh language standards.

NWSSP have ensured that staff across the NHS can now access the opening page of the Electronic Staff record system in Welsh and in English. This is a really positive step forward as the system has been monolingual since its inception. Being able to access personal employee information in the language of choice demonstrates a commitment to the language needs of the NHS employees and NWSSP have provided this.

Other areas of development have included:

- **Translation Support Services:**

The Welsh Language Unit, in NHS Wales Shared Services Partnership have provided translation services for the following NHS organisations during 2021/22:

- NHS Wales Shared Services Partnership's divisions and hosted programmes
- Public Health Wales NHS Trust
- Digital Health and Care Wales
- Velindre University NHS Trust
- Health Education Improvement Wales
- Wales Ambulance Service Trust in the translation of the 111 Website
- Welsh Health Specialised Services Committee
- The All Wales Value in Health Care programme
- Supported NHS Employers in the translation of Job Descriptions and Person Specifications

Totalling over 3.7 million words translated during 2021/22.

- **Translation Bank:**

The NHS is facing unprecedented demand for translation services, this is in response to meeting the requirements of the Welsh language standards in the most part, but also to respond to the need/demand amongst patients and the public.

It is becoming increasingly difficult to recruit qualified and experienced translators to full-time permanent vacancies, and it is also becoming challenging to retain staff, due to the recruitment market being extremely competitive.

To be able to respond to this situation we've established a bank of translators who can work flexibly for us as we require their services.

The bank was established in autumn 2021, and our existing arrangements are working well to date. Our approach to agile working also means that we can recruit translators from different parts of Wales and beyond to assist us with our ability to respond to the demand for translation services.

- **Student Streamlining:**

NHS Wales Shared Services have improved the customer journey through Student Streamlining Service by ensuring the system provides a Welsh language journey throughout the process.

We audited and reviewed our processes, automated services and templates to ensure that there is now a seamless Welsh language offer to students engaging with our service.

As part of this project, we also translated adverts and job descriptions to enable Health Boards to be able to advertise the opportunities through the Student Streamlining programme through both the medium of Welsh and English.

- **All Wales Patient Information Leaflets:**

We undertook a comprehensive audit and review of over 350 Patient Information Leaflets during 2021/22. The leaflets are given to patients as part of the consent process. The audit and review enabled us to make improvements to the language used in the leaflets, to have consistency in terminology as well as making the leaflets wholly bilingual for patients in Wales. Previously Welsh and English versions were available separately. This work will continue in 2022/23 with work being undertaken in partnership with Eido Healthcare to translate easy read versions of the leaflets.

- **ESR Portlets available in Welsh:**

The Welsh Language Unit and the Workforce Information Systems team worked collaboratively with the NHS Business Services Authority and IBM on the development of Welsh Language Portlets on ESR in the autumn of 2021. This now means that the portals on ESR are available to NHS Staff in both Welsh and English to satisfy the requirements of Standard 81 of the Operational Standards.

- **Contact Centre Review Project:**

The purpose of this review project was to audit our existing centre services, establish how our customers currently engage with us, identify improvements, and to increase and improve the self-serve element of the services we provide. As part of this work, the Welsh language provision of services was also scrutinised, and a survey circulated to NHS staff identified that between 10% and 20% of NHS staff wished to engage with us through the medium of Welsh.

Further work will be undertaken with contact centres throughout NWSSP over the coming years.

- **TRAC Recruitment System Updates:**

We have continued to work with the developers of the TRAC system to ensure that the interface for the system continues to be up-to-date and consistent in both Welsh and English.

**Moving Forwards:**

Over the coming year the Trust will revisit its Values and consult proactively with its staff. Culture is central to these values and as we know a positive culture drives better care. We will be considering how we can further integrate our Welsh language and our divisional groups will take forward specific aims and objectives in order to strengthen provision locally.

Nationally we will continue to work with our partners, Local Health Boards and Welsh Government. The language and Culture of Wales belongs to us all and as a Trust we strive to provide the best bilingual care that we can.

---

## CONCLUSION AND FORWARD LOOK

---

We have produced our Integrated Medium Term Plan for 2022 – 2025 ([insert link](#)) which sets out how we will deliver services from 1<sup>st</sup> April 2022 to 31<sup>st</sup> March 2025. It describes what services we will provide, where they will be provided from and how we will continue to ensure patient, donor and staff safety. It also outlines the arrangements we have in place for managing our capacity so that we can meet the expected increase in demand for our services.

The next three years will undoubtedly provide both challenge and opportunity in equal measure. Our intention is to see the challenges as opportunities to support us in taking the learning from the pandemic to place quality, safety and experience at the heart of everything we do. We are committed to working with patients, donors and our health and public service partners to understand, design and deliver services which are truly person focused and deliver the experience and outcomes that people value most.

Whilst this plan sets out our initial view of the 2022 – 2025 period, its primary focus is on the 2022 -2023 period given the level of uncertainty across the globe regarding COVID-19 and its impact. Our focus during this period will be on:

### **Delivering the fundamental cornerstones of healthcare provision**

These include:

- Implementing the requirements of the Health and Social Care (Quality and Engagement) (Wales) Act 2021, the National Quality and Safety Framework and the National Clinical Framework to provide services of the highest possible quality
- Delivering services that meet the national clinical quality and safety standards and provide an excellent experience
- Treating patients as quickly as possible
- Providing blood and blood products to our partner Health Boards to support the provision of treatment and care to people across Wales
- Delivering services which are '*COVID safe*' and reducing / eliminating (as far as is possible) the 5 harms from COVID. This will see us:
  - Focusing on infection prevention control standards
  - Responding quickly and robustly to Public Health Wales/Welsh Government guidelines and translating it into safe operational service delivery
  - Continuing to manage the challenges presented by nosocomial transmission
- Developing agile and flexible capacity plans which allow us to respond quickly to the challenges presented by COVID-19 and its related impacts



- Supporting the health and well-being of our staff who have been working in extremely challenging circumstances for the past two years
- Workforce redesign – optimising multi-professional patient / donor centered care predicated on co-production and top of licence working

We also have a number of important strategic areas of work. These include:

### **Improving population Outcomes and reducing inequalities**

The Trust will work with our Local Health Board and wider partners to identify opportunities where we can support the improvement of public health and population outcomes through primary and primary and secondary prevention. This will focus on a number of areas:

- Improving access to our services to increase uptake and reduce inequalities and ill-health
- Strengthening our decision-making (systems/processes/culture) regarding the Equality Impact Assessment and Socio-Economic Duty to consciously address poor outcomes and inequalities in the communities we serve
- Working with our health partners where it is clear and compelling that we can add value and make a difference
- Developing a range of strategies and plans that enable us to help our staff to improve their health and well-being
- Secondary prevention: making the most of the opportunities of ‘*every contact counts*’ with patients, donors, partners to support them in improving their health and well-being.

### **Annex - Glossary of Terms**

IMTP	Integrated Medium Term Plan
IQPD	Integrated Quality and Planning Delivery
IPC	Infection Prevention Control
Linac	Linear Accelerator
RT	Radiotherapy
SACT	Systemic Anti-Cancer Therapy
VCC	Velindre Cancer Centre
WBS	Welsh Blood Service
CCLG	Collaborative Cancer Leadership Group
nVCC	New Velindre Cancer Centre
WCP	Welsh Clinical Portal
WRP	Welsh Risk Pool
LfER	Learning from Events Report
EAP	Employee Assistance Programme
TCS	Transforming Cancer Services
CDPS	Centre for Digital Public Services
DCW	Digital Communities Wales
WPAS	Welsh Patient Administration System
DHCW	Digital Healthcare Record
WTAIL	Welsh Transplantation & Immunogenetics Laboratory
BECS	Blood Establishment Computer System
WNCR	Welsh Nursing Care Record
NWSSP	NHS Wales Shared Services Partnership
HTW	Health Technology Wales
ESR	Electronic Staff Record

# Velindre University NHS Trust

## Accountability Report

### 2021-2022



---

# CONTENT

---

Scope of Responsibility .....	3
Scope of the Accountability Report .....	6
Corporate Governance Report .....	7
i. The Directors' Report .....	8
ii. Statement of the Chief Executive's Responsibilities as Accountable Officer of Velindre University NHS Trust .....	22
iii. Statement of Director's Responsibilities in respect of the Accounts.....	23
iv. The Governance Statement .....	24
Financial Accountability Report .....	72
Remuneration & Staff Report .....	78
A Parliamentary Accountability & Audit Report.....	95
Audit Certificate and the Auditor General for Wales Report .....	100

---

## VELINDRE UNIVERSITY NHS TRUST SCOPE OF RESPONSIBILITY

---

Velindre University NHS Trust provides specialist services to the people of Wales. The operational delivery of services is managed through the Velindre Cancer Service and the Welsh Blood Service.

The Velindre Cancer Service delivers specialist cancer services for South East Wales using a hub and spoke model and provides a specialist treatment, teaching, research and development centre for non-surgical oncology. We treat patients with chemotherapy, Systemic Anti-Cancer Treatments (SACTs), radiotherapy and related treatments, together with caring for patients with specialist palliative care needs.

The Welsh Blood Service plays a fundamental role in the delivery of healthcare and covers the whole of Wales. It works to ensure that the donor's gift of blood is transformed into safe and effective blood components, which allow NHS Wales to improve the quality of life and save the lives of many thousands of people in Wales every year. We provide an antenatal screening service to several hospitals and offer all customer hospitals specialist laboratory services to assist in the investigation of complex serological problems. The Welsh Transplantation and Immunogenetics Laboratory, within the Welsh Blood Service, provides direct support to local providers of Renal and Stem Cell Transplant Services. It also operates a national panel of unrelated potential blood and stem cell donors – the Welsh Bone Marrow Donor Registry.

Velindre University NHS Trust Board is accountable for Governance, Risk Management, and Internal Control for those services directly managed, and those managed via hosting arrangements. As Accountable Officer, the Chief Executive has responsibility for maintaining appropriate governance structures and procedures as well as a sound system of internal control that supports the achievement of the organisation's policies, aims and objectives, whilst safeguarding the public funds and the organisation's assets for which the Chief Executive is personally responsible. These are carried out in accordance with the responsibilities assigned by the Accounting Officer of NHS Wales.

Velindre University NHS Trust Annual Report outlines the different ways the organisation has had to work both internally and with partners in response to the unprecedented pressure in planning and providing services against the backdrop of the ongoing pandemic. It explains arrangements for ensuring standards of governance are maintained, risks are identified and assurance has been sought and provided. Where necessary additional information is provided in the sections of the Governance Statement, however the intention has been to reduce duplication where possible. It is therefore necessary to review other sections in the Velindre University NHS Trust wider Annual Report alongside this Governance Statement.

Throughout 2021-2022, Velindre University NHS Trust and NHS Wales has continued to face unprecedented and increasing pressure in planning and providing services to meet the needs of those who are affected by COVID-19, details of the impact on delivery of services is provided in the Velindre University NHS Trust Annual Performance Report for the reporting period.

The required response has meant the whole organisation has had to work very differently both internally and with our staff, partners and stakeholders and it has been necessary to revise the way the governance and operational framework is discharged. In recognition of this, at the outset of the pandemic, Dr. Andrew Goodall, the then Director General Health and Social Services/NHS Wales Chief Executive, wrote to all NHS Chief Executives in Wales, with regard to “COVID-19 Decision Making and Financial Guidance”. The letter recognised that organisations would be likely to make potentially difficult decisions at pace and without a firm evidence base or the support of key individuals, which under normal operating circumstances would be available. Nevertheless, it set out a clear expectation of how the organisation is still required to demonstrate that decision-making has been efficient and will stand the test of scrutiny with respect to compliance with Managing Welsh Public Money, demonstrating Value for Money after the COVID-19 crisis has abated, and the organisation returns to more normal operating conditions.

To demonstrate this, Velindre University NHS Trust is recording how the effects of COVID-19 have impacted on any changes to normal decision making processes. Where relevant these, and other actions taken have been explained within this Governance Statement.

During the reporting period 2021-2022, Velindre University NHS Trust also hosted two organisations, which are explained in more detail below. Directors of the Hosted Organisations are bound by a Governance Compliance Statement (or their own Governance Statement in the case of NHS Wales Shared Services Partnership) with the Velindre University NHS Trust Chief Executive and in accordance with the individual hosting agreements with Velindre University NHS Trust. Organisations hosted by Velindre University NHS Trust are:

---

## **NHS WALES SHARED SERVICES PARTNERSHIP (NWSSP)**

---

On 11 May 2012, the Velindre National Health Service Trust Shared Services Committee (Wales) Regulations 2012 No.1261 (W.156) was laid before the National Assembly for Wales and came into force on 1 June 2012. The NWSSP is a dedicated organisation that supports the statutory bodies of NHS Wales through the provision of a comprehensive range of high quality, customer focused support functions and services.

NWSSP is hosted by Velindre University NHS Trust via a formal Hosting Agreement, signed by each statutory organisation in NHS Wales. The Director of NWSSP holds

Accountable Officer status and holds a separate Accountability Statement with the Director General for Health in the Welsh Government. The Director of NWSSP produces and signs his own Governance Statement to support the Trust Chief Executive in signing the Velindre University NHS Trust Governance Statement.

---

## **HEALTH TECHNOLOGY WALES (HTW)**

---

Velindre University NHS Trust received grant funding to continue the operation of Health Technology Wales. HTW is funded by Welsh Government under the Efficiency through Technology Programme. HTW was established to facilitate the timely adoption of clinically and cost effective health technologies in Wales, working with, but independently of, NHS Wales. Its remit covers all health technologies that are not medicines. This could be medical devices, surgical procedures, telemonitoring, psychological therapies, rehabilitation or any health intervention that is not a medicine.

HTW independently critically assesses the best available international evidence about the clinical and cost effectiveness of a health technology. This evidence is reviewed by experts and the HTW Appraisal Panel to put the evidence into the Welsh context. HTW also coordinates a Front Door process to support health technology developers to navigate NHS Wales. As well as its Front Door and appraisal functions, HTW also has roles in horizon scanning, evaluating uptake and disinvestment of technologies and providing advice to health technology developers. It does this in partnership with other organisations in NHS Wales to ensure there is no duplication of work and sharing of limited skilled assessment resources. The Director signs a Governance Compliance Statement to support the Trust Chief Executive in signing the Velindre University NHS Trust Governance Statement.

---

## **SCOPE OF THE ACCOUNTABILITY REPORT**

---

In line with Welsh Government and HM Treasury Guidance, Velindre University NHS Trust has produced an Accountability Report for the financial reporting period 2021 - 2022.

The purpose of the Accountability Report, which sits within the suite of Velindre University NHS Trust Annual Report documents, is to report to the Welsh Government in respect of the key accountability requirements.

The Accountability Report will be signed and dated by the Velindre University NHS Trust's Accountable Officer - Chief Executive, and is made up of the following four sections:

- I. Corporate Governance Report
- II. Financial Accountability Report
- III. Remuneration and Staff Report
- IV. Parliamentary Accountability and Audit Report



---

## CORPORATE GOVERNANCE REPORT

---

The purpose of the Corporate Governance Report is to explain the composition of Velindre University NHS Trust and its governance structures and how these support the achievement of the Trust's objectives.

The Corporate Governance Report includes the following sub sections:

- Director's Report
- The Statement of Accountable Officers' Responsibilities
- The Statement of Directors' Responsibilities in Respect of the Accounts
- The Governance Statement

---

## DIRECTORS' REPORT

---

This Directors' report brings together information about the Velindre University NHS Trust Board including the Independent Members and Executive Directors, the composition of the Trust Board and other elements of its governance and risk management structure. It also includes the disclosures and reporting required by Velindre University NHS Trust relating to the day-to-day execution of the Trust's business.

Velindre University NHS Trust Board is made up of Executive Directors, who are employees of the Trust, and Independent Trust Board Members (IMs), who were appointed to the Trust Board by the Minister via an open and competitive public appointment process. The Board's main role is to add value to the organisation through the exercise of strong leadership and control, including: setting the organisation's strategic direction; establishing and upholding the organisation's governance and accountability framework, including its values and standards of behaviour, and ensuring delivery of the organisation's aims and objectives through effective challenge and scrutiny of the Trust's performance across all areas of activity.

---

### CHAIR & INDEPENDENT MEMBERS OF THE TRUST 2021-2022

---



#### **Professor Donna Mead, OBE, Chair**

##### **Appointment:**

Professor Mead was appointed Chair of Velindre University NHS Trust in May 2018.

##### **Areas of Expertise:**

Higher Education, Research, the NHS and Education, Partnerships and Collaboration.

##### **Trust Board Committee Membership**

Professor Mead Chairs the Trust Board, Remuneration Committee, Advisory Consultant Appointment Committee, Charitable Funds Committee, Academic Partnership Board and the Advancing Radiotherapy Committee. Professor Mead is also a member of the Quality, Safety & Performance Committee, Strategic Development Committee and Research, Development & Innovation Sub-Committee

##### **Champion Role:**

Trust Champion for Armed Forces and Veterans, University Trust.

Professor Mead is supported by six other Independent Members.



**Mr. Stephen Harries, Interim vice Chair and Independent Member**

**Appointment:**

Mr. Harries was appointed as an Independent Member of Velindre University NHS Trust in April 2017. In November 2018, Mr. Harries was appointed as Interim vice Chair of the Trust.

**Areas of Expertise:**

Information Governance, Information Management and Technology.

**Trust Board Committee Membership**

Mr. Harries is Chair of the Strategic Development Committee and Transforming Cancer Services Programme Scrutiny Sub-Committee. He is also a member of the Remuneration Committee and the Quality, Safety & Performance Committee.

**Champion Role:**

Trust Champion for Digital, Mental Health and Equality.



**Professor Donald Fraser, Independent Member**

**Appointment:**

Professor Fraser was appointed as an Independent Member of Velindre University NHS Trust in December 2019. Professor Fraser's appointment with the Trust ended on the 3<sup>rd</sup> September 2021.

**Area of Expertise:**

University Representative.

**Trust Board Committee Membership**

During his tenure Professor Fraser was a member of the Research, Development & Innovation Sub-Committee, Strategic Development Committee, and the Academic Partnership Board.

**Champion Role:**

Professor Fraser was the Trust Champion for Research, Development & Innovation.



**Professor Andrew Westwell,  
Independent Member**

**Appointment:**

Professor Westwell was appointed as an Independent Member of Velindre University NHS Trust in August 2021.

**Area of Expertise:**

University Representative.

**Trust Board Committee Membership**

Professor Westwell is Chair of the Research, Development & Innovation Sub-Committee, and is also a member of the Strategic Development Committee, the Advancing Radiotherapy Fund Programme Board and the Academic Partnership Board.

**Champion Role:**

Trust Champion for Research, Development & Innovation.



**Mrs. Janet Pickles, Independent Member**

**Appointment:**

Mrs. Pickles was appointed as an Independent Member of Velindre University NHS Trust in October 2012. Mrs. Pickle's term came to an end with the Trust on the 30<sup>th</sup> September 2021.

**Area of Expertise:**

Quality & Safety.

**Trust Board Committee Membership**

Mrs. Pickles Chaired the Quality, Safety & Performance Committee and was a member of the Audit Committee, Charitable Funds Committee and the Advancing Radiotherapy Board.

**Champion Role:**

Mrs. Pickles was the Trust Champion for Infection, Prevention & Control, and Vulnerabilities: Older People, Children & Young People and Violence & Aggression.



**Mrs. Vicky Morris, Independent Member**

**Appointment:**

Mrs. Morris was appointed as an Independent Member of Velindre University NHS Trust in November 2021.

**Area of Expertise:**

Quality & Safety.

**Trust Board Committee Membership**

Mrs. Morris Chairs the Quality, Safety & Performance Committee and is a member of the Trust Audit Committee, NWSSP Audit Committee and the Trust Research, Development & Innovation Sub-Committee.

**Champion Role:**

Trust Champion for Infection Prevention, Vulnerability and Violence & Aggression.



**Mrs. Hilary Jones, Independent Member**

**Appointment:**

Mrs. Hilary Jones was appointed as an Independent Member of Velindre University NHS Trust in March 2020.

**Area of Expertise:**

Estates & Planning.

**Trust Board Committee Membership**

Mrs. Jones is a member of the Quality, Safety & Performance Committee, Charitable Funds Committee, Investment Performance Review Sub-Committee, Advancing Radiotherapy Fund Programme Board and Transforming Cancer Services Programme Scrutiny Sub-Committee.

**Champion Role:**

Trust Champion for Patient Engagement & Experience, Sustainable Development and Design.



**Mr. Gareth Jones, Independent Member**

**Appointment:**

Mr. Jones was appointed as an Independent Member of the Velindre University NHS Trust in December 2019.

**Area of Expertise:**

Legal.

**Trust Board Committee Membership**

Mr. Jones is a member of the Strategic Development Committee, Trust Audit Committee, Transforming Cancer Services Programme Scrutiny Sub-Committee and the NWSSP Audit Committee.

**Champion Role:**

Trust Champion for Patient Information and Welsh Language.



**Mr. Martin Veale, JP, Independent Member**

**Appointment:**

Mr. Veale was appointed as an Independent Member of the Velindre University NHS Trust in April 2017.

**Area of Expertise:**

Finance, Audit & Governance.

**Trust Board Committee Membership**

Mr. Veale is Chair of the Trust Audit Committee, NWSSP Audit Committee and the Investment Performance Review Sub-Committee.

Mr. Veale is also a member of the Remuneration Committee and the Charitable Funds Committee.

**Champion Role:**

Trust Champion for Hosted Organisations and Performance Framework.

---

## EXECUTIVE DIRECTORS (BOARD MEMBERS)

---



**Mr. Steve Ham, Chief Executive  
Accountable Officer**

**Trust Board Committee Membership**

Mr. Ham is a member of the Charitable Funds Committee and attends the Quality, Safety and Performance Committee, Strategic Development Committee, Local Partnership Forum, Remuneration Committee and Advisory Consultant Appointments Committee.



**Dr. Jacinta Abraham, Executive Medical Director**

**Trust Board Committee Membership**

Dr. Abraham attends the Quality, Safety and Performance Committee, Strategic Development Committee, Research, Development & Innovation Sub-Committee and Advisory Consultant Appointments Committee.

**Lead Function:** Medical Director and Research



**Mrs. Nicola Williams, Executive Director of  
Nursing, Allied Health Professionals and  
Health Science**

**Trust Board Committee Membership**

Mrs. Williams attends the Quality, Safety and Performance Committee, Strategic Development Committee and Research, Development & Innovation Sub-Committee.

**Lead Function:** Quality, Safety and Nursing.



**Ms. Sarah Morley, Executive Director of Organisational Development & Workforce**

**Trust Board Committee Membership**

Ms. Morley is Joint Chair of the Local Partnership Forum and attends the Strategic Development Committee and the Quality, Safety & Performance Committee.

**Lead Function:** Organisational Development & Workforce



**Mr. Mark Osland, Executive Director of Finance**

Mr. Osland was appointed as Executive Director of Finance for Velindre University NHS Trust on the 5<sup>th</sup> January 2015 to the 30<sup>th</sup> September 2021.

**Trust Board Committee Membership**

Mr. Osland was a member of the Charitable Funds Committee and attended the Investment Performance Review Sub-Committee, Strategic Development Committee, Quality, Safety & Performance Committee, Audit Committee (Trust), Audit Committee (NWSSP) and the Local Partnership Forum.



**Mr. Matthew Bunce, Executive Director of Finance**

Mr. Matthew Bunce was appointed as Executive Director of Finance for Velindre University NHS Trust on the 27<sup>th</sup> September 2021.

**Trust Board Committee Membership**

Mr. Bunce is a member of the Charitable Funds Committee and attends the Investment Performance Review Sub-Committee, Strategic Development Committee, Quality, Safety & Performance Committee, Audit Committee (Trust), Audit Committee (NWSSP) and the Local Partnership Forum.

**Lead Function:** Finance and Charitable Funds.



---

## EXECUTIVE TEAM MEMBERS (NON-BOARD MEMBERS)

---



**Mr. Carl James,  
Director of Strategic Transformation, Planning,  
& Digital**

Responsible for strategic developments and planning and the continuous improvement of performance on behalf of the Trust.

**Lead Function:** Strategic Transformation, Planning, Digital & Estates.



**Mrs. Lauren Fear,  
Director of Corporate Governance & Chief of  
Staff**

Principal advisor to the Trust Board and the organisation as a whole on all aspects of governance and ensuring that the Trust meets the standards of good governance set for the NHS in Wales.

Mrs. Fear commenced a fixed term position with the Trust in December 2019 and was appointed on a permanent basis in September 2020.

**Lead Function:** Governance.



**Mrs. Cath O'Brien, Chief Operating Officer**

Mrs. O'Brien was appointed as Interim Chief Operating Officer for the Trust in March 2019 and was appointed on a permanent basis in November 2021. Prior to that, Mrs. O'Brien was the Director of the Welsh Blood Service.



**Mr. Alan Prosser, Director – Welsh Blood Service**

Mr. Prosser was appointed as Interim Director for the Welsh Blood Service in March 2019 and was appointed on a permanent basis in April 2022. Prior to that, Mr. Prosser was the Deputy Director of the Welsh Blood Service. Mr. Prosser is responsible for the operational management of the Service Division.



**Mr. Paul Wilkins, Interim Director – Velindre Cancer Service**

Mr. Paul Wilkins was appointed as Interim Director of the Velindre Cancer Service in November 2019. As Interim Director of Velindre Cancer Service, Mr. Wilkins is responsible for the operational management of the Service Division.

Further information in respect of the Trust Board, a Review of its Effectiveness, Committee Activity, the System of Internal Control and the Trust Assurance Framework are captured in the Governance Statement section of this report, which starts on page 24 and **Appendix 1** on page 60.

---

## PUBLIC INTEREST DECLARATION

---

Each Velindre University NHS Trust Board Member has stated in writing that they have taken all the steps that they ought to have taken as a Director in order to make the Trust's auditors aware of any relevant audit information.

All Trust Board Members and Senior Managers within the Trust (including Directors of all Hosted Organisations) have declared any interests in companies, which may result in a conflict with their managerial responsibilities. No material interests have been declared during 2021-2022: a full register of interests for 2021-2022 is available upon request from the Director of Corporate Governance & Chief of Staff.

---

## DISCLOSURE STATEMENTS

---

### **Information Governance:**

The Trust operates an Information Governance (IG) Framework that ensures the Trust meets its Mandatory and Statutory obligations and other standards in relation to applicable legislation. Applicable legislation includes but is not exclusive to legislation which supports the principles of the Human Rights Act 1998, the Data Protection Act 2018 (includes the retained EU General Data Protection Regulations 679/2016 (UK GDPR)), Freedom of information Act 2000, Environmental Information Regulations 2004, Common Law Duty of Confidence and the Access to Medical Records Act 1990. This legislation is supported by non-legislative guidance such as; Caldicott Principles and the Records Management Code of Practice for Health and Social Care 2022 which is in itself based on the Freedom of Information Act's Section 46 Information Management Code of Practice.

The Trust's Executive Director of Finance is the designated Senior Information Risk Owner (SIRO) who holds responsibility for information risk to the Trust Board. As an NHS Body, the Trust has in place a Caldicott Guardian, which is the Trust Executive Medical Director. The two main divisions of the Trust also have a Caldicott Guardian in place. The lead for Information Governance for the Trust is the Head of Information Governance (HoIG), the post of Head of Information Governance was vacant between June 2021 and December 2021 which has increased the risk to the Trust overall within the reporting period, it is assessed that this risk will reduce for Financial Year 2022/23 with the new incumbent in post.

The role of the Head of Information Governance is to ensure that there are effective controls and mechanisms in place to ensure that the Trust complies with its Mandatory and Statutory obligations as well as supporting staff ability via the delivery of Training and Awareness to comply with Information Governance fundamental principles and procedures.

The Trust utilises the Welsh Information Governance Toolkit (IG Toolkit) to measure its level of

compliance against national IG standards and legislation. The toolkit is completed annually and provides evidence of areas of improvement achieved and identifies actions for the following year. Due to the departure of the previous HoIG in June 2021, the action plan for 2021/22 was not realised. The HoIG is undertaking the annual completion of this to identify previous areas for improvement and provide background information. The priority areas for improvement will form the basis of the IG work plan for 2022/23.

The Trust processes personal data using the “Privacy by Design” approach when procuring new systems and maintaining existing ones where personal data is processed. “Privacy by Design” enables the Trust to consider risk by using the Information Commission Office mandated Data Protection Impact Assessment process. The process helps analyse, identify and minimise the data protection risks of a system (both electronic and manual records). Article 35 of the UK GDPR states that Data Protection Impact Assessments (DPIA) are a legal requirement for processing data that is likely to result in high risk to the rights and freedoms of individuals. The ICO advises that the completion of a Data protection Impact Assessment is good practice when processing personal data. A Data Protection Impact Assessment does not have to eradicate all risk but should help to minimise and determine whether the level of risk is acceptable in the circumstances. Under UK GDPR, failure to carry out a Data Protection Impact Assessment when required may leave the Trust open to enforcement notice where the Information Commissioners Office will tell the Trust that it MUST carry out an action and if it does not, the Information Commissioners Office may impose a financial penalty at the higher rate of up to 20 million Euros (£16.52m) or 4% of annual turnover, whichever is the highest. In the period 1 April 2021 – 31 March 2022, 5 Data Protection Impact Assessments were approved with another 14 in progress.

The public have the right to request information held by the trust under the Subject Access Process in relation to the Freedom of Information Act 2000 (FOIA) and Environmental Information Regulations 2004 (EIR). In the period 1 April 2021 – 31 March 2022, the Trust received 141 requests for information under the Freedom of Information Act/Environmental Information Regulations. 140 were processed under FOIA, 1 request was processed under EIR, 56 requests breached the 20-working day mandatory response timeframe. The Trust undertook 3 reviews requested by members of the public, 1 of which overturned the original decision to withhold information, the other 2 were acknowledged and apologised for a time limit breach.

The Trust received 3 notices from the Information Commissioner’s Office to produce information under FOIA as requested by members of the public, all notices were enacted within the mandatory response timeframe. In relation to Subject Access Requests made under the Data Protection Act 2018, the Trust received 223 requests of which there are no recorded breaches of the one month statutory deadline.

During 2021/22 the Trust reported 4 personal data breach incidents to the Information Commissioners Office. All notifications were submitted within the 72 hour breach reporting timeframe.

**Reported May 2021** – An individual received clinical correspondence which was not authorized to be sent to the private address of an Occupational Health Advisor. The correspondence included the patient’s demographic data, NHS Number, diagnosis, CT scans and pathology reports and employment status. The Information Commissioners Office was contacted on 11 May 2021 via a formal breach report. A Root Cause Analysis investigation was undertaken within the Trust. The result of the investigation was that medical secretarial teams were reminded that they were not to use private residential address details for Occupational Health Advisors when transmitting patient information as part of the service. The information was returned safely to the Velindre Cancer Service. Welsh Government were notified via the “early warning” process. The patient was informed via a telephone call on 18th May 2021 with written notification sent on 24th May 2021.

**Reported December 2021** – Complaint by protestors against the build for the new Velindre Cancer Hospital that the Trust breached Data Protection legislation by sharing video of individuals (including one individual reported to be under the age of 18) by Trust officers on social media. In addition, a complaint was made that a legal document was shared inappropriately by Trust Officers. Immediate investigation found that the Trust had not shared any data externally on social media, that the data was taken and shared by a member of the public. In relation to the sharing of the legal document, it related to a legal document served on a protestor which was abandoned by the protestor. The investigation found that all data in relation to the complaint was processed and shared lawfully internally in relation to ongoing legal activity in relation to the protests. Reported to the ICO as a precaution on 16 December 2021. The ICO found that the Trust had not breached Data Protection legislation and processed data lawfully with no further action required.

**Reported December 2021** – A second complaint was received by protestors against the build of the new Velindre Cancer Hospital that the Trust breached Data Protection legislation by sharing video of individuals recorded by Trust officers on social media. Immediate investigation found that the Trust had not shared any data externally on social media, that the data was taken and shared by a member of the public. It found that all data recorded was processed and shared lawfully internally in relation to ongoing legal activity in relation to the protests. Reported to the Information Commission Office as a precaution on 16 December 2021. The Information Commission Office found that the Trust had not breached Data Protection legislation and processed data lawfully with no further action required.

**Reported February 2022** – A Data Processor under contract to the Trust reported severe damage to a document storage site in which documentation was assessed by the Processor as completely destroyed. Reported to the Information Commission Office on 24th February 2022. The incident remains ongoing and is subject to review by the Trust Board, Quality, Safety and Performance Committee and Executive Management Board. The Information Commission Office is being kept informed as to the progress of the investigation at the time of writing.

In addition to quarterly reporting to the Executive Management Board and Quality, Safety and Performance Committee, an Annual Information Governance Report is produced which

provides an overview of the previous year's activity to the Board thereby providing assurance that the Trust is meeting its Mandatory and Statutory responsibilities in relation to Information Governance.

### **Corporate Governance Code for Central Government Departments:**

Whilst there is no requirement to comply with all elements of the Corporate Governance Code for Central Government Departments, Velindre University NHS Trust has undertaken an assessment against the main principles as they relate to an NHS public sector organisation in Wales. This assessment has been informed by the Trust's assessment of governance undertaken by the Trust Board in April 2022 (outlined on Page 49 of this report) and also evidenced by internal and external audits. The Trust Board is committed to the continuous review and pursuit of excellence in ensuring good governance. This includes the programme of work underway to review and strengthen the quality/detail of information provided to the Board for assurance.

The Trust is complying with the main principles of the Code where applicable, and follows the spirit of the Code to good effect and is conducting its business openly and in a transparent manner in line with the Code. The Trust Board recognises that not all reporting elements of the Code are outlined in this Governance Statement but are reported more fully in the Trust wider Annual Report. There have been no reported/identified departures from the Corporate Governance Code during the year.

### **Sustainability:**

Our Trust Strategy 'Destination 2032' outlines a clear ambition for the organisation over the coming years; the delivery of high quality, sustainable health care services which reduce our impact on the environment and provides wider value to our communities. This is an exciting challenge for us which will require us to continue to pursue excellence in our clinical services whilst also making a contribution to the wealth, health and prosperity across the country. Our Sustainability Strategy has created a roadmap for us to contribute to our communities and mitigate our impact on the planet whilst continuing to deliver world class services for our donors, patients and carers. These are driven by the United Nations Sustainable Development Goals and the Well-Being of Future Generations Act and are designed to achieve our Trust Well-being Objectives.

The Trust recognises that its day to day operational activities have a direct impact upon the environment and is committed to meeting the legislative drivers set out by Welsh Government. Welsh Government have an ambition for the public sector to be carbon neutral by 2030. This ambition sits alongside the Environment (Wales) Act 2016 and Wellbeing of Future Generations (Wales) Act 2015 as legislative drivers for decarbonisation of the Public Sector in Wales. Aligned with the NHS Wales Decarbonisation Strategy, the Trust has created tangible actions to achieve carbon neutrality. Alongside our major capital infrastructure schemes: new Velindre Cancer Hospital, Radiotherapy Satellite Centre and Talbot Green Infrastructure upgrade, we are actively educating our staff to instigate meaningful behavioural change. The Trust will continue its work on carbon footprint monitoring in line with the recommendations of the NHS Wales Carbon Footprint document. In particular, it will review CO2 emissions arising

from the use of electricity consumption (Scope 2), and those emissions associated with the use of Fleet vehicles (Scope 3).

### **NHS Pension Scheme:**

As an employer with staff entitled to membership of the NHS Pension Scheme, control measures are in place to ensure all employer obligations contained within the Scheme regulations are complied with. This includes ensuring that deductions from salary, employer's contributions and payments in to the Scheme are in accordance with the Scheme rules, and that member Pension Scheme records are accurately updated in accordance with the timescales detailed in the Regulations.

---

## **MINISTERIAL DIRECTIONS**

---

A list of Ministerial Directions issued by the Welsh Government during 2021-2022 is available at: <https://gov.wales/publications>. Whilst Ministerial Directions are received by Local Health Boards, these are not always applicable to Velindre University NHS Trust. Those considered of relevance to the Trust are listed below:

- **Ministerial Direction regarding the NHS Pension Tax Proposal 2019-2020**

The Trust has disseminated this direction as appropriate and reported it to the Trust Remuneration Committee.

All Ministerial Directions issued throughout the year are listed on the Welsh Government website above.

Welsh Health Circulars issued by Welsh Government are logged by the Corporate Governance Function and assigned an Executive Lead(s) to assess the impact to the Trust and take forward any necessary actions as appropriate. A register and action log is maintained by the Corporate Governance Function. A list of Welsh Health Circulars issued by the Welsh Government during 2021-2022 considered of relevance to the Trust are listed in **Appendix 3**.

---

**STATEMENT OF THE CHIEF EXECUTIVE'S  
RESPONSIBILITIES AS ACCOUNTABLE OFFICER  
OF  
VELINDRE UNIVERSITY NHS TRUST**

---

The Welsh Ministers have directed that the Chief Executive should be the Accountable Officer to the Velindre University NHS Trust.

The relevant responsibilities of Accountable Officers, including their responsibility for the propriety and regularity of the public finances for which they are answerable and for the keeping of proper records, are set out in the Accountable Officer's Memorandum issued by the Welsh Government.

The Accountable Officer is required to confirm that, as far as he or she is aware, there is no relevant audit information of which the entity's auditors are unaware and the Accountable Officer has taken all the steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the entity's auditors are aware of that information.

The Accountable Officer is required to confirm that the Annual Report and Accounts as a whole is fair, balanced and understandable and that they take personal responsibility for the Annual Report and Accounts and the judgments required for determining that it is fair, balanced and understandable.

To the best of my knowledge and belief, I have properly discharged the responsibilities set out in my letter of appointment as an Accountable Officer.

Signed by:



Mr. Steve Ham  
Chief Executive

Dated: 14/06/2022



---

## STATEMENT OF DIRECTORS' RESPONSIBILITIES IN RESPECT OF THE ACCOUNTS

---

The directors are required under the National Health Service Act (Wales) 2006 to prepare accounts for each financial year. The Welsh Ministers, with the approval of the Treasury, direct that these accounts give a true and fair view of the state of affairs of the NHS Trust and of the income and expenditure of the NHS Trust for that period.

In preparing those accounts, the directors are required to:

- Apply on a consistent basis accounting principles laid down by the Welsh Ministers with the approval of the Treasury.
- Make judgments and estimates which are responsible and prudent.
- State whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the account.

The directors confirm that they have complied with the above requirements in preparing the accounts.

The directors are responsible for keeping proper accounting records, which disclose with reasonable accuracy at any time the financial position of the Trust and to enable them to ensure that the accounts comply with the requirements outlined in the above mentioned direction by the Welsh Ministers.

### By Order of the Board

#### Signed:



Professor Donna Mead OBE  
Chair

Dated: 14/06/2022



Mr. Steve Ham,  
Chief Executive

Dated: 14/06/2022



Mr. Matthew Bunce,  
Executive Director of Finance

Dated: 14/06/2022

---

## GOVERNANCE STATEMENT

---

---

### GOVERNANCE AND ACCOUNTABILITY FRAMEWORK

---

This Governance Statement details the arrangements in place for discharging the Chief Executive's responsibility to manage and control Velindre University NHS Trust's resources, and the organisations, which it hosts, during the financial year 2021-2022.

Due to the unique Accountable Officer status of the Managing Director of Shared Services Partnership (NWSSP), a Governance Statement for NWSSP has been requested and submitted by the Director of NWSSP to the Trust Chief Executive. This is available from the Director of Corporate Governance & Chief of Staff upon request and helps to inform this report.

The Director of Health Technology Wales (the Trust second hosted body), has also signed and submitted a '*Governance Compliance Statement*', detailing and declaring compliance with Velindre University NHS Trust governance arrangements. This has been submitted to the Velindre University NHS Trust's Chief Executive to provide assurance that Trust policy, systems and processes are being complied with to support good governance.

---

### DISCHARGING RESPONSIBILITIES

---

The Trust Board has been constituted to comply with the National Health Service Wales, Velindre University NHS Trust (Establishment) Order 1993 No.2838 and subsequent Amendment Orders (1995 No. 2492, 1999 No.808, 1999 No 826, 2002 No.442 (W.57) and 2002 No.2199 (W.219 2009 No.2059, 2012 No.1261, 2012 No.1262, 2015 No.22, 2017 No.912, 2018 No.887). In addition to responsibilities and accountabilities set out in terms and conditions of appointment, Trust Board members also fulfil a number of "champion" roles where they act as ambassadors for these matters (detailed on pages 8-12).

The Trust Board discharges its responsibilities through its Committees (listed in the table below) and scheme of delegation, which is set out in its Standing Orders.

There are nine Committees/Partnership Forums reporting directly to the Trust Board, which is supported by sub-Committees/groups in the discharge of functions outlined below:

Committee	Sub Committee
Academic Partnership Board	N/A
Advisory Consultant Appointments Committee	N/A
Audit Committee (Trust)	N/A
Audit Committee (For Shared Services to consider NHS Wales Shared Services Partnership) [NWSSP] Matters)	N/A
Charitable Funds Committee	Investment Performance Review Sub-Committee
Quality, Safety & Performance Committee	<ul style="list-style-type: none"> <li>• Research, Development and Innovation Sub-Committee (for Research &amp; Development activity)</li> <li>• Transforming Cancer Services Programme Scrutiny Sub-Committee (for programme delivery)</li> </ul>
Local Partnership Forum	N/A
Remuneration Committee	N/A
Strategic Development Committee	<ul style="list-style-type: none"> <li>• Research, Development and Innovation Sub-Committee (for Strategic / Innovation activity)</li> <li>• Transforming Cancer Services Programme Scrutiny Sub-Committee (for future direction setting)</li> </ul>

At a local level, the Trust Board has agreed Standing Orders (SOs) for the regulation of proceedings and business.

The *Trust Standing Orders and Standing Financial Instructions* have been adopted from the Welsh Government's Model Standing Orders for NHS Trusts in Wales and are designed to translate the statutory requirements set out in the *National Health Service Trusts (Membership and Procedures) Regulations 1990 (1990/2024)* into day to day operating practice. Together with the adoption of a scheme of matters reserved to the Trust Board; a scheme of delegations to officers and others; and Standing Financial Instructions, the SOs provide the regulatory framework for the business conduct of the Trust and define its 'ways of working'.

These documents, together with the range of policies set by the Trust Board make up the Governance and Accountability Framework. The Standing Orders have been periodically updated to account for alterations in year; details in respect of the reviews are outlined on page 32.

The dates the Trust Board and Committees met during the period 2021-2022 are captured in **Appendix 1** on page 60.

Since the onset of the pandemic, the Trust has continually adapted and made changes to its governance arrangements to meet the challenges faced by COVID 19. The required response has meant that the whole organisation has had to work very differently both internally and with our staff, partners and stakeholders and it has been necessary to revise the way the Board governance and operational framework is discharged.

It is acknowledged that in these unprecedented times, there are limitations on Boards and Committees being able to physically meet where this is not necessary and can be achieved by other means. In accordance with the Public Bodies (Admission to Meetings) Act 1960, the organisation is required to meet in public. As a result of the public health risk linked to the pandemic there have been limitations on public gatherings and has not therefore been possible to allow the public to attend meetings of our Board and Committees since the 24 March 2020. Whilst this is not strictly in compliance with our Standing Orders with regards to allowing the public to attend meetings of our Board and Committees meetings, since that time, to ensure that the Trust's business has continued to be conducted in as open and transparent a manner as possible, the following actions have been taken and remain in place:

- The Trust is inviting all regular attendees to its Public Board and Committees via technological solutions.
- The meetings are closed session i.e. public are not invited to join the meetings in person. This has allowed the Trust to act in accordance with the social distancing guidelines. From July 2020, the Trust has held its virtual Trust Board meeting in public. The public are able to observe the meeting from the widely available video conferencing platform Zoom. A video recording of the meetings is also made available on the Trust website. From March 2021, our Trust Board meetings are

being held in person for Board members and members of the public continue to be able to observe the meeting via the video conferencing platform Zoom. Our Committee meetings will continue to be held virtually for the time being.

- Papers are published in advance of the Trust Board and Committee meetings and the minutes following their formal approval to be an accurate and true record at the subsequent meeting.

At the beginning of Wave #4 of the pandemic, to ensure a combined and coordinated response to the emergence and prevalence of the Omicron variant the Velindre University NHS Trust re-activated its agreed dedicated incident Command and Control structure on the 15/12/2021. The structure provides a formal escalation and de-escalation path and is consistent with the nationally recognised three tiered Command and Control structure. This has included a strengthened clinical support infrastructure, ensuring effective agile decision making with robust clinical oversight, placing clinicians (Medical, Nursing, AHP's, & Health / Clinical Scientists) firmly at the centre of risk based decision making. All decisions have been formally recorded via decision logs in line with the agreed principles for the operation of the Command and Control structure.

The frequency of GOLD COMMAND meetings has been continually assessed and flexed in line with the needs of the incident and its interface with the Welsh Blood Service and Velindre Cancer Service SILVER COMMANDs.

In parallel, the Board agreed revised temporary arrangements which included, streamlining Board Committee agendas utilising a risk based approach to focus key reporting activity and enable all Board Committees to remain operational. As in previous waves, a recovery plan was developed alongside this with two principal aims, namely:

- I. To ensure we continue to manage and oversee those areas and actions that we needed to.
- II. Structured way of cataloguing everything else that was placed in the "Recovery Log," so that this could all be tracked and then re-started in a planned and controlled way.

The Trust Board were sent an email on the 20/12/2021 via Chairs Urgent Action (the route provided for within the Trust Standing Orders), inviting the Board to **APPROVE**:

- I. Re-instatement of the £5m temporary delegated authority limit for COVID-related expenditure for the Chair and Managing Director of NWSSP to the end of June 2022.
- II. Re-establishment of the NWSSP Finance Governance Group noting that the associated Terms of Reference be updated to reflect the recent appointment of Matthew Bunce as the new Executive Director of Finance, replacing Mark Osland following his retirement.
- III. The Trust Interim Vice-Chair, Stephen Harries reassume his role on the NWSSP Financial Governance Group to support Trust oversight and scrutiny of NWSSP procurement requests in response to COVID 19 Personal Protective Equipment

requirements. Due to the role proposed to be reassumed by the Interim Vice-Chair on this group, it should be noted that the Interim Vice-Chair abstained from this approval request.

Due to the urgency of this matter, it could not wait until the January 2022 Trust Board meeting. This was subsequently **APPROVED** with no objections to approval received and formally **RATIFIED** at the January 2022 Trust Board meeting.

An Extra-ordinary Private meeting of the Trust Board was held on the 07/01/2022 for the Trust Board to **APPROVE** an updated 'Velindre Cancer Service Clinical Framework for Defining the Clinical Model and Treatment Decision Making' to respond to the Wave #4 of the pandemic, with the core principles remaining unchanged from the previous three iterations, and optimising the learning and development that has been applied over the past two year period. This was formally **NOTED** and received at the Public January 2022 Trust Board meeting.

In January 2022, fortnightly Trust Board briefings on COVID-19 were also re-instigated and due to the critical role of the Quality, Safety & Performance Committee during the public health emergency, the meeting frequency was increased from bi-monthly to monthly until March 2022, when the incidence and prevalence of the Omicron variant in the community had reduced.

---

## COMMITTEE ACTIVITY

---

In line with the Trust's Standing Orders, each Committee formally reports annually to the Trust Board on its work during the year detailing the business, activities, attendance and main issues dealt with by the Committee in the reporting year. Copies of the Committee Annual Reports for 2021-2022, which outline the activity of each of the Committees for the year ending 31 March 2022, are available on the Trust Internet site [here](#). In addition, each Trust Board meeting receives a highlight report outlining the issues and activity considered and addressed by each Committee at its last meeting. The Trust has a process where Committees schedule a pause at the end of each meeting to discuss the key issues they want to raise with the Trust Board through the highlight report process under the following headings:

<b>ALERT / ESCALATE</b>
<b>ADVISE</b>
<b>ASSURE</b>
<b>INFORM</b>
<b>APPENDICES (<i>as required</i>)</b>

Each Committee Highlight Report is presented to the Trust Board by the Committee Chair. Similarly, each Committee Annual Report is available within the Trust Board papers on the Trust's Internet site [here](#).

The Terms of Reference for each Committee are reviewed annually in line with the Trust's Standing Orders, or more frequently if deemed necessary by the Committee or Trust Board. The Terms of Reference for all Committees are available on the Trust's Internet site [here](#).

Key highlights and issues considered by the Trust Board and its Committees during 2021-2022 are included in **Appendix 1** of the Governance Statement on page 60.

Minutes and papers of all Public Trust Board and Committee meetings are also published on the Trust Internet site [here](#).

During 2021-2022, key aspects of Trust Board business and issues delegated to the Audit Committee for consideration and advice, including action taken, included but were not limited to the following:

- Agreement of the Internal and External Audit Plans for the year.
- Receiving Internal and External Audit Reports and subsequently monitoring progress against Audit Action Plans. The Audit Action Plan, which tracks the implementation of the recommendations of Audits is regularly reviewed by the Audit Committee. A review of the existing monitoring and tracking arrangements has been undertaken at the beginning of 2022-2023 to strengthen this process in partnership with Internal Audit.
- Agreeing the Annual Counter Fraud Plan and monitoring counter fraud activities.
- Regular review of the Declaration of Interests and Gifts, Hospitality, Sponsorship and Honoraria Register.
- Monitoring the development of the Trust's Accountability Report.
- Monitoring of Governance Arrangements across the organisation, including hosted bodies.
- Monitoring overall risk management process by reviewing the Trust Risk Register at each meeting.

Further detail in respect of the activity of the Audit Committee during 2021- 2022 is captured in **Appendix 1** on page 60.

---

## BOARD ASSURANCE FRAMEWORK

---

To provide a holistic overview and avoid duplication, please refer to the **Risk Section** on Page 38 of this **Governance Statement** where the **Board Assurance Framework** is fully detailed in the context of the wider Trust Risk Management Framework.

---

## ENGAGEMENT WITH THE LOCAL PARTNERSHIP FORUM

---

In support of the Trust Board, the Trust also has a Local Partnership Forum that met four times during 2021-2022, with Joint Chairs who are each nominated from the Trade Union Representatives and Executive Directors. The role of the Local Partnership Forum is to supply the main (but not only) forum within the Trust where the Directors of the Trust and Trade Union Representatives can discuss together and develop appropriate directions and responses to all major service development and change management issues.

Examples of engagement with the Local Partnership Forum during 2021-2022 are outlined in **Appendix 1** on page 60.

---

## TRUST BOARD DEVELOPMENT AND EFFECTIVENESS

---

Trust Board Development Sessions were paused at the outset of the Wave #1 of the COVID-19 pandemic to enable Trust Board meetings to increase in frequency from bi-monthly to monthly with additional fortnightly COVID-19 Board Briefings instigated.

The Trust Board continued to operate on this basis, until August 2020 when Trust Board meetings returned to meeting on a bi-monthly basis and fortnightly briefings stood down. However, following the onset of the Wave #2 of the COVID-19 pandemic, Board Briefings were re-established on a fortnightly basis from December 2020 until the end of April 2021, and the new Board Development Programme re-initiated in May 2021. Between May 2021 and March 2022 the Trust Board has received five Board Development sessions covering a number of key areas including the following:

### **May 2021**

- Velindre Cancer Service Show and Tell.
- New Velindre Cancer Hospital Project – Reference and Design.
- Advanced Therapies Programme.
- Transforming Access to Medicines (TrAMS).



## **August 2021**

- Trust's Putting Things Right Responsibilities including Complaints Management.
- Cardiff & Vale University Health Board Strategic Programme – Shaping our Future Hospitals.
- Draft National Quality & Safety Framework.
- Velindre Futures.

## **October 2021**

- Health Education Improvement Wales (HEIW) Key Strategic Programmes and Developments.
- Planning for a Public Inquiry into the COVID Pandemic.
- WBS Update on Blood Health Oversight Group (BHNOC) – NHS Wales Blood Health Plan.
- Infected Blood Inquiry.
- Cyber Security – Board Responsibilities.
- Development of IMTP.
- Organisational Design & Developments.

## **December 2021**

- Safeguarding Training – National Training Framework on Violence against women, domestic abuse and sexual violence.
- Development of Integrated Medium Term Plan.
- Performance Management Framework.
- Trust Strategies.
- Transforming Cancer Services Matters, including Enabling Works, Integrated Radiotherapy Solution and Legal Matters.
- COVID-19 Update.

## **February 2022**

- Development of Integrated Medium Term Plan.
- New Velindre Cancer Hospital Competitive Dialogues.

In addition to the Board Development arrangements outlined above, in September 2020, the Trust also commissioned an external Board Development Programme designed to support the Board and Executive Team in meeting the challenges it is facing in the continually evolving environment within which it is operating. The Programme commenced in October 2020 and continued during 2021-2022 covering but not limited to the following key areas of development:

- Building a high performing leadership team.
- Strategic decision-making capabilities and prioritisation.
- Building organisational capacity and capability including developing a highly effective and business-focused cadre of senior managers.
- Challenging areas of conflicting styles and behaviour.
- Developing clear strategies for harnessing individual differences to enable the Executive Team to work as a cohesive whole.
- Better understanding organisational dynamics in order to improve matrix working and embed change management capability across a diverse and dispersed organisation.

---

## STANDING ORDERS AND STANDING FINANCIAL INSTRUCTIONS

---

The Trust approved a revised set of Standing Orders and Standing Financial Instructions for the regulation of proceedings and business to ensure the following issues were addressed:

- **July 2021** – Issue of revised Model Standing Orders, Reservations and Delegation of Powers (SO's) for NHS Trusts, following a review by officials in association with representatives of the Board Secretaries and Directors of Finance Peer Groups in accordance with the Ministers Powers of direction contained within sections 12(3) (for Local Health Boards) and 19(1) (for NHS Trusts) and 23(1) (Special Health Authorities) of the National Health Service (Wales) Act 2006.
- **January 2022** – Amendments to Standing Orders Schedule 3.0, resulting from the Annual review of the Terms of Reference and Operating Arrangements in respect of the Trust Board:
  - Charitable Funds Committee
  - Strategic Development Committee
  - Quality, Safety & Performance Committee
  - Audit Committee

---

## TRUST BOARD APPOINTMENTS DURING 2021-2022

---

The Trust made the following Trust Board appointments/reappointments during 2021-2022:

### Independent Members

- Mr. Stephen Harries, Interim vice Chair and Independent Member, Information Governance and Digital, commenced his third term with the Trust on the 1<sup>st</sup> May 2021.
- Professor Andrew Westwell commenced his first term with Velindre University NHS

Trust on the 10<sup>th</sup> August 2021.

- Mrs. Vicky Morris commenced her first term with Velindre University NHS Trust on the 12<sup>th</sup> November 2021. Between the 30<sup>th</sup> September 2021 and 12<sup>th</sup> November 2021, Mr. Stephen Harries assumed the role of Acting Chair of the Quality, Safety & Performance Committee, to support the vacancy held for the Quality & Safety Independent Member lead, following the end of Mrs. Jan Pickle's tenure with the Trust.

#### **Executive Team (Non Board Members)**

- Mr. Matthew Bunce was appointed as Executive Director of Finance on the 27<sup>th</sup> September 2021.
- Mrs. Cath O'Brien was appointed as Chief Operating Officer on 1<sup>st</sup> November 2021 on a permanent basis.

Further details on the Trust Board appointments are provided in the Trust Remuneration Report on page 78.

---

## **PURPOSE OF THE SYSTEM OF INTERNAL CONTROL**

---


The system of internal control is designed to manage risk to a reasonable level rather than to eliminate all risks, it can therefore only provide reasonable and not absolute assurances of effectiveness.

The system of internal control is based on an ongoing process designed to identify and prioritise the risks to the achievement of the policies, aims and objectives, to evaluate the likelihood of those risks being realised and the impact should they be realised, and to manage them efficiently, effectively and economically. The system of internal control has been in place for the year ended 31 March 2022, and up to the date of approval of the 2021-2022 Annual Report and Accounts.

The Welsh Government requires that the Trust operates within the wider governance framework set for the NHS in Wales and incorporating the standards of good governance set for the NHS in Wales (as defined within the Citizen Centred Governance principles and Standards for Health Services in Wales), together with its planning and performance management frameworks.

An overarching summary of the Trust's Governance and Accountability Framework is illustrated overleaf:

## Trust's Governance and Accountability Framework



---

## GOVERNANCE OF THE CHARITABLE FUNDS

---

The Velindre University NHS Trust Board was appointed as Corporate Trustee of the Charitable Funds by virtue of the Velindre National Health Service Trust (Establishment) Order No. 2838 that came into existence on 1st December 1993, and the Trust Board serves as its agent in the administration of the Charitable Funds held by the Trust.

As part of their induction programme, new Executive Directors and Independent Members of the Trust are made aware of their responsibilities as Board Members of Velindre University NHS Trust and as Corporate Trustees of Velindre University NHS Trust Charity.

The Trust Board as Corporate Trustee is ultimately accountable for Charitable Funds given to Velindre University NHS Trust Charity. In order to facilitate the administration and management of these funds the Trust Board has established a Charitable Funds Committee (CFC) to provide advice and recommendations to the Board. Committee meetings are held every three months and otherwise as the Committee Chair deems necessary. At least two members must be present to ensure the quorum of the Committee.

The CFC is supported by the Charitable Funds Senior Leadership Group that meets on a monthly basis.

The CFC is also supported by an Investment Performance Review - Sub Committee, to oversee the investments made by the Charity.

Further information in respect of the Charitable Funds is available in the Trustee's Annual Report which can be found on the Trust website [here](#).

---

## HOSTED ORGANISATIONS SYSTEMS OF INTERNAL CONTROL AND ASSURANCE

---

Hosted organisations utilise the existing Trust Committee Structure (Accountability & Governance Framework) illustrated on page 34 of this Governance Statement.

A separate Velindre University NHS Trust Audit Committee is held to consider issues relating specifically to NWSSP, having the same Chair and Independent Membership as the Velindre University NHS Trust Audit Committee. Information relating to the governance arrangements in NWSSP is contained within the Director's Governance Statement to the Velindre University NHS Trust Chief Executive which is available from the Director of Corporate Governance and Chief of Staff upon request.

NWSSP has an 'NHS Wales Shared Services Partnership Committee' which was established as a sub-committee of Velindre University NHS Trust Board in 2012 to comply with Ministerial Directions. The NWSSP Committee has membership from each statutory body in NHS Wales, and is chaired by an Independent Chair. The NWSSP Committee reports to Velindre University NHS Trust Board and all other health body Boards in Wales via their representative member on the Committee. NWSSP have their own Standing Orders which are appended to the Velindre University NHS Trust Standing Orders.


Currently, organisations hosted by Velindre University NHS Trust are able to link with Trust Board Committees and Management Groups where appropriate to ensure assurance is provided for the governance arrangements, including statutory compliance for the areas remaining within the Trust's area of responsibility.

In May 2021, a review was undertaken by Velindre University NHS Trust in partnership with NWSSP to consider arrangements for Quality & Safety governance in respect of the Shared Services Partnership Committee. This included consideration of the culture and approach adopted by the Velindre Board following the creation of the Quality, Safety & Performance Committee in November 2020. In addition, it also considered the approaches with other hosted organisations to support in considering different models and what may work best to fulfill the purpose agreed by the Shared Services Partnership Committee – to “advise and assure the Shared Services Partnership Committee and Accountable Officer on whether effective arrangements are in place for quality and safety” (in line with the approved NWSSP Standing Orders). This was coupled with ensuring that Velindre University NHS Trust Board, as the host organisation and statutory body, also having

appropriate assurance to fulfill its accountabilities in this respect. The review recommended that an additional section be added to the start of each Trust Quality, Safety & Performance Committee to cover NWSSP Quality and Safety business. This approach was considered sufficient for the volume of business at this time, although this will be kept under review as the NWSSP business model continues to develop.

In line with the arrangements for the Velindre Audit Committee for Shared Services, it was proposed that a separate highlight report would be produced for this section of the Committee and this would then be shared with the Shared Services Partnership Committee and ultimately to the Trust Board to provide assurance. The recommended approach was approved by the Velindre University NHS Trust Board at its May 2021 meeting. A summary overview of these arrangements is provided below:

### **Quality & Safety (Q&S) Governance Arrangements for NHS Wales Shared Services Partnership Committee (SSPC)**



A review of the existing governance reporting arrangements in place for Health Technology Wales has also been initiated and will be taken forward for development and implementation during the 2022-2023 reporting period onwards.

---

## CAPACITY TO HANDLE RISK

---

The organisations hosted by Velindre University NHS Trust maintain and manage their own risk registers and comply with the Trust escalation processes to ensure the Trust Board is made aware of any significant relevant risks relating to the Trust Board's responsibilities via the Trust Risk Register as necessary.

Risks relating to hosted organisations will only be escalated to the Velindre University NHS Trust risk register where matters directly affecting the Trust are apparent. Matters relating to service delivery and performance are a matter for hosted bodies to receive, manage, and escalate as necessary to the relevant sponsor body.

The Trust involves its public stakeholders in managing risks that impact on them. For example, there is ongoing public engagement as an integral part of the development process of the Transforming Cancer Services (TCS) Programme and the new Velindre Cancer Centre (nVCC) Project. A series of stakeholder events have been undertaken, and will continue throughout the lifespan of the TCS Programme. Risks from the TCS Programme are reviewed and monitored by the TCS Programme Scrutiny Sub-Committee and are escalated to the Trust risk register in accordance with the Trust risk escalation process. Information on the risks managed and mitigated during 2021-2022 is detailed in the Trust Risk Register which is received by the Trust Board. Trust Board papers are available on the Trust Internet site [here](#).

---

## RISK MANAGEMENT

---

The Trust has an approved Risk and Assurance Framework and associated policies in place. The policies detail a robust risk assessment process to identify, assess and manage organisational risks, which are reported on a risk register to the Trust Board, in line with risk appetite levels set by the Trust Board. The underlying risk principles applied throughout this framework are consistent with the overarching principles of HM Treasury's Orange Book *'Management of Risk – Principles and Concepts'*, 2020; and ISO 31000: 2018 *'Risk Management – Guidelines'*. The framework also supports the UK Corporate Governance Code 2018 and the Financial Reporting Council's *'Guidance on Risk Management, Internal Control and Related Financial and Business Reporting'*.

The refreshed Trust Risk Management Framework, approved by the Trust Board in September 2020 sets out the risk strategy, which can be summarised as:



*The management of risk is a key factor in the provision of high-quality care to our patients, donors and service users. Of equal importance is the legal duty of the Trust to control any potential risk to staff and the general public, as well as safeguarding the assets of the Trust. It is the responsibility of all staff to be involved in the identification and reduction of risks.*

It also sets out risk governance; key accountabilities, roles and responsibilities; risk domains and categories; risk and control interdependencies; risk documentation; risk reporting; and view of implementation, training and support. Alongside the Risk Management Framework, the Trust Board also approved a Risk Management Process document which explains the detail of risk assessment, in terms of risk identification, analysis and evaluation; model for assessing risk treatment and response including how to prepare and implement risk treatment and actions plans, taking into account any weaknesses in the control environment; risk recording and reporting processes; and process for risk monitoring and review, including how to assess effectiveness. The core of the risk culture the refreshed Framework is addressing is that risk is everyone's responsibility to assess and record risks. The systems and processes are now aligned to support this important part of our culture. Staff are trained or equipped to manage risk in a way appropriate to their authority and duties. This now includes a training package of three levels of training, for all staff, for management level and for leadership level. The full roll out of the newly approved Risk Framework and Risk Processes was paused during the second wave of Covid-19 response. The final elements of the core implementation and associated training are due to complete by June 2022.

The Trust Board is ultimately responsible for overseeing the Trust's risk register and holding the Executive to account for ensuring management action is taken to minimise risk. The Trust Board delegates' responsibility to the Trust's Quality, Safety and Performance Committee for overseeing the risk management process and the Trust's Audit Committee retains the oversight to ensure the system of risk management is effective. The overall aim of the Trust's Risk Management approach is to progress a comprehensive risk management programme to ensure that:

- There is compliance with statutory legislation.
- All sources and consequences of risk are identified.
- Risks are assessed and either eliminated or minimised.
- Damage and injuries are reduced, and people's health and well-being is optimised.
- Resources diverted away from patient/service user care to fund risk reduction are minimised.
- Lessons are learnt from concerns in order to share best practice and prevent re-occurrence.

The Trust has a series of controls in place to manage and mitigate these risks.

The Chief Executive, as Accountable Officer for the Trust, has overall accountability and responsibility for having an effective risk management system in place within the Trust, including hosted organisations. The Chief Executive is responsible for meeting all statutory requirements and adhering to guidance issued by the Welsh Government Department of Health & Social Services in respect of governance. Within the Trust's Risk Management Policy, the Chief Executive has set clear measurable risk management objectives for the Executive Directors and Service Directors with delegated responsibility for risk management and governance.

The Director of Corporate Governance & Chief of Staff has organisational lead responsibility for the risk framework to the Chief Executive and the Board. Each Executive Director is responsible for overseeing effective management of risk within their area of responsibility, and Executive Directors are supported in these duties by the Service Directors and Senior Managers across the organisation.

Every member of staff, including clinicians, is responsible for ensuring that their own actions contribute to the wellbeing of patients/service users, staff, visitors and the organisation. They are expected to contribute to the identification, reporting and assessment of risks and to take positive action to manage them appropriately.

Risk management is embedded in Trust decision making and service delivery. This is supported by continually considering and assessing Trust compliance with key clinical guidance including:

- Guidance and technology appraisals from the National Institute for Health and Care Excellence (NICE).
- National Service Frameworks (NSFs).
- National Enquiries for example Confidential Inquiries.
- Patient Safety Alerts.
- Professional Guidelines for example from Royal Colleges.
- Guidelines or standards from other national/local bodies.
- Local and national audit.
- Research & Development.
- Participation in clinical trials.
- Health and Care Standards (Wales).

Risk Management and risk resourcing is managed by Divisional Directors through their business plans. All divisions/departments have processes for assessing risk and risk registers are created as appropriate. Risks are updated and reviewed within the service divisions. The divisional Senior Management Team (SMT) and Senior Leadership Team (SLT) works with their supporting

groups/Committees to ensure effective controls are in place for their risks to be managed at a tolerable level.

Risks are referred to the appropriate Committees of the Trust Board for scrutiny and to identify additional control measures. In turn, the Committees provide assurance to the Trust Board that all reasonably practicable steps have been taken to reduce the risk, that effective controls are in place and the risk is being managed at a tolerable level.

---

## **TRUST RISK REGISTERS**

---

The organisation's risk profile is visible through the Trust Risk Registers. Risks are identified at the commencement of new or amended activities and through the ongoing review of existing risks. Risk assessments are undertaken to assess the impact upon the service and other stakeholders. Public Stakeholders are involved in the assessment of risk through public consultations, Patient Liaison Group representation and Community Health Council at Trust Board and Committee meetings, feedback received in respect of Patient Experience surveys and Donor Forums and learning from Concerns received from patients, donors, relatives and/or carers.

All risks are assessed and awarded a score, informed by potential impact and likelihood. Risks are escalated resulting in the highest level of risk being referred to the Executive Management Trust Board for appraisal prior to inclusion on the Trust's risk register and reported to Trust Board and relevant Trust Board Committee/s. Each risk entered onto the Trust register is given a 'target' score informed by the appetite for the risk, which is the level of risk the Trust Board is prepared to accept before action is deemed necessary to reduce it. The risk appetite is used in decision making to inform the prioritisation of actions and the resources required to mitigate risks on the Trust risk register. The system of record and for risk management is Datix. The Trust is updating the module used in Datix and the revised forms have been aligned to the refreshed framework. This is due for full roll out by June 2022 for all parts of the organisation.

During the period of the waves of the Covid-19, the approach to risk management reporting was adapted in response to the pandemic and also as part of the review of the overall framework. Risk reporting, through a quality and safety lens, has been a strong feature of Divisional reporting into the Quality, Safety and Performance Committee. Management of Covid-19 related risks has been through the Covid-19 Incident Command Structure and then reported into Trust Board as part of the Covid-19 reporting mechanisms. This has also been captured in the formal planning cycles during

the year, approved by the Trust Board. In addition, key risks have been reported into the relevant Committees – for instance regarding Transforming Cancer Services and Research, Development and Innovation. Divisional risks have been reported through each Quality, Safety & Performance Committee. Significant risk matters have also been escalated to the Trust Board during the period. During the period the overall Trust Risk Register was not presented to the Trust Board between April and September 2021. Whilst this approach was agreed informally with Independent Members, it was acknowledged in the November 2021 Internal Audit review of the Trust Assurance Framework that this decision had not been recorded formally in Board or Committee minutes.

During the period, Internal Audit reviewed the Divisional Risk Frameworks in October 2021, which were assessed as reasonable assurance level, with Policies and Procedure at substantial assurance level. Regarding reporting to Trust Board, taking into account the reporting approach set out in the paragraph above, was also assessed as reasonable assurance. As part of the Internal Audit review of the Trust Assurance Framework, corporate risk management was also assessed, with substantial assurance being provided over the Risk Management Framework. The full audit findings were reported to the Trust Audit Committee in October 2021 and January 2022, and are available [here](#). Improvement opportunities identified from the Internal Audit Report will be managed by the Executive Management Board, and ongoing continued progress will be monitored via the Audit Committee by scrutiny of the Audit Action Plan.

The highest scored risks as at end of March 2022, governed through the May Committee and Trust Board cycle are summarised below, for access to fuller detail, including mitigating actions and controls, please review the May 2022 Trust Board Risk Paper [here](#).

Risk Type	Division	Title	Rating (Current)	Rating (Target)
Workforce and OD	Transforming Cancer Services	There is a risk that the lack of appropriate project support for Project 5, Outreach, from the programme will lead to delays in developing the solutions required for the project success.	20	6

Risk Type	Division	Title	Rating (Current)	Rating (Target)
Performance and Service Sustainability	Velindre Cancer Service	There is a risk that patient treatment is delayed as a result of a lack of medical workforce holding a prostate brachytherapy practitioners Licence.	16	10
Performance and Service Sustainability	Velindre Cancer Service	There is a risk that patient treatment is delayed due to lack of staffing because of COVID 19 related absence.	16	6
Workforce and OD	Corporate Services	Digital Services Capacity / Skill Mix.	16	8
Performance and Service Sustainability	Velindre Cancer Service	There is a risk that lack of Medical Physics Expert cover impacts on the Molecular Radiotherapy (Nuclear Medicine) services.	16	4
Compliance	Velindre Cancer Centre	There is a risk of increased infection transmission within the cancer centre due to poor ventilation resulting in increased sickness and absence of staff and patients.	16	8
Financial Sustainability	Velindre Cancer Centre	VCC may face financial loss, legal action, inadequate service provision as a result of no coordinated system for SLAs, contracts.	16	6

Risk Type	Division	Title	Rating (Current)	Rating (Target)
Performance and Service Sustainability	Transforming Cancer Services	There is a risk that Programme Master Plan objectives / outcomes are delayed and/or not met.	16	6
Financial Sustainability	Transforming Cancer Services	Risk of Inflation leading to increased costs.	16	12
Financial Sustainability	Transforming Cancer Services	There is a risk that the competitive dialogue participants' tenders exceed the CAPEX limit leading to increase project costs.	16	12

A link to the Trust Board papers for the period can be found [here](#).

---

## RISK APPETITE STATEMENT

---

The Trust faces a broad range of risks reflecting its responsibilities. The risks arising from its responsibilities can be significant. These risks are managed through detailed processes that emphasise the importance of integrity, intelligent inquiry, maintaining high quality staff and public accountability.

The Trust makes resources available to control operational risks at acceptable levels and we recognise that it is not possible or indeed necessarily desirable to eliminate some of the risks inherent in our activities. Acceptance of some risk is often necessary to foster innovation within the services for which we are responsible.

The Trust's Risk Appetite Statement was refreshed and approved at Trust Board in September 2020, and considers the most significant risks to which the Trust is exposed. It provides an outline of the approach to managing these risks. All strategic and business plans for operational areas must be consistent with this Statement. Given the range of the Trust's activities and responsibilities, it is not appropriate to make a single overarching statement of the Trust's attitude to risk. Instead, a range of risk appetite statements arising from the different areas of our work has been developed and approved by the Trust Board, in the following areas. The Risk Appetite categorisation approach is based on the Good Governance Institute (GGI) Risk Appetite for NHS Organisations Matrix.

- Safety - 1 - Minimal
- Quality - 2 - Cautious
- Compliance - 2 - Cautious
- Research & Development – 3 - Open
- Reputation & Public Confidence - 2 - Cautious
- Performance & Service Sustainability - 2 - Cautious
- Financial Sustainability - 2 - Cautious
- Workforce & Organisational Development - 2 - Cautious
- Partnerships – 4 - Seek

---

## TRUST ASSURANCE FRAMEWORK (TAF)


---

The Audit Committee and Trust Board approved a new Board Assurance Framework (BAF) in September 2020. It was agreed to name this document and process the Trust Assurance Framework (TAF) to firstly reflect the fact that the process should be of value for the whole Trust and secondly to reflect the ambition of this framework to, in time, effectively link with both the Quality & Safety and Performance frameworks.

The TAF enables the Board to identify and understand the principal risks to achieving its strategic objectives; receive assurance that suitable controls are in place to manage these risks, and where improvements are needed suitable action plans are in place and being delivered; and to provide an assessment of the risk to achieving the related objective.

The TAF is the key source of information that links the Velindre University NHS Trust's Strategic Objectives to risk and assurance, as demonstrated in **Figure 1**:

**Figure 1: Information flows between the Trust Risk Register & TAF**



There is not expected to be significant movement in the articulation of the Trust's principal risks in the short-term, instead these would be reviewed and evolved in line with the organisation's strategic development cycles or in response to significant external changes.

The focus of the management of the TAF is twofold:

- I. Setting out the key controls, identifying any gaps in controls and taking action to address these;
- II. Setting out the sources of assurance, from first, second and third line of defence sources, and then tracking the insight that each of these sources of assurance is demonstrating against each of the risks. In addition, identifying any gaps in assurance and taking action to address these. To clarify on these terms:
  - **First line of defence** – are sources of assurance from the functions that own and manage the risk.
  - **Second line of defence** – are sources from the functions that oversee the day-to-day operations – e.g. Quality & Safety, Corporate / Clinical Governance.
  - **Third line of defence** – are sources from functions that provide independent assurance – e.g. Internal /External Audit, Regulators, Audit Wales.



Each of the risks has an Executive owner, who is responsible for co-ordinating the actions required to improve the effectiveness of the key controls and assurance on an on-going basis. The Head of Corporate Governance works with each of the Executive owners to update the Trust Assurance Framework on a bi-monthly basis for reporting at Audit Committee, Strategic Development Committee and Trust Board. Work on populating the TAF recommenced in the summer 2021 following its initial pause during the first and second wave of the pandemic, with progress updates being provided to the Trust Strategic Development Committee and Audit Committee in June and July 2021 respectively. The first iteration of the TAF was subsequently reported to the Trust Board in September 2021. Since then, the Trust has continued to further develop, mature and operationalise the TAF. This has been further enhanced and supported by an independent assessment undertaken by Shared Services Partnership Audit and Assurance Services in November 2021, which sought to provide the Trust with assurance that the TAF is robust, and that the Trust is managing its principal risks. The audit findings were reported to the Trust Audit Committee in January 2022, and are available [here](#). Improvement opportunities identified from the Internal Audit Report will be managed by the Executive Management Board, and ongoing continued progress will be monitored via the Audit Committee by scrutiny of the Audit Action Plan.

---

## HEALTH & CARE STANDARDS FOR WALES

---

The Health and Care Standards published in April 2015, set out the requirements for the delivery of health care in Wales at every level and in every setting. The 'Health and Care Standards' programme for NHS Wales provides a framework for ensuring compliance and ongoing improvements in the provision of high quality, safe and effective care.

In 2020, the Trust reviewed its internal self-assessment process with the Health Care Standards, and it was recognised that in order to drive quality improvement, the Health and Care Standards needed to be more firmly embedded into the core business of the Divisional and Corporate Teams. As such, it was agreed by the Executive Management Team that the Trust would adopt a more rigorous approach to the Health and Care Standards, which would include a quarterly review and progress update at a Divisional, and a bi-annual Executive Review.

2021-2022 is the first year in which the Trust has implemented the strengthened process for the Health and Care Standards. The Divisional and Corporate Teams have undertaken a comprehensive review of their compliance with the Health and Care Standards during each quarter of 2021-2022, and have also ensured that the Improvement Plan has been updated. The Trust Health and Care Standards Compliance Report with the enhanced quarterly Health and Care Standards self-assessment process is reported to both the Trust Quality, Safety & Performance

Committee and Trust Board.

It was agreed during the Internal Audit Annual Planning Process for 2021/22 that Internal Audit would not undertake an independent review of the Trust's compliance against the Health and Care Standards at the end of Quarter 4 2021-2022. This was based on risk assessment, previous audits undertaken in this area and discussions/agreement with Executive Management Board and the Trust Audit Committee, combined with it no longer being an audit mandated by Welsh Government. Internal Audit links its audit briefs to the relevant Health and Care Standards where the audit may contribute to assurance over compliance. It remains the Trust's responsibility to assess the level of assurance it can take from these reports in terms of the Health and Care Standards.

A national review of the Health and Care Standards has commenced in order to ensure they reflect the requirements of the Wales Quality and Engagement Act (2020) and the national Quality & Safety Framework (2021) requirements. The revised standards are not expected until later in 2022.

---

## GOVERNANCE & ACCOUNTABILITY ASSESSMENT / TRUST BOARD EFFECTIVENESS

---

The Trust Board is required to undertake an annual self-assessment of its effectiveness. The approach taken this year was to bring together the various sources of assurance, internal and external, that would support the Board in considering its overall level of maturity for the Trust in respect of good governance and Board effectiveness. At the Trust's Annual Board Governance and Effectiveness Assessment meeting on the 26 April 2022, Board members were taken through the process and concluded that the Trust's self-assessment of the overall maturity level for 2021-2022 was assessed at Level (4).

<b>Governance, Leadership &amp; Accountability – Self Assessment</b>	1. Do not yet have a clear, agreed understanding of where they are (or how they are doing) and what / where they need to improve.	2. Are aware of the improvements that need to be made and have prioritised them, but are not yet able to demonstrate meaningful action.	3. Are developing plans and processes and can demonstrate progress with some of their key areas for improvement.	4. Have well developed plans and processes and can demonstrate sustainable improvement throughout the organisation /business.	5. Can demonstrate sustained good practice and innovation that is shared throughout the organisation/ business, and which others can learn from.
<b>Rating</b>				✓	

The above assessment was informed by contributions from the Interim Head and Interim Deputy Head of Internal Audit. Both were in attendance to present the Head of Internal Audit Opinion for 2021-2022 and support any queries arising from the findings of the Board Committee Effectiveness Internal Audit Report, provided as an additional source of assurance. Improvement opportunities identified from the Board Committee Effectiveness Internal Audit Report will be managed by the Executive Management Board, and ongoing continued progress will be monitored via the Audit Committee by scrutiny of the Audit Action Plan.

---

## **REVIEW OF EFFECTIVENESS (ADDITIONAL SOURCES OF ASSURANCE)**

---

As Accountable Officer, the Chief Executive has responsibility for reviewing the effectiveness of the system of internal control. The Chief Executive's review of the effectiveness of the system of internal control is informed by the work of Internal and External Auditors, the Executive Directors and other assessment and assurance reports, including the work of Healthcare Inspectorate Wales. The Chief Executive has listened to the Board on their views of the strengths and opportunities in the system of internal control and been advised by the work of the Audit Committee and other Committees established by the Board.

The Chief Executive's performance in the discharge of these personal responsibilities is assessed by the Director General of the Department of Health & Social Services/Chief Executive of NHS Wales.

At the Annual Board Governance and Effectiveness Assessment meeting (mentioned above) the Trust Board concluded an overall maturity level for 2021-2022 as Level (4); which is defined as 'having well developed plans and processes and can demonstrate sustainable improvement throughout the organisation'. The scrutiny of these arrangements is in part informed through the internal mechanisms already referred to, but also through the independent and impartial views expressed by a range of bodies external to the Trust, these include:

- Children's Commissioner.
- Community Health Councils.
- Health & Safety Executive.
- Healthcare Inspectorate Wales.
- Older Peoples Commissioner.
- Audit Wales.
- Welsh Government.
- Internal Audit (NHS Wales Shared Services).
- Welsh Language Commissioner.
- Welsh Risk Pool Services.
- Equality & Human Rights Commission.
- Future Generations Commissioner.
- Other accredited bodies.

---

## INTERNAL AUDIT OPINION & SCORES FOR 2021–2022

---

Internal audit provides the Chief Executive as Accountable Officer and the Trust Board through the Audit Committee with a flow of assurance on the system of internal control. The Chief Executive and Internal Audit agreed a programme of audit work, which was approved by the Audit Committee, and delivered in accordance with Public Sector Internal Audit Standards by the NHS Wales Internal Audit Service, part of the NHS Wales Shared Services Partnership. The programme of audit work is designed to focus on significant risks and local improvement priorities. The eight areas used to frame the 2021/22 internal audit planning process were:

1. Corporate Governance, Risk and Regulatory Compliance
2. Strategic Planning, Performance Management and Reporting
3. Financial Governance and Management
4. Clinical Governance Quality & Safety
5. Information Governance and Security
6. Operational Service and Functional Management
7. Workforce Management
8. Capital and Estates

The overall opinion by the Head of Internal Audit on governance, risk management and control is a function of this risk based audit programme and contributes to the picture of assurance available to the Board in reviewing effectiveness and supporting our drive for continuous improvement.

The programme has been impacted by the need to respond to the COVID-19 pandemic with some audits deferred, cancelled or curtailed as the organisation has responded to the pandemic. The Head of Internal Audit is satisfied that there has been sufficient internal audit coverage during the reporting period in order to provide the Head of Internal Audit Annual Opinion. In forming the Opinion the Head of Internal Audit has considered the impact of the audits that have not been completed.

A summary of the audits undertaken in the year and their results is outlined in the table overleaf. Improvement opportunities identified from the findings are actively being addressed by the Executive Management Board, and ongoing continued progress will be monitored via the Audit Committee by scrutiny of the Audit Action Plan.

Substantial Assurance	Reasonable Assurance
<ul style="list-style-type: none"> <li>• New Velindre Cancer Centre (nVCC) Mutual Investment Model (MIM) Governance</li> <li>• nVCC Financial Reporting (draft report)</li> <li>• nVCC MIM Procurement (draft report)</li> </ul>	<ul style="list-style-type: none"> <li>• Infection Prevention &amp; Control</li> <li>• Digital Health &amp; Care Record for Cancer (CaNISC Replacement)</li> <li>• Divisional Review – Incident Management</li> <li>• Divisional Review – Risk Management</li> <li>• Board Committee Effectiveness</li> <li>• Trust Assurance Framework</li> <li>• Financial Systems</li> <li>• Scrutiny of Expenditure above £100,000</li> <li>• Estates Assurance – Waste Management</li> <li>• Disclosure Barring Service Checks</li> <li>• Charitable Funds</li> <li>• Follow-up of prior year recommendations</li> <li>• nVCC Contract Management</li> </ul>
Limited Assurance	Advisory/Non-Opinion
N/A	<ul style="list-style-type: none"> <li>• Use of Technology – Fit for the Future</li> <li>• Wellbeing of Future Generations Act</li> </ul>
No Assurance	
N/A	

---


## THE HEAD OF INTERNAL AUDIT OPINION FOR 2021–2022)

---

The Head of Internal Audit is satisfied that sufficient audit work has been undertaken during the year to be able to give an overall opinion in line with the requirements of the Public Sector Internal Audit Standards. Regular audit progress reports have been submitted to the Audit Committee during the year.


The Head of Internal Audit assessment should be interpreted in this context when reviewing the effectiveness of the system of internal control and be seen as an internal driver for continuous improvement.

The Head of Internal Audit opinion on the overall adequacy and effectiveness of the organisation’s framework of governance, risk management, and control is set out below. The overall opinion was classified as Reasonable Assurance.

<b>Reasonable assurance</b>		<p>The Board can take <b>reasonable assurance</b> that arrangements to secure governance, risk management and internal control, within those areas under review, are suitably designed and applied effectively. Some matters require management attention in control design or compliance with low to moderate impact on residual risk exposure until resolved.</p>
-----------------------------	-----------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In reaching this opinion the Head of Internal Audit identified that all reviews during the year concluded positively with robust control arrangements operating in some areas. From the reports issued during the year, two were allocated Substantial Assurance and fourteen were allocated Reasonable Assurance. There were no limited or no assurance reports. In total 18 audits were reported during the year. The chart below presents the assurance ratings and the number of audits derived for each.

### Summary of audit ratings



---

## AUDIT WALES STRUCTURED ASSESSMENT 2021 - 2022

---

The Trust's External Auditors, Audit Wales, conducted a Structured Assessment during 2021 that was designed in the context of the ongoing response to the pandemic. The work was undertaken in two phases:

- I. **Phase 1** considered the planning arrangements underpinning the developments and delivery of the operational plan for quarters three and four of 2020-2021.
- II. **Phase 2** considered how corporate governance and financial management arrangement adapted over the year. Auditors also paid attention to progress made to address previous recommendations.

The main conclusions from **Phases 1** and **2** are outlined below:

### **Operational planning arrangements**

The Trust's planning framework was assessed with regard to the maintenance of effective and efficient operational planning arrangements to guide its response to the pandemic as well as responding to winter pressures and laying the foundations for effective recovery of services. It was determined that:

- The Trust's arrangements for developing operational plans and monitoring their delivery are effective and have the flexibility to respond to changing circumstances.
- The Trust's Quarters' 3-4 Plan for 2020-2021 was submitted to the Welsh Government within the required timeframe, covers all necessary areas within the planning framework guidance and received the required Board scrutiny.
- The Trust has maintained the same approach for developing its quarterly plans as was the case for developing plans in previous years. The Quarters' 3-4 Plan is a progression from the previous two quarterly plans and is underpinned with the best possible information available given the uncertainty the pandemic presents. Arrangements to deliver the Quarters' 3-4 Plan are dynamic and have responded to the changing circumstances and supported the wider NHS.
- The Trust has effective operational and strategic arrangements to monitor progress against operational plans. The Board regularly reviews progress in delivering the priorities set out in operational plans.

## **Governance arrangements**

The Trust's ability to maintain sound governance arrangements while having to respond to the unprecedented challenges presented by the pandemic was assessed. The key focus of the work assessed the corporate arrangements for ensuring that resources are used efficiently, effectively, and economically. It also considered how business deferred in 2020 was reinstated and how learning from the pandemic is shaping future arrangements for ensuring continued good governance and recovery. It was determined that:

- The Trust has good arrangements to conduct Board and Committee business.
- The Trust has good governance arrangements which adapted well to the pandemic. The Trust has streamlined its Board Committee structure, and postponed Board and Committee business is being reactivated.
- The quality and presentation of information at Board and Committees is good, on occasions, papers include content which is perhaps too detailed.
- Transparency of Board business to the public is good, there are some opportunities for improvements, including ensuring that video recordings and Committee papers are uploaded to the website shortly after meetings. It was noted at the time of issuing the report that measures to address this have already been addressed and actioned.
- The Trust has introduced improved risk management arrangements and is currently refreshing quality governance arrangements. The Trust is developing detailed plans to ensure ongoing business continuity and increase capacity to respond to increasing demand for services. Further work is being progressed to include time bound actions for delivery to support implementation of the Trust's strategic priorities.

## **Managing financial resources**

The Trust's financial performance, financial controls and arrangements for monitoring and reporting financial performance was assessed. It was determined that:

- The Trust achieved its financial duties at the end of 2020-2021, and a clear financial plan to deliver services in 2021-2022.
- The Trust has good arrangements to manage its financial resources and continues year on year to meet its financial duties. Financial controls are effective, and the Trust uses clear, timely financial information to monitor and report its performance.

Improvement opportunities identified from **Phase 1** and **2** are actively being addressed by the Executive Management Board, and ongoing continued progress will be monitored via the Audit Committee by scrutiny of the Audit Action Plan.



---

## BUSINESS CONTINUITY AND EMERGENCY PREPAREDNESS

---

The Trust continues to make significant progress in its Business Continuity and Emergency Preparedness framework. A Trust wide Business Continuity & Emergency Preparedness steering group supports the framework and governance within the Trust. This is supported by a Trust wide policy, communications plan and command and control guidance.

The focus of the Trust for the past year has continued around the planning and response to the evolving Covid-19 global pandemic, and in ensuring the Trust continues to deliver core service provision throughout this exceptional time. The Covid-19 pandemic presented a number of challenges to the organisation.

The response to Covid-19 has been unprecedented in UK history, in terms of the scale, duration and impact. This response required prolonged establishment of UK and Welsh structures, including Local Resilience Forum structures. Robust incident management structures were put in place across the Trust to manage the Covid-19 response. The Trust has actively engaged with UK activities, Welsh Government and Public Health Wales on the Coronavirus Planning & Response.

Both the Welsh Blood Service and Velindre Cancer Service have focused on reviewing its Business Impact Analyses and Major Incident Plan to ensure the learning from Covid-19 and other business continuity related incidents are captured and mitigated.

As previously reported, the Trust completed a significant amount of work with regards to EU Exit consisting of detailed planning and preparation to mitigate against core service disruption encountered from EU Exit. This position has been maintained until Q4 2022, where an assurance position has been reached.

The changing environment of risk results in the strategies and plans being reviewed regularly and in line with the National and Wales Risk Registers. Emerging threats are considered in the development and enhancement of risk mitigation strategies and the organisations response mechanisms. These plans are commensurate with the level of risk the Trust anticipates exposure to.

### **Co-operation and Information Sharing:**

The Trust has continued to engage with multi-faceted planning and based on risk, across a number of varying themes and integrated with NHS Wales, Local Authorities, the Welsh Government and the Local Resilience Forum it partners with and key stakeholders. In addition, the Welsh Blood

Service continues to work closely with UK Blood services to further enhance the mutual aid arrangements between services to ensure the continuity and safety of the blood supply chain. Over the next 12 months, the Welsh Blood Service plans to encourage focused work around the alignment of blood shortage plans across the UK.

### **Training and Exercising:**

The Trust continues to engage with Welsh Government Emergency Planning Advisory Group and Local Resilience Forums around key strategies for workload, training and exercises. Over the past 12 months, in addition to exercising internal Business Continuity Plans (planned and unplanned), the Trust has participated in the following training and exercising:

- Participation of key individuals across the Trust on Local Resilience Forum led Wales Gold and Wales Silver training.
- Participation of key individuals across the Trust for Strategic Management and Tactical Management training delivered by Emergency Planning College.
- Major Incident awareness training delivered to key staff.
- Major Incident Communications test and workshop,
- Clinical Emergency Communication tests
- Participation in Exercise Wales Connect
- Welsh Government supported Cyber Incident exercise
- Celtic Consolidation Exercise

Engagement in such multidisciplinary exercises allows the Trust to encompass lessons learned, align to wider health emergency planning and to further improve the current procedures.

Site wide security assessments have been completed in partnership with the Counter Terrorism unit of South and North Wales Police.

### **Work Programme 2022/2023:**

During 2022/2023, the Trust plans to continually review and enhance its business continuity management system to ensure alignment with current best practice guidelines and to ensure the Trust is prepared in any future emergency planning and business continuity arrangements.

---

## **INTEGRATED MEDIUM TERM PLAN (IMTP)2022-2025**

---

We are an ambitious organisation striving to provide services which are recognised as outstanding by the people who use them, the people who work in them and by our peer organisations.

Velindre University NHS Trust purpose is to ‘improve lives’ and we have a vision of ‘excellent care,

inspirational learning and healthier people’.

Our guiding principles are founded upon the Well-being of Future Generations Act (Wales) 2015.



Our purpose and vision are supported by a clear set of five Strategic Goals to be achieved through a focused set of key deliverables, which provide the framework for our IMTP over the coming three years:

1. Outstanding for quality, safety and experience
2. Internationally renowned provider of exceptional clinical services that always meet, and routinely exceed, expectations
3. Beacon for research, development and innovation in our stated areas of priority
4. Established ‘University’ Trust which provides highly valued knowledge and learning for all
5. Sustainable organization that plays its part in creating a better future for people across the globe

The NHS in Wales is a planned system and each Health Board and Trust is required to have a fully costed three-year rolling Integrated Medium Term Plan. In accordance with the set statutory duty, we have submitted our IMTP, covering the period 2022-2025, to Welsh Government. However, the focus of the first year of our IMTP remains upon the challenges of COVID-19 pandemic and recovery. Following review by Welsh Government we were informed that:

***‘Following a robust assessment, your IMTP is considered to be approvable, which stands you in good stead for the future and provides a baseline for future planning discussions’.***

During 2021-2022 the full three year IMTP process was paused, and Health Boards and Trusts were required to produce a one year plan to respond to the particular challenges of COVID-19. Quarterly progress reports against our one year plan have continued during 2021-2022, with all plans formally scrutinised by the Executive Management Board, Quality, Safety and Performance Committee and Trust Board. Despite the very real pressures caused by the pandemic, it is clear that great progress has been made across the organisation in working towards the realisation of the Velindre Cancer Service (VCS) and the Welsh Blood Service (WBS) strategic objectives.

In respect of financial performance, the Trust reported an overall underspend of £41k for the Trust and consequently delivered on our statutory duty to achieve a financial breakeven over a three year period. This underspend includes an amount of £11k for NWSSP and £30k against our core services.

---

## **EQUALITY & DIVERSITY**

---

Control measures are in place to ensure that all the organisation’s obligations under equality, diversity and inclusion are complied with.

The control measures include:

- Trust Strategic Equality Plan and Objectives (2020 – 2024).
- Trust Gender Pay Gap Report
- Trust Annual Equality Monitoring Report.
- Equality reports to Quality, Safety & Performance Committee on the Trust’s Equality Objectives and Actions.
- Reports to the Equality and Human Rights Commissions’ enquiries.
- Report to the Welsh Government Equalities Team.
- Provision of evidence to the Health Care Standards Audit, specifically Standard 2.
- Integrated Equality Impact Assessments.

---

## CONCLUSION

---

As indicated throughout this statement, the need to plan and respond to the ongoing COVID-19 pandemic has continued to have a significant impact on the organisation, wider NHS and society as a whole. It has required a dynamic response which has presented a number of opportunities in addition to the risks. The need to respond, reset and recover from the pandemic will be with the organisation and wider society throughout 2022-2023 and beyond. I will ensure our Governance Framework considers and responds to this need.

The system of internal control has been in place for the year ended 31 March 2022 and up to the date of approval of the 2021-2022 Annual Report and Accounts.

There have been no significant governance issues identified during this period.

Signed by:



Mr. Steve Ham  
Chief Executive

Date: 14/06/2022

## APPENDIX 1 – GOVERNANCE STATEMENT – TRUST BOARD & COMMITTEE ACTIVITY 2021-2022

The table below outlines the key highlights and activity considered by the Trust Board and its Committees during 2021-2022, please note this is not an exhaustive list.

Meeting:	Meeting Dates:	Activity:
<p><b>Velindre University NHS Trust - Public Trust Board meeting.</b></p> <p>Meeting Agendas, Minutes and Papers are available on the Trust Internet site here:</p> <p><a href="https://velindre.nhs.wales/about-us/trust-board/public-trust-board-meetings/">https://velindre.nhs.wales/about-us/trust-board/public-trust-board-meetings/</a></p>	<ul style="list-style-type: none"> <li>• 08.06.2021</li> <li>• 29.07.2021</li> <li>• 30.09.2021</li> <li>• 25.11.2021</li> <li>• 27.01.2022</li> <li>• 31.03.2022</li> </ul> <p>All meetings were quorate.</p>	<p>High level summary/headlines of key topics received by the Trust Board during 2021-2022:</p> <ul style="list-style-type: none"> <li>• Chair and CEO Update Reports</li> <li>• Chair's Urgent Actions Reports</li> <li>• Commitment of Expenditure Exceeding Chief Executive's Limit</li> <li>• Policy Update Reports</li> <li>• Documents 'Sealed' Reports</li> <li>• Board Committee Highlight &amp; Annual Reports</li> <li>• Welsh Health Specialist Services Committee &amp; Emergency Ambulance Services Committee Joint Committee Briefings</li> <li>• Performance Reports</li> <li>• Financial Reporting</li> <li>• Annual Report and Accounts 2020/21</li> <li>• Trust Risk Register and TAF</li> <li>• Development of Integrated Medium Term Plan &amp; Progress Delivery Reports</li> <li>• Equality, Diversity &amp; Inclusion Ambassadors Showcases</li> <li>• Trust Strategy 2022-2032 and Overarching Cancer R&amp;D Ambitions for 2021-2031</li> <li>• Revisions to Velindre University NHS Trust Model Standing Orders and Standing Financial Instructions</li> <li>• Decision Making Framework in Command Structure</li> <li>• COVID-19 Updates</li> <li>• Support for the All Wales Positron Emission Tomography Programme (PET) Programme Business Case</li> <li>• South East Wales Acute Oncology Service Business Case</li> </ul>

Meeting:	Meeting Dates:	Activity:
		<ul style="list-style-type: none"> <li>• Infected Blood Inquiry Reporting</li> <li>• Wales Infected Blood Support Service (WIBSS) Annual Report</li> <li>• Velindre University NHS Trust Clinical Audit Report 2020/21</li> <li>• Blaenavon Data Centre Transition Project Update</li> <li>• Memorandum of Understanding for Partnership Board with Cardiff &amp; Vale UHB</li> <li>• Cardiff Cancer Research Hub, Proposal for Tripartite partnership between Cardiff and Vale UHB, Cardiff University and Velindre University NHS Trust</li> </ul>
<b>Advisory Consultant Appointments Committee</b>	Panels were held: <ul style="list-style-type: none"> <li>• 12.01.2022</li> <li>• 17.01.2022</li> <li>• 09.02.2022</li> </ul>	As and when required the Advisory Consultant Appointment Committee meet to manage the arrangements for appointments to NHS Consultant posts within the Trust.
<b>Trust Audit Committee</b>  Meeting Agendas, Minutes and Papers are available on the Trust Internet site here:  <a href="https://velindre.nhs.wales/about-us/audit-committee/">https://velindre.nhs.wales/about-us/audit-committee/</a>	<ul style="list-style-type: none"> <li>• 08.06.2021</li> <li>• 08.07.2021</li> <li>• 14.10.2021</li> <li>• 11.01.2022</li> </ul> All meetings were quorate.	The purpose of the Audit Committee is to:  Advise and assure the Board and the Accountable Officer on whether effective arrangements are in place - through the design and operation of the Trust's system of assurance - to support them in their decision taking and in discharging their accountabilities for securing the achievement of the Trust's objectives, in accordance with the standards of good governance determined for the NHS in Wales.  Where appropriate, the Committee will advise the Board and the Accountable Officer on where and how its system of assurance may be strengthened and developed further.  The Audit Committee Annual Report which outlines the activity of the Committee for the year ending 31 December 2021 was approved by the Audit Committee on 11 January 2022 and is available on the Trust Internet site here:  <a href="https://velindre.nhs.wales/about-us/audit-">https://velindre.nhs.wales/about-us/audit-</a>

Meeting:	Meeting Dates:	Activity:
<p><b>NHS Wales Shared Services Partnership Committee (SSPC)</b></p> <p>Meeting Agendas, Minutes and Papers are available on the Trust Internet site here:</p> <p><a href="https://nwssp.nhs.wales/nwssp-governance-and-assurance-arrangements/committee-schedule-and-papers/">https://nwssp.nhs.wales/nwssp-governance-and-assurance-arrangements/committee-schedule-and-papers/</a></p>	<ul style="list-style-type: none"> <li>• 21.01.2021</li> <li>• 18.03.2021</li> <li>• 20.05.2021</li> <li>• 22.07.2021</li> <li>• 23.09.2021</li> <li>• 18.11.2021</li> <li>• 24.03.2022</li> </ul> <p>All meetings were quorate.</p>	<p><a href="https://nwssp.nhs.wales/committee-papers-2022/audit-committee-agenda-and-papers-11-01-2022/">committee-papers-2022/audit-committee-agenda-and-papers-11-01-2022/</a></p> <p>The SSPC has been established for the purpose of exercising Velindre’s functions in relation to Shared Services, including the setting of policy and strategy and the management and provision of Shared Services to HBs, Trusts and Special Health Authority in Wales.</p>
<p><b>NHS Wales Shared Services Partnership Audit Committee (NWSSP)</b></p> <p>Meeting Agendas, Minutes and Papers are available on the Trust Internet site here:</p> <p><a href="https://nwssp.nhs.wales/nwssp-governance-and-assurance-arrangements/committee-schedule-and-papers/">https://nwssp.nhs.wales/nwssp-governance-and-assurance-arrangements/committee-schedule-and-papers/</a></p>	<ul style="list-style-type: none"> <li>• 20.04.2021</li> <li>• 29.06.2021</li> <li>• 12.10.2021</li> <li>• 25.01.2022</li> </ul> <p>All meetings were quorate.</p>	<p>The NWSSP Audit Committee Annual Review will be received at its July 2022. The previous review is available on the NWSSP website: <a href="https://nwssp.nhs.wales/about-us/our-publications/annual-review/">https://nwssp.nhs.wales/about-us/our-publications/annual-review/</a></p>
<p><b>Charitable Funds Committee</b></p> <p>Meeting Agendas, Minutes and Papers are available on the Trust Internet site here:</p> <p><a href="https://velindre.nhs.wales/about-us/charitable-funds/">https://velindre.nhs.wales/about-us/charitable-funds/</a></p>	<ul style="list-style-type: none"> <li>• 06.05.2021</li> <li>• 14.09.2021</li> <li>• 04.11.2021</li> <li>• 03.02.2022</li> </ul> <p>All meetings were quorate.</p>	<p>The Velindre University NHS Trust Board was appointed as Corporate Trustee of the Charitable Funds by virtue of the Velindre National Health Service Trust (Establishment) Order No. 2838 that came into existence on 1st December 1993 and that its Board serves as its agent in the administration of the Charitable Funds held by the Trust.</p> <p>The purpose of the Committee “is to make and monitor arrangements for the control and management of the Trust’s Charitable Funds”.</p> <p>The Charitable Funds Committee Annual Report for 2021/22, which outlines the activity of the Committee for the year ending 31 March 2022, will be received by the Committee for approval in May 2022.</p>



Meeting:	Meeting Dates:	Activity:
<p><b>Local Partnership Forum (LPF)</b></p>	<ul style="list-style-type: none"> <li>• 03.03.2021</li> <li>• 22.07.2021</li> <li>• 21.10.2021</li> <li>• 13.01.2022</li> </ul> <p>All meetings were quorate.</p>	<p>The purpose of the Local Partnership Forum (LPF) is:</p> <p>To provide a formal mechanism where the Trust, as employer and trade unions / professional bodies representing Trust employees (hereafter referred to as staff organisations) work together to improve health services for the citizens served by the Trust – achieved through a regular and timely process of consultation, negotiation and communication. In doing so, the LPF must effectively represent the Trust’s workforce.</p> <p>It is the forum where the Trust and staff organisations will engage with each other to inform, debate and seek to agree local priorities on workforce and health service issues; and inform thinking around national priorities on health matters.</p> <p>The Trust may specifically request advice and feedback from the LPF on any aspect of its business and the LPF may also offer advice and feedback even if not specifically requested by the Trust. The LPF may provide advice to the Board:</p> <ul style="list-style-type: none"> <li>○ In written advice or,</li> <li>○ In any other form specified by the Board.</li> </ul> <p>The Local Partnership Forum Annual Report for 2021/22, which outlines the activity of the Committee for the year ending 31 March 2022 will be submitted for approval at its meeting in insert date.</p>
<p><b>Quality, Safety &amp; Performance Committee</b></p> <p>Meeting Agendas, Minutes and Papers are available on the Trust Internet site here:</p> <p><a href="https://velindre.nhs.wales/about-">https://velindre.nhs.wales/about-</a></p>	<ul style="list-style-type: none"> <li>• 15.03.2021</li> <li>• 13.05.2021</li> <li>• 15.07.2021</li> <li>• 16.09.2021</li> <li>• 18.11.2021</li> <li>• 20.01.2022</li> <li>• 24.03.2022</li> </ul>	<p>The purpose of the Quality, Safety and Performance Committee is to provide:</p> <p>Evidence based and timely advice to the Board to assist it in discharging its functions and meeting its responsibilities with regard to the: quality, safety and performance of healthcare; all aspects of workforce; digital</p>

Meeting:	Meeting Dates:	Activity:
<a href="https://velindre.nhs.wales/about-us/quality-safety-performance/">us/quality-safety-performance/</a>	<p>All meetings were quorate.</p>	<p>delivery and information governance; and</p> <p>Assurance to the Board in relation to the Trust's arrangements for safeguarding and improving the quality, safety and performance of patient and service user centred healthcare, workforce matters, digital delivery and information governance in accordance with its stated objectives, legislative responsibilities and the requirements and standards determined for the NHS in Wales.</p> <p>The Quality, Safety &amp; Performance Committee Annual Report for the year ending 31 December 2021 was approved by the Committee on 18 November 2021 and is available on the Trust Internet site: <a href="https://velindre.nhs.wales/about-us/trust-board/trust-board-meeting-papers-2021/trust-board-agenda-and-papers-25-11-2021/">https://velindre.nhs.wales/about-us/trust-board/trust-board-meeting-papers-2021/trust-board-agenda-and-papers-25-11-2021/</a></p>
<p><b>Strategic Development Committee</b></p> <p>Meeting Agendas, Minutes and Papers are available on the Trust Internet site here:</p> <p><a href="https://velindre.nhs.wales/about-us/strategic-development-committee/">https://velindre.nhs.wales/about-us/strategic-development-committee/</a></p>	<ul style="list-style-type: none"> <li>• 08.04.2021</li> <li>• 10.06.2021</li> <li>• 12.08.2021</li> <li>• 07.10.2021</li> <li>• 08.11.2021</li> <li>• 09.12.2021</li> <li>• 10.02.2022</li> </ul> <p>All meetings were quorate.</p>	<p>The purpose of the Strategic Development Committee is to provide:</p> <p>Evidence based and timely advice to the Board to assist it in discharging its functions and responsibilities with regard to the:</p> <ul style="list-style-type: none"> <li>• strategic direction</li> <li>• strategic planning and related matters</li> <li>• organisational development</li> <li>• digital services, estates and other enabler services</li> <li>• sustainable development and the implementation of strategy through the spirit and intention of the Well Being of Future Generations Act</li> <li>• investment in accordance with Value-based healthcare</li> </ul> <p>Assurance to the Board in relation to strategic decision-making, ensuring it is supported with a robust understanding of risks in relation to the achievement of organisational goals and strategic objectives.</p> <p>Where appropriate, the Committee will advise</p>

Meeting:	Meeting Dates:	Activity:
		<p>the Board and the Accountable Officer on where, and how, its system of assurance may be strengthened and developed further.</p> <p>The Strategic Development Committee Annual Report which outlines the activity of the Committee for the year ending 31 December 2021 will be approved by the Committee on 23<sup>rd</sup> March 2022.</p>
<p><b>Remuneration Committee</b></p>	<ul style="list-style-type: none"> <li>• 28.04.2021</li> <li>• 24.06.2021</li> <li>• 26.08.2021</li> <li>• 28.10.2021</li> <li>• 30.12.2021</li> <li>• 24.02.2022</li> </ul> <p>All meetings were quorate.</p>	<p>The purpose of the Remuneration Committee is to provide:</p> <ul style="list-style-type: none"> <li>• <b>advice</b> to the Board on remuneration and terms of service for the Chief Executive, Executive Directors and other senior staff within the framework set by the Welsh Assembly Government; and</li> <li>• <b>assurance</b> to the Board in relation to the Trust's arrangements for the remuneration and terms of Service, including contractual arrangements, for <i>all staff</i>, in accordance with the requirements and standards determined for the NHS in Wales.</li> </ul> <p>And to perform certain, specific functions on behalf of the Board.</p>
<p><b>Research, Development &amp; Innovation (RDI) Sub-Committee</b></p> <p>Meeting Agendas, Minutes and Papers are available on the Trust Internet site here:</p> <p><a href="https://velindre.nhs.wales/about-us/research-development-and-innovation/research-development-and-innovation-meeting-papers/">https://velindre.nhs.wales/about-us/research-development-and-innovation/research-development-and-innovation-meeting-papers/</a></p>	<ul style="list-style-type: none"> <li>• 28.04.2021</li> <li>• 22.07.2021</li> <li>• 21.10.2021</li> <li>• 13.01.2022</li> </ul> <p>All meetings were quorate.</p>	<p>The purpose of the RD&amp;I Sub-Committee is to provide:</p> <ul style="list-style-type: none"> <li>• Strategy and policy oversight for Innovation and Research activities at the Trust and advise on and monitor performance in these areas.</li> <li>• Promotion and encouragement of an Innovation and Research ethos and culture which is integral to the Trusts vision, mission and values.</li> <li>• Evidence based timely advice to the Board to assist it in discharging its functions and meeting its responsibilities with regards to the quality and safety of Innovation and Research activity. In the relation to research this includes activity carried out within the Trust both as a research sponsor and host organisation.</li> <li>• Assurance to the Board in relation to the</li> </ul>

Meeting:	Meeting Dates:	Activity:
		<p>Trust's arrangements for ensuring compliance with the, and the EU Clinical Trials Directive 2004 as amended from time to time.</p> <ul style="list-style-type: none"> <li>• Foster collaboration and make recommendations on adoption and dissemination.</li> <li>• Consideration of relevant matters with reference to the parameters identified for risk appetite in relation to research, development and innovation as set by the Board.</li> </ul> <p>The RD&amp;I Sub-Committee Annual Report for 2021/22, which outlines the activity of the Committee for the year ending 31 March 2022 will be received for approval by the Committee in April 2022.</p>
<p><b>Transforming Cancer Services Programme Scrutiny Sub-Committee</b></p> <p>Meeting Agendas, Minutes and Papers are available on the Trust Internet site <a href="#">here</a>:</p>	<ul style="list-style-type: none"> <li>• 19.04.2021</li> <li>• 20.05.2021</li> <li>• 24.06.2021</li> <li>• 20.07.2021</li> <li>• 21.09.2021</li> <li>• 25.10.2021</li> <li>• 11.11.2021</li> <li>• 22.12.2021</li> <li>• 19.01.2022</li> <li>• 22.02.2022</li> <li>• 22.03.2022</li> </ul> <p>All meetings were quorate.</p>	<p>The purpose of the Transforming Cancer Services (TCS) Programme Scrutiny Sub-Committee is to:</p> <ul style="list-style-type: none"> <li>• Provide assurance that the leadership, management and governance arrangements are sufficiently robust to deliver the outcomes and benefits of the programme.</li> <li>• Scrutinise the progress of the programme and provide the Trust Board with assurance that implementation is effective, efficient and within the budget available.</li> <li>• Undertake any other scrutiny activity relating to the TCS Programme as directed by the Trust Board or Senior Responsible Owner (SRO).</li> <li>• Seek advice and guidance from appropriate Technical Advisors as well as the MIM Transactor (if relating to the nVCC Project) to assist the Committee with their scrutiny of the TCS Programme.</li> <li>• Provide assurance to the Trust Board on all aspects of the TCS Programme in relation to approvals sought on all decisions reserved for the full Board.</li> <li>• Receive all audit, gateway and</li> </ul>

Meeting:	Meeting Dates:	Activity:
		<p>assurance reviews pertaining to the programme or its constituent projects and provide assurance (or otherwise) to the Trust that the programme is being delivered in accordance with all professional, financial and Trust standards.</p> <ul style="list-style-type: none"> <li>• Provide assurance to the Trust Board and support to the Senior Responsible Officer in signalling the TCS closure activities once it has met its objectives.</li> <li>• Where appropriate, the Committee will advise the Trust Board and the Accountable Officer on where, and how, its system of assurance in relation to the TCS Programme may be strengthened and developed further.</li> </ul>

## APPENDIX 2–Board Member Attendance Trust Board Meetings 2021 - 2022

Key: ✓ In Attendance  
 ☒ Not in Attendance

Board Member	08/06/2021	29/07/2021	30/09/2021	25/11/2021	27/01/2022	31/03/2022
Prof. Donna Mead, Chair	✓	✓	✓	✓	✓	✓
Mr. Stephen Harries, Interim Vice Chair and Independent Member	✓	✓	✓	✓	✓	✓
Mr. Martin Veale, Independent Member	✓	✓	✓	✓	✓	✓
Mrs. Janet Pickles, Independent Member <b>(up to 30 September 2021)</b>	✓	✓	✓	N/A	N/A	N/A
Mrs. Vicky Morris, Independent Member <b>(from November 2021)</b>	N/A	N/A	N/A	✓	✓	✓
Mrs. Hilary Jones, Independent Member	✓	✓	✓	✓	✓	✓
Mr. Gareth Jones, Independent Member	✓	✓	☒	✓	✓	✓

Board Member	08/06/2021	29/07/2021	30/09/2021	25/11/2021	27/01/2022	31/03/2022
Professor Donald Fraser Independent Member <b>(up to 3 September 2021)</b>	<input checked="" type="checkbox"/>	✓	N/A	N/A	N/A	N/A
Professor Andrew Westwell Independent Member <b>(from August 2021)</b>	N/A	N/A	✓	✓	✓	✓
Mr. Steve Ham, Chief Executive	✓	✓	✓	✓	✓	✓
Mr. Mark Osland, Executive Director of Finance <b>(up to 30 September 2021)</b>	✓	✓	N/A	N/A	N/A	N/A
Mr. Matthew Bunce, Executive Director of Finance <b>(from 27 September 2021)</b>	N/A	N/A	✓	✓	✓	✓
Dr. Jacinta Abraham, Executive Medical Director	<input checked="" type="checkbox"/>	✓	<input checked="" type="checkbox"/>	✓	✓	<input checked="" type="checkbox"/>
Ms. Sarah Morley, Executive Director of Organisational Development & Workforce	✓	✓	✓	✓	✓	✓
Mrs. Nicola Williams, Executive Director of Nursing, AHPs & Health Science	✓	✓	✓	✓	✓	✓

## APPENDIX 3 – Ministerial Directions (Welsh Health Circulars)

Ministerial Directions (Welsh Health Circulars)	Date/Year of Adoption	Executive Lead(s)	Status
<b>(WHC/2021/012)</b> Implementing the agreed approach to preventing Violence & Aggression towards NHS staff in Wales.	22 April 2021	Director of Strategic Transformation, Planning & Digital and Chief Operating Officer.	This Ministerial Direction has been enacted.
<b>(WHC/2021/011)</b> 2021/22LHB, SHA & Trust Monthly Financial Monitoring Return Guidance.	23 April 2021	Executive Director of Finance.	This Ministerial Direction has been enacted.
<b>(WHC/2021/019)</b> The National Influenza Immunisation Programme.	04 August 2021	Executive Director of Nursing, Allied Health Professions and Health Science.	This Ministerial Direction has been enacted.
<b>(WHC/2021/024)</b> NHS Wales' contribution towards a net-zero public sector by 2030.	08 September 2021	Director of Strategic Transformation, Planning & Digital.	This Ministerial Direction has been enacted.
<b>(WHC/2021/010)</b> Amendment to model standing orders, reservation and delegation of powers and model standing financial instructions – NHS Wales.	16 September 2021	Director of Corporate Governance & Chief of Staff and Executive Director of Finance.	This Ministerial Direction has been enacted.
<b>(WHC/2021/022)</b> Publication of the quality and safety framework.	17 September 2021	Executive Director of Nursing, Allied Health Professions and Health Science.	This Ministerial Direction has been enacted.
<b>(WHC/2021/023)</b> Care Decisions for the Last Days of Life.	23 September 2021	Executive Director of Nursing, Allied Health Professions and Health Science.	This Ministerial Direction has been enacted.
<b>(WHC/2021/027)</b> NHS Wales Blood Health Plan	27 September 2021	Chief Operating Officer.	This Ministerial Direction has been enacted.



Ministerial Directions (Welsh Health Circulars)	Date/Year of Adoption	Executive Lead(s)	Status
<b>(WHC/2021/031)</b> NHS Wales Planning Framework 2022-2025	09 November 2021	Director of Strategic Transformation, Planning & Digital.	This Ministerial Direction has been enacted.
<b>(WHC/2021/034)</b> Health Board Allocations 2022-2023	09 February 2022	Executive Director of Finance.	This Ministerial Direction has been enacted.
<b>(WHC/2022/014)</b> AMR & HCAI Improvement Goals For 2021-23	01 March 2022	Executive Director of Nursing, Allied Health Professions and Health Science.	This Ministerial Direction has been enacted.
<b>(WHC/2022/011)</b> COVID 19 Patient Testing Framework – Updated Guidance	24 March 2022	Executive Director of Nursing, Allied Health Professions and Health Science.	This Ministerial Direction has been enacted.
<b>(WHC/2022/005)</b> Data requirements for Value Based Healthcare	24 March 2022	Executive Director of Finance and Director of Strategic Transformation, Planning & Digital.	This Ministerial Direction has been enacted.
<b>(WHC/2022/010)</b> Reimbursable vaccines and eligible cohorts for the 2022/23 NHS Seasonal Influenza (flu) Vaccination Programme	29 March 2022	Executive Director of Nursing, Allied Health Professions and Health Science.	This Ministerial Direction has been enacted.

---

## FINANCIAL ACCOUNTABILITY REPORT

---

The Trust continues to operate in a challenging financial environment like all organisations in NHS Wales, which was particularly difficult in 2021/2022 as a result of the ongoing impact of the COVID-19 pandemic. Despite the pandemic, opportunities to make efficiency savings and identify recurring reductions in costs whilst maintaining and improving services are sought wherever possible by Directors, finance teams and staff across the organisation.

The Core Trust Services incurred additional revenue spend of £11.521m and capital spend of £675k (2020/2021 revenue spend of £6.291m and capital spend of £1.845m) in its response to the pandemic. Welsh Government provided the Trust with funding to cover these COVID-19 related issues which ensured they did not impact on the Trust meeting the key target of its expenditure not exceeding income.

Despite these challenges, the Trust was able to achieve all three financial targets set by Welsh Government in 2021/2022. This will remain a difficult task in 2022/2023 and the foreseeable future as the Trust continues to respond to the transition out of the pandemic and invest in additional capacity to enable it to deal with activity backlogs, which will require additional Commissioner and Welsh Government funding in order that the Trust can continue to meet its financial targets.

The Trust remains committed to providing high value, quality and safe care with the best possible outcomes for its patients, while striving to deliver this through efficient and effective services, and therefore seeking opportunities to make efficiency savings and identify recurring reductions in costs will continue to be a priority focus for the organisation.

---

## FINANCIAL TARGETS

---

The Trust has met all three of its financial targets for the year ended 31<sup>st</sup> March 2022:

- Breakeven duty - The Trust achieved a surplus of £41k in 2021/2022 (2020/2021: surplus of £38k; 2019/2020 surplus of £24k), resulting in a surplus of £103k over a three year period. The Trust has therefore achieved its statutory financial duty to achieve financial breakeven over a rolling three year period.
- Duty to prepare a 3 year integrated plan – Due to the pandemic, the process for the 2020/2023 integrated plan was paused in spring 2020 and temporary quarterly planning arrangements were implemented. As a result, the extant planning duty for 2021/2022 remains the

requirement to submit and have approved a 2019/2022 integrated plan, as set out in the NHS Wales Planning Framework 2019/2022. The Trust submitted a 2019/2022 integrated plan in accordance with the planning framework and has therefore met its statutory duty to have an approved financial plan.

- Creditor payments - The Trust is required to pay 95% of the number of non- NHS bills within 30 days of the receipt of goods or a valid invoice (whichever is the later). The Trust has met this target, paying 95.7% (2020/2021: 96.7%) within the required time.

The Trust ordinarily would have four financial targets to meet: the fourth being the External Finance Limit (EFL). The Welsh Government temporarily removed this target in 2019/2020 and are expected to reintroduce it in 2022/2023.

---

## **FEES & CHARGES - AUDITOR REMUNERATION**

---

Fees paid to Audit Wales for their statutory audit and performance audit work were £223,783 by the Trust, and £15,000 by the Trust's Charitable Fund.

---

## **MATERIAL REMOTE CONTINGENT LIABILITIES**

---

The Trust hosts the Welsh Risk Pool (WRP) as part of NHS Wales Shared Services Partnership (NWSSP). The WRP returns from Welsh Health Organisations estimate that in 2021/2022 the Trust has remote contingent liabilities of £60m (2020/2021: £61m) which relate to potential litigation claims against NHS Wales that could arise in the future due to known incidents. Due to the nature and uncertainty of these potential claims, no provision has been made for them within the accounts.

## LONG TERM EXPENDITURE TRENDS

	2017/2018	2018/2019	2019/2020	2020/2021	2021/2022
	£000	£000	£000	£000	£000
<b>Total Revenue</b>	<b>712,828</b>	<b>525,607</b>	<b>572,642</b>	<b>848,405</b>	<b>1,044,074</b>
Pay	149,866	160,551	182,684	242,072	294,020
Non Pay	549,774	352,075	373,015	587,320	738,544
Depreciation	17,595	16,466	17,186	17,554	10,222
<b>Total Expenditure</b>	<b>717,235</b>	<b>529,092</b>	<b>572,885</b>	<b>846,946</b>	<b>1,042,786</b>
<b>Non-operating revenue and costs</b>	<b>5,613</b>	<b>3,295</b>	<b>440</b>	<b>(207)</b>	<b>(953)</b>
<b>Total consolidated surplus / (deficit)</b>	<b>1,206</b>	<b>(190)</b>	<b>197</b>	<b>1,252</b>	<b>335</b>

The table above includes the income and expenditure of the Trust's charitable fund and assets that have been donated to the Trust, and, in the case of 2021/2022, assets that have been donated by NWSSP. The Trust's annual surplus / (deficit) excluding the charitable fund and donated assets is shown below:

	2017/2018	2018/2019	2019/2020	2020/2021	2021/2022
	£000	£000	£000	£000	£000
<b>Surplus / (deficit) excluding charitable fund and donated assets</b>	<b>49</b>	<b>31</b>	<b>24</b>	<b>38</b>	<b>41</b>

### Notes

- During 2018/2019 the Wales Workforce Education & Development Services (WEDS), which was part of the NHS Wales Shared Services Partnership (NWSSP), was transferred from the Trust into the newly established Health Education & Improvement Wales (HEIW). The transfer of WEDS resulted in a significant reduction in the income and expenditure reported within the above table, but had no impact on the surplus / deficit for the year.
- During 2019/2020 two new all Wales services were established within NWSSP - the Medical Examiner Scheme and the General Medical Practice Indemnity Scheme.
- During 2020/2021 a new All Wales service was established within NWSSP – the Collaborative Bank Partnership; and two existing services commenced expansion – the Single Lead Employer Scheme and the General Medical Practice Indemnity Scheme to include the first phased intake to the Existing Liability Scheme.

- 2021/2022 saw the NHS Wales Informatics Service (NWIS), transition out of the Trust on 1<sup>st</sup> April 2021 to the newly established Special Health Authority, Digital Health & Care Wales (DHCW). NWSSP continued expansion of the Single Lead Employer Scheme and established a new All Wales service – the All Wales Laundry Service.

---

## **MODERN SLAVERY ACT 2015**

### **TRANSPARENCY IN SUPPLYCHAINS STATEMENT 2021/2022**

---

This statement is made to comply with Section 54 of the Modern Slavery Act 2015 and the Welsh Government’s Code of Practice: Ethical Employment in Supply Chains. The Statement sets out the steps that Velindre University NHS Trust has taken and is continuing to take, to make sure that modern slavery and / or human trafficking is not taking place within the Trust or its supply chains during the year ending 31<sup>st</sup> March 2022.

Modern slavery encompasses slavery, servitude, human trafficking and forced labour. The Trust has a zero-tolerance approach to any form of modern slavery (slavery, servitude, human trafficking and forced labour). We are committed to acting ethically and with integrity and transparency in all business activity and to establish effective systems and controls, to safeguard against any form of modern slavery occurring within the Trust’s supply chains.

The Trust is also fully committed to complying with its legal obligations. In doing so, it is committed as an NHS employer, to eradicate modern slavery and human trafficking, by combating unlawful and unethical employment practices and to support those affected.

The Trust will not undertake any employment practices that;

- Support modern slavery and human rights abuses;
- Support or abet the operation of blacklist / prohibited lists;
- Facilitate false self-employment;
- Permits the use of unfair umbrella schemes;
- Provide employees or workers with zero hours contracts; and
- Facilitate the payment of salaries which are lower than the National Living Wage.

## **Current Policies and Initiatives**

The Trust is fully aware of its responsibilities towards patients, donors, service users, employees and the local community, and expects all employees and suppliers to act ethically and with integrity, in all our business relationships.

The Trust produced its first 'Ethical Employment Statement' in 2019, which was approved by the Trust Board and published in the 2019/2020 Annual Report and on the Trust's Internet / Intranet sites. This report set out the Trust's commitment to producing an annual written statement, in relation to its obligations under the Modern Slavery Act (2015) in 2019.

The Trust takes the following steps, to ensure that there is no modern slavery or human trafficking in our supply chains or in any part of our business:

### **People**

- The Trust is fully compliant with the six NHS pre-employment check requirements, to verify that applicants meet the preconditions of the role they are applying for. This includes a right to work in the UK check;
- The Trust has a robust IR35 policy and processes in place, which ensures that there is no unfair use of false self-employed workers or workers being engaged under umbrella schemes. This process ensures the fair and appropriate engagement of all workers and prevents individuals from avoiding paying Tax and National Insurance contributions.
- The Trust does not engage or employ employees or workers on Zero Hours Contracts. The Trust does employ Bank Staff, but these staff are provided with the opportunity to apply for substantive posts should they wish to.
- The Trust pays our lowest paid employees on Pay Band 2 (the lowest NHS Wales pay band). This salary is compliant with the National Living Wage.
- The Trust has an Equality and Diversity Policy and a range of processes and procedures which ensures that no potential applicant, employee or worker engaged by the Trust is in any way unduly disadvantaged in terms of pay, employment rights, employment, training and development and career opportunities;
- In 2020 the Trust has launched a Working in Confidence platform that allows staff to raise and resolve concerns confidentially
- The Trust has in place a range of workforce policies e.g. Respect and Resolution Policy, Grievance Policy, Dignity at Work Procedure, Anonymous Communications, Violence, Domestic Abuse and Sexual Violence in the Workplace; etc. Our policies enable our employees to raise concerns about poor working practices.
- The Trust complies fully with the Transfer of Undertaking (Protection of Employment)

Regulations ensuring that Trust employees that may be required to transfer to a new organisation, will retain their current NHS Terms and Conditions of Service; and

- The Trust does not make use of blacklist / prohibited list information.

## **Procurement and our Supply Chain**

- The Trust's Procurement Team operates within the current UK and NHS procurement regulations and includes a mandatory exclusion question regarding the Modern Slavery Act 2015.
- The Trust's NWSSP Supplier Policy sets out the manner in which we behave as an organisation and how we expect procurement employees and suppliers to act.
- The Trust's Procurement Team's approach to procurement and our supply chain includes:
  - Ensuring that our suppliers are carefully selected through robust supplier selection criteria/processes;
  - Requiring that the main contractor provides details of its sub- contractor(s), to enable the Procurement Team on behalf of the Trust to check their credentials;
  - Randomly request that the main contractor provide details of its supply chain;
  - Ensuring invitation to tender documents contain a clause on human rights issues;
  - Ensuring invitation to tender documents also contain clauses giving the Trust the right to terminate a contract for failure to comply with labour laws;
  - Using a Supplier Selection Questionnaire which includes a section on Modern Day Slavery;
  - Trust staff must contact and work with the Procurement Team when looking to work with new suppliers, to ensure that appropriate checks can be undertaken;
  - Ensuring supplier adherence to the Trust and NHS Wales values. We are zero tolerant to slavery and human trafficking and thereby expect all our direct and indirect suppliers /contractors to be compliant;
- Assurances are sought from suppliers, via the tender process, that they do not make use of blacklists/prohibited lists. The Trust is also able to provide confirmation and assurances that the Trust does not make use of blacklist/prohibited list information.
- The Transparency in Supply Chain (TISC) Report – Modern Slavery Act (2015) compliance tracker is used, through contracts procured by NWSSP Procurement Services on the Trust's behalf.

## **Training**

- Advice and training about modern slavery and human trafficking is provided to employees

through our mandatory safeguarding children and adults training programmes, our safeguarding policies and procedures and our safeguarding lead. The Trust is exploring new ways to continuously increase awareness within our organisation and to ensure a high level of understanding of the risks involved with modern slavery and human trafficking, in our supply chains and in our business.

## **Policies and Initiatives 2021 /2022**

In the forthcoming year, the Trust is committed to taking the following actions to continue to ensure that modern slavery and / or human trafficking is not taking place within our organisation or supply chain during the year ending 31<sup>st</sup> March 2022.

### **People**

- The Trust complies with the IR35 Legislation, which came into effect on the 6<sup>th</sup> April 2021.
- The Trust will use internal communications to promote and raise employee awareness of modern slavery and human trafficking.
- The Trust has purchased a Working in Confidence Platform
- The Trust's Safeguarding lead will be updating the Safeguarding Guidance Booklet for staff to include the modern slavery pathway.

---

## **REMUNERATION & STAFF REPORT**

---

The details of the Remuneration Relationship are reported on page 83 of the Accountability Report, and note 10.6 of the Annual Accounts.

The pay and terms and conditions of employment for the Executive Team and senior managers have been and will be determined by the Velindre University NHS Trust Remuneration and Terms of Service Committee, within the framework set by the Welsh Government. The Remuneration and Terms of Service Committee also considered and approved applications relating to the voluntary early release scheme. The Trust Remuneration Committee members are Independent Members of the Board and a Trade Union Representative. The Committee is chaired by the Trust Chair. Details of the membership of the Remuneration & Terms of Service Committee are captured on pages 8-12 of the Directors' Report section of this report.

Existing public sector pay arrangements apply to all staff including members of the Executive Team. All members of the Executive Team are on pay points and not pay scales. The performance of



members of the Executive Team is assessed against personal objectives and against the overall performance of the Trust. The Trust does not operate a performance related pay scheme.

All Executive Directors have the option to have a lease car, under the terms of the Trust's lease car agreement.

The Chief Executive and Executive Directors are employed on permanent contracts, which can be terminated by giving due notice unless for reasons of misconduct.

There have been no payments to former Executives or other former senior managers during the year.

The remuneration report is required to contain information about senior managers' remuneration. The senior management team consists of the Chief Executive, the Executive Directors and the Independent Members (Non-Executive Directors), the Director of Transformation, Planning, and Digital, the Chief Operating Officer and the Director of Corporate Governance / Board Secretary / Chief of Staff. Full details of senior managers' remuneration are shown later in the table that starts on page 84.

The totals in some of the following tables may differ from those in the Annual Accounts as they represent staff in post as at 31<sup>st</sup> March 2022 whilst the Annual Accounts (note 10.2) shows the average number of operational employees during the year.

## **Transparency of senior remuneration in the devolved Welsh Public Sector – ANNEX 10.**

### **Guide to Tackling Unfair Employment Practices and False Self-Employment -**

<https://gov.wales/docs/dpsp/publications/valuewales/170620-unfair-employment-en.pdf> - ANNEX 10

---

## **STAFF COMPOSITION BY SEX**

---

A breakdown of the workforce by sex is set out in the table below. This figure represents the composition as at 31<sup>st</sup> March 2022. To note it excludes those in Bank, Locum and Honorary positions.

\*FTE – Full-time Equivalent

Sex	Headcount	FTE*	% of Headcount
Female	1,221	1,050.84	75.00%
Male	407	381.52	25.00%
<b>Grand Total</b>	<b>1,628</b>	<b>1,432.35</b>	<b>100%</b>

A breakdown of the Trust Executive Directors and Senior Managers by sex is set out in the table below. This figure represents the composition as at 31<sup>st</sup> March 2022. The data confirms that there are more female than male Trust Executive Directors and Senior Managers. Female employees are employed in five out of the eight Trust Executive Directors and Senior Manager posts.

Job Title	Sex	Headcount	FTE*	% of Headcount
Chief Executive Officer	Male	1	1	12.50%
Chief Operating Officer	Female	1	1	12.50%
Executive Director of Finance	Male	1	1	12.50%
Executive Medical Director	Female	1	1	12.50%
Executive Director of Nursing, AHP and Healthcare Science	Female	1	1	12.50%
Executive Director of Organisational Development & Workforce	Female	1	1	12.50%
Director of Strategic Transformation, Planning & Digital	Male	1	1	12.50%
Director of Corporate Governance & Chief of Staff	Female	1	1	12.50%
<b>Grand Total</b>		<b>8</b>	<b>8</b>	<b>100%</b>
	<b>Male</b>	<b>3</b>		<b>37.50%</b>
	<b>Female</b>	<b>5</b>		<b>62.50%</b>

---

## STAFF COMPOSITION BY STAFF GROUP

---

During 2021/2022 the average full time equivalent (FTE) number of operational staff permanently employed by the Trust was 3,606. The average number of employees is calculated as the full time

equivalent number of employees in each week of the financial year divided by the number of weeks in the financial year. The table below provides a breakdown of the workforce by staff grouping and in addition to permanently employed staff, shows staff on inward Secondment, agency staff and other staff.

	Average FTE Number of Operational Employees						
	Permanently Employed	Staff on Inward Secondment	Agency Staff	Specialist Trainee	Other Staff	2021/2022 Total	2020/2021 Total
Administrative, Clerical and Board Members	1,957	13	21	0	38	<b>2,029</b>	2,643
Medical and Dental	95	4	0	13	5	<b>117</b>	121
Nursing and Midwifery Registered	198	0	0	0	6	<b>204</b>	195
Professional, Scientific and Technical Staff	72	0	0	0	1	<b>73</b>	65
Additional Clinical Services	219	0	3	0	25	<b>247</b>	316
Allied Health Professionals	130	3	6	0	0	<b>139</b>	132
Healthcare Scientists	144	1	0	0	8	<b>153</b>	142
Estates and Ancillary	503	0	45	0	93	<b>641</b>	456
Students	3	0	0	0	0	<b>3</b>	3
<b>Total</b>	<b>3,321</b>	<b>21</b>	<b>75</b>	<b>13</b>	<b>176</b>	<b>3,606</b>	<b>4,073</b>

## SICKNESS ABSENCE DATA 2021/22

The data shows that, whilst more staff have had sickness absence during 2021/22, the average length of absence has been shorter than in 2020/21.

<b>Report</b>	<b>2021/22</b>	<b>2020/21</b>	<b>Variance</b>
Total Days Lost (Long Term):	23793	43443	-19,649
Total Days Lost (Short Term):	9803	14089	-4,286
<b>Total Days Lost:</b>	<b>33596</b>	<b>57532</b>	<b>-23935.96</b>
Average Staff Employed in the Period – FTE	2618.27	4378.12	-1759.85
<b>Average Working Days Lost (FTE):</b>	<b>9.40</b>	<b>13.72</b>	<b>-4.32</b>
Total Staff Employed in Period:	2083	4796	-2713
Total Staff Employed in Period with No Sickness Absence (Headcount):	645	3133	-2,488
<b>Percentage Staff with No Sick Leave:</b>	<b>40.09</b>	<b>62.19</b>	<b>-22.1</b>

The Workforce team work with Divisions to manage the wellbeing of staff and sickness absence. Monthly performance reports are developed for Divisions and Executive colleagues to monitor sickness and COVID sickness absence. Interventions to support managers are aligned to reasons for sickness to ensure effective interventions that support staff. Regular sickness audits are undertaken and manager drop in session are available to support managers in ensuring staff are encouraged back to work.

The Trust also offers and provides staff with free access to a diverse range of traditional medical, psychological and complementary therapy interventions, to assist them to proactively and reactively manage their health and wellbeing. This includes an Employee Assistance Programme (EAP), which family members can also access for free.

The top reason for sickness absence across the Trust continues to be psychological ill health. To provide staff with appropriate and additional support in an unprecedented year, the Trust has focused on interventions to support the psychological wellbeing of our staff. This has included drop in session with our wellbeing team as well as on site support from our EAP service. As part of our Health and Wellbeing plan we are training mental health first aid champions and run a number of staff networks to support staff.

---

## **STAFF POLICIES**

---

All Trust policies and procedures are equality impact assessed against the nine protected characteristics, to ensure that they do not discriminate against people who apply to work in the Trust or are employed by the Trust. All Trust policies and procedures are available to access via the Trust Internet website.

---

### **SALARY AND PENSION DISCLOSURE TABLES (AUDITED) – SINGLE TOTAL FIGURE OF REMUNERATION**

---

This Remuneration Report includes a single total figure of remuneration. The amount of pension benefits for the year which contributes to the single total figure is calculated based on guidance provided by the NHS Business Services Authority Pensions Agency.

The amount included in the table for pension benefit is based on the increase in accrued pension adjusted for inflation. This will generally take into account an additional year of service together with any changes in pensionable pay. This is not an amount which has been paid to an individual by the Trust during the year; it is a calculation which uses information from the pension benefit table. These figures can be influenced by many factors e.g. changes in a person's salary, whether or not they choose to make additional contributions to the pension scheme from their pay, and other valuation factors affecting the pension scheme as a whole.

The salary and pension disclosures reflect the senior managers' information. As indicated on pages 8-16 the senior management team consists of the Chief Executive, the Executive Directors and the Independent Members (Non-Executive Directors), the Director of Strategic Transformation, Planning, and Digital, the Chief Operating Officer, and the Director of Corporate Governance / Board Secretary / Chief of Staff.

**SALARY AND PENSION DISCLOSURE TABLES (AUDITED) –  
SINGLE TOTAL FIGURE OF REMUNERATION (CONTINUED)**

Name and Title	2021/2022					2020/2021				
	Salary (bands of £5,000)	Other Remuneration (bands of £5,000)	Benefits in Kind (to the nearest £100)	Pension benefits (to the nearest £1,000)	Total (to the nearest £5,000)	Salary (bands of £5,000)	Other Remuneration (bands of £5,000)	Benefits in Kind (to the nearest £100)	Pension benefits (to the nearest £1,000)	Total (to the nearest £5,000)
<b>Executive Directors and Senior Managers</b>										
Steve Ham Chief Executive	145-150	0	0	45	190-195	140-145	0	0	23	165-170
Mark Osland Executive Director of Finance <sup>1</sup>	55-60	0	0	16	70-75	105-110	0	0	27	130-135
Matthew Bunce Executive Director of Finance <sup>2</sup>	55-60	0	0	79	135-140					
Jacinta Abraham Executive Medical Director <sup>3</sup>	115-120	30-35	0	86	230-235	110-115	25-30	0	48	190-195
Catherine O'Brien Chief Operating Officer <sup>4</sup>	120-125	0	0	63	180-185	115-120	0	0	22	135-140
Lauren Fear Director of Corporate Governance	90-95	0	0	22	110-115	85-90	0	0	21	105-110
Nicola Williams Executive Director of Nursing, AHP and Healthcare Scientists	110-115	0	0	53	165-170	105-110	0	0	38	145-150

Name and Title	2021/2022					2020/2021				
	Salary (bands of £5,000)	Other Remuneration (bands of £5,000)	Benefits in Kind (to the nearest £100)	Pension benefits (to the nearest £1,000)	Total (to the nearest £5,000)	Salary (bands of £5,000)	Other Remuneration (bands of £5,000)	Benefits in Kind (to the nearest £100)	Pension benefits (to the nearest £1,000)	Total (to the nearest £5,000)
Sarah Morley Executive Director of Organisational Development and Workforce	95-100	0	0	38	135-140	95-100	0	0	26	120-125
Carl James Director of Strategic Transformation, Planning, and Digital <sup>5</sup>	120-125	0	1	50	170-175	115-120	0	40	32	150-155

Notes:

1. M Osland left the Trust on 30/09/2021. The annualised salary band for this role was £110-115k.
2. M Bunce was appointed to the role of Executive Director of Finance on 27/09/2021. The annualised salary band for this role was £110-115k. The Pensions Agency are unable to provide comparator information for 2020/2021 as it was not generated at the time and cannot be reproduced at a later date.
3. Other remuneration for J Abraham relates to clinical responsibilities
4. C O'Brien was appointed on an interim basis in 2019. This appointment was made permanent on 01/11/2021
5. Benefits in kind for C James relate to the use of a Trust lease car and taxable mileage payments

**SALARY AND PENSION DISCLOSURE TABLES (AUDITED) –  
SINGLE TOTAL FIGURE OF REMUNERATION (CONTINUED)**

Name and Title	2021/2022					2020/2021				
	Salary (bands of £5,000)	Other Remuneration (bands of £5,000)	Benefits in Kind (to the nearest £100)	Pension benefits (to the nearest £1,000)	Total (to the nearest £5,000)	Salary (bands of £5,000)	Other Remuneration (bands of £5,000)	Benefits in Kind (to the nearest £100)	Pension benefits (to the nearest £1,000)	Total (to the nearest £5,000)
<b>Independent Members/Non -Executive Directors</b>										
Donna Mead	40-45	0	0	0	40-45	40-45	0	0	0	40-45
Janet Pickles <sup>1</sup>	0-5	0	0	0	0-5	5-10	0	0	0	5-10
Martin Veale	5-10	0	0	0	5-10	5-10	0	0	0	5-10
Stephen Harries	30-35	0	0	0	30-35	30-35	0	0	0	30-35
Donald Fraser <sup>2</sup>	0-5	0	0	0	0-5	5-10	0	0	0	5-10
Gareth Jones	5-10	0	0	0	5-10	5-10	0	0	0	5-10
Hilary Jones	5-10	0	0	0	5-10	5-10	0	0	0	5-10
Andrew Westwell <sup>3</sup>	0-5	0	0	0	0-5					
Vicky Morris <sup>4</sup>	0-5	0	0	0	0-5					

- 1 J Pickles' term ended on 30/09/2021
- 2 D Fraser's term ended on 03/09/2021
- 3 A Westwell's term started on 10/08/2021
- 4 V Morris' term stated on 12/11/2021



---

## **SALARY AND PENSION DISCLOSURE**

---

---

### **CASH EQUIVALENT TRANSFER VALUES**

---

A Cash Equivalent Transfer Value (CETV) is the actuarially assessed capital value of the pension scheme benefits accrued by a member at a particular point in time. The benefits valued are the member's accrued benefits and any contingent spouse's pension payable from the scheme. A CETV is a payment made by a pension scheme or an arrangement to secure pension benefits in another pension scheme or an arrangement when the member leaves a scheme and chooses to transfer the benefits accrued in their former scheme.

The pension figures shown relate to the benefits that the individual has accrued as a consequence of their total membership of the pension scheme, not just their service in a senior capacity to which disclosure applies. The CETV figures and the other pension details include the value of any pension benefits in another scheme or arrangement which the individual has transferred to the NHS pension scheme. They also include any additional pension benefit accrued to the member as a result of their purchasing additional years of pension service in the scheme at their own cost. CETVs are calculated within the guidelines and framework prescribed by the Institute and Faculty of Actuaries.

---

### **REAL INCREASE IN CETV**

---

This reflects the increase in CETV effectively funded by the employer. It takes account of the increase in accrued pension due to inflation, contributions paid by the employee (including the value of any benefits transferred from another scheme or arrangement) and uses common market valuation factors for the start and end of the period.

**SALARY AND PENSION DISCLOSURE TABLES (AUDITED) – BOARD MEMBER AND VERY SENIOR MANAGER PENSIONS**

Name and Title	Real increase in pension at pension age (bands of £2,500)	Real increase in pension lump sum at pension age (bands of £2,500)	Total accrued pension at pension age at 31 March 2022 (bands of £5,000)	Lump sum at pension age related to accrued pension at 31 March 2022 (bands of £5,000)	Cash Equivalent Transfer Value at 31 March 2022	Cash Equivalent Transfer Value at 31 March 2021	Real increase in Cash Equivalent Transfer Value	Employer's contribution to stakeholder pension
	£000	£000	£000	£000	£000	£000	£000	£000
Steve Ham Chief Executive <sup>1</sup>	2.5-5	7.5-10	40-45	130-135	-	-	-	-
Mark Osland Executive Director of Finance <sup>2</sup>	0-2.5	0	10-15	0	185	143	12	-
Matthew Bunce Executive Director of Finance <sup>3</sup>	2.5-5	10-12.5	45-50	110-115	948	756	75	-
Jacinta Abraham Executive Medical Director	5-7.5	5-7.5	50-55	100-105	1,035	919	89	-
Catherine O'Brien Chief Operating Officer <sup>4</sup>	2.5-5	0	25-30	0	419	347	51	-
Lauren Fear Director of Corporate Governance	0-2.5	0	0-5	0	35	19	4	-
Nicola Williams Executive Director Nursing, AHP and Healthcare Scientists	2.5-5	2.5-5	50-55	130-135	1,035	956	59	-

Name and Title	Real increase in pension at pension age (bands of £2,500)	Real increase in pension lump sum at pension age (bands of £2,500)	Total accrued pension at pension age at 31 March 2022 (bands of £5,000)	Lump sum at pension age related to accrued pension at 31 March 2022 (bands of £5,000)	Cash Equivalent Transfer Value at 31 March 2022	Cash Equivalent Transfer Value at 31 March 2022	Real increase in Cash Equivalent Transfer Value	Employer's contribution to stakeholder pension
	£000	£000	£000	£000	£000	£000	£000	£000
Sarah Morley Executive Director of Organisational Development and Workforce	0-2.5	0-2.5	30-35	65-70	638	581	40	-
Carl James Director of Strategic Transformation, Planning & Digital	2.5-5	0	50-55	0	706	647	38	-

Notes:

1. S Ham - no CETV will be shown for senior managers over Normal Pension Age (NPA)
2. M Osland left the Trust on 30/09/2021
3. M Bunce was appointed on 27/09/2021
4. C O'Brien was appointed on an interim basis in 2019. This appointment was made permanent on 01/11/2021

As Independent Members do not receive pensionable remuneration, there are no entries in respect of pensions for Independent Members.

---

## **REPORTING OF OTHER COMPENSATION SCHEMES – EXIT PACKAGES**

---

During 2021/2022 exit packages were approved for 2 staff with a value of £101,773 (7 staff, value £252,756 2020/2021). £25,899 exit costs were paid in 2021/2022, the year of departure (£34,419 2020/2021). These packages were paid in accordance with recognised NHS terms and conditions of service/Trust Policy. None of the exit packages reported related to senior officers. None of the payments related to a special severance payment. The actual date of departure might be in a subsequent period.

---

## **REMUNERATION RELATIONSHIP**

---

Reporting bodies are required to disclose the relationship between the remuneration of the highest paid Director in their organisation and the median remuneration of the organisation's workforce.

The banded remuneration of the highest paid director in Velindre University NHS Trust in the financial year 2021/2022 was £145,000 - £150,000 (2020/2021, £140,000 - £145,000). This was 5.6 times (2020/2021, 4.7) the median remuneration of the workforce, which was £26,365 (2020/2021, £30,516).

In 2021/2022, 8 (2020/2021, 13) employees received remuneration in excess of the highest paid Director.

Remuneration for all staff ranged from £18,600 to £227,500 (2020/2021 £18,000 to £234,100).

Total remuneration includes salary and benefits in kind. It does not include severance payments, employer pension contributions and the cash equivalent transfer value of pensions.

Overtime payments are included in the calculation of both elements of the relationship.

The NHS and social care financial recognition scheme bonus of £735 payment to reward eligible NHS staff has not been included in the NHS Remuneration Report calculations. This bonus payment was not a contractual payment, but a one off payment to reward eligible staff for their commitment and tireless efforts in the most challenging circumstances. The cost of this payment was included in the operating expenses reported in the year 2020/2021, whilst the payment was made in early 2021/2022.

---

## EXPENDITURE ON CONSULTANCY

---

During 2021/2022 the Trust spent £4.224m of its revenue funding on external consultancy fees (£3.383m related to the NHS Wales Shared Services Partnership); and £2.407m of its capital funding on external consultancy fees (£nil related to the NHS Wales Shared Services Partnership).

Examples include:

- Accountancy fees
- Legal fees
- Design fees
- Project management fees & support costs
- IT consultancy and advice
- Fees relating to building management, including surveyor & electrical costs.

---

## TAX ASSURANCE FOR OFF-PAYROLL ENGAGEMENTS

---

Following the Review of Tax Arrangements of Public Sector Appointees published by the Chief Secretary to the Treasury on 23<sup>rd</sup> May 2012, departments must publish information on their highly paid and/or senior off-payroll engagements. The information, contained in the three tables below, includes all off-payroll engagements as at 31<sup>st</sup> March 2022 for those earning more than £245 per day for the core Trust and its hosted organisations.

**Table 1:** For all off-payroll engagements as of 31<sup>st</sup> March 2022, for those earning more than £245 per day

No. of Existing Engagements as of 31 <sup>st</sup> March 2022	16
Of which the number that have existed.	
for less than one year at time of reporting.	8
for between one and two years at time of reporting.	2
for between two and three years at time of reporting.	3
for between three and four years at time of reporting.	0
for four or more years at time of reporting.	3

Within the total number of off-payroll engagements disclosed, four engagements related to staff seconded from other NHS Wales Organisations.

All the off-payroll engagements, outlined above, have at some point been subject to a risk based assessment as to whether assurance is required that the individual is paying the right amount of tax, and where necessary, that assurance has been sought.

**Table 2:** For all new off-payroll engagements between 1<sup>st</sup> April 2021 and 31<sup>st</sup> March 2022, for more than £245 per day

No. of new engagements, between 1 <sup>st</sup> April 2021 and 31 <sup>st</sup> March 2022	8
Of which:	
No. assessed as caught by IR 35.	6
No. assessed as not caught by IR 35.	2
No. engaged directly (via PSC contracted to department) and are on the departmental payroll.	1
No. of engagements reassessed for consistency/assurance purposes during the year.	5
No. of engagements that saw a change to IR 35 status following the consistency review.	0

Within the total number of new off-payroll engagements disclosed, no engagements related to staff seconded from other NHS Wales Organisations.

**Table 3:** For any off-payroll engagements of board members, and/or, senior officials with significant financial responsibility, between 1<sup>st</sup> April 2021 and 31<sup>st</sup> March 2022

No. of off-payroll engagements of board members, and/or, senior officials with significant financial responsibility, during the financial year.	0
No. of individuals that have been deemed “board members, and/or, senior officials with significant financial responsibility”, during the financial year. This figure should include both off-payroll and on-payroll engagements.	0

---

## PARLIAMENTARY ACCOUNTABILITY AND AUDIT REPORT

---

Where the Trust undertakes activities that are not funded by the Welsh Government the Trust receives income to cover its costs. Further detail of income received is published in the Trust's annual accounts; within note 4 headed 'other operating revenue'.

The Trust confirms it has complied with cost allocation and the charging requirements set out in HM Treasury guidance during the year.

The Trust ensures public funds are used appropriately and to deliver the intended objectives. With the exception of the expenditure of £337k outlined by the Auditor General for Wales in the 'Basis of Qualified Regularity Opinion' section of his report, shown on page 95, that we incurred in line with a Ministerial Direction, we consider that expenditure this year was again regular and compliant with the relevant legislation. Fees and charges for services provided by public sector organisations pass on the full cost of providing those services and are in accord with Welsh Government requirements.

The Trust hosts the Welsh Risk Pool (WRP) as part of NHS Wales Shared Services Partnership (NWSSP) and therefore its accounts include the estimates of remote contingent liabilities from Welsh Health Organisations for potential litigation claims that could arise in the future due to known incidents. In 2021/2022, the financial statements of the Trust are reporting total remote contingent liabilities of £60m.



---

# AUDIT CERTIFICATE AND AUDITOR GENERAL FOR WALES REPORT

---

---

## REPORT ON THE AUDIT OF THE FINANCIAL STATEMENTS

---

### **Opinion on financial statements**

I certify that I have audited the financial statements of Velindre University NHS Trust and its group for the year ended 31 March 2022 under Section 61 of the Public Audit (Wales) Act 2004. These comprise the Consolidated Statement of Comprehensive Income, the Consolidated Statement of Financial Position, the Consolidated Cash Flow Statement and the Consolidated Statement of Changes in Taxpayers' Equity and related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and UK adopted international accounting standards as interpreted and adapted by HM Treasury's Financial Reporting Manual.

In my opinion the financial statements:

- give a true and fair view of the state of affairs of Velindre University NHS Trust and its group as at 31 March 2022 and of its surplus for the year then ended;
- have been properly prepared in accordance with UK adopted international accounting standards as interpreted and adapted by HM Treasury's Financial Reporting Manual; and
- have been properly prepared in accordance with the National Health Service (Wales) Act 2006 and directions made there under by Welsh Ministers.

### **Opinion on regularity**

In my opinion, except for the matter described in the Basis for Qualified Regularity Opinion section of my report, in all material respects, the expenditure and income in the financial statements have been applied to the purposes intended by the Senedd and the financial transactions recorded in the financial statements conform to the authorities which govern them.

### **Basis for Qualified Opinion on regularity**

I have qualified my opinion on the regularity of Velindre University NHS Trust and its group's financial statements because those statements include a provision of £337,000 relating to the Trust's estimated liability arising from the Ministerial Direction dated 18 December 2019 on senior clinicians' pensions.

In my view, this expenditure is irregular and material by its nature. Further detail is set out in my Report starting on page 101.

### **Basis of opinions**

I conducted my audit in accordance with applicable law and International Standards on Auditing in the UK (ISAs (UK)) and Practice Note 10 'Audit of Financial Statements of Public Sector Entities in the United Kingdom'. My responsibilities under those standards are further described in the auditor's responsibilities for the audit of the financial statements section of my report. I am independent of the trust and its group in accordance with the ethical requirements that are relevant to my audit of the financial statements in the UK including the Financial Reporting Council's Ethical Standard, and I have fulfilled my other ethical responsibilities in accordance with these requirements. I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my opinions.

### **Conclusions relating to going concern**

In auditing the financial statements, I have concluded that the use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work I have performed, I have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the body's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from when the financial statements are authorised for issue.

My responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

### **Other Information**

The other information comprises the information included in the annual report other than the financial statements and my auditor's report thereon. The Chief Executive is responsible for the other information contained within the annual report. My opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in my report, I do not express any form of assurance conclusion thereon.

My responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If I identify such material inconsistencies or apparent material misstatements, I am required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work I have performed, I conclude that there is a material misstatement of this other information, I am required to report that fact.

I have nothing to report in this regard.

## **Report on other requirements**

### **Opinion on other matters**

In my opinion, the part of the Remuneration and Staff Report to be audited has been properly prepared in accordance with the National Health Service (Wales) Act 2006 and directions made there under by Welsh Ministers.

In my opinion, based on the work undertaken in the course of my audit:

- the information given in the Governance Statement for the financial year for which the financial statements are prepared is consistent with the financial statements and the Governance Statement has been prepared in accordance with Welsh Ministers' guidance;
- the information given in the Performance and Accountability Report for the financial year for which the financial statements are prepared is consistent with the financial statements and the Performance Report has been prepared in accordance with Welsh Ministers' guidance.

### **Matters on which I report by exception**

In the light of the knowledge and understanding of the Trust and its environment obtained in the course of the audit, I have not identified material misstatements in the Performance Report, Accountability Report or the Governance Statement.

I have nothing to report in respect of the following matters, which I report to you, if, in my opinion:

- adequate accounting records have not been kept, or returns adequate for my audit have not been received from branches not visited by my team;
- the financial statements and the audited part of the Remuneration and Staff Report are not in agreement with the accounting records and returns;

- information specified by HM Treasury or Welsh Ministers regarding remuneration and other transactions is not disclosed; or
- I have not received all the information and explanations I require for my audit.

## **Responsibilities**

### **Responsibilities of Directors and the Chief Executive for the financial statements**

As explained more fully in the Statements of Directors' and Chief Executive's Responsibilities set out on pages 22 and 23, the Directors and the Chief Executive are responsible for the preparation of financial statements which give a true and fair view and for such internal control as the Directors and Chief Executive determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Directors and Chief Executive are responsible for assessing the Trust's ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless deemed inappropriate.

### **Auditor's responsibilities for the audit of the financial statements**

My objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes my opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. I design procedures in line with my responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud.

My procedures included the following:

- Enquiring of management, internal audit and those charged with governance, including obtaining and reviewing supporting documentation relating to Velindre University NHS Trust's policies and procedures concerned with:

- identifying, evaluating and complying with laws and regulations and whether they were aware of any instances of non-compliance;
- detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected or alleged fraud; and
- the internal controls established to mitigate risks related to fraud or non-compliance with laws and regulations.
- Considering as an audit team how and where fraud might occur in the financial statements and any potential indicators of fraud. As part of this discussion, I identified potential for fraud in the following areas: revenue recognition and the posting of unusual journals; and
- Obtaining an understanding of Velindre University NHS Trust's framework of authority as well as other legal and regulatory frameworks that the Trust operates in, focusing on those laws and regulations that had a direct effect on the financial statements or that had a fundamental effect on the operations of Velindre University NHS Trust and its group.

In addition to the above, my procedures to respond to identified risks included the following:

- reviewing the financial statement disclosures and testing to supporting documentation to assess compliance with relevant laws and regulations discussed above;
- enquiring of management, the Audit Committee and legal advisors about actual and potential litigation and claims;
- reading minutes of meetings of those charged with governance and the Board; and
- in addressing the risk of fraud through management override of controls, testing the appropriateness of journal entries and other adjustments; assessing whether the judgements made in making accounting estimates are indicative of a potential bias; and evaluating the business rationale of any significant transactions that are unusual or outside the normal course of business.

I also communicated relevant identified laws and regulations and potential fraud risks to all audit team and remained alert to any indications of fraud or non-compliance with laws and regulations throughout the audit.

The extent to which my procedures are capable of detecting irregularities, including fraud, is affected by the inherent difficulty in detecting irregularities, the effectiveness of Velindre University NHS Trust and its group's controls, and the nature, timing and extent of the audit procedures performed.

A further description of the auditor's responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website [www.frc.org.uk/auditorsresponsibilities](http://www.frc.org.uk/auditorsresponsibilities). This description forms part of my auditor's report.

## **Responsibilities for regularity**

The Chief Executive is responsible for ensuring the regularity of financial transactions.

I am required to obtain sufficient evidence to give reasonable assurance that the expenditure and income have been applied to the purposes intended by the Senedd and the financial transactions conform to the authorities which govern them.

## **Report**

Please see my Report on pages 101 to 102.

Adrian Crompton

Auditor General for Wales

15 June 2022

24 Cathedral Road

Cardiff

CF11 9LJ

## **Report of the Auditor General to the Senedd**

### **Introduction**

Under the Public Audit Wales Act 2004, I am responsible for auditing, certifying and reporting on Velindre University NHS Trust (the Trust) financial statements. I am reporting on these financial statements for the year ended 31 March 2022 to draw attention to one key matter for my audit. This concerns the qualification of my ‘regularity’ opinion relating to expenditure recognised as a result of the ministerial direction on senior clinicians’ pensions. I have not qualified my ‘true and fair’ opinion in respect of any of these matters.

### **Ministerial direction on senior clinicians’ pensions**

NHS Pension scheme and pension tax legislation is not devolved to Wales. HM Treasury’s changes to the tax arrangements on pension contributions in recent years included the reduction in the Annual Allowance limit from over £200k in 2011-12 to £40k in 2018-19. As a result, in cases where an individual’s pension contributions exceed certain annual and / or lifetime pension contribution allowance limits, then they are taxed at a higher rate on all their contributions, creating a sharp increase in tax liability.

In a Written Statement on 13 November 2019, the Minister for Health and Social Services had noted that NHS Wales’ bodies were: ‘regularly reporting that senior clinical staff are unwilling to take on additional work and sessions due to the potentially punitive tax liability’. In certain circumstances this could lead to additional tax charges in excess of any additional income earned.

On 18 December 2019, the First Minister (mirroring earlier action by the Secretary of State for Health and Social Care for England) issued a Ministerial Direction to the Permanent Secretary to proceed with plans to commit to making payments to clinical staff to restore the value of their pension benefits packages. If NHS clinicians opted to use the ‘Scheme Pays’ facility to settle annual allowance tax charges arising from their 2019-20 NHS pension savings (i.e. settling the charge by way of reduced annual pension, rather than by making an immediate one-off payment), then their NHS employers would meet the impact of those tax charges on their pension when they retire.

The Ministerial Direction was required because this solution could be viewed by HMRC to constitute tax planning and potentially tax avoidance, hence making the expenditure irregular. Managing Welsh Public Money (which mirrors its English equivalent) specifically states that ‘public sector organisations should not engage in...tax evasion, tax avoidance or tax planning’.

A Ministerial Direction does not make regular what would otherwise be irregular, but it does move the accountability for such decisions from the Accounting Officer to the Minister issuing the direction.

The solution applies only to annual allowance tax charges arising from an increase in the benefits accrued in the NHS Pension Scheme during the tax year ended 5 April 2020. For the tax year ended 5 April 2021, the Chancellor increased the thresholds for

the tapered annual allowance and, as a result, it is anticipated that the risk to the supply of clinical staff has been mitigated.

The Trust has received sufficient information to calculate and recognise an estimate of the potential costs of compensating senior clinical staff for pension benefits that they would otherwise have lost, by using the 'Scheme Pays' arrangement. As a result, expenditure has been recognised as a provision as shown in notes 5.1 and 23 of the financial statements.

All NHS bodies will be held harmless for the impact of the Ministerial Direction, however in my opinion, the transactions included in the Trust's financial statements to recognise this liability are irregular and material by their nature. This is because the payments are contrary to paragraph 5.6.1 of Managing Public Money and constitute a form of tax planning which will leave the Exchequer as a whole worse off. The Minister's direction alone does not regularise the scheme. Furthermore, the arrangements are novel and contentious and potentially precedent setting. As a result, I have qualified my 'regularity' opinion for 2021-22.

**Adrian Crompton**  
**Auditor General for Wales**  
**15 June 2022**



# Velindre University NHS Trust

## Finance Report

### 2021-2022



GIG  
CYMRU  
NHS  
WALES

Ymddiriedolaeth GIG  
Prifysgol Felindre  
Velindre University  
NHS Trust



Canolfan Ganser Felindre  
Velindre Cancer Centre



Gwasanaeth Gwaed Cymru  
Welsh Blood Service

# Velindre University NHS Trust

## Foreword

These accounts for the period ended 31 March 2022 have been prepared to comply with International Financial Reporting Standards (IFRS) adopted by the European Union, in accordance with HM Treasury's FReM by Velindre University NHS Trust under schedule 9 section 178 Para 3 (1) of the National Health Service (Wales) Act 2006 (c.42) in the form in which the Welsh Ministers, with the approval of the Treasury, directed.

These are Group accounts showing the accounts of the Trust including those organisations hosted by it (see 'Statutory background' below), and are consolidated with the Trust's Charitable Fund of which the Trust is the Corporate Trustee.

## Statutory background

The Trust was established by Statutory Instrument on 1 April 1994 and at that time was a single speciality Trust providing only Cancer Services. Over the last 28 years, the Trust has significantly evolved and expanded. The main function of the Trust is to provide all-Wales and regional clinical health services to the NHS and the people of Wales. The Trust consists of two clinical divisions: the Welsh Blood Service and Velindre Cancer Centre.

In addition to the above services, the Trust is host to two organisations. At period ended 31 March 2022, these were:

- NHS Wales Shared Services Partnership (NWSSP) which was set up on 1 April 2011; following which the functions of a number of separate services were transferred into NWSSP. NWSSP became a hosted body within Velindre NHS Trust on 1 June 2012. One new All Wales service was established within NWSSP during 2021-2022: the All Wales Laundry Service; and one existing service commenced expansion - the Single Lead Employer Scheme to include the phased intake of core and specialty medical trainees, the rollout of which will continue until May 2022.
- Health Technology Wales (HTW) which was established on 1 April 2016 and continued to receive grant funding from Welsh Government under the Efficiency through Technology Programme.

The NHS Wales Informatics Service (NWIS) which had been established as a hosted body on 1 April 2010 transferred out of the Trust on 1 April 2021 into a new Special Health Authority, Digital Health & Care Wales.

## Performance Management and Financial Results

This Welsh Health Circular WHC/2016/054 replaces WHC/2015/014 'Statutory and Administrative Financial Duties of NHS Trusts and Local Health Boards' and further clarifies the statutory financial duties of NHS Wales bodies and is effective for 2021-2022. The annual financial duty has been revoked and the statutory breakeven duty has reverted to a three year duty, with the first assessment of this duty in 2016-2017.

Under the National Health Services (Wales) Act 2006 the financial obligations of the NHS Trust are contained within Schedules 4 2(1) and 4 2(2). Each NHS trust must ensure that its revenue is not less than sufficient, taking one financial year with another, to meet outgoings properly chargeable to the revenue account. The first assessment of performance against the 3-year statutory duty under Schedules 4 2(1) and 4 2(2) was at the end of 2016-2017, being the first three year period of assessment.

STATEMENT OF COMPREHENSIVE INCOME FOR THE YEAR ENDED 31 MARCH 2022

	Note	2021-22 £000 NHS Trust	2020-21 £000	2021-22 £000 Consolidated	2020-21 £000
Revenue from patient care activities	3	736,708	576,716	736,708	576,716
Other operating revenue	4	307,091	271,507	307,366	271,689
Operating expenses	5.1	(1,042,935)	(846,661)	(1,042,786)	(846,946)
<b>Operating (deficit)/surplus</b>		<b>864</b>	<b>1,562</b>	<b>1,288</b>	<b>1,459</b>
Investment revenue	6	23	0	137	133
Other gains and losses	7	3	25	3	25
Finance costs	8	(1,093)	(365)	(1,093)	(365)
<b>Consolidated Total</b>				<b>335</b>	<b>1,252</b>
<b>Retained surplus/(deficit)</b> (including donated assets received or issued)	2.1.1	<b>(203)</b>	<b>1,222</b>		
<b>Other Comprehensive Income</b>					
<b>Items that will not be reclassified to net operating costs:</b>					
Net gain/(loss) on revaluation of property, plant and equipment		3,074	1,543	3,074	1,543
Net gain/(loss) on revaluation of intangible assets		0	0	0	0
Net gain/(loss) on revaluation of financial assets		0	0	124	727
Movements in other reserves		9,833	0	9,833	0
Net gain/(loss) on revaluation of PPE and Intangible assets held for sale		0	0	0	0
Impairments and reversals		0	0	0	0
Transfers between reserves		0	0	0	0
Reclassification adjustment on disposal of available for sale financial assets		0	0	0	0
<b>Sub total</b>		<b>12,907</b>	<b>1,543</b>	<b>13,031</b>	<b>2,270</b>
<b>Items that may be reclassified subsequently to net operating costs</b>					
Net gain/(loss) on revaluation of financial assets held for sale		0	0	0	0
<b>Sub total</b>		<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Total other comprehensive income for the year</b>		<b>12,907</b>	<b>1,543</b>	<b>13,031</b>	<b>2,270</b>
<b>Total comprehensive income for the year</b>		<b>12,704</b>	<b>2,765</b>	<b>13,366</b>	<b>3,522</b>

The notes on pages 6 to 75 form part of these accounts.

## STATEMENT OF FINANCIAL POSITION AS AT 31 MARCH 2022

	Note	31 March 2022	31 March 2021	31 March 2022	31 March 2021
		NHS Trust		Consolidated	
		£000	£000	£000	£000
<b>Non-current assets</b>					
Property, plant and equipment	13	143,136	136,558	143,136	136,558
Intangible assets	14	8,667	20,821	8,667	20,821
Trade and other receivables	17.1	1,092,008	817,142	1,092,008	817,142
Other financial assets	18	0	0	5,826	5,613
<b>Total non-current assets</b>		<b>1,243,811</b>	<b>974,521</b>	<b>1,249,637</b>	<b>980,134</b>
<b>Current assets</b>					
Inventories	16.1	65,207	95,564	65,207	95,564
Trade and other receivables	17.1	540,227	548,836	539,146	548,529
Other financial assets	18	0	0	0	0
Cash and cash equivalents	19	30,404	43,263	33,116	44,811
		<b>635,838</b>	<b>687,663</b>	<b>637,469</b>	<b>688,904</b>
Non-current assets held for sale	13.2	0	0	0	0
<b>Total current assets</b>		<b>635,838</b>	<b>687,663</b>	<b>637,469</b>	<b>688,904</b>
<b>Total assets</b>		<b>1,879,649</b>	<b>1,662,184</b>	<b>1,887,106</b>	<b>1,669,038</b>
<b>Current liabilities</b>					
Trade and other payables	20	(277,601)	(353,136)	(277,649)	(353,243)
Borrowings	21	0	(8)	0	(8)
Other financial liabilities	22	0	0	0	0
Provisions	23	(341,123)	(316,959)	(341,123)	(316,959)
<b>Total current liabilities</b>		<b>(618,724)</b>	<b>(670,103)</b>	<b>(618,772)</b>	<b>(670,210)</b>
<b>Net current assets/(liabilities)</b>		<b>17,114</b>	<b>17,560</b>	<b>18,697</b>	<b>18,694</b>
<b>Total assets less current liabilities</b>		<b>1,260,925</b>	<b>992,081</b>	<b>1,268,334</b>	<b>998,828</b>
<b>Non-current liabilities</b>					
Trade and other payables	20	(7,336)	(7,301)	(7,336)	(7,301)
Borrowings	21	0	0	0	0
Other financial liabilities	22	0	0	0	0
Provisions	23	(1,094,206)	(818,782)	(1,094,206)	(818,782)
<b>Total non-current liabilities</b>		<b>(1,101,542)</b>	<b>(826,083)</b>	<b>(1,101,542)</b>	<b>(826,083)</b>
<b>Total assets employed</b>		<b>159,383</b>	<b>165,998</b>	<b>166,792</b>	<b>172,745</b>
<b>Financed by Taxpayers' equity:</b>					
Public dividend capital		112,982	122,468	112,982	122,468
Retained earnings		15,466	15,552	15,466	15,552
Revaluation reserve		30,935	27,978	30,935	27,978
Other reserves		0	0	0	0
Funds Held on Trust Reserves				7,409	6,747
<b>Total taxpayers' equity</b>		<b>159,383</b>	<b>165,998</b>	<b>166,792</b>	<b>172,745</b>

The financial statements were approved by the Board on 14 June 2022 and signed on behalf of the Board by:



Steve Ham, Chief Executive and Accountable Officer

Date: 14 June 2022

The notes on pages 6 to 75 form part of these accounts.

## STATEMENT OF CHANGES IN TAXPAYERS' EQUITY

2021-22	Public Dividend Capital £000	Retained earnings £000	Revaluation reserve £000	Total £000	FHOT Reserves £000	Consolidated Total £000
<b>Changes in taxpayers' equity for 2021-22</b>						
Balance as at 31 March 2021	122,468	15,552	27,978	165,998	6,747	172,745
NWIS to DHCW Transfer adjustment	(27,872)	(9,833)	0	(37,705)	0	(37,705)
<b>Balance at 1 April 2021</b>	<b>94,596</b>	<b>5,719</b>	<b>27,978</b>	<b>128,293</b>	<b>6,747</b>	<b>135,040</b>
Retained surplus/(deficit) for the year		(203)		(203)		(203)
Net gain/(loss) on revaluation of property, plant and equipment		0	3,074	3,074		3,074
Net gain/(loss) on revaluation of intangible assets		0	0	0		0
Net gain/(loss) on revaluation of financial assets		0	0	0	124	124
Net gain/(loss) on revaluation of assets held for sale		0	0	0		0
Net gain/(loss) on revaluation of financial assets held for sale		0	0	0		0
Impairments and reversals		0	0	0		0
Other reserve movement		9,833	0	9,833		9,833
Transfers between reserves		117	(117)	0		0
Reclassification adjustment on disposal of available for sale financial assets		0	0	0		0
Reserves eliminated on dissolution	0			0		0
Total in year movement	0	9,747	2,957	12,704	124	12,828
New Public Dividend Capital received	18,386			18,386		18,386
Public Dividend Capital repaid in year				0		0
Public Dividend Capital extinguished/written off	0			0		0
Other movements in PDC in year	0			0		0
FHoT - Endowment					0	0
FHoT - Restricted					0	0
FHoT - Unrestricted					538	538
<b>Balance at 31 March 2022</b>	<b>112,982</b>	<b>15,466</b>	<b>30,935</b>	<b>159,383</b>	<b>7,409</b>	<b>166,792</b>

The notes on pages 6 to 75 form part of these accounts.

**STATEMENT OF CHANGES IN TAXPAYERS' EQUITY**

2020-21	Public Dividend Capital £000	Retained earnings £000	Revaluation reserve £000	Total £000	Funds held on Trust Reserves £000	Consolidated Total £000
<b>Changes in taxpayers' equity for 2020-21</b>						
<b>Balance at 31 March 2020</b>	113,118	12,432	28,333	153,883	5,990	159,873
<b>Adjustment</b>	0	0	0	0	0	0
<b>Balance at 1 April 2020</b>	113,118	12,432	28,333	153,883	5,990	159,873
Retained surplus/(deficit) for the year		1,222		1,222		1,222
Net gain/(loss) on revaluation of property, plant and equipment		0	1,543	1,543		1,543
Net gain/(loss) on revaluation of intangible assets		0	0	0		0
Net gain/(loss) on revaluation of financial assets		0	0	0	727	727
Net gain/(loss) on revaluation of assets held for sale		0	0	0		0
Net gain/(loss) on revaluation of financial assets held for sale		0	0	0		0
Impairments and reversals		0	0	0		0
Other reserve movement		0	0	0		0
Transfers between reserves		1,898	(1,898)	0		0
Reclassification adjustment on disposal of available for sale financial assets		0	0	0		0
Reserves eliminated on dissolution	0			0		0
<b>Total in year movement</b>	<b>0</b>	<b>3,120</b>	<b>(355)</b>	<b>2,765</b>	<b>727</b>	<b>3,492</b>
New Public Dividend Capital received	9,485			9,485		9,485
Public Dividend Capital repaid in year	(135)			(135)		(135)
Public Dividend Capital extinguished/written off	0			0		0
Other movements in PDC in year	0			0		0
FHoT - Endowment					0	0
FHoT - Restricted					0	0
FHoT - Unrestricted					30	30
<b>Balance at 31 March 2021</b>	<b>122,468</b>	<b>15,552</b>	<b>27,978</b>	<b>165,998</b>	<b>6,747</b>	<b>172,745</b>

The notes on pages 6 to 75 form part of these accounts.

## STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 MARCH 2022

	Note	2021-22 £000	2020-21 £000	2021-22 £000	2020-21 £000
<b>Cash flows from operating activities</b>					
Operating surplus/(deficit)	<b>SOCI</b>	<b>864</b>	1,562	<b>1,288</b>	1,459
Movements in working capital	<b>30</b>	<b>(315,095)</b>	25,279	<b>(314,364)</b>	25,751
Other cash flow adjustments	<b>31</b>	<b>453,490</b>	127,532	<b>453,490</b>	127,532
Provisions utilised		<b>(143,680)</b>	<b>(111,055)</b>	<b>(143,680)</b>	<b>(111,055)</b>
Interest paid		<b>0</b>	0	<b>0</b>	0
<b>Net cash inflow (outflow) from operating activities</b>		<b>(4,421)</b>	43,318	<b>(3,266)</b>	43,687
<b>Cash flows from investing activities</b>					
Interest received		23	0	<b>137</b>	133
(Payments) for property, plant and equipment		<b>(22,771)</b>	<b>(19,738)</b>	<b>(22,771)</b>	<b>(19,738)</b>
Proceeds from disposal of property, plant and equipment		11,931	192	<b>11,931</b>	192
(Payments) for intangible assets		<b>(4,103)</b>	<b>(7,783)</b>	<b>(4,103)</b>	<b>(7,783)</b>
Proceeds from disposal of intangible assets		15,976	0	<b>15,976</b>	0
Payments for investments with Welsh Government		0	0	<b>0</b>	0
Proceeds from disposals with Welsh Government		0	0	<b>0</b>	0
(Payments) for financial assets.		0	0	<b>(2,005)</b>	<b>(1,886)</b>
Proceeds from disposal of financial assets.		0	0	<b>1,900</b>	1,460
<b>Net cash inflow (outflow) from investing activities</b>		<b>1,056</b>	<b>(27,329)</b>	<b>1,065</b>	<b>(27,622)</b>
<b>Net cash inflow (outflow) before financing</b>		<b>(3,365)</b>	15,989	<b>(2,201)</b>	16,065
<b>Cash flows from financing activities</b>					
Public Dividend Capital received		<b>0</b>	9,485	<b>0</b>	9,485
Public Dividend Capital repaid		<b>(9,486)</b>	<b>(135)</b>	<b>(9,486)</b>	<b>(135)</b>
Loans received from Welsh Government		<b>0</b>	0	<b>0</b>	0
Other loans received		<b>0</b>	0	<b>0</b>	0
Loans repaid to Welsh Government		<b>0</b>	0	<b>0</b>	0
Other loans repaid		<b>0</b>	0	<b>0</b>	0
Other capital receipts		<b>0</b>	0	<b>0</b>	0
Capital elements of finance leases and on-SOFP PFI		<b>(8)</b>	<b>(21)</b>	<b>(8)</b>	<b>(21)</b>
Cash transferred (to)/from other NHS Wales bodies		<b>0</b>	<b>(318)</b>	<b>0</b>	<b>(318)</b>
<b>Net cash inflow (outflow) from financing activities</b>		<b>(9,494)</b>	9,011	<b>(9,494)</b>	9,011
<b>Net increase (decrease) in cash and cash equivalents</b>		<b>(12,859)</b>	25,000	<b>(11,695)</b>	25,076
<b>Cash [and] cash equivalents at the beginning of the financial year</b>	<b>19</b>	<b>43,263</b>	18,263	<b>44,811</b>	19,735
<b>Cash [and] cash equivalents at the end of the financial year</b>	<b>19</b>	<b>30,404</b>	43,263	<b>33,116</b>	44,811

The notes on pages 6 to 75 form part of these accounts.

## **Notes to the Accounts**

### **1. Accounting policies**

The Minister for Health and Social Services has directed that the financial statements of NHS Trusts (NHST) in Wales shall meet the accounting requirements of the NHS Wales Manual for Accounts. Consequently, the following financial statements have been prepared in accordance with the 2021-2022 Manual for Accounts. The accounting policies contained in that manual follow the 2021-2022 Financial Reporting Manual (FRoM), in accordance with international accounting standards in conformity with the requirements of the Companies Act 2006 except for IFRS 16 Leases, which is deferred until 1 April 2022; to the extent that they are meaningful and appropriate to the NHS in Wales.

Where the NHST Manual for Accounts permits a choice of accounting policy, the accounting policy which is judged to be most appropriate to the particular circumstances of the NHST for the purpose of giving a true and fair view has been selected. The particular policies adopted by the NHST are described below. They have been applied consistently in dealing with items considered material in relation to the accounts.

#### **1.1 Accounting convention**

These accounts have been prepared under the historical cost convention modified to account for the revaluation of property, plant and equipment, intangible assets and inventories.

#### **1.2 Acquisitions and discontinued operations**

Activities are considered to be 'acquired' only if they are taken on from outside the public sector. Activities are considered to be 'discontinued' only if they cease entirely. They are not considered to be 'discontinued' if they transfer from one public sector body to another.

#### **1.3 Revenue**

Revenue in respect of services provided is recognised when, and to the extent that, performance occurs, and is measured at the fair value of the consideration receivable.



From 2018-2019, IFRS 15 Revenue from Contracts with Customers has been applied, as interpreted and adapted for the public sector, in the FReM. It replaces the previous standards IAS 11 Construction Contracts and IAS 18 Revenue and related IFRIC and SIC interpretations. The potential amendments identified as a result of the adoption of IFRS 15 are significantly below materiality levels.

Income is accounted for applying the accruals convention. Income is recognised in the period in which services are provided. Where income is received from third parties for a specific activity to be delivered in the following financial year, that income will be deferred.

Only non-NHS income may be deferred.

#### **1.4 Employee benefits**

##### **Short-term employee benefits**

Salaries, wages and employment-related payments are recognised in the period in which the service is received from employees. The cost of leave earned but not taken by employees at the end of the period is recognised in the financial statements to the extent that employees are permitted to carry forward leave into the following period.

##### **Retirement benefit costs**

Past and present employees are covered by the provisions of the NHS Pensions Scheme. The scheme is an unfunded, defined benefit scheme that covers NHS employers, General Practices and other bodies, allowed under the direction of the Secretary of State, in England and Wales. The scheme is not designed to be run in a way that would enable NHS bodies to identify their share of the underlying scheme assets and liabilities. Therefore, the scheme is accounted for as if it were a defined contribution scheme: the cost to the NHS body of participating in the scheme is taken as equal to the contributions payable to the scheme for the accounting period.

The latest NHS Pension Scheme valuation results indicated that an increase in benefit required a 6.3% increase (14.38% to 20.68%) which was implemented from 1 April 2019.

As an organisation within the full funding scope, the joint (in NHS England and NHS Wales) transitional arrangement operated from 2019-2020 where employers in the Scheme would continue to pay 14.38% employer contributions under their normal monthly payment process, and in Wales the additional 6.3% would be funded by Welsh Government directly to the Pension Scheme administrator, the NHS Business Services Authority (BSA, the NHS Pensions Agency).

However, NHS Wales organisations are required to account for **their staff** employer contributions of 20.68% in full and on a gross basis, in their annual accounts. Payments made on their behalf by Welsh Government are accounted for on a notional basis. For detailed information see Note 37 'Other Information' on page 72 of these accounts.

For early retirements other than those due to ill health the additional pension liabilities are not funded by the scheme. The full amount of the liability for the additional costs is charged to expenditure at the time the NHS Wales organisation commits itself to the retirement, regardless of the method of payment.

Where employees are members of the Local Government Superannuation Scheme, which is a defined benefit pension scheme this is disclosed. The scheme assets and liabilities attributable to those employees can be identified and are recognised in the NHS Wales organisation's accounts. The assets are measured at fair value and the liabilities at the present value of the future obligations. The increase in the liability arising from pensionable service earned during the year is recognised within operating expenses. The expected gain during the year from scheme assets is recognised within finance income. The interest cost during the year arising from the unwinding of the discount on the scheme liabilities is recognised within finance costs.

### **NEST Pension Scheme**

An alternative pensions scheme for employees not eligible to join the NHS Pensions scheme has to be offered. The NEST (National Employment Savings Trust) Pension scheme is a defined contribution scheme and therefore the cost to the NHS body of participating in the scheme is equal to the contributions payable to the scheme for the accounting period.

### **1.5 Other expenses**

Other operating expenses for goods or services are recognised when, and to the extent that, they have been received. They are measured at the fair value of the consideration payable.

### **1.6 Property, plant and equipment**

#### **Recognition**

Property, plant and equipment is capitalised if:

- it is held for use in delivering services or for administrative purposes;
- it is probable that future economic benefits will flow to, or service potential will be supplied to, the NHS Wales organisation;
- it is expected to be used for more than one financial year;
- the cost of the item can be measured reliably; and
- the item has cost of at least £5,000; or
- collectively, a number of items have a cost of at least £5,000 and individually have a cost of more than £250, where the assets are functionally interdependent, they had broadly simultaneous purchase dates, are anticipated to have simultaneous disposal dates and are under single

managerial control; or

- items form part of the initial equipping and setting-up cost of a new building, ward or unit, irrespective of their individual or collective cost.

Where a large asset, for example a building, includes a number of components with significantly different asset lives, the components are treated as separate assets and depreciated over their own useful economic lives.

### **Valuation**

All property, plant and equipment are measured initially at cost, representing the cost directly attributable to acquiring or constructing the asset and bringing it to the location and condition necessary for it to be capable of operating in the manner intended by management.

Land and buildings used for services or for administrative purposes are stated in the Statement of Financial Position (SoFP) at their revalued amounts, being the fair value at the date of revaluation less any subsequent accumulated depreciation and impairment losses. Revaluations are performed with sufficient regularity to ensure that carrying amounts are not materially different from those that would be determined at the end of the reporting period. Fair values are determined as follows:

- Land and non-specialised buildings – market value for existing use
- Specialised buildings – depreciated replacement cost

HM Treasury has adopted a standard approach to depreciated replacement cost valuations based on modern equivalent assets and, where it would meet the location requirements of the service being provided, an alternative site can be valued. NHS Wales' organisations have applied these new valuation requirements from 1 April 2009.

Properties in the course of construction for service or administration purposes are carried at cost, less any impairment loss. Cost includes professional fees but not borrowing costs, which are recognised as expenses immediately, as allowed by IAS 23 for assets held at fair value. Assets are revalued and depreciation commences when they are brought into use.

In 2017-2018 a formal revaluation exercise was applied to land and properties. The carrying value of existing assets at that date will be written off over their remaining useful lives and new fixtures and equipment are carried at depreciated historic cost as this is not considered to be materially different from fair value.

An increase arising on revaluation is taken to the revaluation reserve except when it reverses an impairment for the same asset previously recognised in expenditure, in which case it is credited to expenditure to the extent of the decrease previously charged there. A revaluation decrease that does not result from a loss of economic value or service potential is recognised as an impairment charged to the revaluation reserve to the extent that there is a balance on the reserve for the asset and, thereafter, to expenditure. Impairment losses that arise from a clear consumption of economic benefit should be taken to expenditure.

References in IAS 36 to the recognition of an impairment loss of a revalued asset being treated as a revaluation decrease to the extent that the impairment does not exceed the amount in the revaluation surplus for the same asset, are adapted such that only those impairment losses that do not result from a clear consumption of economic benefit or reduction of service potential (including as a result of loss or damage resulting from normal business operations) should be taken to the revaluation reserve. Impairment losses that arise from a clear consumption of economic benefit should be taken to the Statement of Comprehensive Income (SoCI).

From 2015-2016, IFRS 13 Fair Value Measurement must be complied with in full. However IAS 16 and IAS 38 have been adapted for the public sector context which limits the circumstances under which a valuation is prepared under IFRS 13. Assets which are held for their service potential and are in use should be measured at their current value in existing use. For specialised assets current value in existing use should be interpreted as the present value of the assets remaining service potential, which can be assumed to be at least equal to the cost of replacing that service potential. Where there is no single class of asset that falls within IFRS 13, disclosures should be for material items only.

In accordance with the adaptation of IAS 16 in table 6.2 of the FReM, for non-specialised assets in operational use, current value in existing use is interpreted as market value for existing use which is defined in the RICS Red Book as Existing Use Value (EUV).

Assets which were most recently held for their service potential but are surplus should be valued at current value in existing use, if there are restrictions on the NHS organisation or the asset which would prevent access to the market at the reporting date. If the NHS organisation could access the market then the surplus asset should be used at fair value using IFRS 13. In determining whether such an asset which is not in use is surplus, an assessment should be made on whether there is a clear plan to bring the asset back into use as an operational asset. Where there is a clear plan, the asset is not surplus and the current value in existing use should be maintained. Otherwise the asset should be assessed as being surplus and valued under IFRS13.

Assets which are not held for their service potential should be valued in accordance with IFRS 5 or IAS 40 depending on whether the asset is actively held for sale. Where an asset is not being used to deliver services and there is no plan to bring it back into use, with no restrictions on sale, and it does not meet the IAS 40 and IFRS 5 criteria, these assets are surplus and are valued at fair value using IFRS 13.

### **Subsequent expenditure**

Where subsequent expenditure enhances an asset beyond its original specification, the directly attributable cost is capitalised. Where subsequent expenditure restores the asset to its original specification, the expenditure is capitalised and any carrying value of the item replaced is written-out and charged to the SoCI. As highlighted in previous years the NHS in Wales does not have systems in place to ensure that all items being "replaced" can be identified and hence the cost involved to be quantified. The NHS in Wales has thus established a national protocol to ensure it complies with the standard as far as it is able to which is outlined in the capital accounting chapter of the Manual For Accounts. This ensures that asset carrying values are not materially overstated.

For All Wales Capital Schemes that are completed in a financial year, NHS Wales organisations are required to obtain a revaluation during that year (prior to them being brought into use) and also similar revaluations are needed for all Discretionary Building Schemes completed which have a spend greater than £0.5m. The write downs so identified are then charged to operating expenses.

## **1.7 Intangible assets**

### **Recognition**

Intangible assets are non-monetary assets without physical substance, which are capable of sale separately from the rest of the business or which arise from contractual or other legal rights. They are recognised only when it is probable that future economic benefits will flow to, or service potential be provided to, the NHS Wales organisation; where the cost of the asset can be measured reliably, and where the cost is at least £5,000.

Intangible assets acquired separately are initially recognised at fair value. Software that is integral to the operating of hardware, for example an operating system, is capitalised as part of the relevant item of property, plant and equipment. Software that is not integral to the operation of hardware, for example application software, is capitalised as an intangible asset. Expenditure on research is not capitalised: it is recognised as an operating expense in the period in which it is incurred. Internally-generated assets are recognised if, and only if, all of the following have been demonstrated:

- the technical feasibility of completing the intangible asset so that it will be available for use
- the intention to complete the intangible asset and use it
- the ability to use the intangible asset
- how the intangible asset will generate probable future economic benefits
- the availability of adequate technical, financial and other resources to complete the intangible asset and use it
- the ability to measure reliably the expenditure attributable to the intangible asset during its development.

### **Measurement**

The amount initially recognised for internally-generated intangible assets is the sum of the expenditure incurred from the date when the criteria above are initially met. Where no internally-generated intangible asset can be recognised, the expenditure is recognised in the period in which it is incurred.

Following initial recognition, intangible assets are carried at fair value by reference to an active market, or, where no active market exists, at amortised replacement cost (modern equivalent assets basis), indexed for relevant price increases, as a proxy for fair value. Internally-developed software is held at historic cost to reflect the opposing effects of increases in development costs

and technological advances.

### **1.8 Depreciation, amortisation and impairments**

Freehold land, assets under construction and assets held for sale are not depreciated.

Otherwise, depreciation and amortisation are charged to write off the costs or valuation of property, plant and equipment and intangible non-current assets, less any residual value, over their estimated useful lives, in a manner that reflects the consumption of economic benefits or service potential of the assets. The estimated useful life of an asset is the period over which the NHS Wales organisation expects to obtain economic benefits or service potential from the asset. This is specific to the NHS Wales organisation and may be shorter than the physical life of the asset itself. Estimated useful lives and residual values are reviewed each year end, with the effect of any changes recognised on a prospective basis. Assets held under finance leases are depreciated over the shorter of the lease term and estimated useful lives.

At each reporting period end, the NHS Wales organisation checks whether there is any indication that any of its tangible or intangible non-current assets have suffered an impairment loss. If there is indication of an impairment loss, the recoverable amount of the asset is estimated to determine whether there has been a loss and, if so, its amount. Intangible assets not yet available for use are tested for impairment annually.

Impairment losses that do not result from a loss of economic value or service potential are taken to the revaluation reserve to the extent that there is a balance on the reserve for the asset and, thereafter, to the SoCI. Impairment losses that arise from a clear consumption of economic benefit are taken to the SoCI. The balance on any revaluation reserve (up to the level of the impairment) to which the impairment would have been charged under IAS 36 are transferred to retained earnings.

### **1.9 Research and Development**

Research and development expenditure is charged to operating costs in the year in which it is incurred, except insofar as it relates to a clearly defined project, which can be separated from patient care activity and benefits therefrom can reasonably be regarded as assured. Expenditure so deferred is limited to the value of future benefits expected and is amortised through the SoCI on a systematic basis over the period expected to benefit from the project.

### **1.10 Non-current assets held for sale**

Non-current assets are classified as held for sale if their carrying amount will be recovered principally through a sale transaction rather than through continuing use. This condition is regarded as met when the sale is highly probable, the asset is available for immediate sale in its present condition and management is committed to the sale, which is expected to qualify for recognition as a completed sale within one year from the date of classification. Non-current assets held for sale are measured at the lower of their previous carrying amount and fair value less costs to sell. Fair value is open market value including alternative uses.

The profit or loss arising on disposal of an asset is the difference between the sale proceeds and the carrying amount and is recognised in the SoCl. On disposal, the balance for the asset on the revaluation reserve is transferred to retained earnings.

Property, plant and equipment that is to be scrapped or demolished does not qualify for recognition as held for sale. Instead it is retained as an operational asset and its economic life adjusted. The asset is derecognised when it is scrapped or demolished.

### **1.11 Leases**

Leases are classified as finance leases when substantially all the risks and rewards of ownership are transferred to the lessee. All other leases are classified as operating leases.

#### **1.11.1 The NHS Wales organisation as lessee**

Property, plant and equipment held under finance leases are initially recognised, at the inception of the lease, at fair value or, if lower, at the present value of the minimum lease payments, with a matching liability for the lease obligation to the lessor. Lease payments are apportioned between finance charges and reduction of the lease obligation so as to achieve a constant rate of interest on the remaining balance of the liability. Finance charges are recognised in calculating the NHS Trust's surplus/deficit charged.

Operating lease payments are recognised as an expense on a straight-line basis over the lease term. Lease incentives are recognised initially as a liability and subsequently as a reduction of rentals on a straight-line basis over the lease term. Contingent rentals are recognised as an expense in the period in which they are incurred.

Where a lease is for land and buildings, the land and building components are separated and individually assessed as to whether they are operating or finance leases.

#### **1.11.2 The NHS Wales organisation as lessor**

Amounts due from lessees under finance leases are recorded as receivables at the amount of the NHS Wales organisation net investment in the leases. Finance lease income is allocated to accounting periods so as to reflect a constant periodic rate of return on the NHS Wales organisation's net investment outstanding in respect of the leases.

Rental income from operating leases is recognised on a straight-line basis over the term of the lease. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset and recognised on a straight-line basis over the lease term.

### **1.12 Inventories**

Whilst it is accounting convention for inventories to be valued at the lower of cost and net realisable value using the weighted average or "first-in first-out" cost formula, it should be recognised that the NHS is a special case in that inventories are not generally held for the intention of resale and indeed there is no market readily available where such items could be sold. Inventories are valued at cost and this is considered to be a reasonable approximation to fair value due to the high turnover of stocks. Where inventories are not subject to high turnover levels, stocks are valued at current purchase price as an approximation to net realisable value and fair value.

Work-in-progress comprises goods in intermediate stages of production. Partially completed contracts for patient services are not accounted for as work-in-progress.

### **1.13 Cash and cash equivalents**

Cash is cash in hand and deposits with any financial institution repayable without penalty on notice of not more than 24 hours. Cash equivalents are investments that mature in 3 months or less from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value. In the Statement of Cash flows (SoCF), cash and cash equivalents are shown net of bank overdrafts that are repayable on demand and that form an integral part of the cash management.

### **1.14 Provisions**

Provisions are recognised when the NHS Wales organisation has a present legal or constructive obligation as a result of a past event, it is probable that the NHS Wales organisation will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation. The amount recognised as a provision is the best estimate of the expenditure required to settle the obligation at the end of the reporting period, taking into account the risks and uncertainties. Where a provision is measured using the cash flows estimated to settle the obligation, its carrying amount is the present value of those cash flows using the discount rate supplied by HM Treasury.

When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, the receivable is recognised as an asset if it is virtually certain that reimbursements will be received and the amount of the receivable can be measured reliably.

Present obligations arising under onerous contracts are recognised and measured as a provision. An onerous contract is considered to exist where the NHS Wales organisation has a contract under which the unavoidable costs of meeting the obligations under the contract exceed the economic benefits expected to be received under it.

A restructuring provision is recognised when the NHS Wales organisation has developed a detailed formal plan for the restructuring and has raised a valid expectation in those affected that it will carry out the restructuring by starting to implement the plan or announcing its main features to those affected by it.



The measurement of a restructuring provision includes only the direct expenditures arising from the restructuring, which are those amounts that are both necessarily entailed by the restructuring and not associated with ongoing activities of the entity.

#### **1.14.1 Clinical negligence and personal injury costs**

The Welsh Risk Pool Services (WRPS) operate a risk pooling scheme which is co-funded by the Welsh Government with the option to access a risk sharing agreement funded by the participating NHS Wales bodies. The risk sharing option was implemented in 2021-2022, 2020-2021 and 2019-2020. The WRPS is hosted by the Trust.

#### **1.14.2 Future Liability Scheme (FLS)**

##### **General Medical Practice Indemnity (GMPI)**

The FLS is a state backed scheme to provide clinical negligence General Medical Practice Indemnity (GMPI) for providers of GP services in Wales.

In March 2019, the Minister issued a Direction to Velindre University NHS Trust to enable Legal and Risk Services to operate the Scheme. The GMPI is underpinned by new secondary legislation, The NHS (Clinical Negligence Scheme) (Wales) Regulations 2019 which came into force on 1 April 2019.

#### **1.15 Financial Instruments**

From 2018-2019 IFRS 9 Financial Instruments is applied, as interpreted and adapted for the public sector, in the FReM. The principal impact of IFRS 9 adoption by NHS Wales organisations is a change to the calculation basis for bad debt provisions: changing from an incurred loss basis to a lifetime expected credit loss (ECL) basis.

#### **1.16 Financial assets**

Financial assets are recognised on the SoFP when the NHS Wales organisation becomes party to the financial instrument contract or, in the case of trade receivables, when the goods or services have been delivered. Financial assets are derecognised when the contractual rights have expired or the asset has been transferred.

The accounting policy choice allowed under IFRS 9 for long term trade receivables, contract assets which do contain a significant financing component (in accordance with IFRS 15), and lease receivables within the scope of IAS 17 has been withdrawn and entities should always recognise a loss allowance at an amount equal to lifetime Expected Credit Losses.

All entities applying the FReM should utilise IFRS 9's simplified approach to impairment for relevant assets.

IFRS 9 requirements required a revised approach for the calculation of the bad debt provision, applying the principles of expected credit loss, using the practical expedients within IFRS 9 to construct a provision matrix.

#### **1.16.1 Financial assets are initially recognised at fair value**

Financial assets are classified into the following categories: financial assets 'at fair value' through SoCI; 'held to maturity investments'; 'available for sale' financial assets, and 'loans and receivables'. The classification depends on the nature and purpose of the financial assets and is determined at the time of initial recognition.

#### **1.16.2 Financial assets at fair value through SoCI**

Embedded derivatives that have different risks and characteristics to their host contracts, and contracts with embedded derivatives whose separate value cannot be ascertained, are treated as financial assets at fair value through SoCI. They are held at fair value, with any resultant gain or loss recognised in the SoCI. The net gain or loss incorporates any interest earned on the financial asset.

#### **1.16.3 Held to maturity investments**

Held to maturity investments are non-derivative financial assets with fixed or determinable payments and fixed maturity, and there is a positive intention and ability to hold to maturity. After initial recognition, they are held at amortised cost using the effective interest method, less any impairment. Interest is recognised using the effective interest method.

#### **1.16.4 Available for sale financial assets**

Available for sale financial assets are non-derivative financial assets that are designated as available for sale or that do not fall within any of the other three financial asset classifications. They are measured at fair value with changes in value taken to the revaluation reserve, with the exception of impairment losses. Accumulated gains or losses are recycled to the SoCI on de-recognition.

#### **1.16.5 Loans and receivables**

Loans and receivables are non-derivative financial assets with fixed or determinable payments which are not quoted in an active market. After initial recognition, they are measured at amortised cost using the effective interest method, less any impairment. Interest is recognised using the effective interest method.

Fair value is determined by reference to quoted market prices where possible, otherwise by valuation techniques.

The effective interest rate is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset, to the net carrying amount of the financial asset.

At the SOFP date, the NHS Wales organisation assesses whether any financial assets, other than those held at 'fair value through profit and loss' are impaired. Financial assets are impaired and impairment losses recognised if there is objective evidence of impairment as a result of one or more events which occurred after the initial recognition of the asset and which has an impact on the estimated future cash flows of the asset.

For financial assets carried at amortised cost, the amount of the impairment loss is measured as the difference between the asset's carrying amount and the present value of the revised future cash flows discounted at the asset's original effective interest rate. The loss is recognised in the expenditure and the carrying amount of the asset is reduced directly, or through a provision of impairment of receivables.

If, in a subsequent period, the amount of the impairment loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognised, the previously recognised impairment loss is reversed through the expenditure to the extent that the carrying amount of the receivable at the date of the impairment is reversed does not exceed what the amortised cost would have been had the impairment not been recognised.

#### **1.16.6 Other financial assets**

Listed investments are stated at market value. Unlisted investments are included at cost as an approximation to market value. Quoted stocks are included in the balance sheet at mid-market price, and where holdings are subject to bid / offer pricing their valuations are shown on a bid price. The shares are not held for trading and accordingly are classified as available for sale. Other financial assets are classified as available for sale investments carried at fair value within the financial statements.

#### **1.17 Financial liabilities**

Financial liabilities are recognised on the SOFP when the NHS Wales organisation becomes party to the contractual provisions of the financial instrument or, in the case of trade payables, when the goods or services have been received. Financial liabilities are de-recognised when the liability has been discharged, that is, the liability has been paid or has expired. Loans from Welsh Government are recognised at historical cost.

##### **1.17.1 Financial liabilities are initially recognised at fair value through SoCI**

Financial liabilities are classified as either financial liabilities at fair value through the SoCI or other financial liabilities.

### **1.17.2 Financial liabilities at fair value through the SoCI**

Embedded derivatives that have different risks and characteristics to their host contracts, and contracts with embedded derivatives whose separate value cannot be ascertained, are treated as financial liabilities at fair value through profit and loss. They are held at fair value, with any resultant gain or loss recognised in the SoCI. The net gain or loss incorporates any interest earned on the financial asset.

### **1.17.3 Other financial liabilities**

After initial recognition, all other financial liabilities are measured at amortised cost using the effective interest method. The effective interest rate is the rate that exactly discounts estimated future cash payments through the life of the asset, to the net carrying amount of the financial liability. Interest is recognised using the effective interest method.

### **1.18 Value Added Tax (VAT)**

Most of the activities of the NHS Wales organisation are outside the scope of VAT and, in general, output VAT does not apply and input VAT on purchases is not recoverable. Irrecoverable VAT is charged to the relevant expenditure category or included in the capitalised purchase cost of fixed assets. Where output VAT is charged or input VAT is recoverable, the amounts are stated net of VAT.

### **1.19 Foreign currencies**

Transactions denominated in a foreign currency are translated into sterling at the exchange rate ruling on the dates of the transactions. Resulting exchange gains and losses are taken to the SoCI. At the SoFP date, monetary items denominated in foreign currencies are retranslated at the rates prevailing at the reporting date.

### **1.20 Third party assets**

Assets belonging to third parties (such as money held on behalf of patients) are not recognised in the accounts since the NHS Wales organisation has no beneficial interest in them. Details of third party assets are given in the Notes to the accounts.

### **1.21 Losses and Special Payments**

Losses and special payments are items that the Welsh Government would not have contemplated when it agreed funds for the health service or passed legislation. By their nature they are items that ideally should not arise. They are therefore subject to special control procedures compared with the generality of payments. They are divided into different categories, which govern the way each individual case is handled.

Losses and special payments are charged to the relevant functional headings in the SoCI on an accruals basis, including losses which would have been made good through insurance cover had the NHS Wales organisation not been bearing their own risks (with insurance premiums then being included as normal revenue expenditure). However, the note on losses and special payments is compiled directly from the losses register which is prepared on a cash basis.

The NHS Wales organisation accounts for all losses and special payments gross (including assistance from the WRPS).

The NHS Wales organisation accrues or provides for the best estimate of future payouts for certain liabilities and discloses all other potential payments as contingent liabilities, unless the probability of the liabilities becoming payable is remote.

All claims for losses and special payments are provided for, where the probability of settlement of an individual claim is over 50%. Where reliable estimates can be made, incidents of clinical negligence against which a claim has not, as yet, been received are provided in the same way. Expected reimbursements from the WRP are included in debtors. For those claims where the probability of settlement is between 5-50%, the liability is disclosed as a contingent liability.

### **1.22 Pooled budget**

The NHS Wales organisation has not entered into pooled budgets with Local Authorities.

### **1.23 Critical Accounting Judgements and key sources of estimation uncertainty**

In the application of the accounting policies, management is required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources.

The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from those estimates. The estimates and underlying assumptions are continually reviewed. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or the period of the revision and future periods if the revision affects both current and future periods.

#### **1.24 Key sources of estimation uncertainty**

The following are the key assumptions concerning the future, and other key sources of estimation uncertainty at the SoFP date, that have a significant risk of causing material adjustment to the carrying amounts of assets and liabilities within the next financial year.

Significant estimations are made in relation to on-going clinical negligence and personal injury claims. Assumptions as to the likely outcome, the potential liabilities and the timings of these litigation claims are provided by independent legal advisors. Any material changes in liabilities associated with these claims would be recoverable through the WRPS.

#### **1.25 Provisions for legal or constructive obligations for clinical negligence, personal injury & defence costs**

The NHS Wales organisation provides for legal or constructive obligations for clinical negligence, personal injury and defence costs that are of uncertain timing or amount at the balance sheet date on the basis of the best estimate of the expenditure required to settle the obligation.

Claims are funded via the WRPS which receives an annual allocation from Welsh Government to cover the cost of reimbursement requests submitted to the bi-monthly WRPS Committee. Following settlement to individual claimants by the NHS Wales organisations, the full cost is recognised in year and matched to income (less a £25K excess) via a WRPS debtor, until reimbursement has been received from the WRPS Committee.

**Probable & Certain Cases – Accounting Treatment**

A provision for these cases is calculated in accordance with IAS 37. Cases are assessed and divided into four categories according to their probability of settlement:

<b>Remote</b>	Probability of Settlement	0 – 5%
	Accounting Treatment	Contingent Liability
<b>Possible</b>	Probability of Settlement	6% - 49%
	Accounting Treatment	Defence Fee - Provision*
		Contingent Liability for all other estimated expenditure
<b>Probable</b>	Probability of Settlement	50% - 94%
	Accounting Treatment	Full Provision
<b>Certain</b>	Probability of Settlement	95% - 100%
	Accounting Treatment	Full Provision

\* *Personal injury cases - Defence fee costs are provided for at 100%.*

The provision for probable and certain cases is based on case estimates of individual reported claims received by Legal & Risk Services within NHS Wales Shared Services Partnership.

The solicitor will estimate the case value including defence fees, using professional judgement and from obtaining counsel advice. Valuations are then discounted for the future loss elements using individual life expectancies and the Government Actuary’s Department actuarial tables (Ogden tables) and Personal Injury Discount Rate of -0.25%.

Future liabilities for certain & probable cases with a probability of 95%-100% and 50%-94% respectively are held as a provision on the Trust’s balance sheet. Cases typically take a number of years to settle, particularly for high value cases where a period of development is necessary to establish the full extent of the injury caused.

**Discounting provisions**

The WRPS discounts estimated future lump sums within the provisions which are assumed to settle over a 3 year period.

A proportion of the lump sum estimates are assumed to settle with RPI indexed annual payments and the remainder as Annual Survey of Hours and Earnings (ASHE) indexed annual payments.

The HM Treasury short term nominal discount rate of 0.47% (2020/2021: -0.02%) is applied to the RPI proportion of the lump sum estimate using the retail price index (RPI) inflation rates of 5.00% for Year 1, 3.6% for Year 2 and 3% for Year 3. The RPI rates have been calculated by reference to CPI for general provisions, with a 1% margin added to CPI indices to the period to 31<sup>st</sup> January 2030 and 0.1% thereafter. These are the rates recommended by the Government’s Actuary’s Department in lieu of published RPI rates which were omitted from the December 2021 HMT Public Expenditure System (PES) paper.

The remainder is discounted by applying the Annual Survey of Hours and Earnings (ASHE) nominal discount rate of 1.9% (3.7% 2021) with the underlying RPI rates for Years 1 – 3 as above.

### **PPO Provisions**

The majority of high value (>£1M) claims settle with a Periodical Payment Order (PPO) where part or all of the final settlement value is paid over the life time of the claimant.

When cases settle with a PPO arrangement, an individual provision is created by multiplying the claimants' index linked annual payment value by the number of years' life expectancy.

Future cashflows are modelled based on individual claim data and include any agreed future steps in payment value.

The number of years' life expectancy is discounted according to the Ogden table multipliers using HM Treasury's nominal discount rate for general provisions issued annually in the Public Expenditure System (PES) paper and an inflation factor.

For 2021-2022, the nominal short, medium, long and very long term rates are: 0.47%, (0-5 years), 0.70%, (+5-10 years) 0.95%(+10-40 years) and 0.66% (over 40 years) respectively.

The inflation factor applied is dependent upon the rate agreed as part of the settlement of the claimant's case. Where annual payments are required to be uplifted by the RPI, the RPI rate of 3.22% has been used for the period up to and including 31st January 2030 and 2.32% thereafter. Where annual payments are required to be uplifted based on market data for carers' wages, the annual survey of hours and earnings (ASHE) discount rate of 0.7% has been applied.

The probabilities of survival for each claimant are based on estimated life expectancy, agreed by medical experts in each case.

### **1.26 Discount Rates**

Where discount is applied, a disclosure detailing the impact of the discounting on liabilities will be included for the relevant notes. The disclosure should include where possible undiscounted values to demonstrate the impact. An explanation of the source of the discount rate or how the discount rate has been determined will be included.

### **1.27 Private Finance Initiative (PFI) transactions**

The Trust has no PFI arrangements.

### **1.28 Contingencies**

A contingent liability is a possible obligation that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the NHS Wales organisation, or a present obligation that is not recognised because it is not probable that a payment will be required to settle the obligation or the amount of the obligation cannot be measured sufficiently reliably. A contingent liability is disclosed unless the possibility of a payment is remote.

A contingent asset is a possible asset that arises from past events and whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the NHS Wales organisation. A contingent asset is disclosed where an inflow of economic benefits is probable.



Where the time value of money is material, contingencies are disclosed at their present value.

Remote contingent liabilities are those that are disclosed under Parliamentary reporting requirements and not under IAS 37 and, where practical, an estimate of their financial effect is required.

### **1.29 Absorption accounting**

Transfers of function are accounted for as either by merger or by absorption accounting, dependent upon the treatment prescribed in the FReM. Absorption accounting requires that entities account for their transactions in the period in which they took place with no restatement of performance required.

For transfers of functions involving NHS Wales Trusts in receipt of PDC the double entry for the fixed asset NBV value and the net movement in assets is PDC.

### **1.30 Accounting standards that have been issued but not yet been adopted**

The following accounting standards have been issued and or amended by the IASB and IFRIC but have not been adopted because they are not yet required to be adopted by the FReM:

IFRS14 Regulatory Deferral Accounts - Applies to first time adopters of IFRS after 1 January 2016. Therefore not applicable.

IFRS 16 Leases is to be effective from 1 April 2022.

IFRS 17 Insurance Contracts, Application required for accounting periods beginning on or after 1 January 2021, but not yet adopted by the FReM: early adoption is not therefore permitted.

### **1.31 Accounting standards issued that have been adopted early**

During 2021-2022 there have been no accounting standards that have been adopted early. All early adoption of accounting standards will be led by HM Treasury.

### **1.32 Charities**

Following Treasury's agreement to apply IAS 27 to NHS Charities from 1 April 2013, the Trust has established that as it is the corporate trustee of the Velindre University NHS Trust Charitable Fund it is therefore considered for accounting standards compliance to have control of Velindre University NHS Trust Charitable Fund as a subsidiary, and with the agreement of Welsh Government has made the decision to consolidate the Velindre University NHS Trust Charitable Fund within the statutory accounts of the Trust.

The determination of control is an accounting standard test of control and there has been no change to the operation of the Velindre University NHS Trust Charitable Fund or its independence in its management of charitable funds.

Welsh Government as the ultimate parent of the NHS Wales organisations will disclose the Charitable Accounts in the Welsh Government Consolidated Accounts. Details of the transactions with the charity are included in the related parties notes.

### **1.33 Subsidiaries**

Material entities over which the NHS Wales organisation has the power to exercise control so as to obtain economic or other benefits are classified as subsidiaries and are consolidated. Their income and expenses; gains and losses; assets, liabilities and reserves; and cash flows are consolidated in full into the appropriate financial statement lines. Appropriate adjustments are made on consolidation where the subsidiary's accounting policies are not aligned with the NHS Wales organisation or where the subsidiary's accounting date is before 1 January or after 30 June.

Subsidiaries that are classified as 'held for sale' are measured at the lower of their carrying amount or 'fair value less costs to sell'.

### **1.34 Borrowing costs**

Borrowing costs are recognised as expenses as they are incurred.

### **1.35 Public Dividend Capital (PDC) and PDC dividend**

PDC represents taxpayers' equity in the NHS Wales organisation. At any time the Minister for Health and Social Services with the approval of HM Treasury can issue new PDC to, and require repayments of, PDC from the NHS Wales organisation. PDC is recorded at the value received. As PDC is issued under legislation rather than under contract, it is not treated as an equity financial instrument.

From 1 April 2010 the requirement to pay a public dividend over to the Welsh Government ceased.

2. Financial Performance

2.1 STATUTORY FINANCIAL DUTIES

Under the National Health Services (Wales) Act 2006 the financial obligations of the NHS Trust are contained within Schedules 4 2(1) and 4(2).

The Trust is required to achieve financial breakeven over a rolling 3 year period.

Welsh Health Circular WHC/2016/054 replaced WHC/2015/014 'Statutory and Financial Duties of Local Health Boards and NHS Trusts' and further clarifies the statutory financial duties of NHS Wales bodies.

2.1.1 Financial Duty

	Annual financial performance			2019-20 to 2021-22
	2019-20 £000	2020-21 £000	2021-22 £000	Financial duty £000
Retained surplus / (deficit)	41	1,222	(203)	1,060
Less Donated asset / grant funded revenue adjustment	(17)	(1,184)	244	(957)
Adjusted surplus/ (Deficit)	24	38	41	103

Velindre University NHS Trust has met its financial duty to break even over the 3 years 2019-2020 to 2021-2022.

In 2021/2022 the Trust, via NWSSP, issued assets totalling £244k that had previously been donated by DHSC in 2020/2021. This is in contrast to previous years where assets have been donated to the Trust.

2.1.2 Integrated Medium Term Plan (IMTP)

Due to the pandemic, the process for the 2020-2023 integrated plan was paused in Spring 2020 temporary planning arrangements were implemented.

As a result the extant planning duty for 2021-2022 remains the requirement to submit and have approved a 2019-2022 integrated plan, as set out in the NHS Wales Planning Framework 2019-2022.

Velindre University NHS Trust submitted a 2019-2022 integrated plan in accordance with the planning framework.

The Minister for Health and Social Services extant approval.

Status	<b>Approved</b>
Date	26/03/2019

Velindre University NHS Trust has therefore met its statutory duty to have an approved financial plan.

## 2. Financial Performance (cont)

### 2.2 ADMINISTRATIVE REQUIREMENTS

#### 2.2.1. External financing

Due to circumstances that arose as a result of the COVID 19 pandemic, the requirement to achieve the External Financing Target has been suspended for 2021-2022. It is expected to be reintroduced for 2022-2023.

#### 2.3. Creditor payment

The Trust is required to pay 95% of the number of non-NHS bills within 30 days of receipt of goods or a valid invoice (whichever is the later). The Trust has achieved the following results:

	2021-22	2020-21
Total number of non-NHS bills paid	72,627	76,838
Total number of non-NHS bills paid within target	69,488	74,285
Percentage of non-NHS bills paid within target	95.7%	96.7%
<b>The Trust has met the target.</b>		

3. Revenue from patient care activities	2021-22	2020-21	2021-22	2020-21
	NHS Trust		Consolidated	
	£000	£000	£000	£000
Local health boards	88,569	74,582	88,569	74,582
Welsh Health Specialised & Emergency Ambulance Services Committees (WHSSC & EASC)	49,172	47,099	49,172	47,099
Welsh NHS Trusts	1,512	2,506	1,512	2,506
Welsh Special Health Authorities	1,465	993	1,465	993
Foundation Trusts	0	62	0	62
Other NHS England bodies	107	52	107	52
Other NHS Bodies	1	0	1	0
Local Authorities	0	0	0	0
Welsh Government	13,533	11,144	13,533	11,144
<b>Welsh Government Welsh Risk Pool Reimbursements</b>				
NHS Wales Secondary Health Sector	424,563	120,386	424,563	120,386
NHS Wales Primary Sector Future Liability Scheme Reimbursement	93	0	93	0
NHS Wales Redress	1,679	2,491	1,679	2,491
Other	0	0	0	0
Welsh Government - Hosted Bodies	153,833	315,169	153,833	315,169
Non NHS:				
Private patient income	2,017	1,952	2,017	1,952
Overseas patients (non-reciprocal)	0	0	0	0
Injury Costs Recovery (ICR) Scheme	0	0	0	0
Other revenue from activities	164	280	164	280
<b>Total</b>	<b>736,708</b>	<b>576,716</b>	<b>736,708</b>	<b>576,716</b>

Injury Cost Recovery (ICR) Scheme income:

2021-22	2020-21
%	%

To reflect expected rates of collection ICR income is subject to a provision for impairment of:

23.76	22.43
-------	-------

4. Other operating revenue	2021-22	2020-21	2021-22	2020-21
	NHS Trust		Consolidated	
	£000	£000	£000	£000
Income generation	842	1,027	842	1,027
Patient transport services	0	0	0	0
Education, training and research	5,431	4,452	5,431	4,452
Charitable and other contributions to expenditure	3,105	3,998	314	1,497
Incoming FHoT Revenue				
Unrestricted - donations and legacies			3,066	2,683
Restricted - donations and legacies			0	0
Receipt of Covid Items free of charge from other NHS Wales Organisations	0	0	0	0
Receipt of Covid Items free of charge from other organisations	0	0	0	0
Receipt of donations for capital acquisitions	0	50	0	50
Receipt of government grants for capital acquisitions	0	1,134	0	1,134
Non-patient care services to other bodies	936	705	936	705
Rental revenue from finance leases	0	0	0	0
Rental revenue from operating leases	133	0	133	0
Other revenue:				
Provision of pathology/microbiology services	0	0	0	0
Accommodation and catering charges	180	105	180	105
Mortuary fees	0	0	0	0
Staff payments for use of cars	103	158	103	158
Business unit	0	0	0	0
Scheme Pays Reimbursement Notional	339	0	339	0
Other	296,022	259,878	296,022	259,878
<b>Total</b>	<b>307,091</b>	<b>271,507</b>	<b>307,366</b>	<b>271,689</b>
<b>Total Patient Care and Operating Revenue</b>	<b>1,043,799</b>	<b>848,223</b>	<b>1,044,074</b>	<b>848,405</b>

Other revenue comprises:

NHS Wales Shared Services Partnership	291,705	223,532	291,705	223,532
NHS Wales Informatics Services	0	33,813	0	33,813
Other	4,317	2,533	4,317	2,533
<b>Total</b>	<b>296,022</b>	<b>259,878</b>	<b>296,022</b>	<b>259,878</b>

Note 37.2 provides detail on the Welsh Government funding received in relation to the COVID 19 pandemic.

In addition to the income shown in the above note, the Trust also received £4.5m of pass through funding from Welsh Government for Hospices which has been netted off within the accounts to ensure Trust income and expenditure was not overstated.

On 1st April 2019 employer pension contributions increased by 6.3%. Welsh Government funded this by making payment directly to the NHS Business Services Agency on the Trust's behalf. The notional income of £11.4m is reported with the above notes, with further detail provided in note 37.1.

On 1st April 2021 the NHS Wales Informatics Service (NWIS) transitioned out of the Trust into a Special Health Authority, Digital Health and Care Wales (DHCW), and therefore there is no income included in the 2021/2022 statements in relation to this organisation. NWIS income reported in 2020/2021 totalled £101,929k.

Revenue rental from operating leases totalled £111k in 2020/2021 and was reported as 'other' income.

5. Operating expenses	2021-22	2020-21	2021-22	2020-21
5.1 Operating expenses	£000	£000	£000	£000
	NHS Trust		Consolidated	
Local Health Boards	11,464	9,861	11,464	9,861
Welsh NHS Trusts	23	753	23	753
Welsh Special Health Authorities	1,170	19	1,170	19
Goods and services from other non Welsh NHS bodies	0	0	0	0
WHSSC/EASC	0	0	0	0
Local Authorities	0	174	0	174
Purchase of healthcare from non-NHS bodies	0	0	0	0
Welsh Government	0	0	0	0
Other NHS Trusts	514	506	514	506
Directors' costs	1,392	1,353	1,392	1,353
Operational Staff costs	153,982	177,956	153,982	177,956
Non operational trainee staff costs	137,379	62,340	137,379	62,340
Non operational collaborative bank staff costs	234	176	234	176
Single lead employer Staff Trainee Cost	1,033	247	1,033	247
Collaborative Bank Staff Cost	0	0	0	0
Supplies and services - clinical	96,226	130,206	96,226	130,206
Supplies and services - general	117,995	61,768	117,995	61,768
Consultancy Services	4,224	5,972	4,224	5,972
Establishment	12,383	15,128	12,383	15,128
Transport	3,160	2,709	3,160	2,709
Premises	24,771	65,218	24,771	65,218
FHoT Resources expended				
Costs of generating funds			157	90
Charitable activities			(306)	183
Governance Costs			(15)	0
Impairments and Reversals of Receivables	0	0	0	0
Depreciation	9,110	11,739	9,110	11,739
Amortisation	1,112	5,815	1,112	5,815
Impairments and reversals of property, plant and equipment	0	0	0	0
Impairments and reversals of intangible assets	0	0	0	0
Impairments and reversals of financial assets	0	0	0	0
Impairments and reversals of non current assets held for sale	0	0	0	0
Audit fees	224	216	239	228
Other auditors' remuneration	0	0	0	0
Losses, special payments and irrecoverable debts	447,889	128,176	447,889	128,176
Research and development	0	0	0	0
NWSSP centrally purchased and donated Covid assets issued free of charge to NHS Wales organisations	0	49,598	0	49,598
NWSSP centrally purchased Covid assets issued free of charge to other organisations	0	100,247	0	100,247
Other operating expenses	18,650	16,484	18,650	16,484
<b>Total</b>	<b>1,042,935</b>	<b>846,661</b>	<b>1,042,786</b>	<b>846,946</b>

On 1st April 2019 employer pension contributions increased by 6.3%. Welsh Government funded this by making payment directly to the NHS Pensions Agency on the Trust's behalf. The notional expenditure of £11.406m (£9.725m 2020/2021) is reported above under the various staff cost headings. Further detail is provided in note 37.1.

Staff costs are split over a number of different headings. Operational staff costs are those staff employed by the Trust and deemed operational within it. Non-operational trainee staff costs are those trainees employed by NWSSP under the All Wales Single Lead Employer Scheme (SLE) on behalf of other NHS Wales organisations, and who are operational within those organisations rather than the Trust. Where NWSSP employ staff under the SLE scheme on behalf of the Trust, these costs are reported as Single Lead Employer Staff Trainee costs. Staff employed under another NWSSP scheme, which commenced in 2020/2021, the All Wales Collaborative Bank, are also identified separately and split between those operational within the Trust and those operational in other NHS Wales organisations. Further analysis of these costs is shown in notes 10.1 and 10.7, with details of average numbers of employees shown in notes 10.2 and 10.8.

On 1st April 2021 the NHS Wales Informatics Service (NWIS) transitioned out of the Trust into a Special Health Authority, Digital Health and Care Wales (DHCW), and therefore there is no expenditure included in the 2021/2022 statements in relation to this organisation. NWIS expenditure reported in 2020/2021 totalled £101,929k.

Other operating expenses include £244k of assets donated to NWSSP by DHSC in 2020/2021 that were donated free of charge to other organisations during 2021/2022.

5. Operating expenses (continued)

5.2 Losses, special payments and irrecoverable debts:

Charges to operating expenses	2021-22 £000	2020-21 £000	2021-22 £000	2020-21 £000
Increase/(decrease) in provision for future payments:	NHS Trust		Consolidated	
Clinical negligence:-				
Secondary care	299,158	126,411	299,158	126,411
Primary care	92	122	92	122
Redress Secondary Care	951	1,754	951	1,754
Redress Primary Care	0	0	0	0
Personal injury	(1,777)	4,205	(1,777)	4,205
All other losses and special payments	23,441	5,761	23,441	5,761
Defence legal fees and other administrative costs	2,057	1,901	2,057	1,901
Structured Settlements Welsh Risk Pool	123,967	(11,978)	123,967	(11,978)
Gross increase/(decrease) in provision for future payments	447,889	128,176	447,889	128,176
Contribution to Welsh Risk Pool	0	0	0	0
Premium for other insurance arrangements	0	0	0	0
Irrecoverable debts	0	0	0	0
Less: income received/ due from Welsh Risk Pool	0	0	0	0
<b>Total charge</b>	<b>447,889</b>	<b>128,176</b>	<b>447,889</b>	<b>128,176</b>

The Clinical Negligence figure includes £1,908,747 (2020/2021 £1,478,645) in respect of payments made under Redress during 2021/2022. The Redress creditor reduced by £229,000 in 2021/22 compared to the increase in the creditor movement of £1,012,000 in 2020/21.

Other losses includes: donations of £11.8m in respect of PPE, equipment and other aid to India, Namibia and Ukraine; stock losses of £11.2m; plus a foreign exchange loss of £0.3m.

	2021-22 £	2020-21 £
Permanent injury included within personal injury:	0	0

6. Investment revenue	2021-22	2020-21	2021-22	2020-21
	£000	£000	£000	£000
Rental revenue :	NHS Trust		Consolidated	
PFI finance lease revenue:				
Planned	0	0	0	0
Contingent	0	0	0	0
Other finance lease revenue	0	0	0	0
<b>Interest revenue:</b>				
Bank accounts	23	0	23	0
Other loans and receivables	0	0	0	0
Impaired financial assets	0	0	0	0
Other financial assets	0	0	114	133
<b>Total</b>	<b>23</b>	<b>0</b>	<b>137</b>	<b>133</b>

On 19th March 2020, the interest rate on the Trust's bank accounts was reduced to nil and remained at that rate until 16th December 2021. Interest received in 2021/2022 therefore relates to the period 16th December 2021 to 31st March 2022.

7. Other gains and losses	2021-22	2020-21	2021-22	2020-21
	£000	£000	£000	£000
	NHS Trust		Consolidated	
Gain/(loss) on disposal of property, plant and equipment	3	25	3	25
Gain/(loss) on disposal of intangible assets	0	0	0	0
Gain/(loss) on disposal of assets held for sale	0	0	0	0
Gain/(loss) on disposal of financial assets	0	0	0	0
Gains/(loss) on foreign exchange	0	0	0	0
Change in fair value of financial assets at fair value through income statement	0	0	0	0
Change in fair value of financial liabilities at fair value through income statement	0	0	0	0
Recycling of gain/(loss) from equity on disposal of financial assets held for sale	0	0	0	0
<b>Total</b>	<b>3</b>	<b>25</b>	<b>3</b>	<b>25</b>

8. Finance costs	2021-22	2020-21	2021-22	2020-21
	£000	£000	£000	£000
	NHS Trust		Consolidated	
Interest on loans and overdrafts	0	0	0	0
Interest on obligations under finance leases	0	0	0	0
Interest on obligations under PFI contracts:				
Main finance cost	0	0	0	0
Contingent finance cost	0	0	0	0
Interest on late payment of commercial debt	0	0	0	0
Other interest expense	0	0	0	0
<b>Total interest expense</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
Provisions unwinding of discount	(50)	(183)	(50)	(183)
Periodical Payment Order unwinding of discount	1,143	548	1,143	548
Other finance costs	0	0	0	0
<b>Total</b>	<b>1,093</b>	<b>365</b>	<b>1,093</b>	<b>365</b>



9. Operating leases

9.1 Trust as lessee

Operating lease payments represent rentals payable by Velindre University NHS Trust for properties and equipment.

Payments recognised as an expense	2021-22	2020-21	2021-22	2020-21
	£000	£000	£000	£000
	NHS Trust		Consolidated	
Minimum lease payments	2,276	2,863	2,276	2,863
Contingent rents	0	0	0	0
Sub-lease payments	0	0	0	0
<b>Total</b>	<b>2,276</b>	<b>2,863</b>	<b>2,276</b>	<b>2,863</b>

Total future minimum lease payments	2021-22	2020-21	2021-22	2020-21
	£000	£000	£000	£000
Payable:	NHS Trust		Consolidated	
Not later than one year	1,762	2,733	1,762	2,733
Between one and five years	2,843	4,260	2,843	4,260
After 5 years	570	967	570	967
<b>Total</b>	<b>5,175</b>	<b>7,960</b>	<b>5,175</b>	<b>7,960</b>

Total future sublease payments expected to be received	0	0	0	0
--------------------------------------------------------	---	---	---	---

9. Operating leases (continued)

9.2 Trust as lessor

NWSSP leases an area of the IP5 warehouse to DHSC for the lighthouse laboratory. It also leased an area of the IP5 warehouse to a commercial entity, but this arrangement ended during 2021/2022.

Following the purchase of Matrix House in Swansea on 30th March 2022, NWSP leases areas of Matrix House to the Welsh Ambulance NHS Trust and Public Health Wales NHS Trust, and also leases further parts of the building to two commercial entities.

Velindre Cancer Centre has an ongoing agreement with Cancer Research Wales to lease space in the research block building of Velindre Cancer Centre.

Rental Revenue

Receipts recognised as income

	2021-22	2020-21	2021-22	2020-21
	£000	£000	£000	£000
	NHS Trust		Consolidated	
Rent	133	111	133	111
Contingent rent	0	0	0	0
Other	0	0	0	0
<b>Total rental revenue</b>	<b>133</b>	<b>111</b>	<b>133</b>	<b>111</b>

Total future minimum lease payments

Receivable:	2021-22	2020-21	2021-22	2020-21
	£000	£000	£000	£000
	NHS Trust		Consolidated	
Not later than one year	266	55	266	55
Between one and five years	691	0	691	0
After 5 years	414	0	414	0
<b>Total</b>	<b>1,371</b>	<b>55</b>	<b>1,371</b>	<b>55</b>

10. Employee costs and numbers

10.1 Employee costs Operational Staff	Permanently employed staff	Staff on Inward Secondment	Agency Staff	Specialist Trainee (SLE)	Other Staff	2021-22	2020-21
						£000	£000
	£000	£000	£000	£000	£000	£000	£000
Salaries and wages	110,716	1,131	3,095	828	5,830	121,600	138,710
Social security costs	12,606	8	0	97	190	12,901	14,432
Employer contributions to NHS Pensions Scheme	22,661	6	0	108	472	23,247	28,879
Other pension costs	42	0	0	0	0	42	44
Other post-employment benefits	0	0	0	0	5	5	(3)
Termination benefits	102	0	0	0	0	102	0
<b>Total</b>	<b>146,127</b>	<b>1,145</b>	<b>3,095</b>	<b>1,033</b>	<b>6,497</b>	<b>157,897</b>	<b>182,062</b>

Of the total above:

Charged to capital	1,633	2,639
Charged to revenue	156,264	179,423
<b>Total</b>	<b>157,897</b>	<b>182,062</b>

Net movement in accrued employee benefits (untaken staff leave total accrual included in note above) 35 1,610

The net movement in accrued employee benefits footnote above includes Covid 19 Net movement in accrued employee benefits 538 1,546

The net movement in accrued employee benefits footnote includes accruals that transferred to DHCW on 1st April 2021 of £503k.

Other staff includes temporary workers paid directly by the Trust and staff sub-contracted or recharged from other NHS or public bodies.

Since 1st April 2019, Welsh Government have paid additional employer's pension contributions to the NHS Business Services Agency. This is recognised in the "employer contributions to NHS pensions scheme" line above. Further information is provided in note 37.1.

Staff costs and average number of employees for 2020/2021 included costs for NWIS who left the Trust on 1st April 2021. Their staff costs in 2020/2021 were £35,989k and average number of employees 698.

10.2 Average number of employees

	Permanently Employed	Staff on Inward Secondment	Agency Staff	Specialist Trainee (SLE)	Other Staff	2021-22	2020-21
						Total	Total
						Number	Number
Administrative, clerical and board members	1,957	13	21	0	38	2,029	2,643
Medical and dental	95	4	0	13	5	117	121
Nursing, midwifery registered	198	0	0	0	6	204	195
Professional, scientific and technical staff	72	0	0	0	1	73	65
Additional Clinical Services	219	0	3	0	25	247	316
Allied Health Professions	130	3	6	0	0	139	132
Healthcare scientists	144	1	0	0	8	153	142
Estates and Ancillary	503	0	45	0	93	641	456
Students	3	0	0	0	0	3	3
<b>Total</b>	<b>3,321</b>	<b>21</b>	<b>75</b>	<b>13</b>	<b>176</b>	<b>3,606</b>	<b>4,073</b>

The average number is calculated using the full time equivalent (FTE) of employees.

10.3. Retirements due to ill-health

	2021-22	2020-21
Number	5	6
Estimated additional pension costs £	310,700	228,710

The estimated additional pension costs of these ill-health retirements have been calculated on an average basis and are borne by the NHS Pension Scheme.

10.4 Employee benefits

The Trust operates four salary sacrifice schemes (childcare vouchers, cycle to work, home electronics and lease cars) for the financial benefit of its employees. In addition, staff have access to a non contributory Employee Assistance Programme which provides financial wellbeing support, and a financial wellbeing scheme to provide staff with access to simple financial education, salary deducted loans, and a range of savings and investment products.

10.5 Reporting of other compensation schemes - exit packages

	2021-22	2021-22	2021-22	2021-22	2020-21
Exit packages cost band (including any special payment element)	Number of compulsory redundancies Whole numbers only	Number of other departures Whole numbers only	Total number of exit packages Whole numbers only	Number of departures where special payments have been made Whole numbers only	Total number of exit packages Whole numbers only
less than £10,000	0	0	0	0	2
£10,000 to £25,000	0	0	0	0	1
£25,000 to £50,000	1	0	1	0	2
£50,000 to £100,000	0	1	1	0	2
£100,000 to £150,000	0	0	0	0	0
£150,000 to £200,000	0	0	0	0	0
more than £200,000	0	0	0	0	0
<b>Total</b>	<b>1</b>	<b>1</b>	<b>2</b>	<b>0</b>	<b>7</b>

	2021-22	2021-22	2021-22	2021-22	2020-21
Exit packages cost band (including any special payment element)	Cost of compulsory redundancies £	Cost of other departures £	Total cost of exit packages £	Cost of special element included in exit packages £	Total cost of exit packages £
less than £10,000	0	0	0	0	16,302
£10,000 to £25,000	0	0	0	0	18,117
£25,000 to £50,000	25,899	0	25,899	0	71,669
£50,000 to £100,000	0	75,874	75,874	0	146,668
£100,000 to £150,000	0	0	0	0	0
£150,000 to £200,000	0	0	0	0	0
more than £200,000	0	0	0	0	0
<b>Total</b>	<b>25,899</b>	<b>75,874</b>	<b>101,773</b>	<b>0</b>	<b>252,756</b>

Exit costs paid in year of departure	Total paid in year 2021-22 £	Total paid in year 2020-21 £
Exit costs paid in year	25,899	34,419
<b>Total</b>	<b>25,899</b>	<b>34,419</b>

Redundancy and other departure costs have been paid in accordance with the provisions of the relevant schemes or legislation. Where the Trust has agreed early retirements or compulsory redundancies, the additional costs are met by the Trust and not by the NHS Pensions Scheme. Ill-health retirement costs are met by the NHS Pensions Scheme and are not included in the table (see notes 10.3 & 10.9 for details of ill health retirement costs).

The disclosure reports the number and value of exit packages agreed in the year in line with the Welsh Government manual for accounts. The values payable to the individuals are shown. Any on costs are excluded as they do not form part of the payment to the individual.

There were no special payments agreed in 2021/2022.

## 10.6 Fair Pay disclosures

### 10.6.1 Remuneration Relationship

Reporting bodies are required to disclose the relationship between the remuneration of the highest-paid director / employee in their organisation and the 25th percentile, median and 75th percentile remuneration of the organisation's workforce. The 2021-22 financial year is the first year disclosures in respect of the 25th percentile pay ratio and 75th percentile pay ratio are required.

	2021-2022 £000 Chief	2021-2022 £000 Employee	2021-2022 Ratio	2020-2021 £000 Chief	2020-2021 £000 Employee	2020-2021 Ratio
<b>Total pay and benefits</b>	<b>Executive</b>	<b>Employee</b>	<b>Ratio</b>	<b>Executive</b>	<b>Employee</b>	<b>Ratio</b>
25th percentile pay ratio	147.5	22.0	6.7	142.5	22.0	6.5
Median pay	147.5	26.4	5.6	142.5	31.0	4.7
75th percentile pay ratio	147.5	40.3	3.7	142.5	45.0	3.2
<b>Salary component of total pay and benefits</b>						
25th percentile pay ratio	147.5	21.8	6.8	142.5	19.7	7.2
Median pay	147.5	24.9	5.9	142.5	25.8	5.5
75th percentile pay ratio	147.5	40.1	3.7	142.5	37.9	3.8

	Highest Paid Director	Employee	Ratio	Highest Paid Director	Employee	Ratio
<b>Total pay and benefits</b>						
25th percentile pay ratio						
Median pay						
75th percentile pay ratio						
<b>Salary component of total pay and benefits</b>						
25th percentile pay ratio						
Median pay						
75th percentile pay ratio						

In 2021-22, 8 (2020-2021, 13) employees received remuneration in excess of the highest-paid director / Chief Executive.

Remuneration for all staff ranged from £18,600 to £227,500 (2020-2021, £18,000 to £234,100).

The all staff range includes directors (including the highest paid director) and excludes pension benefits of all employees.

As the highest paid director has no control over the performance of the Trust, the information in the lower half of the table has not been completed.

The NHS and social care financial recognition scheme bonus of £735 to reward eligible NHS staff has not been included in the NHS Remuneration Report calculations. This bonus payment was not a contractual payment, but a one off payment to reward eligible staff for their commitment and tireless efforts in the most challenging circumstances. The cost of this payment was included in the operating expenses reported in the year 2020-2021, whilst the payment was made in early 2021-2022.

Annual salary figures are shown prior to any reduction as a result of any salary sacrifice scheme.

#### Financial year summary

The current financial year's pay ratios are not dissimilar to the previous year. The increase in the median pay ratio is generally attributable to an increase in the banding of the remuneration of the Chief Executive combined with a lower median pay for the Trust's employees taken as a whole.

	2020-2021 to 2021-2022	2019-2020 to 2020-2021
<b>10.6.2 Percentage Changes</b>		
% Change from previous financial year in respect of Chief Executive	%	%
Salary and allowances	3.5	0
Performance pay and bonuses	0	0
% Change from previous financial year in respect of highest paid director		
Salary and allowances		
Performance pay and bonuses		
Average % Change from previous financial year in respect of employees taken as a whole		
Salary and allowances	-5.6	3.7
Performance pay and bonuses	0	0

The average % change from the previous financial year in respect of employees taken as a whole has reduced primarily due to the transfer of the NWIS staff on 1st April 2021 from the Trust to Digital Health and Care Wales. Generally the NWIS workforce were paid at higher salaries than the whole Trust average.

The employees of the Trust do not receive any performance pay or bonuses.

10.7 Operational and Non Operational Employee costs

	Non operational staff			Total 2021-22	2020-21
	Operational Staff Total	SLE Trainee Staff	Collaborative Bank Staff		
	£000	£000	£000	£000	£000
Salaries and wages	121,600	109,228	199	231,027	188,600
Social security costs	12,901	12,710	11	25,622	20,103
Employer contributions to NHS Pension Scheme	23,247	15,441	24	38,712	35,835
Other pension costs	42	0	0	42	44
Other employment benefits	5	0	0	5	(3)
Termination benefits	102	0	0	102	0
<b>Total</b>	<b>157,897</b>	<b>137,379</b>	<b>234</b>	<b>295,510</b>	<b>244,579</b>
Charged to capital	1,633	0	0	1,633	2,639
Charged to revenue	156,264	137,379	234	293,877	241,940
	157,897	137,379	234	295,510	244,579

Net movement in accrued employee benefits (untaken staff leave total accrual included in note above) **35** **0** **0** **35** 1,610

The net movement in accrued employee benefits footnote above includes Covid 19 net movement in accrued employee benefits **538** **0** **0** **538** 1,546

The net movement in accrued benefits footnote includes accruals that transferred to DHCW on 1st April 2021 **(503)** **0** **0** **(503)** 0

10.8 Average number of operational and non operational employees

	Non operational staff			Total 2021-22	2020-21
	Operational Staff Total Number	SLE Trainee Staff Number	Collaborative Bank Staff Number		
Administrative, clerical and board members	2,029	0	0	2,029	2,643
Medical and dental	117	2,014	0	2,131	1,061
Nursing, midwifery registered	204	0	5	209	198
Professional, Scientific, and technical staff	73	0	0	73	65
Additional Clinical Services	247	121	0	368	381
Allied Health Professions	139	0	0	139	132
Healthcare Scientists	153	0	0	153	142
Estates and Ancillary	641	0	0	641	456
Students	3	0	0	3	3
<b>Total</b>	<b>3,606</b>	<b>2,135</b>	<b>5</b>	<b>5,746</b>	<b>5,081</b>

10.9. Retirements due to ill-health

There are no retirements due to ill-health for the Single Lead Employer Trainees therefore the figures reported in Note 10.3 remain unchanged.

10.10 Employee benefits

The Single Lead Employer Trainees are entitled to the same employee benefits as the Velindre operational staff.

10.11 Reporting of other compensation schemes - exit packages

There have been no exit package payments for the Single Lead Employer Trainee staff, therefore the figures reported in Note 10.5 remain unchanged.

## 11. Pensions

### PENSION COSTS

Past and present employees are covered by the provisions of the two NHS Pension Schemes. Details of the benefits payable and rules of the Schemes can be found on the NHS Pensions website at [www.nhsbsa.nhs.uk/pensions](http://www.nhsbsa.nhs.uk/pensions). Both are unfunded defined benefit schemes that cover NHS employers, GP practices and other bodies, allowed under the direction of the Secretary of State for Health and Social Care in England and Wales. They are not designed to be run in a way that would enable NHS bodies to identify their share of the underlying scheme assets and liabilities. Therefore, each scheme is accounted for as if it were a defined contribution scheme: the cost to the NHS body of participating in each scheme is taken as equal to the contributions payable to that scheme for the accounting period.

In order that the defined benefit obligations recognised in the financial statements do not differ materially from those that would be determined at the reporting date by a formal actuarial valuation, the FReM requires that “the period between formal valuations shall be four years, with approximate assessments in intervening years”. An outline of these follows:

#### **a) Accounting valuation**

A valuation of scheme liability is carried out annually by the scheme actuary (currently the Government Actuary’s Department) as at the end of the reporting period. This utilises an actuarial assessment for the previous accounting period in conjunction with updated membership and financial data for the current reporting period, and is accepted as providing suitably robust figures for financial reporting purposes. The valuation of the scheme liability as at 31 March 2022, is based on valuation data as 31 March 2021, updated to 31 March 2022 with summary global member and accounting data. In undertaking this actuarial assessment, the methodology prescribed in IAS 19, relevant FReM interpretations, and the discount rate prescribed by HM Treasury have also been used.

The latest assessment of the liabilities of the scheme is contained in the report of the scheme actuary, which forms part of the annual NHS Pension Scheme Accounts. These accounts can be viewed on the NHS Pensions website and are published annually. Copies can also be obtained from The Stationery Office.

#### **b) Full actuarial (funding) valuation**

The purpose of this valuation is to assess the level of liability in respect of the benefits due under the schemes (taking into account recent demographic experience), and to recommend contribution rates payable by employees and employers.

The latest actuarial valuation undertaken for the NHS Pension Scheme was completed as at 31 March 2016. The results of this valuation set the employer contribution rate payable from April 2019 to 20.6% of pensionable pay.

The 2016 funding valuation also tested the cost of the Scheme relative to the employer cost cap that was set following the 2012 valuation. There was initially a pause to the cost control element of the 2016 valuations, due to the uncertainty around member benefits caused by the discrimination ruling relating to the McCloud case.

HMT published valuation directions dated 7 October 2021 (see [Amending Directions 2021](#)) that set out the technical detail of how the costs of remedy are included in the 2016 valuation process. Following these directions, the scheme actuary has completed the cost control element of the 2016 valuation for the NHS Pension Scheme, which concludes no changes to benefits or member contributions are required. The 2016 valuation reports can be found on the NHS Pensions website at <https://www.nhsbsa.nhs.uk/nhs-pension-scheme-accounts-and-valuation-reports>.

### **c) National Employment Savings Trust (NEST)**

NEST is a workplace pension scheme, which was set up by legislation and is treated as a trust-based scheme. The Trustee responsible for running the scheme is NEST Corporation. It's a non-departmental public body (NDPB) that operates at arm's length from government and is accountable to Parliament through the Department for Work and Pensions (DWP).

NEST Corporation has agreed a loan with the Department for Work and Pensions (DWP). This has paid for the scheme to be set up and will cover expected shortfalls in scheme costs during the earlier years while membership is growing.

NEST Corporation aims for the scheme to become self-financing while providing consistently low charges to members.

Using qualifying earnings to calculate contributions, currently the legal minimum level of contributions is 8% of a jobholder's qualifying earnings, for employers whose legal duties have started. The employer must pay at least 3% of this.

The earnings band used to calculate minimum contributions under existing legislation is called qualifying earnings. Qualifying earnings are currently those between £6,240 and £50,000 for the 2021-2022 tax year (2020-2021 £6,240 and £50,000).

Restrictions on the annual contribution limits were removed on 1st April 2017.



**12. Public Sector Payment Policy**

**12.1 Prompt payment code - measure of compliance**

The Welsh Government requires that trusts pay all their trade creditors in accordance with the CBI prompt payment code and Government Accounting rules. The Welsh Government has set as part of the trust financial targets a requirement to pay 95% of the number of non-NHS creditors within 30 days of delivery or receipt of a valid invoice, whichever is the later.

	<b>2021-22</b>	<b>2021-22</b>	2020-21	2020-21
	<b>Number</b>	<b>£000</b>	Number	£000
<b>NHS</b>				
Total bills paid in year	<b>2,635</b>	<b>90,939</b>	2,677	54,304
Total bills paid within target	<b>2,388</b>	<b>81,381</b>	2,209	42,844
Percentage of bills paid within target	<b>90.6%</b>	<b>89.5%</b>	82.5%	78.9%
<b>Non-NHS</b>				
Total bills paid in year	<b>72,627</b>	<b>279,961</b>	76,838	619,674
Total bills paid within target	<b>69,488</b>	<b>270,196</b>	74,285	580,699
Percentage of bills paid within target	<b>95.7%</b>	<b>96.5%</b>	96.7%	93.7%
<b>Total</b>				
Total bills paid in year	<b>75,262</b>	<b>370,900</b>	79,515	673,978
Total bills paid within target	<b>71,876</b>	<b>351,577</b>	76,494	623,543
Percentage of bills paid within target	<b>95.5%</b>	<b>94.8%</b>	96.2%	92.5%

**12.2 The Late Payment of Commercial Debts (Interest) Act 1998**

	<b>2021-22</b>	2020-21
	<b>£</b>	£
Amounts included within finance costs from claims made under legislation	<b>0</b>	0
Compensation paid to cover debt recovery costs under legislation	<b>0</b>	0
<b>Total</b>	<b>0</b>	0

13. Property, plant and equipment :

2021-22

	Land	Buildings, excluding dwellings	Dwellings	Assets under construction and payments on account	Plant & machinery	Transport Equipment	Information Technology	Furniture and fittings	Total	FHoT	Consolidated Total
Cost or valuation	£000	£000	£000	£000	£000	£000	£000	£000	£000	£000	£000
At 31 March 2021	17,463	72,876	270	23,315	36,743	6,409	42,072	1,864	201,012	0	201,012
NWIS to DHCW Transfer adjustment	0	(1,428)	0	(29)	(172)	(9)	(23,047)	(5)	(24,690)	0	(24,690)
At 1 April 2021	17,463	71,448	270	23,286	36,571	6,400	19,025	1,859	176,322	0	176,322
Indexation	214	3,333	13	0	0	0	0	0	3,560	0	3,560
Additions - purchased	0	8,628	0	8,459	2,500	1,502	2,171	7	23,267	0	23,267
Additions - donated	0	0	0	0	0	0	0	0	0	0	0
Additions - government granted	0	0	0	0	0	0	0	0	0	0	0
Transfers from/(into) other NHS bodies	79	1,077	0	0	5,933	70	31	0	7,190	0	7,190
Reclassifications	0	2	0	(2,081)	0	0	0	0	(2,079)	0	(2,079)
Revaluation	0	0	0	0	0	0	0	0	0	0	0
Reversal of impairments	0	0	0	0	0	0	0	0	0	0	0
Impairments	0	0	0	0	0	0	0	0	0	0	0
Reclassified as held for sale	0	0	0	0	0	0	0	0	0	0	0
Disposals other than by sale	0	0	0	0	(1,596)	(62)	(19)	0	(1,677)	0	(1,677)
At 31 March 2022	17,756	84,488	283	29,664	43,408	7,910	21,208	1,866	206,583	0	206,583
<b>Depreciation</b>											
At 31 March 2021	0	11,679	36	0	23,970	3,297	24,578	894	64,454	0	64,454
NWIS to DHCW Transfer adjustment	0	(729)	0	0	(34)	(9)	(12,016)	(5)	(12,793)	0	(12,793)
At 1 April 2021	0	10,950	36	0	23,936	3,288	12,562	889	51,661	0	51,661
Indexation	0	485	1	0	0	0	0	0	486	0	486
Transfers from/(into) other NHS bodies	0	415	0	0	3,322	70	29	0	3,836	0	3,836
Reclassifications	0	0	0	0	0	0	0	0	0	0	0
Revaluation	0	0	0	0	0	0	0	0	0	0	0
Reversal of impairments	0	0	0	0	0	0	0	0	0	0	0
Impairments	0	0	0	0	0	0	0	0	0	0	0
Reclassified as held for sale	0	0	0	0	0	0	0	0	0	0	0
Disposals other than by sale	0	0	0	0	(1,565)	(62)	(19)	0	(1,646)	0	(1,646)
Charged during the year	0	3,120	9	0	3,170	664	1,970	177	9,110	0	9,110
At 31 March 2022	0	14,970	46	0	28,863	3,960	14,542	1,066	63,447	0	63,447
<b>Net book value</b>											
At 1 April 2021	17,463	60,498	234	23,286	12,635	3,112	6,463	970	124,661	0	124,661
At 31 March 2022	17,756	69,518	237	29,664	14,545	3,950	6,666	800	143,136	0	143,136
<b>Net book value at 31 March 2022 comprises :</b>											
Purchased	17,756	65,002	237	29,664	14,496	3,950	6,660	800	138,565	0	138,565
Donated	0	4,516	0	0	49	0	6	0	4,571	0	4,571
Government Granted	0	0	0	0	0	0	0	0	0	0	0
At 31 March 2022	17,756	69,518	237	29,664	14,545	3,950	6,666	800	143,136	0	143,136
<b>Asset Financing:</b>											
Owned	17,756	69,518	237	29,664	14,545	3,950	6,666	800	143,136	0	143,136
Held on finance lease	0	0	0	0	0	0	0	0	0	0	0
On-SoFP PFI contract	0	0	0	0	0	0	0	0	0	0	0
PFI residual interest	0	0	0	0	0	0	0	0	0	0	0
At 31 March 2022	17,756	69,518	237	29,664	14,545	3,950	6,666	800	143,136	0	143,136

The net book value of land, buildings and dwellings at 31 March 2022 comprises :

	£000	£000	£000
Freehold	66,047	0	66,047
Long Leasehold	21,464	0	21,464
Short Leasehold	0	0	0
<b>Total</b>	<b>87,511</b>	<b>0</b>	<b>87,511</b>

The land and buildings were revalued by the Valuation Office Agency with an effective date of 1st April 2017. The valuation has been prepared in accordance with the terms of the latest version of the Royal Institute of Chartered Surveyors' Valuation Standards. Trusts are required to apply the revaluation model set out in IAS 16 and value its capital assets to fair value. Fair value is defined by IAS 16 as the amount for which an asset could be exchanged between knowledgeable, willing parties in an arms length transaction. This has been undertaken on the assumption that the property is sold as part of the continuing enterprise in occupation.

The Trust transferred NWIS assets to Digital Health & Care Wales (DHCW) on 1st April 2021. The transfer had a net effect of (£27,872,928): a transfer out of gross assets (£69,544,253), and a transfer out of depreciation £41,672,325. These values include both tangible (note 13) and intangible (note 14) assets. Those relating to tangible assets are shown above.

The Trust received laundry assets from the following University Health Boards: Swansea Bay, Cwm Taf Morgannwg, Hywel Dda and Aneurin Bevan. The transfers have a net effect of £3,353,930: a transfer in of gross assets £7,189,927, and a transfer in of depreciation (£3,835,997). All assets are tangible and the elements can be found in their relevant categories above under "transfer from / (into) other NHS Bodies".

13. Property, plant and equipment :

2020-21

	Land	Buildings, excluding dwellings	Dwellings	Assets under construction and payments on account	Plant & machinery	Transport Equipment	Information Technology	Furniture and fittings	Total	FHoT	Consolidated Total
Cost or valuation	£000	£000	£000	£000	£000	£000	£000	£000	£000	£000	£000
<b>At 1 April 2020</b>	17,928	67,428	263	24,983	32,316	5,809	33,528	1,451	183,706	0	183,706
Indexation	(353)	1,973	7	0	0	0	0	0	1,627	0	1,627
Additions - purchased	0	2,405	0	3,336	2,724	944	7,846	439	17,694	0	17,694
Additions - donated	0	50	0	0	29	0	0	0	79	0	79
Additions - government granted	0	0	0	0	0	0	0	0	0	0	0
Transfers from/(into) other NHS bodies	(131)	0	0	0	(273)	0	0	0	(404)	0	(404)
Reclassifications	0	1,110	0	(5,004)	2,189	0	1,705	0	0	0	0
Revaluation	149	0	0	0	0	0	0	0	149	0	149
Reversal of impairments	0	0	0	0	0	0	0	0	0	0	0
Impairments	0	0	0	0	0	0	0	0	0	0	0
Reclassified as held for sale	0	0	0	0	0	0	0	0	0	0	0
Disposals other than by sale	(130)	(90)	0	0	(242)	(344)	(1,007)	(26)	(1,839)	0	(1,839)
<b>At 31 March 2021</b>	<b>17,463</b>	<b>72,876</b>	<b>270</b>	<b>23,315</b>	<b>36,743</b>	<b>6,409</b>	<b>42,072</b>	<b>1,864</b>	<b>201,012</b>	<b>0</b>	<b>201,012</b>
<b>Depreciation</b>											
<b>At 1 April 2020</b>	0	8,750	26	0	21,334	3,055	20,216	771	54,152	0	54,152
Indexation	0	232	1	0	0	0	0	0	233	0	233
Transfers from/(into) other NHS bodies	0	0	0	0	0	0	0	0	0	0	0
Reclassifications	0	0	0	0	0	0	0	0	0	0	0
Revaluation	0	0	0	0	0	0	0	0	0	0	0
Reversal of impairments	0	0	0	0	0	0	0	0	0	0	0
Impairments	0	0	0	0	0	0	0	0	0	0	0
Reclassified as held for sale	0	0	0	0	0	0	0	0	0	0	0
Disposals other than by sale	0	(90)	0	0	(242)	(344)	(969)	(26)	(1,671)	0	(1,671)
Charged during the year	0	2,787	9	0	2,878	586	5,331	149	11,740	0	11,740
<b>At 31 March 2021</b>	<b>0</b>	<b>11,679</b>	<b>36</b>	<b>0</b>	<b>23,970</b>	<b>3,297</b>	<b>24,578</b>	<b>894</b>	<b>64,454</b>	<b>0</b>	<b>64,454</b>
<b>Net book value</b>											
<b>At 1 April 2020</b>	17,928	58,678	237	24,983	10,982	2,754	13,312	680	129,554	0	129,554
<b>Net book value</b>											
<b>At 31 March 2021</b>	<b>17,463</b>	<b>61,197</b>	<b>234</b>	<b>23,315</b>	<b>12,773</b>	<b>3,112</b>	<b>17,494</b>	<b>970</b>	<b>136,558</b>	<b>0</b>	<b>136,558</b>
<b>Net book value at 31 March 2021 comprises :</b>											
Purchased	17,463	56,717	234	23,315	12,702	3,112	17,485	970	131,998	0	131,998
Donated	0	4,480	0	0	71	0	9	0	4,560	0	4,560
Government Granted	0	0	0	0	0	0	0	0	0	0	0
<b>At 31 March 2021</b>	<b>17,463</b>	<b>61,197</b>	<b>234</b>	<b>23,315</b>	<b>12,773</b>	<b>3,112</b>	<b>17,494</b>	<b>970</b>	<b>136,558</b>	<b>0</b>	<b>136,558</b>
<b>Asset Financing:</b>											
Owned	17,463	61,197	234	23,315	12,773	3,112	17,486	970	136,550	0	136,550
Held on finance lease	0	0	0	0	0	0	8	0	8	0	8
On-SoFP PFI contract	0	0	0	0	0	0	0	0	0	0	0
PFI residual interest	0	0	0	0	0	0	0	0	0	0	0
<b>At 31 March 2021</b>	<b>17,463</b>	<b>61,197</b>	<b>234</b>	<b>23,315</b>	<b>12,773</b>	<b>3,112</b>	<b>17,494</b>	<b>970</b>	<b>136,558</b>	<b>0</b>	<b>136,558</b>
<b>The net book value of land, buildings and dwellings at 31 March 2021 comprises :</b>											
							£000	£000	£000		
Freehold							61,657	0	61,657		
Long Leasehold							4,950	0	4,950		
Short Leasehold							12,288	0	12,288		
Total							<u>78,895</u>	<u>0</u>	<u>78,895</u>		

The land and buildings were revalued by the Valuation Office Agency with an effective date of 1st April 2017. The valuation has been prepared in accordance with the terms of the latest version of the Royal Institute of Chartered Surveyors' Valuation Standards. LHB s are required to apply the revaluation model set out in IAS 16 and value its capital assets to fair value. Fair value is defined by IAS 16 as the amount for which an asset could be exchanged between knowledgeable, willing parties in an arms length transaction. This has been undertaken on the assumption that the property is sold as part of the continuing enterprise in occupation.

Ventilators with a net book value of £0.273m were transferred to NHS Wales organisations during 2020/2021 which was recorded through the S1 process.

**13. Property, plant and equipment :**

**Disclosures:**

**i) Donated Assets**

Velindre University NHS Trust received no donated assets during the financial year 2021/2022.

**ii) Valuations**

The Trust's land and Buildings were revalued by the Valuation Office Agency with an effective date of 1st April 2017. The valuation has been prepared in accordance with the terms of the latest version of the Royal Institute of Chartered Surveyors' Valuation Standards.

The Trust is required to apply the revaluation model set out in IAS 16 and value its capital assets to fair value. Fair value is defined by IAS 16 as the amount for which an asset could be exchanged between knowledgeable, willing parties in an arms length transaction. This has been undertaken on the assumption that the property is sold as part of the continuing enterprise in operation.

The next District Valuation is due to take place during 2022/2023.

**iii) Asset Lives**

Depreciated as follows:

- Land is not depreciated.
- Buildings as determined by the Valuation Office Agency.
- Equipment 5-15 years.

**iv) Compensation**

There has been no compensation received from third parties for assets impaired, lost or given up, that is included in the income statement.

**v) Write Downs**

There have been no write downs during the year.

**vi)** The Trust does not hold any property where the value is materially different from its open market value.

**vii) Assets Held for Sale or Sold in the Period**

The Trust does not hold any assets for sale at the end of the financial year.

The Trust sold a Cobra Jet (plant & machinery) with a net book value of £37,876 for £36,000 resulting in a net loss on the sale of (£1,876).

The Trust sold a Support Vehicle (transport equipment) with a net book value of £nil for £5,000 resulting in a net gain on the sale of £5,000.

**vii) Consultancy Services**

The Trust capitalised a total of £2,407,491 of consultancy services during the financial year.

**Gain/(Loss) on Sale**

Asset description	Reason for sale	Gain/(Loss) on sale £000
Cobra Jet (laboratory equipment) V003424	Sale of asset	(2)
Support Vehicle V000541	Sale of asset	5
		<u>3</u>

## 13.2 Non-current assets held for sale

	Land	Buildings, including dwellings	Other property plant and equipment	Intangible assets	Other assets	Total	FHoT assets	Consolidated Total
	£000	£000	£000	£000	£000	£000	£000	£000
<b>Balance b/f 1 April 2021</b>	0	0	0	0	0	0	0	0
Plus assets classified as held for sale in year	0	0	0	0	0	0	0	0
Revaluation	0	0	0	0	0	0	0	0
Less assets sold in year	0	0	0	0	0	0	0	0
Plus reversal of impairments	0	0	0	0	0	0	0	0
Less impairment for assets held for sale	0	0	0	0	0	0	0	0
Less assets no longer classified as held for sale for reasons other than disposal by sale	0	0	0	0	0	0	0	0
<b>Balance c/f 31 March 2022</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Balance b/f 1 April 2020</b>	0	0	0	0	0	0	0	0
Plus assets classified as held for sale in year	0	0	0	0	0	0	0	0
Revaluation	0	0	0	0	0	0	0	0
Less assets sold in year	0	0	0	0	0	0	0	0
Plus reversal of impairments	0	0	0	0	0	0	0	0
Less impairment for assets held for sale	0	0	0	0	0	0	0	0
Less assets no longer classified as held for sale for reasons other than disposal by sale	0	0	0	0	0	0	0	0
<b>Balance c/f 31 March 2021</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>

## 14. Intangible assets

	Computer software purchased	Computer software internally developed	Licenses and trade-marks	Patents	Development expenditure internally generated	Total	FHoT	Consolidated Total
Cost or valuation	£000	£000	£000	£000	£000	£000	£000	£000
<b>At 31 March 2021</b>	<b>42,122</b>	<b>6,710</b>	<b>4,658</b>	<b>0</b>	<b>0</b>	<b>53,490</b>	<b>0</b>	<b>53,490</b>
NWIS to DHCW Transfer adjustment	(37,352)	(4,183)	(3,319)	0	0	(44,854)	0	(44,854)
<b>At 1 April 2021</b>	<b>4,770</b>	<b>2,527</b>	<b>1,339</b>	<b>0</b>	<b>0</b>	<b>8,636</b>	<b>0</b>	<b>8,636</b>
Revaluation		0			0	0	0	0
Reclassifications	1,340	739	0	0	0	2,079	0	2,079
Reversal of impairments	0	0	0	0	0	0	0	0
Impairments	0	0	0	0	0	0	0	0
Additions								
- purchased	1,797	1,055	3	0	0	2,855	0	2,855
- internally generated	0	0	0	0	0	0	0	0
- donated	0	0	0	0	0	0	0	0
- government granted	0	0	0	0	0	0	0	0
Reclassified as held for sale	0	0	0	0	0	0	0	0
Transfers from/(into) other NHS bodies	0	0	0	0	0	0	0	0
Disposals other than by sale	0	0	0	0	0	0	0	0
<b>At 31 March 2022</b>	<b>7,907</b>	<b>4,321</b>	<b>1,342</b>	<b>0</b>	<b>0</b>	<b>13,570</b>	<b>0</b>	<b>13,570</b>
<b>Amortisation</b>								
<b>At 31 March 2021</b>	<b>26,793</b>	<b>1,759</b>	<b>4,117</b>	<b>0</b>	<b>0</b>	<b>32,669</b>	<b>0</b>	<b>32,669</b>
NWIS to DHCW Transfer adjustment	(24,344)	(1,528)	(3,006)	0	0	(28,878)	0	(28,878)
<b>At 1 April 2021</b>	<b>2,449</b>	<b>231</b>	<b>1,111</b>	<b>0</b>	<b>0</b>	<b>3,791</b>	<b>0</b>	<b>3,791</b>
Revaluation		0			0	0	0	0
Reclassifications	0	0	0	0	0	0	0	0
Reversal of impairments	0	0	0	0	0	0	0	0
Impairments	0	0	0	0	0	0	0	0
Charged during the year	855	112	145	0	0	1,112	0	1,112
Reclassified as held for sale	0	0	0	0	0	0	0	0
Transfers from/(into) other NHS bodies	0	0	0	0	0	0	0	0
Disposals other than by sale	0	0	0	0	0	0	0	0
<b>Accumulated amortisation at 31 March 2022</b>	<b>3,304</b>	<b>343</b>	<b>1,256</b>	<b>0</b>	<b>0</b>	<b>4,903</b>	<b>0</b>	<b>4,903</b>
Net book value								
At 1 April 2021	2,321	2,296	228	0	0	4,845	0	4,845
<b>Net book value</b>								
<b>At 31 March 2022</b>	<b>4,603</b>	<b>3,978</b>	<b>86</b>	<b>0</b>	<b>0</b>	<b>8,667</b>	<b>0</b>	<b>8,667</b>
<b>Net book value</b>								
Purchased	4,599	3,978	86	0	0	8,663	0	8,663
Donated	4	0	0	0	0	4	0	4
Government granted	0	0	0	0	0	0	0	0
Internally Generated	0	0	0	0	0	0	0	0
<b>At 31 March 2022</b>	<b>4,603</b>	<b>3,978</b>	<b>86</b>	<b>0</b>	<b>0</b>	<b>8,667</b>	<b>0</b>	<b>8,667</b>

The Trust transferred NWIS assets to Digital Health & Care Wales (DHCW) on 1st April 2021. **The transfer had a net effect of (£27,872,928):** a transfer out of gross assets (£69,544,253), and a transfer out of depreciation £41,672,325. These values include both tangible (note 13) and intangible (note 14) assets. Those relating to intangible assets are shown above.

14. Intangible assets

	Computer software purchased	Computer software internally developed	Licenses and trade-marks	Patents	Development expenditure internally generated	Total	FHoT	Consolidated Total
Cost or valuation	£000	£000	£000	£000	£000	£000	£000	£000
<b>At 1 April 2020</b>	47,919	7,412	4,905	0	0	60,236	0	60,236
Revaluation		0			0	0	0	0
Reclassifications	0	0	0	0	0	0	0	0
Reversal of impairments	0	0	0	0	0	0	0	0
Impairments	0	0	0	0	0	0	0	0
Additions								
- purchased	7,097	1,172	0	0	0	8,269	0	8,269
- internally generated	0	0	0	0	0	0	0	0
- donated	0	0	0	0	0	0	0	0
- government granted	0	0	0	0	0	0	0	0
Reclassified as held for sale	0	0	0	0	0	0	0	0
Transfers from/(into) other NHS bodies	531	191	0	0	0	722	0	722
Disposals other than by sale	(13,425)	(2,065)	(247)	0	0	(15,737)	0	(15,737)
<b>At 31 March 2021</b>	<b>42,122</b>	<b>6,710</b>	<b>4,658</b>	<b>0</b>	<b>0</b>	<b>53,490</b>	<b>0</b>	<b>53,490</b>
<b>Amortisation</b>								
<b>At 1 April 2020</b>	35,843	2,955	3,794	0	0	42,592	0	42,592
Revaluation		0			0	0	0	0
Reclassifications	0	0	0	0	0	0	0	0
Reversal of impairments	0	0	0	0	0	0	0	0
Impairments	0	0	0	0	0	0	0	0
Charged during the year	4,375	870	570	0	0	5,815	0	5,815
Reclassified as held for sale	0	0	0	0	0	0	0	0
Transfers from/(into) other NHS bodies	0	0	0	0	0	0	0	0
Disposals other than by sale	(13,425)	(2,066)	(247)	0	0	(15,738)	0	(15,738)
<b>Accumulated amortisation at 31 March 2021</b>	<b>26,793</b>	<b>1,759</b>	<b>4,117</b>	<b>0</b>	<b>0</b>	<b>32,669</b>	<b>0</b>	<b>32,669</b>
Net book value								
At 1 April 2020	12,076	4,457	1,111	0	0	17,644	0	17,644
<b>Net book value</b>								
<b>At 31 March 2021</b>	<b>15,329</b>	<b>4,951</b>	<b>541</b>	<b>0</b>	<b>0</b>	<b>20,821</b>	<b>0</b>	<b>20,821</b>
<b>Net book value</b>								
Purchased	15,323	4,951	541	0	0	20,815	0	20,815
Donated	6	0	0	0	0	6	0	6
Government granted	0	0	0	0	0	0	0	0
Internally Generated	0	0	0	0	0	0	0	0
<b>At 31 March 2021</b>	<b>15,329</b>	<b>4,951</b>	<b>541</b>	<b>0</b>	<b>0</b>	<b>20,821</b>	<b>0</b>	<b>20,821</b>

#### 14. Intangible assets

##### Disclosures:

##### **i) Donated Assets**

There were no intangible assets donated or received by Government Grant this financial year.

##### **ii) Recognition**

Intangible assets comprise of licences for use of purchased IT software such as financial systems, internally generated IT software and various licences and trade marks.

An assessment is performed on an annual basis to determine that the assets are still available for use and that there is a continued market for their use. The fair values are based on the original cost and amortised based upon finite lives detailed below, and are as detailed in the notes to the accounts.

Intangible assets acquired separately are initially recognised at fair value. The amount recognised for internally-generated intangible assets is the sum of the expenditure incurred to date when the criteria for recognising internally generated assets has been met (see accounting policy 1.7 for criteria).

##### **iii) Asset Lives**

The useful economic life (UEL) of intangible non-current assets are assigned on an individual asset basis. Software is generally assigned a 5 year UEL and the UEL of internally generated software is based on the professional judgement of Trust professionals and Finance staff. No intangible assets are assessed as having indefinite useful lives.

##### **iv) Additions During the Period**

Intangible additions were acquired from All Wales & Discretionary funding during the year, and have been analysed into the relevant categories on line 18 of note 14.

##### **v) Disposals During the Period**

The Trust did not dispose of any intangible assets during the year, other than the those that transferred to DHCW and can be seen on lines 11 and 28 of note 14.



15. Impairments

Impairments in the period arose from:	2021-22		2020-21	
	Property, plant & equipment	Intangible assets	Property, plant & equipment	Intangible assets
	£000	£000	£000	£000
Loss or damage from normal operations	0	0	0	0
Abandonment of assets in the course of construction	0	0	0	0
Over specification of assets (Gold Plating)	0	0	0	0
Loss as a result of a catastrophe	0	0	0	0
Unforeseen obsolescence	0	0	0	0
Changes in market price	0	0	0	0
Other	0	0	0	0
Reversal of impairment	0	0	0	0
<b>Impairments charged to operating expenses</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
FHoT Impairments charged to operating expenses	0	0	0	0
<b>Consolidated impairment charged to operating expenses</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>

Analysis of impairments :

Operating expenses in Statement of Comprehensive Income	0	0	0	0
Revaluation reserve	0	0	0	0
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
FHoT Operating expenses in SoCNI	0	0	0	0
FHoT reserves	0	0	0	0
<b>NHS Consolidated Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>

There have been no impairments of capitalised assets during the year ended 31st March 2022.

16. Inventories

16.1 Inventories

	31 March 2022 £000	31 March 2021 £000	31 March 2022 £000	31 March 2021 £000
	NHS Trust		Consolidated	
Drugs	2,217	1,730	2,217	1,730
Consumables	57,422	89,692	57,422	89,692
Energy	0	0	0	0
Work in progress	0	0	0	0
Other	5,568	4,142	5,568	4,142
<b>Total</b>	<b>65,207</b>	<b>95,564</b>	<b>65,207</b>	<b>95,564</b>
<b>Of which held at net realisable value:</b>	<b>2,290</b>	<b>0</b>	<b>2,290</b>	<b>0</b>

	31 March 2022		31 March 2021	
DH Assets within other covered under	Capital £000	Revenue £000	Capital £000	Revenue £000
Memorandum of Understanding 1	227	0	561	544
Memorandum of Understanding 2	0	0		
Memorandum of Understanding 3	0	0		
	<b>227</b>	<b>0</b>	<b>561</b>	<b>544</b>

Department of Health and Social Care and National Health Commissioning Board Donated Assets

	31 March 2022		31 March 2021	
	Capital £000	Revenue £000	Capital £000	Revenue £000
At 1 April 2021	561	544		
Transferred under Memorandum of Understanding 1			5,294	2,438
Transferred under Memorandum of Understanding 2	730	86		
Transferred under Memorandum of Understanding 3	1,491	0		
Issued to NHS Wales bodies	(2,234)	(317)	(4,733)	(1,894)
Other Issues	(321)	(313)	0	0
AME Impairment	0	0	0	0
Returned to DH	0	0	0	0
Replacement from DH	0	0	0	0
<b>As at 31 March</b>	<b>227</b>	<b>0</b>	<b>561</b>	<b>544</b>

16.2 Inventories recognised in expenses

	31 March 2022 £000	31 March 2021 £000	31 March 2022 £000	31 March 2021 £000
	NHS Trust		Consolidated	
Inventories recognised as an expense in the period	173,686	181,745	173,686	181,745
Write-down of inventories (including losses)	13,066	5,823	13,066	5,823
Reversal of write-downs that reduced the expense	0	0	0	0
<b>Total</b>	<b>186,752</b>	<b>187,568</b>	<b>186,752</b>	<b>187,568</b>

Of the stock balance at 31st March 2022, approximately £48m is due to COVID and the Welsh Government request for NWSSP to hold 16 weeks stock of PPE to meet NHS Wales' demand. This is a reduction from the 24 weeks stock held at 31st March 2021.

£0.565m of COVID equipment stock is held at 31st March 2022, of which £0.227m was donated from DHSC in 2020/2021. There have been two further donations of equipment in 2021/2022 from DHSC totalling £2.307m which have been issued in full to NHS Wales organisations.

The continued high value of inventories recognised as an expense in the period is reported due to the significant quantities of PPE that continue to be issued from NWSSP stores to support the pandemic during 2021/2022.

Included in the write down of inventories is a loss of £10.25m in respect of the revaluation of stocks to net realisable value, the write off of £0.603m of expired COVID test kits, and £1.981m of provisions for the potential write off of items nearing their expiry date that are unlikely to be utilised.

During 2021/2022 donations were made to other countries to support their COVID responses. £0.522m of equipment was donated to India, and PPE, test kits and ventilators totalling £11.147m were provided to Namibia. In addition an aid package totalling £0.131m was made to support the Ukraine which included both COVID and medical items.

17. Trade and other receivables

17.1 Trade and other receivables

	31 March 2022 £000	31 March 2021 £000	31 March 2022 £000	31 March 2021 £000
<b>Current</b>				
	<b>NHS Trust</b>		<b>Consolidated</b>	
Welsh Government	498,807	478,271	498,807	478,271
WHSSC & EASC	81	7	81	7
Welsh Health Boards	15,859	14,235	15,859	14,235
Welsh NHS Trusts	710	1,241	710	1,241
Welsh Special Health Authorities	2,911	938	2,911	938
Non - Welsh Trusts	160	0	160	0
Other NHS	141	145	141	145
2019-20 Scheme Pays - Welsh Government Reimbursement	339	0	339	0
Welsh Risk Pool Claim reimbursement:-	0	0	0	0
NHS Wales Secondary Health Sector	9	382	9	382
NHS Wales Primary Sector FLS Reimbursement	0	0	0	0
NHS Wales Redress	0	0	0	0
Other	0	0	0	0
Local Authorities	0	431	0	431
Capital debtors- Tangible	0	187	0	187
Capital debtors- Intangible	0	0	0	0
Other debtors	16,934	20,085	15,849	19,746
FHoT debtor			4	32
Provision for impairment of trade receivables	(5,276)	(2,411)	(5,276)	(2,411)
Pension Prepayments				
NHS Pensions Agency	0	0	0	0
NEST	0	0	0	0
Other prepayments	5,103	30,308	5,103	30,308
Accrued income	4,449	5,017	4,449	5,017
Sub-total	540,227	548,836	539,146	548,529
<b>Non-current</b>				
Welsh Government	1,091,598	816,440	1,091,598	816,440
WHSSC & EASC	0	0	0	0
Welsh Health Boards	0	0	0	0
Welsh NHS Trusts	0	0	0	0
Welsh Special Health Authorities	0	0	0	0
Non - Welsh Trusts	0	0	0	0
Other NHS	23	22	23	22
2019-20 Scheme Pays - Welsh Government Reimbursement	0	0	0	0
Welsh Risk Pool Claim reimbursement	0	0	0	0
NHS Wales Secondary Health Sector	0	0	0	0
NHS Wales Primary Sector FLS Reimbursement	0	0	0	0
NHS Wales Redress	0	0	0	0
Other	0	0	0	0
Local Authorities	128	0	128	0
Capital debtors- Tangible	0	0	0	0
Capital debtors- Intangible	0	0	0	0
Other debtors	0	0	0	0
FHoT debtor			0	0
Provision for impairment of trade receivables	0	0	0	0
Pension Prepayments				
NHS Pensions Agency	0	0	0	0
NEST	0	0	0	0
Other prepayments	259	680	259	680
Accrued income	0	0	0	0
Sub-total	1,092,008	817,142	1,092,008	817,142
<b>Total trade and other receivables</b>	<b>1,632,235</b>	<b>1,365,978</b>	<b>1,631,154</b>	<b>1,365,671</b>

The great majority of trade is with other NHS bodies. As NHS bodies are funded by Welsh Government, no credit scoring of them is considered necessary.

The value of trade receivables that are past their payment date but not impaired is £3,935,000 (£8,756,000 in 2020-21).

**17.2 Receivables past their due date but not impaired**

	<b>31 March</b>	31 March	<b>31 March</b>	31 March
	<b>2022</b>	2021	<b>2022</b>	2021
	<b>£000</b>	£000	<b>£000</b>	£000
	<b>NHS Trust</b>		<b>Consolidated</b>	
By up to 3 months	2,236	6,907	2,236	6,907
By 3 to 6 months	1,040	1,213	1,040	1,213
By more than 6 months	659	636	659	636
<b>Balance at end of financial year</b>	<b>3,935</b>	<b>8,756</b>	<b>3,935</b>	<b>8,756</b>

The balances at 31st March 2022 show a significant reduction in the recovery of debts up to 6 months old. These are now much closer to values reported in 2018/2019, prior to the COVID pandemic.

**17.3 Expected Credit Losses (ECL) Allowance for bad and doubtful debts**

	<b>31 March</b>	31 March	<b>31 March</b>	31 March
	<b>2022</b>	2021	<b>2022</b>	2021
	<b>£000</b>	£000	<b>£000</b>	£000
	<b>NHS Trust</b>		<b>Consolidated</b>	
Balance at 1 April	(2,411)	(1,809)	(2,411)	(1,809)
Transfer to other NHS Wales body	0	0	0	0
Provision utilised (Amount written off during the year)	100	8	100	8
Provision written back during the year no longer required	0	0	0	0
(Increase)/Decrease in provision during year	(3,567)	(610)	(3,567)	(610)
ECL/Bad debts recovered during year	602	0	602	0
<b>Balance at end of financial year</b>	<b>(5,276)</b>	<b>(2,411)</b>	<b>(5,276)</b>	<b>(2,411)</b>

The increase in the provision during the year is primarily due to a full provision for a NWSSP doubtful debt of £3.248m.

The increase in the value of provision utilised has arisen as very aged irrecoverable debt write offs have been processed in year.

**17.4 Receivables VAT**

	<b>31 March</b>	31 March	<b>31 March</b>	31 March
	<b>2022</b>	2021	<b>2022</b>	2021
	<b>£000</b>	£000	<b>£000</b>	£000
	<b>NHS Trust</b>		<b>Consolidated</b>	
Trade receivables	252	94	252	94
Other	0	0	0	0
<b>Total</b>	<b>252</b>	<b>94</b>	<b>252</b>	<b>94</b>

18. Other financial assets

	31 March 2022 £000	31 March 2021 £000	31 March 2022 £000	31 March 2021 £000
	NHS Trust		Consolidated	
<b>Current</b>				
Shares and equity type investments				
Held to maturity investments at amortised costs	0	0	0	0
At fair value through SOCI	0	0	0	0
Available for sale at FV	0	0	0	0
Deposits	0	0	0	0
Loans	0	0	0	0
Derivatives	0	0	0	0
Other (Specify)				
Held to maturity investments at amortised costs	0	0	0	0
At fair value through SOCI	0	0	0	0
Available for sale at FV	0	0	0	0
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Non-Current</b>				
Shares and equity type investments				
Held to maturity investments at amortised costs	0	0	0	0
At fair value through SOCI	0	0	0	0
Available for sale at FV	0	0	0	0
Deposits	0	0	0	0
Loans	0	0	0	0
Derivatives	0	0	0	0
Other (Specify)				
Held to maturity investments at amortised costs	0	0	0	0
At fair value through SOCI	0	0	5,826	5,613
Available for sale at FV	0	0	0	0
<b>Total</b>	<b>0</b>	<b>0</b>	<b>5,826</b>	<b>5,613</b>

19. Cash and cash equivalents

	<b>31 March</b>	31 March	<b>31 March</b>	31 March
	<b>2022</b>	2021	<b>2022</b>	2021
	<b>£000</b>	£000	<b>£000</b>	£000
	<b>NHS Trust</b>		<b>Consolidated</b>	
Balance b/f	43,263		44,811	
NWIS to DHCW Transfer adjustment	<b>0</b>		<b>0</b>	
Opening Balance	<b>43,263</b>	18,263	<b>44,811</b>	19,735
Net change in year	<b>(12,859)</b>	25,000	<b>(11,695)</b>	25,076
<b>Closing Balance</b>	<b>30,404</b>	43,263	<b>33,116</b>	44,811
<b>Made up of:</b>				
Cash with Government Banking Service (GBS)	<b>30,385</b>	43,244	<b>30,385</b>	43,244
Cash with Commercial banks	<b>0</b>	0	<b>2,712</b>	1,548
Cash in hand	<b>19</b>	19	<b>19</b>	19
<b>Total cash</b>	<b>30,404</b>	43,263	<b>33,116</b>	44,811
Current investments	<b>0</b>	0	<b>0</b>	0
<b>Cash and cash equivalents as in SoFP</b>	<b>30,404</b>	43,263	<b>33,116</b>	44,811
Bank overdraft - GBS	<b>0</b>	0	<b>0</b>	0
Bank overdraft - Commercial banks	<b>0</b>	0	<b>0</b>	0
<b>Cash &amp; cash equivalents as in Statement of Cash Flows</b>	<b>30,404</b>	43,263	<b>33,116</b>	44,811

The opening cash balance was higher than usual, and was primarily due to the need to pay a number of large invoices in early April 2021, and the temporary closure of the National Loans Fund to deposits on 31st March 2021. There has since been a subsequent reduction in the closing cash balance at 31st March 2022, which is more in line with previous years.

In response to the IAS 7 requirement for additional disclosure, the changes in liabilities arising for financing activities are:

Lease Liabilities £nil  
PFI liabilities £nil

The movement relates to cash, no comparative information is required by IAS 7 in 2021-22.

20. Trade and other payables at the SoFP Date	31 March	31 March	31 March	31 March
	2022	2021	2022	2021
Current	£000	£000	£000	£000
	NHS Trust		Consolidated	
Welsh Government	51,216	120,136	51,216	120,136
WHSSC & EASC	877	2,011	877	2,011
Welsh Health Boards	163,061	148,416	163,061	148,416
Welsh NHS Trusts	3,363	2,334	3,363	2,334
Welsh Special Health Authorities	62	16	62	16
Other NHS	2,418	2,285	2,418	2,285
Taxation and social security payable / refunds:				
Refunds of taxation by HMRC	0	0	0	0
VAT payable to HMRC	0	2,064	0	2,064
Other taxes payable to HMRC	26	151	26	151
National Insurance contributions payable to HMRC	155	121	155	121
Non-NHS trade payables - revenue	22,305	26,143	22,305	26,143
Local Authorities	91	360	91	360
Capital payables-Tangible	8,097	4,434	8,097	4,434
Capital payables- Intangible	537	1,785	537	1,785
Overdraft	0	0	0	0
FHoT payables	0	0	48	107
Rentals due under operating leases	0	0	0	0
Obligations due under finance leases and HP contracts	0	0	0	0
Imputed finance lease element of on SoFP PFI contracts	0	0	0	0
Pensions: staff	3,918	3,540	3,918	3,540
Non NHS Accruals	20,307	38,130	20,307	38,130
Deferred Income:				
Deferred income brought forward	1,210	1,985	1,210	1,985
Deferred income additions	753	559	753	559
Transfer to/from current/non current deferred income	0	(301)	0	(301)
Released to the Income Statement	(795)	(1,033)	(795)	(1,033)
Other liabilities - all other payables	0	0	0	0
PFI assets – deferred credits	0	0	0	0
PFI - Payments on account	0	0	0	0
Sub-total	277,601	353,136	277,649	353,243

The Trust aims to pay all invoices within the 30 day period directed by the Welsh Government.

20. Trade and other payables at the SoFP Date (cont)

Non-current	31 March	31 March	31 March	31 March
	2022	2021	2022	2021
	£000	£000	£000	£000
	NHS Trust		Consolidated	
Welsh Government	7,000	7,000	7,000	7,000
WHSSC & EASC	0	0	0	0
Welsh Health Boards	0	0	0	0
Welsh NHS Trusts	0	0	0	0
Welsh Special Health Authorities	0	0	0	0
Other NHS	0	0	0	0
Taxation and social security payable / refunds:				
Refunds of taxation by HMRC	0	0	0	0
VAT payable to HMRC	0	0	0	0
Other taxes payable to HMRC	0	0	0	0
National Insurance contributions payable to HMRC	0	0	0	0
Non-NHS trade payables - revenue	0	0	0	0
Local Authorities	0	0	0	0
Capital payables- Tangible	0	0	0	0
Capital payables- Intangible	0	0	0	0
Overdraft	0	0	0	0
FHoT payables			0	0
Rentals due under operating leases	0	0	0	0
Obligations due under finance leases and HP contracts	0	0	0	0
Imputed finance lease element of on SoFP PFI contracts	0	0	0	0
Pensions: staff	0	0	0	0
Non NHS Accruals	0	0	0	0
Deferred Income:				
Deferred income brought forward	301	0	301	0
Deferred income additions	35	301	35	301
Transfer to/from current/non current deferred income	0	0	0	0
Released to the Income Statement	0	0	0	0
Other liabilities - all other payables	0	0	0	0
PFI assets –deferred credits	0	0	0	0
Payments on account	0	0	0	0
Sub-total	<b>7,336</b>	<b>7,301</b>	<b>7,336</b>	<b>7,301</b>
<b>Total</b>	<b>284,937</b>	<b>360,437</b>	<b>284,985</b>	<b>360,544</b>



21. Borrowings	31 March	31 March	31 March	31 March
	2022	2021	2022	2021
Current	£000	£000	£000	£000
	<b>NHS Trust</b>		<b>Consolidated</b>	
Bank overdraft - Government Banking Service (GBS)	0	0	0	0
Bank overdraft - Commercial bank	0	0	0	0
Loans from:				
Welsh Government	0	0	0	0
Other entities	0	0	0	0
PFI liabilities:				
Main liability	0	0	0	0
Lifecycle replacement received in advance	0	0	0	0
Finance lease liabilities	0	8	0	8
Other	0	0	0	0
<b>Total</b>	<b>0</b>	<b>8</b>	<b>0</b>	<b>8</b>
<b>Non-current</b>				
Bank overdraft - GBS	0	0	0	0
Bank overdraft - Commercial bank	0	0	0	0
Loans from:				
Welsh Government	0	0	0	0
Other entities	0	0	0	0
PFI liabilities:				
Main liability	0	0	0	0
Lifecycle replacement received in advance	0	0	0	0
Finance lease liabilities	0	0	0	0
Other	0	0	0	0
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>

### 21.2 Loan advance/strategic assistance funding

Amounts falling due:	31 March	31 March	31 March	31 March
	2022	2021	2022	2021
	£000	£000	£000	£000
In one year or less	0	0	0	0
Between one and two years	0	0	0	0
Between two and five years	0	0	0	0
In five years or more	0	0	0	0
Sub-total	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
Wholly repayable within five years	0	0	0	0
Wholly repayable after five years, not by instalments	0	0	0	0
Wholly or partially repayable after five years by instalments	0	0	0	0
Sub-total	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
Total repayable after five years by instalments	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>

The Trust has not received a loan advance or strategic funding from the Welsh Government.

22. Other financial liabilities

	31 March	31 March	31 March	31 March
	2022	2021	2022	2021
Current	£000	£000	£000	£000
	NHS Trust		Consolidated	
<b>Financial Guarantees</b>				
At amortised cost	0	0	0	0
At fair value through SoCI	0	0	0	0
Derivatives at fair value through SoCI	0	0	0	0
<b>Other</b>				
At amortised cost	0	0	0	0
At fair value through SoCI	0	0	0	0
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>

	31 March	31 March	31 March	31 March
	2022	2021	2022	2021
Non-current	£000	£000	£000	£000
	NHS Trust		Consolidated	
<b>Financial Guarantees</b>				
At amortised cost	0	0	0	0
At fair value through SoCI	0	0	0	0
Derivatives at fair value through SoCI	0	0	0	0
<b>Other</b>				
At amortised cost	0	0	0	0
At fair value through SoCI	0	0	0	0
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>

23. Provisions  
2021-22

	At 1 April 2021	Structured settlement cases transferred to Risk Pool	Transfers to creditors	Transfers between current and non current	Transfers (to)/from other NHS body	Arising during the year	Utilised during the year	Reversed unused	Unwinding of discount	At 31 March 2022
	£000	£000	£000	£000	£000	£000	£000	£000	£000	£000
<b>Current</b>										
Clinical negligence:-										
Secondary Care	286,428	(56,929)	(8,495)	(9,360)	0	285,210	(94,727)	(93,594)	(50)	308,483
Primary Care	122	0	0	0	0	134	(81)	(42)	0	133
Redress Secondary Care	2,843	0	227	(10)	0	3,176	(1,712)	(2,224)	0	2,300
Redress Primary Care	0	0	0	0	0	0	0	0	0	0
Personal injury	6,428	0	(229)	1,292	0	5,932	(1,911)	(7,709)	0	3,803
All other losses and special payments	0	0	0	0	0	23,441	(23,441)	0	0	0
Defence legal fees and other administration	5,590	0	0	420	0	3,725	(1,930)	(2,401)	0	5,404
Structured Settlements - WRPS	15,111	1,700	0	0	0	18,568	(16,645)	(1,807)	1,143	18,070
Pensions relating to: former directors	0	0	0	0	0	0	0	0	0	0
Pensions relating to: other staff	18	0	(6)	22	0	0	(19)	0	0	15
2019-20 Scheme Pays - Reimbursement	0	0	0	0	0	2	0	0	0	2
Restructurings	0	0	0	0	0	0	0	0	0	0
Other	419	0	0	0	0	3,311	0	(817)	0	2,913
<b>Total</b>	<b>316,959</b>	<b>(55,229)</b>	<b>(8,503)</b>	<b>(7,636)</b>	<b>0</b>	<b>343,499</b>	<b>(140,466)</b>	<b>(108,594)</b>	<b>1,093</b>	<b>341,123</b>
FHoT	0	0	0	0	0	0	0	0	0	0
<b>Consolidated Total</b>	<b>316,959</b>	<b>(55,229)</b>	<b>(8,503)</b>	<b>(7,636)</b>	<b>0</b>	<b>343,499</b>	<b>(140,466)</b>	<b>(108,594)</b>	<b>1,093</b>	<b>341,123</b>

<b>Non Current</b>										
Clinical negligence:-										
Secondary Care	359,188	0	0	9,195	0	130,985	(3,100)	(23,443)	0	472,825
Primary Care	0	0	0	0	0	0	0	0	0	0
Redress Secondary Care	6	0	0	9	0	10	(2)	(11)	0	12
Redress Primary Care	0	0	0	0	0	0	0	0	0	0
Personal injury	1,292	0	0	(1,292)	0	0	0	0	0	0
All other losses and special payments	0	0	0	0	0	0	0	0	0	0
Defence legal fees and other administration	3,289	0	0	(254)	0	1,026	(112)	(293)	0	3,656
Structured Settlements - WRPS	452,672	55,229	0	0	0	108,342	0	(1,136)	0	615,107
Pensions relating to: former directors	0	0	0	0	0	0	0	0	0	0
Pensions relating to: other staff	71	0	0	(22)	0	4	0	0	0	53
2019-20 Scheme Pays - Reimbursement	0	0	0	0	0	337	0	0	0	337
Restructurings	0	0	0	0	0	0	0	0	0	0
Other	2,264	0	0	0	0	642	0	(690)	0	2,216
<b>Total</b>	<b>818,782</b>	<b>55,229</b>	<b>0</b>	<b>7,636</b>	<b>0</b>	<b>241,346</b>	<b>(3,214)</b>	<b>(25,573)</b>	<b>0</b>	<b>1,094,206</b>
FHoT	0	0	0	0	0	0	0	0	0	0
<b>Consolidated Total</b>	<b>818,782</b>	<b>55,229</b>	<b>0</b>	<b>7,636</b>	<b>0</b>	<b>241,346</b>	<b>(3,214)</b>	<b>(25,573)</b>	<b>0</b>	<b>1,094,206</b>

<b>TOTAL</b>										
Clinical negligence:-										
Secondary Care	645,616	(56,929)	(8,495)	(165)	0	416,195	(97,827)	(117,037)	(50)	781,308
Primary Care	122	0	0	0	0	134	(81)	(42)	0	133
Redress Secondary Care	2,849	0	227	(1)	0	3,186	(1,714)	(2,235)	0	2,312
Redress Primary Care	0	0	0	0	0	0	0	0	0	0
Personal injury	7,720	0	(229)	0	0	5,932	(1,911)	(7,709)	0	3,803
All other losses and special payments	0	0	0	0	0	23,441	(23,441)	0	0	0
Defence legal fees and other administration	8,879	0	0	166	0	4,751	(2,042)	(2,694)	0	9,060
Structured Settlements - WRPS	467,783	56,929	0	0	0	126,910	(16,645)	(2,943)	1,143	633,177
Pensions relating to: former directors	0	0	0	0	0	0	0	0	0	0
Pensions relating to: other staff	89	0	(6)	0	0	4	(19)	0	0	68
2019-20 Scheme Pays - Reimbursement	0	0	0	0	0	339	0	0	0	339
Restructurings	0	0	0	0	0	0	0	0	0	0
Other	2,683	0	0	0	0	3,953	0	(1,507)	0	5,129
<b>Total</b>	<b>1,135,741</b>	<b>0</b>	<b>(8,503)</b>	<b>0</b>	<b>0</b>	<b>584,845</b>	<b>(143,680)</b>	<b>(134,167)</b>	<b>1,093</b>	<b>1,435,329</b>
FHoT	0	0	0	0	0	0	0	0	0	0
<b>Consolidated Total</b>	<b>1,135,741</b>	<b>0</b>	<b>(8,503)</b>	<b>0</b>	<b>0</b>	<b>584,845</b>	<b>(143,680)</b>	<b>(134,167)</b>	<b>1,093</b>	<b>1,435,329</b>

Expected timing of cash flows:

	In year to 31 March 2023 £000	Between 01-Apr-23 to 31 March 2027 £000	Thereafter £000	Totals £000
Clinical negligence:-				
Secondary Care	308,483	356,924	115,901	781,308
Primary Care	133	0	0	133
Redress Secondary Care	2,300	12	0	2,312
Redress Primary Care	0	0	0	0
Personal injury	3,803	0	0	3,803
All other losses and special payments	0	0	0	0
Defence legal fees and other administration	5,404	3,656	0	9,060
Structured Settlements - WRPS	18,070	77,846	537,261	633,177
Pensions - former directors	0	0	0	0
Pensions - other staff	15	50	3	68
2019-20 Scheme Pays - Reimbursement	2	1	336	339
Restructuring	0	0	0	0
Other	2,913	1,997	219	5,129
<b>Total</b>	<b>341,123</b>	<b>440,486</b>	<b>653,720</b>	<b>1,435,329</b>
FHoT	0	0	0	0
<b>Consolidated Total</b>	<b>341,123</b>	<b>440,486</b>	<b>653,720</b>	<b>1,435,329</b>

23. Provisions NHS Trust  
2021-22

	At 1 April 2021	Structured settlement cases transferred to Risk Pool	Transfers to creditors	Transfers between current and non current	Transfers (to)/from other NHS body	Arising during the year	Utilised during the year	Reversed unused	Unwinding of discount	At 31 March 2022
	£000	£000	£000	£000	£000	£000	£000	£000	£000	£000
<b>Current</b>										
Clinical negligence:-										
Secondary Care	54	0	0	0	0	90	0	(54)	0	90
Primary Care	0	0	0	0	0	0	0	0	0	0
Redress Secondary Care	0	0	0	0	0	0	0	0	0	0
Redress Primary Care	0	0	0	0	0	0	0	0	0	0
Personal injury	18	0	0	0	0	22	0	(14)	0	26
All other losses and special payments	0	0	0	0	0	23,441	(23,441)	0	0	0
Defence legal fees and other administration	90	0	0	0	0	93	0	(94)	0	89
Structured Settlements - WRPS	0	0	0	0	0	0	0	0	0	0
Pensions relating to: former directors	0	0	0	0	0	0	0	0	0	0
Pensions relating to: other staff	18	0	(6)	22	0	0	(19)	0	0	15
2019-20 Scheme Pays - Reimbursement	0	0	0	0	0	2	0	0	0	2
Restructurings	0	0	0	0	0	0	0	0	0	0
Other	419	0	0	0	0	3,311	0	(816)	0	2,914
<b>Total</b>	<b>599</b>	<b>0</b>	<b>(6)</b>	<b>22</b>	<b>0</b>	<b>26,959</b>	<b>(23,460)</b>	<b>(978)</b>	<b>0</b>	<b>3,136</b>
FHoT	0	0	0	0	0	0	0	0	0	0
<b>Consolidated Total</b>	<b>599</b>	<b>0</b>	<b>(6)</b>	<b>22</b>	<b>0</b>	<b>26,959</b>	<b>(23,460)</b>	<b>(978)</b>	<b>0</b>	<b>3,136</b>

<b>Non Current</b>										
Clinical negligence:-										
Secondary Care	0	0	0	0	0	0	0	0	0	0
Primary Care	0	0	0	0	0	0	0	0	0	0
Redress Secondary Care	0	0	0	0	0	0	0	0	0	0
Redress Primary Care	0	0	0	0	0	0	0	0	0	0
Personal injury	0	0	0	0	0	0	0	0	0	0
All other losses and special payments	0	0	0	0	0	0	0	0	0	0
Defence legal fees and other administration	0	0	0	0	0	0	0	0	0	0
Structured Settlements - WRPS	0	0	0	0	0	0	0	0	0	0
Pensions relating to: former directors	0	0	0	0	0	0	0	0	0	0
Pensions relating to: other staff	71	0	0	(22)	0	4	0	0	0	53
2019-20 Scheme Pays - Reimbursement	0	0	0	0	0	337	0	0	0	337
Restructurings	0	0	0	0	0	0	0	0	0	0
Other	2,264	0	0	0	0	642	0	(690)	0	2,216
<b>Total</b>	<b>2,335</b>	<b>0</b>	<b>0</b>	<b>(22)</b>	<b>0</b>	<b>983</b>	<b>0</b>	<b>(690)</b>	<b>0</b>	<b>2,606</b>
FHoT	0	0	0	0	0	0	0	0	0	0
<b>Consolidated Total</b>	<b>2,335</b>	<b>0</b>	<b>0</b>	<b>(22)</b>	<b>0</b>	<b>983</b>	<b>0</b>	<b>(690)</b>	<b>0</b>	<b>2,606</b>

<b>TOTAL</b>										
Clinical negligence:-										
Secondary Care	54	0	0	0	0	90	0	(54)	0	90
Primary Care	0	0	0	0	0	0	0	0	0	0
Redress Secondary Care	0	0	0	0	0	0	0	0	0	0
Redress Primary Care	0	0	0	0	0	0	0	0	0	0
Personal injury	18	0	0	0	0	22	0	(14)	0	26
All other losses and special payments	0	0	0	0	0	23,441	(23,441)	0	0	0
Defence legal fees and other administration	90	0	0	0	0	93	0	(94)	0	89
Structured Settlements - WRPS	0	0	0	0	0	0	0	0	0	0
Pensions relating to: former directors	0	0	0	0	0	0	0	0	0	0
Pensions relating to: other staff	89	0	(6)	0	0	4	(19)	0	0	68
2019-20 Scheme Pays - Reimbursement	0	0	0	0	0	339	0	0	0	339
Restructurings	0	0	0	0	0	0	0	0	0	0
Other	2,683	0	0	0	0	3,953	0	(1,506)	0	5,130
<b>Total</b>	<b>2,934</b>	<b>0</b>	<b>(6)</b>	<b>0</b>	<b>0</b>	<b>27,942</b>	<b>(23,460)</b>	<b>(1,668)</b>	<b>0</b>	<b>5,742</b>
FHoT	0	0	0	0	0	0	0	0	0	0
<b>Consolidated Total</b>	<b>2,934</b>	<b>0</b>	<b>(6)</b>	<b>0</b>	<b>0</b>	<b>27,942</b>	<b>(23,460)</b>	<b>(1,668)</b>	<b>0</b>	<b>5,742</b>

Expected timing of cash flows:

	In year to 31 March 2023	Between 01-Apr-23 to 31 March 2027	Thereafter	Totals
	£000	£000	£000	£000
Clinical negligence:-				
Secondary Care	90	0	0	90
Primary Care	0	0	0	0
Redress Secondary Care	0	0	0	0
Redress Primary Care	0	0	0	0
Personal injury	26	0	0	26
All other losses and special payments	0	0	0	0
Defence legal fees and other administration	89	0	0	89
Structured Settlements - WRPS	0	0	0	0
Pensions - former directors	0	0	0	0
Pensions - other staff	15	50	3	68
2019-20 Scheme Pays - Reimbursement	2	1	336	339
Restructuring	0	0	0	0
Other	2,914	1,997	219	5,130
<b>Total</b>	<b>3,136</b>	<b>2,048</b>	<b>558</b>	<b>5,742</b>
FHoT	0	0	0	0
<b>Consolidated Total</b>	<b>3,136</b>	<b>2,048</b>	<b>558</b>	<b>5,742</b>

23. Provisions WRP  
2021-22

	At 1 April 2021	Structured settlement cases transferred to Risk Pool	Transfers to creditors	Transfers between current and non current	Transfers (to)/from other NHS body	Arising during the year	Utilised during the year	Reversed unused	Unwinding of discount	At 31 March 2022
	£000	£000	£000	£000	£000	£000	£000	£000	£000	£000
<b>Current</b>										
Clinical negligence:-										
Secondary Care	286,397	(56,929)	(8,495)	(9,360)	0	285,096	(94,728)	(93,540)	(50)	308,391
Primary Care	122	0	0	0	0	134	(81)	(42)	0	133
Redress Secondary Care	2,843	0	218	(10)	0	3,194	(1,720)	(2,224)	0	2,301
Redress Primary Care	0	0	0	0	0	0	0	0	0	0
Personal injury	6,410	0	(229)	1,292	0	5,910	(1,911)	(7,695)	0	3,777
All other losses and special payments	0	0	0	0	0	0	0	0	0	0
Defence legal fees and other administration	5,532	0	0	420	0	3,655	(1,967)	(2,324)	0	5,316
Structured Settlements - WRPS	15,111	1,700	0	0	0	18,568	(16,645)	(1,807)	1,143	18,070
Pensions relating to: former directors	0		0	0	0	0	0	0	0	0
Pensions relating to: other staff	0		0	0	0	0	0	0	0	0
2019-20 Scheme Pays - Reimbursement	0		0	0	0	0	0	0	0	0
Restructurings	0		0	0	0	0	0	0		0
Other	0		0	0	0	0	0	0		0
<b>Total</b>	<b>316,415</b>	<b>(55,229)</b>	<b>(8,506)</b>	<b>(7,658)</b>	<b>0</b>	<b>316,557</b>	<b>(117,052)</b>	<b>(107,632)</b>	<b>1,093</b>	<b>337,988</b>
FHoT	0	0	0	0	0	0	0	0	0	0
<b>Consolidated Total</b>	<b>316,415</b>	<b>(55,229)</b>	<b>(8,506)</b>	<b>(7,658)</b>	<b>0</b>	<b>316,557</b>	<b>(117,052)</b>	<b>(107,632)</b>	<b>1,093</b>	<b>337,988</b>
<b>Non Current</b>										
Clinical negligence:-										
Secondary Care	359,188	0	0	9,195	0	130,985	(3,100)	(23,443)	0	472,825
Primary Care	0	0	0	0	0	0	0	0	0	0
Redress Secondary Care	6	0	0	9	0	10	(2)	(11)	0	12
Redress Primary Care	0	0	0	0	0	0	0	0	0	0
Personal injury	1,292	0	0	(1,292)	0	0	0	0	0	0
All other losses and special payments	0	0	0	0	0	0	0	0	0	0
Defence legal fees and other administration	3,289	0	0	(254)	0	1,025	(112)	(293)	0	3,655
Structured Settlements - WRPS	452,672	55,229	0	0	0	108,342	0	(1,136)	0	615,107
Pensions relating to: former directors	0		0	0	0	0	0	0	0	0
Pensions relating to: other staff	0		0	0	0	0	0	0	0	0
2019-20 Scheme Pays - Reimbursement	0		0	0	0	0	0	0	0	0
Restructurings	0		0	0	0	0	0	0		0
Other	0		0	0	0	0	0	0		0
<b>Total</b>	<b>816,447</b>	<b>55,229</b>	<b>0</b>	<b>7,658</b>	<b>0</b>	<b>240,362</b>	<b>(3,214)</b>	<b>(24,883)</b>	<b>0</b>	<b>1,091,599</b>
FHoT	0	0	0	0	0	0	0	0	0	0
<b>Consolidated Total</b>	<b>816,447</b>	<b>55,229</b>	<b>0</b>	<b>7,658</b>	<b>0</b>	<b>240,362</b>	<b>(3,214)</b>	<b>(24,883)</b>	<b>0</b>	<b>1,091,599</b>
<b>TOTAL</b>										
Clinical negligence:-										
Secondary Care	645,585	(56,929)	(8,495)	(165)	0	416,081	(97,828)	(116,983)	(50)	781,216
Primary Care	122	0	0	0	0	134	(81)	(42)	0	133
Redress Secondary Care	2,849	0	218	(1)	0	3,204	(1,722)	(2,235)	0	2,313
Redress Primary Care	0	0	0	0	0	0	0	0	0	0
Personal injury	7,702	0	(229)	0	0	5,910	(1,911)	(7,695)	0	3,777
All other losses and special payments	0	0	0	0	0	0	0	0	0	0
Defence legal fees and other administration	8,821	0	0	166	0	4,680	(2,079)	(2,617)	0	8,971
Structured Settlements - WRPS	467,783	56,929	0	0	0	126,910	(16,645)	(2,943)	1,143	633,177
Pensions relating to: former directors	0		0	0	0	0	0	0	0	0
Pensions relating to: other staff	0		0	0	0	0	0	0	0	0
2019-20 Scheme Pays - Reimbursement	0		0	0	0	0	0	0	0	0
Restructurings	0		0	0	0	0	0	0		0
Other	0		0	0	0	0	0	0		0
<b>Total</b>	<b>1,132,862</b>	<b>0</b>	<b>(8,506)</b>	<b>0</b>	<b>0</b>	<b>556,919</b>	<b>(120,266)</b>	<b>(132,515)</b>	<b>1,093</b>	<b>1,429,587</b>
FHoT	0	0	0	0	0	0	0	0	0	0
<b>Consolidated Total</b>	<b>1,132,862</b>	<b>0</b>	<b>(8,506)</b>	<b>0</b>	<b>0</b>	<b>556,919</b>	<b>(120,266)</b>	<b>(132,515)</b>	<b>1,093</b>	<b>1,429,587</b>

Expected timing of cash flows:

	In year to 31 March 2023 £000	Between 01-Apr-23 to 31 March 2027 £000	Thereafter £000	Totals £000
Clinical negligence:-				
Secondary Care	308,391	356,925	115,901	781,217
Primary Care	133	0	0	133
Redress Secondary Care	2,301	11	0	2,312
Redress Primary Care	0	0	0	0
Personal injury	3,777	0	0	3,777
All other losses and special payments	0	0	0	0
Defence legal fees and other administration	5,316	3,655	0	8,971
Structured Settlements - WRPS	18,070	77,846	537,261	633,177
Pensions - former directors	0	0	0	0
Pensions - other staff	0	0	0	0
2019-20 Scheme Pays - Reimbursement	0	0	0	0
Restructuring	0	0	0	0
Other	0	0	0	0
<b>Total</b>	<b>337,988</b>	<b>438,437</b>	<b>653,162</b>	<b>1,429,587</b>
FHoT	0	0	0	0
<b>Consolidated Total</b>	<b>337,988</b>	<b>438,437</b>	<b>653,162</b>	<b>1,429,587</b>

The provisions relate to amounts over £25,000 in respect of ongoing claims against the NHS in Wales, the outcome of which will not be determined until the case has been finalised.

Timings of cashflow have been profiled to match total current liabilities. However, the total will include cases which may settle with a structured settlement, so the underlying cashflows will be over a number of years. Also, there can be delays in settlement dates anticipated for next year which will further impact the cashflow timings.

23. Provisions (continued)

2020-21

NHS Trust and Welsh Risk Pool

	At 1 April 2020	Structured settlement cases transferred to Risk Pool	Transfers to creditors	Transfers between current and non current	Transfers (to)/from other NHS body	Arising during the year	Utilised during the year	Reversed unused	Unwinding of discount	At 31 March 2021
	£000	£000	£000	£000	£000	£000	£000	£000	£000	£000
<b>Current</b>										
Clinical negligence:-										
Secondary Care	244,404	(53,022)	(17,397)	123,233	0	126,936	(80,728)	(56,815)	(183)	286,428
Primary Care	0	0	0	0	0	122	0	0	0	122
Redress Secondary Care	3,335	0	(664)	34	0	3,451	(1,611)	(1,702)	0	2,843
Redress Primary Care	0	0	0	0	0	0	0	0	0	0
Personal injury	4,803	0	(134)	(1,060)	0	5,681	(1,504)	(1,358)	0	6,428
All other losses and special payments	1	0	0	0	0	5,761	(5,762)	0	0	0
Defence legal fees and other administration	4,614	0	0	1,080	0	2,854	(1,584)	(1,374)	0	5,590
Structured Settlements - WRPS	14,555	988	0	0	0	15,785	(14,873)	(1,892)	548	15,111
Pensions relating to: former directors	0		0	0	0	0	0	0	0	0
Pensions relating to: other staff	19		(6)	24	0	0	(19)	0	0	18
2019-20 Scheme Pays - Reimbursement	0		0	0	0	0	0	0	0	0
Restructurings	0		0	0	0	0	0	0		0
Other	645		0	0	0	745	0	(971)		419
<b>Total</b>	<b>272,376</b>	<b>(52,034)</b>	<b>(18,201)</b>	<b>123,311</b>	<b>0</b>	<b>161,335</b>	<b>(106,081)</b>	<b>(64,112)</b>	<b>365</b>	<b>316,959</b>
FHoT	0	0	0	0	0	0	0	0	0	0
<b>Consolidated Total</b>	<b>272,376</b>	<b>(52,034)</b>	<b>(18,201)</b>	<b>123,311</b>	<b>0</b>	<b>161,335</b>	<b>(106,081)</b>	<b>(64,112)</b>	<b>365</b>	<b>316,959</b>

Non Current

Clinical negligence:-										
Secondary Care	431,038	0	0	(123,354)	0	61,390	(4,786)	(5,100)	0	359,188
Primary Care	0	0	0	0	0	0	0	0	0	0
Redress Secondary Care	40	0	0	(39)	0	5	0	0	0	6
Redress Primary Care	0	0	0	0	0	0	0	0	0	0
Personal injury	341	0	0	1,069	0	91	0	(209)	0	1,292
All other losses and special payments	0	0	0	0	0	0	0	0	0	0
Defence legal fees and other administration	4,019	0	0	(963)	0	943	(188)	(522)	0	3,289
Structured Settlements - WRPS	426,508	52,034	0	0	0	3,866	0	(29,736)	0	452,672
Pensions relating to: former directors	0		0	0	0	0	0	0	0	0
Pensions relating to: other staff	90		0	(24)	0	5	0	0	0	71
2019-20 Scheme Pays - Reimbursement	0		0	0	0	0	0	0	0	0
Restructurings	0		0	0	0	0	0	0		0
Other	1,223		0	0	0	1,110	0	(69)		2,264
<b>Total</b>	<b>863,259</b>	<b>52,034</b>	<b>0</b>	<b>(123,311)</b>	<b>0</b>	<b>67,410</b>	<b>(4,974)</b>	<b>(35,636)</b>	<b>0</b>	<b>818,782</b>
FHoT	0	0	0	0	0	0	0	0	0	0
<b>Consolidated Total</b>	<b>863,259</b>	<b>52,034</b>	<b>0</b>	<b>(123,311)</b>	<b>0</b>	<b>67,410</b>	<b>(4,974)</b>	<b>(35,636)</b>	<b>0</b>	<b>818,782</b>

TOTAL

Clinical negligence:-										
Secondary Care	675,442	(53,022)	(17,397)	(121)	0	188,326	(85,514)	(61,915)	(183)	645,616
Primary Care	0	0	0	0	0	122	0	0	0	122
Redress Secondary Care	3,375	0	(664)	(5)	0	3,456	(1,611)	(1,702)	0	2,849
Redress Primary Care	0	0	0	0	0	0	0	0	0	0
Personal injury	5,144	0	(134)	9	0	5,772	(1,504)	(1,567)	0	7,720
All other losses and special payments	1	0	0	0	0	5,761	(5,762)	0	0	0
Defence legal fees and other administration	8,633	0	0	117	0	3,797	(1,772)	(1,896)	0	8,879
Structured Settlements - WRPS	441,063	53,022	0	0	0	19,651	(14,873)	(31,628)	548	467,783
Pensions relating to: former directors	0		0	0	0	0	0	0	0	0
Pensions relating to: other staff	109		(6)	0	0	5	(19)	0	0	89
2019-20 Scheme Pays - Reimbursement	0		0	0	0	0	0	0	0	0
Restructurings	0		0	0	0	0	0	0		0
Other	1,868		0	0	0	1,855	0	(1,040)		2,683
<b>Total</b>	<b>1,135,635</b>	<b>0</b>	<b>(18,201)</b>	<b>0</b>	<b>0</b>	<b>228,745</b>	<b>(111,055)</b>	<b>(99,748)</b>	<b>365</b>	<b>1,135,741</b>
FHoT	0	0	0	0	0	0	0	0	0	0
<b>Consolidated Total</b>	<b>1,135,635</b>	<b>0</b>	<b>(18,201)</b>	<b>0</b>	<b>0</b>	<b>228,745</b>	<b>(111,055)</b>	<b>(99,748)</b>	<b>365</b>	<b>1,135,741</b>

## 24 Contingencies

### 24.1 Contingent liabilities

Provision has not been made in these accounts for the following amounts:

	31 March 2022 £000	31 March 2021 £000	31 March 2022 £000	31 March 2021 £000
	NHS Trust		Consolidated	
Legal claims for alleged medical or employer negligence;				
Secondary care	1,252,357	1,346,180	1,252,357	1,346,180
Primary Care	1,790	275	1,790	275
Secondary care - Redress	712	1,173	712	1,173
Primary Care - Redress	0	0	0	0
Doubtful debts	0	0	0	0
Equal pay cases	0	0	0	0
Defence costs	0	0	0	0
Other	0	0	0	0
<b>Total value of disputed claims</b>	<b>1,254,859</b>	<b>1,347,628</b>	<b>1,254,859</b>	<b>1,347,628</b>
Amount recovered under insurance arrangements in the event of these claims being successful	(1,254,460)	(1,347,156)	(1,254,460)	(1,347,156)
<b>Net contingent liability</b>	<b>399</b>	<b>472</b>	<b>399</b>	<b>472</b>

Other litigation claims could arise in the future due to known incidents. The expenditure which may arise from such claims cannot be determined and no provision has been made for them.

Liability for Permanent Injury Benefit under the NHS Injury Benefit Scheme lies with the employer. Individual claims to the NHS Pensions Agency could arise due to known incidents.

Contingent liabilities includes claims relating to alleged clinical negligence, personal injury and permanent injury benefits under the NHS Injury Benefits Scheme. The above figures include contingent liabilities for all Health Bodies in Wales.

### 24.2. Remote contingent liabilities

	31 March 2022 £000	31 March 2021 £000	31 March 2022 £000	31 March 2021 £000
	NHS Trust		Consolidated	
Guarantees	0	0	0	0
Indemnities	60,204	60,981	60,204	60,981
Letters of comfort	0	0	0	0
Total	<b>60,204</b>	<b>60,981</b>	<b>60,204</b>	<b>60,981</b>

### 24.3 Contingent assets

	31 March 2022 £000	31 March 2021 £000	31 March 2022 £000	31 March 2021 £000
	NHS Trust		Consolidated	
	0	0	0	0
	0	0	0	0
	0	0	0	0
	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>

## 25. Capital commitments

Commitments under capital expenditure contracts at the statement of financial position sheet date were:

	<b>31 March</b>	31 March	<b>31 March</b>	31 March
	<b>2022</b>	2021	<b>2022</b>	2021
	<b>NHS Trust</b>		<b>Consolidated</b>	
	<b>£000</b>	£000	<b>£000</b>	£000
Property, plant and equipment	<b>19,553</b>	1,565	<b>19,553</b>	1,565
Intangible assets	<b>83</b>	6,656	<b>83</b>	6,656
<b>Total</b>	<b>19,636</b>	8,221	<b>19,636</b>	8,221

Following business case approval, enabling works for the new hospital site development will progress. The Capital commitments above largely relate to contract obligations in that respect, requiring financial obligations during 2022/2023.



**26. Losses and special payments**

Losses and special payments are charged to the Income statement in accordance with IFRS but are recorded in the losses and special payments register when payment is made. Therefore this note is prepared on a cash basis.

**Gross loss to the Exchequer**

Number of cases and associated amounts paid out during the financial year

	Amounts paid out during year to 31 March 2022	
	Number	£
Clinical negligence	332	96,367,599
Personal injury	89	3,606,150
All other losses and special payments	350	28,172,483
Structured Settlements managed by WRP	235	16,644,570
<b>Total</b>	<b>1,006</b>	<b>144,790,802</b>
FHoT losses and special payments	0	0
<b>Consolidated Total</b>	<b>1,006</b>	<b>144,790,802</b>

**Analysis of cases in excess of £300,000**

	Case Type	In year claims in excess of £300,000		Cumulative claims in excess of £300,000	
		Number	£	Number	£
<b>Cases in excess of £300,000:</b>					
Velindre University NHS Trust	Clinical Negligence	2	522,400	2	825,846
Velindre University NHS Trust	Other Losses	7	24,653,257	7	24,653,257
<b>WRP - Secondary Care:</b>					
Aneurin Bevan UHB	Clinical Negligence 1 X Personal Injury,	8	8,275,298	8	8,275,298
Betsi Cadwaladr UHB	6 X Clinical Negligence	7	7,641,020	7	7,641,020
Cardiff and Vale UHB	Clinical Negligence	11	14,843,969	11	15,437,620
Cwm Taf Morgannwg UHB	Clinical Negligence	18	19,319,263	18	26,756,801
Hywel Dda UHB	Clinical Negligence 11 X Clinical Negligence, 1 X Personal Injury	6	6,209,435	6	7,138,218
Swansea Bay UHB	Personal Injury	12	20,461,188	12	25,359,561
Welsh Ambulance Services NHS Trust	Clinical Negligence	1	681,646	1	681,646
<b>Sub-total</b>		<b>72</b>	<b>102,607,476</b>	<b>72</b>	<b>116,769,267</b>
<b>All other cases</b>		929	40,453,981	929	88,663,484
Structured Settlements managed by WRP		5	1,729,345	5	11,241,522
<b>Total cases</b>		<b>1,006</b>	<b>144,790,802</b>	<b>1,006</b>	<b>216,674,273</b>

The Welsh Risk Pool (WRP) reimburses Trusts, Local Health Boards and Special Health Authorities for payments made in year.

The WRP also manages annual payments directly to WRP claimants. These were not reported in last year's Note 26 but are included from 2021/22. They arise when a case settles with a Structured Settlement arrangement. The comparative figure of annual payments for 2020/21 is £14,873,393 for 251 transactions. Structured settlements relate to cases which have settled with a lower lump sum element within the total settlement value, plus annual payments over the lifetime of the claimant (the Periodical Payment Order). They typically relate to high value cases over £1M and are primarily used to meet the future care costs of the claimant as they fall due.

**26.2 Velindre NHS Trust excluding WRP Losses and special payments**

Losses and special payments are charged to the Income statement in accordance with IFRS but are recorded in the losses and special payments register when payment is made. Therefore this note is prepared on a cash basis.

**Gross loss to the Exchequer**

Number of cases and associated amounts paid out during the financial year

	<b>Amounts paid out during year to 31 March 2022</b>	
	<b>Number</b>	<b>£</b>
Clinical negligence	3	43,751
Personal injury	1	8,406
All other losses and special payments	15	25,425,903
Structured Settlements managed by WRP	0	0
<b>Total</b>	<b>19</b>	<b>25,478,060</b>
FHoT losses and special payments	<b>0</b>	<b>0</b>
<b>Consolidated Total</b>	<b>19</b>	<b>25,478,060</b>

**Analysis of cases in excess of £300,000**

	<b>In year claims in excess of £300,000</b>		<b>Cumulative claims in excess of £300,000</b>	
	<b>Number</b>	<b>£</b>	<b>Number</b>	<b>£</b>
<b>Cases in excess of £300,000:</b>				
Clinical Negligence	2	522,400	2	825,846
Other Losses	7	24,653,257	7	24,653,257
<b>Sub-total</b>	<b>9</b>	<b>25,175,657</b>	<b>9</b>	<b>25,479,103</b>
<b>All other cases</b>	<b>10</b>	<b>302,402</b>	<b>10</b>	<b>648,363</b>
<b>Total cases</b>	<b>19</b>	<b>25,478,059</b>	<b>19</b>	<b>26,127,466</b>

Other losses includes donations of £11.8m in respect of PPE, equipment and other aid to India, Namibia and Ukraine; stock losses of £11.2m; plus a foreign exchange loss of £0.3m.

**26.3 WRP Losses and special payments**

Losses and special payments are charged to the Income statement in accordance with IFRS but are recorded in the losses and special payments register when payment is made. Therefore this note is prepared on a cash basis.

**Gross loss to the Exchequer**

Number of cases and associated amounts paid out during the financial year

	Amounts paid out during year to 31 March 2022	
	Number	£
Clinical negligence	329	96,323,848
Personal injury	88	3,597,744
All other losses and special payments	335	2,746,581
Structured Settlements managed by WRP	235	16,644,570
<b>Total</b>	<b>987</b>	<b>119,312,743</b>
FHoT losses and special payments	<b>0</b>	<b>0</b>
<b>Consolidated Total</b>	<b>987</b>	<b>119,312,743</b>

**Analysis of cases in excess of £300,000**

	In year claims in excess of £300,000		Cumulative claims in excess of £300,000	
	Number	£	Number	£
<b>Cases in excess of £300,000:</b>				
Aneurin Bevan UHB	8	8,275,298	8	8,275,298
Betsi Cadwaladr UHB	7	7,641,020	7	7,641,020
Cardiff and Vale UHB	11	14,843,969	11	15,437,620
Cwm Taf Morgannwg UHB	18	19,319,263	18	26,756,801
Hywel Dda UHB	6	6,209,435	6	7,138,218
Swansea Bay UHB	12	20,461,188	12	25,359,561
Welsh Ambulance Services NHS Trust	1	681,646	1	681,646
<b>Sub-total</b>	<b>63</b>	<b>77,431,819</b>	<b>63</b>	<b>91,290,164</b>
WRP Managed Structured Settlements	5	1,729,345	5	11,241,522
<b>All other cases</b>	<b>919</b>	<b>40,151,579</b>	<b>919</b>	<b>88,015,121</b>
<b>Total cases</b>	<b>987</b>	<b>119,312,743</b>	<b>987</b>	<b>190,546,807</b>

The Welsh Risk Pool (WRP) reimburses Trusts, Local Health Boards and Special Health Authorities for payments made in year.

The WRP also manages annual payments directly to WRP claimants. These were not reported in last year's Note 26 but are included from 2021/22. They arise when a case settles with a Structured Settlement arrangement. The comparative figure of annual payments for 2020/21 is £14,873,393 for 251 transactions. Structured settlements relate to cases which have settled with a lower lump sum element within the total settlement value, plus annual payments over the lifetime of the claimant (the Periodical Payment Order). They typically relate to high value cases over £1M and are primarily used to meet the future care costs of the claimant as they fall due.

27. Finance leases

27.1 Finance leases obligations (as lessee)

The Trust currently has no finance lease obligations.

Amounts payable under finance leases:

LAND	31 March	31 March	31 March	31 March
	2022	2021	2022	2021
	£000	£000	£000	£000
	NHS Trust		Consolidated	
<b>Minimum lease payments</b>				
Within one year	0	0	0	0
Between one and five years	0	0	0	0
After five years	0	0	0	0
Less finance charges allocated to future periods	0	0	0	0
<b>Minimum lease payments</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
Included in:				
Current borrowings	0	0	0	0
Non-current borrowings	0	0	0	0
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Present value of minimum lease payments</b>				
Within one year	0	0	0	0
Between one and five years	0	0	0	0
After five years	0	0	0	0
<b>Total present value of minimum lease payments</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
Included in:				
Current borrowings	0	0	0	0
Non-current borrowings	0	0	0	0
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>

27.1 Finance leases obligations (as lessee) continued

Amounts payable under finance leases:

**BUILDINGS**

	31 March 2022 £000	31 March 2021 £000	31 March 2022 £000	31 March 2021 £000
	NHS Trust		Consolidated	
<b>Minimum lease payments</b>				
Within one year	0	0	0	0
Between one and five years	0	0	0	0
After five years	0	0	0	0
Less finance charges allocated to future periods	0	0	0	0
<b>Minimum lease payments</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
Included in: Current borrowings	0	0	0	0
Non-current borrowings	0	0	0	0
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Present value of minimum lease payments</b>				
Within one year	0	0	0	0
Between one and five years	0	0	0	0
After five years	0	0	0	0
<b>Total present value of minimum lease payments</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
Included in: Current borrowings	0	0	0	0
Non-current borrowings	0	0	0	0
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>

**OTHER**

	31 March 2022 £000	31 March 2021 £000	31 March 2022 £000	31 March 2021 £000
	NHS Trust		Consolidated	
<b>Minimum lease payments</b>				
Within one year	0	8	0	8
Between one and five years	0	0	0	0
After five years	0	0	0	0
Less finance charges allocated to future periods	0	0	0	0
<b>Minimum lease payments</b>	<b>0</b>	<b>8</b>	<b>0</b>	<b>8</b>
Included in: Current borrowings	0	8	0	8
Non-current borrowings	0	0	0	0
<b>Total</b>	<b>0</b>	<b>8</b>	<b>0</b>	<b>8</b>
<b>Present value of minimum lease payments</b>				
Within one year	0	8	0	8
Between one and five years	0	0	0	0
After five years	0	0	0	0
<b>Total present value of minimum lease payments</b>	<b>0</b>	<b>8</b>	<b>0</b>	<b>8</b>
Included in: Current borrowings	0	8	0	8
Non-current borrowings	0	0	0	0
<b>Total</b>	<b>0</b>	<b>8</b>	<b>0</b>	<b>8</b>

27.2 Finance lease receivables (as lessor)

The Trust has no finance lease receivables.

Amounts receivable under finance leases:

	<b>31 March 2022 £000</b>	31 March 2021 £000	<b>31 March 2022 £000</b>	31 March 2021 £000
	<b>NHS Trust</b>		<b>Consolidated</b>	
<b>Gross investment in leases</b>				
Within one year	0	0	0	0
Between one and five years	0	0	0	0
After five years	0	0	0	0
Less finance charges allocated to future periods	0	0	0	0
<b>Present value of minimum lease payments</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
Included in:				
Current borrowings	0	0	0	0
Non-current borrowings	0	0	0	0
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Present value of minimum lease payments</b>				
Within one year	0	0	0	0
Between one and five years	0	0	0	0
After five years	0	0	0	0
Less finance charges allocated to future periods	0	0	0	0
<b>Total present value of minimum lease payments</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
Included in:				
Current borrowings	0	0	0	0
Non-current borrowings	0	0	0	0
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>

**27.3 Finance Lease Commitment**

The Trust does not have any commitments becoming operational in a future period.

**28. Private finance transactions**

**Private Finance Initiatives (PFI) / Public Private Partnerships (PPP)**

The Trust has no PFI or PPP Schemes.

## 29. Financial Risk Management

IFRS 7, Derivatives and Other Financial Instruments, requires disclosure of the role that financial instruments have had during the period in creating or changing the risks an entity faces in undertaking its activities.

NHS Trusts are not exposed to the degree of financial risk faced by business entities. Financial instruments play a much more limited role in creating or changing risk than would be typical of the listed companies to which IFRS 7 mainly applies. NHS Trusts have limited powers to borrow or invest surplus funds and financial assets and liabilities are generated by day to day operational activities rather than being held to change the risks facing NHS Trusts in undertaking its activities.

The Trust's treasury management operations are carried out by the finance department within parameters defined formally within the Trust's standing financial instructions and policies agreed by the board of directors. The Trust treasury activity is subject to review by the Trust's internal auditors.

### Liquidity risk

The Trust's net operating costs are incurred under annual service agreements with various Health bodies, which are financed from resources voted annually by parliament. NHS Trusts also largely finance their capital expenditure from funds made available from the Welsh Government under agreed borrowing limits. NHS Trusts are not, therefore, exposed to significant liquidity risks.

### Interest-rate risks

The great majority of NHS Trusts' financial assets and financial liabilities carry nil or fixed rates of interest. NHS Trusts are not, therefore, exposed to significant interest-rate risk.

### Foreign currency risk

NHS Trusts have no significant foreign currency income or expenditure and any such risk for Velindre University NHS Trust is underwritten by Welsh Government.

### Credit Risk

Because the majority of the Trust's income comes from contracts with other public sector bodies, the Trust has low exposure to credit risk. The maximum exposures are in receivables from customers as disclosed in the trade and other receivables note.

### General

The powers of the Trust to invest and borrow are limited. The Board has determined that in order to maximise income from cash balances held, any balance of cash which is not required will be invested. The Trust does not borrow from the private sector. All other financial instruments are held for the sole purpose of managing the cash flow of the Trust on a day to day basis or arise from the operating activities of the Trust. The management of risks around these financial instruments therefore relates primarily to the Trust's overall arrangements for managing risks to their financial position, rather than the Trust's treasury management procedures.



### 30. Movements in working capital

	31 March 2022 £000	31 March 2021 £000	31 March 2022 £000	31 March 2021 £000
	NHS Trust		Consolidated	
<b>Movements in working capital</b>				
(Increase) / decrease in inventories	30,357	(82,430)	30,357	(82,430)
(Increase) / decrease in trade and other receivables - non-current	(274,866)	45,820	(274,866)	45,820
(Increase) / decrease in trade and other receivables - current	8,609	(134,576)	9,383	(134,176)
Increase / (decrease) in trade and other payables - non-current	35	7,301	35	7,301
Increase / (decrease) in trade and other payables - current	(75,535)	186,866	(75,594)	186,793
<b>Total</b>	<b>(311,400)</b>	22,981	<b>(310,685)</b>	23,308
Adjustment for accrual movements in fixed assets - creditors	(2,415)	1,455	(2,415)	1,455
Adjustment for accrual movements in fixed assets - debtors	(187)	103	(187)	103
Other adjustments	(1,093)	740	(1,077)	885
<b>Total</b>	<b>(315,095)</b>	25,279	<b>(314,364)</b>	25,751

### 31. Other cash flow adjustments

	31 March 2022 £000	31 March 2021 £000	31 March 2022 £000	31 March 2021 £000
	NHS Trust		Consolidated	
<b>Other cash flow adjustments</b>				
Depreciation	9,110	11,740	9,110	11,740
Amortisation	1,112	5,815	1,112	5,815
(Gains)/Loss on Disposal	0	0	0	0
Impairments and reversals	0	0	0	0
Release of PFI deferred credits	0	0	0	0
NWSSP Covid assets issued debited to expenditure but non-cash	0	0	0	0
NWSSP Covid assets received credited to revenue but non-cash	0	0	0	0
Donated assets received credited to revenue but non-cash	0	(50)	0	(50)
Government Grant assets received credited to revenue but non-cash	0	(1,134)	0	(1,134)
Non-cash movements in provisions	443,268	111,161	443,268	111,161
<b>Total</b>	<b>453,490</b>	127,532	<b>453,490</b>	127,532

**32. Events after reporting period**

These financial statements were authorised for issue by the Chief Executive and Accountable Officer on the date the financial statements were certified by the Auditor General for Wales.

33. Related Party transactions

The Trust is a body corporate established by order of the Welsh Minister for Health and Social Services.

The Welsh Government is regarded as a related party. During the year, the Trust has had a significant number of material transactions with the Welsh Government and with other entities for which the Welsh Government is regarded as the parent body, namely:

Related Party	Expenditure to related party £000	Income from related party £000	Amounts owed to related party £000	Amounts due from related party £000
Welsh Government	33,021	160,352	58,216	14,833
WHSSC	0	49,274	877	81
Aneurin Bevan UHB	7,599	63,783	5,118	3,543
Betsi Cadwaladr UHB	6,164	39,833	2,613	2,133
Cardiff and Vale UHB	5,341	66,954	1,677	4,509
Cwm Taf Morgannwg UHB	8,117	51,139	2,985	2,262
Hywel Dda UHB	5,136	22,490	3,068	1,514
Powys THB	780	3,358	431	610
Swansea Bay UHB	5,213	26,268	992	1,288
Public Health Wales NHS Trust	379	3,649	63	491
Welsh Ambulance Service NHS Trust	1,021	2,311	181	219
Health Education & Improvement Wales	11	46,645	0	2,824
Digital Health & Care Wales	2,511	299	169	87
Welsh Risk Pool	0	418	0	9
Welsh Local Authorities (excluding those listed below where declarations of interest have been received):	1,505	31	83	128

Parties where specific interests have been declared	Name of individual declaring interest	Nature of the relationship				
Blaenau Gwent County Borough Council	Martin Veale, Independent Member	Lay Member of Audit Committee	2	0	0	0
Merthyr Tydfil County Borough Council	Martin Veale, Independent Member	Lay Member of Standards Committee	1	0	0	0
Pembrokeshire County Council	Martin Veale, Independent Member	Lay Member of Audit Committee	15	0	6	0
Cardiff University	Donna Mead, Chair	Visiting Professor	1,260	410	187	115
University of Wales Trinity St David	Donna Mead, Chair	Consultancy	14	0	13	0
Capita	Donna Mead, Chair	Party employs son	20	0	23	0
City Hospice	Stephen Harries, Vice Chair	Member	222	300	79	24
	Sarah Morley, Executive Director of Organisational Development & Workforce	Deputy President & Trustee	13	0	1	0
Healthcare People Management Association	Bethan Tranter, Chief Pharmacist	Joint working arrangement	0	21	0	0
IPSEN	Cath O'Brien, Chief Operating Officer	Director	50	0	4	0
Life Sciences Hub	Donna Mead, Chair	Director	4	0	2	0
Llandarcy Park Ltd	David Mason Hawes, Head of Digital Delivery	Personal friend	1	0	0	0
Matthew Tyson Design						
			<b>78,400</b>	<b>537,535</b>	<b>76,788</b>	<b>34,670</b>

In addition, the Trust has had a number of material transactions with other Government departments and other central and local Government bodies. The majority of these transactions have been with universities; and other transactions include payments to English, Scottish and Irish NHS organisations amounting to £10,053,000 (2020/2021 £7,409,000); of this total £1,610,550 (2020/2021 £1,442,000) related to an English Trust that provides a lease car salary sacrifice scheme to Trust employees.

The Trust Board is the corporate trustee of Velindre University NHS Trust Charitable Funds. During the year the Trust received £2,791,000 (2020/2021 £2,501,000) from Velindre University NHS Trust Charitable Funds.

Welsh Government expenditure excludes £9,486,000 that relates to Public Dividend Capital (PDC) repaid during 2021/2022 (2020/2021 £9,485,000 was received).

Transactions with Cardiff University, University of Wales Trinity St David, Capita, City Hospice, Healthcare People Management Association, IPSEN, Life Sciences Hub, Llandarcy Park Ltd and Matthew Tyson Design have been disclosed due to senior Trust managers declaring an interest in these parties and as the transactions could be of material value to these companies.

**34. Third party assets**

The Trust held £nil cash at bank and in hand at 31 March 2022 (31 March 2021, £nil ) which relates to monies held by the Trust on behalf of patients. Cash held in Patient's Investment Accounts amounted to £nil at 31 March 2022 (31 March 2021, £nil).

**35. Pooled budgets**

Velindre University NHS Trust has no pooled budgets.

36. Operating Segments

IFRS 8 requires organisations to report information about each of its operating segments.

36. Operating Segments

	VELINDRE		NWIS		NWSSP		WRP		TOTAL		FHOT		ELIMINATIONS		CONSOLIDATED	
	2021-22	2020-21	2021-22	2020-21	2021-22	2020-21	2021-22	2020-21	2021-22	2020-21	2021-22	2020-21	2021-22	2020-21	2021-22	2020-21
	£000	£000	£000	£000	£000	£000	£000	£000	£000	£000	£000	£000	£000	£000	£000	£000
<b>Operating Revenue</b>																
Segmental Income	171,601	148,746	0	101,929	444,770	470,735	427,428	126,811	1,043,799	848,223	3,066	2,683	(2,791)	(2,501)	1,044,074	848,405
	171,601	148,746	0	101,929	444,770	470,735	427,428	126,811	1,043,799	848,223	3,066	2,683	(2,791)	(2,501)	1,044,074	848,405
<b>Operating Expenses</b>																
Local Health Boards	250	218	0	3,416	11,214	6,227	0	0	11,464	9,861	0	0	0	0	11,464	9,861
Welsh NHS Trusts	0	0	0	732	23	21	0	0	23	753	0	0	0	0	23	753
Health Education and Improvement Wales	10	0	0	19	1,160	0	0	0	1,170	19	0	0	0	0	1,170	19
Goods and services from other NHS bodies	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WHSSC & EASC	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Local Authorities	0	0	0	174	0	0	0	0	0	174	0	0	0	0	0	174
Purchase of healthcare from non-NHS bodies	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Welsh Government	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other NHS Trusts	0	0	0	0	514	506	0	0	514	506	0	0	0	0	514	506
Directors' costs	1,392	1,353	0	0	0	0	0	0	1,392	1,353	0	0	0	0	1,392	1,353
Operational staff costs	72,919	69,894	0	35,989	81,063	72,073	0	0	153,982	177,956	0	0	0	0	153,982	177,956
Non operational trainee staff costs	0	0	0	0	137,379	62,340	0	0	137,379	62,340	0	0	0	0	137,379	62,340
Non operational collaborative bank staff costs	0	0	0	0	234	176	0	0	234	176	0	0	0	0	234	176
Single lead employer staff trainee costs	1,033	0	0	0	0	247	0	0	1,033	247	0	0	0	0	1,033	247
Collaborative bank staff costs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Supplies and services - clinical	77,334	61,940	0	(319)	18,892	68,584	0	0	96,226	130,205	0	0	0	0	96,226	130,205
Supplies and services - general	292	1,693	0	148	117,703	59,927	0	0	117,995	61,768	0	0	0	0	117,995	61,768
Consultancy Services	841	700	0	4,337	3,383	935	0	0	4,224	5,972	0	0	0	0	4,224	5,972
Establishment	3,053	2,304	0	6,279	9,330	6,544	0	0	12,383	15,127	0	0	0	0	12,383	15,127
Transport	811	1,058	0	10	2,349	1,640	0	0	3,160	2,708	0	0	0	0	3,160	2,708
Premises	5,891	6,659	0	42,647	18,880	15,914	0	0	24,771	65,220	0	0	0	0	24,771	65,220
Costs of generating funds	0	0	0	0	0	0	0	0	0	0	362	267	(205)	(177)	157	90
Charitable activities	0	0	0	0	0	0	0	0	0	0	2,206	2,471	(2,512)	(2,288)	(306)	183
Governance Costs	0	0	0	0	0	0	0	0	0	0	59	36	(74)	(36)	(15)	0
Impairments and Reversals of Receivables	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	5,987	5,943	0	3,504	3,123	2,292	0	0	9,110	11,739	0	0	0	0	9,110	11,739
Amortisation	680	411	0	5,019	432	385	0	0	1,112	5,815	0	0	0	0	1,112	5,815
Impairments and reversals of property, plant and equipment	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Impairments and reversals of intangible assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Impairments and reversals of financial assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Impairments and reversals of non current assets held for sale	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Audit fees	224	216	0	0	0	0	0	0	224	216	15	12	0	0	239	228
Other auditors' remuneration	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Losses, special payments and irrecoverable debts	472	(4,413)	0	0	21,082	6,143	426,335	126,446	447,889	128,176	0	0	0	0	447,889	128,176
Research and development	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
COVID items issued free of charge to NHS Wales organisations	0	(570)	0	0	0	50,167	0	0	0	49,597	0	0	0	0	0	49,597
COVID items issued free of charge to other organisations	0	0	0	0	0	100,247	0	0	0	100,247	0	0	0	0	0	100,247
Other operating expenses	408	1,275	0	(26)	18,242	15,236	0	0	18,650	16,486	0	0	0	0	18,650	16,486
<b>Total</b>	<b>171,597</b>	<b>148,681</b>	<b>0</b>	<b>101,929</b>	<b>445,003</b>	<b>469,604</b>	<b>426,335</b>	<b>126,446</b>	<b>1,042,935</b>	<b>846,661</b>	<b>2,642</b>	<b>2,786</b>	<b>(2,791)</b>	<b>(2,501)</b>	<b>1,042,786</b>	<b>846,946</b>
Investment Revenue	23	0	0	0	0	0	0	0	23	0	114	133	0	0	137	133
Other Gains and Losses	3	30	0	0	0	(5)	0	0	3	25	0	0	0	0	3	25
Finance Costs	0	0	0	0	0	0	(1,093)	(365)	(1,093)	(365)	0	0	0	0	(1,093)	(365)
<b>SURPLUS / (DEFICIT)</b>	<b>30</b>	<b>95</b>	<b>0</b>	<b>0</b>	<b>(233)</b>	<b>1,126</b>	<b>0</b>	<b>0</b>	<b>(203)</b>	<b>1,222</b>	<b>538</b>	<b>30</b>	<b>0</b>	<b>0</b>	<b>335</b>	<b>1,252</b>
<i>(excluding donated assets received or issued)</i>																

**37. Other Information**

**37.1. 6.3% Staff Employer Pension Contributions - Notional Element**

The value of notional transactions is based on estimated costs for the twelve month period 1 April 2021 to 31 March 2022. This has been calculated from actual Welsh Government expenditure for the 6.3% staff employer pension contributions between April 2021 and February 2022 alongside Trust data for March 2022.

Transactions include notional expenditure in relation to the 6.3% paid to NHS BSA by Welsh Government and notional funding to cover that expenditure as follows:

	<b>2021-22</b>	<b>2020-21</b>
<b>STATEMENT OF COMPREHENSIVE INCOME</b>		
<b>FOR THE YEAR ENDED 31 MARCH 2022</b>	<b>£000</b>	<b>£000</b>
Revenue from patient care activities	11,406	9,725
Operating expenses	11,406	9,725
<b>3. Analysis of gross operating costs</b>		
<b>3. Revenue from patient care activities</b>		
Welsh Government	3,160	2,972
Welsh Government - Hosted Bodies	3,535	4,633
<b>4. Other Operating Revenue</b>		
Other	4,711	2,120
<b>5.1 Operating expenses</b>		
Directors' costs	58	66
Operational staff costs	6,604	7,532
Non operational trainee staff costs	4,704	2,114
Non operational collaborative bank staff costs	7	6
Single lead employer staff trainee cost	33	8
Collaborative bank staff cost	0	0

Notional income from Local Health Boards, Welsh NHS Trusts and Welsh Special Health Authorities shown above is in respect of the Single Lead Employer (SLE) trainees employed via NWSSP and operational within the respective organisation.

The increase this year is primarily due to increases in NWSSP operational and non operational staff, and is offset by a reduction in the values previously attributed to NWIS who left the Trust on 1st April 2021.

## 37. Other Information (continued)

## 37.2 Other (continued)

## Welsh Government Covid 19 Funding

Details of Covid 19 Pandemic Welsh Government funding amounts provided to the Trust:

	NWSSP 2021-22 £000	Velindre 2021-22 £000	Total 2021-22 £000	Total 2020-21 £000	
<b>Capital</b>					
Capital Funding Field Hospitals				0	
Capital Funding Equipment & Works	0	675	675	5,062	
Capital Funding other (Specify)	0	0	0	674	
<b>Welsh Government Covid 19 Capital Funding</b>	<b>-</b>	<b>675</b>	<b>675</b>	<b>5,736</b>	
					<b>As previously reported in 2020-21 £000</b>
<b>Revenue</b>					
Sustainability Funding					10,448
C-19 Pay Costs Q1 (Future Quarters covered by SF)					1,947
Field Hospital (Set Up Costs, Decommissioning & Consequential losses)					0
Bonus Payment					4,135
Independent Health Sector					0
Stability Funding	5,328	2,078	7,406	16,530	
Covid Recovery	0	3,479	3,479	0	
Cleaning Standards	0	769	769	0	
PPE (including All Wales Equipment via NWSSP)	46,954	226	47,180	152,918	
Testing / TTP- Testing & Sampling - Pay & Non Pay	3,941	0	3,941	1,222	
Tracing / TTP - NHS & LA Tracing - Pay & Non Pay	0	0	0	3,061	
Extended Flu Vaccination / Vaccination - Extended Flu Programme	0	0	0	0	
Mass Covid-19 Vaccination / Vaccination - COVID-19	1,461	392	1,853	1,826	
Annual Leave Accrual - Increase due to Covid	0	0	0	0	
Urgent & Emergency Care	0	77	77	0	
Private Providers Adult Care / Support for Adult Social Care Providers	0	0	0	0	
Hospices	0	4,500	4,500	9,300	
Other Mental Health / Mental Health	0	0	0	0	
Other Primary Care	0	0	0	300	
Social Care	0	0	0	0	
Other	0	0	0	4,060	
<b>Welsh Government Covid 19 Revenue Funding</b>	<b>57,684</b>	<b>11,521</b>	<b>69,205</b>	<b>189,217</b>	

Velindre also received £4.5m (2020/2021 £9.3m) of pass through funding from Welsh Government for Hospices which has been netted off within the accounts to ensure Trust income and expenditure is not overstated.

2020/2021 costs included £2.1m capital and £8.9m revenue funding for NWIS, who left the Trust on 1st April 2021.

### 37. Other Information (continued)

#### 37.3 Changes to accounting standards not yet effective - IFRS 16 Impact

IFRS 16 Leases supersedes IAS 17 Leases and is effective in the public sector from 1 April 2022. IFRS 16 provides a single lessee accounting model and requires a lessee to recognise right-of-use assets and liabilities for leases with a term more than 12 months unless the underlying value is of low value. The FReM makes two public sector adaptations:

- The definition of a contract is expanded to include intra UK government agreements that are not legally enforceable;
- The definition of a contract is expanded to include agreements that have nil consideration.

IFRS 16 gives a narrower definition of a lease than IAS 17 and IFRIC 4 by requiring that assets and liabilities will be recognised initially at the discounted value of minimum lease payments. After initial recognition, right of use assets will be depreciated on a straight line basis and interest recognised on the liabilities. Except where modified for revaluation where material, the cost model will be applied to assets other than peppercorn leases which will be measured on a depreciated replacement cost basis. The right of use asset in a peppercorn lease is accounted for similarly to a donated asset.

As required by the FReM IFRS 16 will be implemented using the accumulated catch up method.

#### Core Trust services

The right of use assets and leasing obligation have been calculated and indicated that the total discounted value of right of use assets and liabilities under IFRS 16 is higher than the value of minimum lease commitments under IAS 17. The impact of implementation is:

- a decrease in expenditure of £199k;
- an increase in assets of £476k and an increase in liabilities of £476k.

#### NWSSP

The right of use assets and leasing obligation have been calculated and indicated that the total discounted value of right of use assets and liabilities under IFRS 16 is lower than the value of minimum lease commitments under IAS 17. The impact of implementation is:

- a decrease in expenditure of £3.684m;
- an increase in assets of £7.105m and an increase of liabilities of £3.605m.

These figures are calculated before intercompany eliminations are made, and may have a material impact on the figures.



37. Other Information (continued)

37.3 Changes to accounting standards not yet effective - IFRS 16 Impact (continued)

Right of Use (RoU) Assets Impact

	Property £000	Non Property £000	Total £000
<b>Statement of financial Position</b>			
<b>RoU Asset Recognition</b>			
+ Transitioning Adjust	6,923	658	7,581
+ As at 1 April 2022	6,923	658	7,581
+ Renewal / New RoU Assets 2022-23	419	407	826
- Less (Depreciation)	(1,526)	(236)	(1,762)
+ As at 31 March	5,816	829	6,645
<b>RoU Asset Liability</b>			
	Property £000	Non Property £000	Total £000
- Transitioning Adjust	(3,423)	(658)	(4,081)
- As at 1 April 2022	(3,423)	(658)	(4,081)
- Renewal / New RoU Liability 2022-23	(419)	(407)	(826)
+ Working Capital	1,214	239	1,453
- Interest	(30)	(8)	(38)
- As at 31 March	(2,658)	(834)	(3,492)
<b>Charges</b>			
	Property £000	Non Property £000	Total £000
Expenditure			
RoU Asset depreciation <sup>(1)</sup>	1,526	236	1,762
Interest on obligations under RoU Asset leases <sup>(2)</sup>	30	8	38
	1,556	244	1,800

Notes:

<sup>(1)</sup> Operating Expenses

<sup>(2)</sup> Finance Costs

**THE NATIONAL HEALTH SERVICE IN WALES ACCOUNTS DIRECTION GIVEN BY WELSH MINISTERS IN ACCORDANCE WITH SCHEDULE 9 SECTION 178 PARA 3(1) OF THE NATIONAL HEALTH SERVICE (WALES) ACT 2006 (C.42) AND WITH THE APPROVAL OF TREASURY**

**NHS TRUSTS**

1. Welsh Ministers direct that an account shall be prepared for the financial year ended 31 March 2010 and subsequent financial years in respect of the NHS Wales Trusts in the form specified in paragraphs [2] to [7] below.

**BASIS OF PREPARATION**

2. The account of the NHS Wales Trusts shall comply with:

(a) the accounting guidance of the Government Financial Reporting Manual (FRoM), which is in force for the financial year for which the accounts are being prepared, as detailed in the NHS Wales Trust Manual for Accounts;

(b) any other specific guidance or disclosures required by the Welsh Government.

**FORM AND CONTENT**

3. The account of the Trust for the year ended 31 March 2010 and subsequent years shall comprise a foreword, an income statement, a statement of financial position, a statement of cash flows and a statement of changes in taxpayers' equity as long as these statements are required by the FRoM and applied to the NHS Wales Manual for Accounts, including such notes as are necessary to ensure a proper understanding of the accounts.

4. For the financial year ended 31 March 2010 and subsequent years, the account of the Trust shall give a true and fair view of the state of affairs as at the end of the financial year and the operating costs, changes in taxpayers' equity and cash flows during the year.

5. The account shall be signed and dated by the Chief Executive.

**MISCELLANEOUS**

6. The direction shall be reproduced as an appendix to the published accounts.

7. The notes to the accounts shall, inter alia, include details of the accounting policies adopted.

Signed by the authority of Welsh Ministers

Signed : Chris Hurst

Dated : 17.06.2010

1 Please see regulation 3 of the 2009 No 1558(W.153); NATIONAL HEALTH SERVICE, WALES; The National Health Service Trusts (Transfer of Staff, Property Rights and Liabilities)